0001841258 false 00-0000000 CH NASDAQ NASDAQ NASDAQ 0001841258 2022-10-17 2022-10-17 0001841258 dei:FormerAddressMember 2022-10-17 2022-10-17 0001841258 EBAC:UnitsEachConsistingOfOneClassOrdinaryShareAndOnethirdOfOneRedeemableWarrantMember 2022-10-17 2022-10-17 0001841258 EBAC:ClassOrdinarySharesParValue0.0001PerShareMember 2022-10-17 2022-10-17 0001841258 EBAC:WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member 2022-10-17 2022-10-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION  

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): October 17, 2022

 

EUROPEAN BIOTECH ACQUISITION CORP. 

(Exact name of registrant as specified in its charter)

 

Commission File Number: 001-40211

 

Cayman Islands     N/A
(State or other jurisdiction of incorporation or organization)     (IRS Employer Identification No.)

 

EPFL Innovation Park Building  

1015 Lausanne

Switzerland 

(Address of principal executive offices, including zip code)

 

+41 77 976 21 09

(Registrant’s telephone number, including area code)

 

Johannes Vermeerplein 9

1071 DV Amsterdam, Netherlands

(Former address)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 140.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant EBACU The NASDAQ Stock Market LLC
Class A ordinary shares, par value $0.0001 per share EBAC The NASDAQ Stock Market LLC
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 EBACW The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

Business Combination Agreement

 

On October 17, 2022, European Biotech Acquisition Corp., a Cayman Islands exempted company (“EBAC”), entered into a Business Combination Agreement (as it may be amended and/or restated from time to time, the “Business Combination Agreement”) with Oculis SA, a public limited liability company (société anonyme) incorporated and existing under the laws of Switzerland (“Oculis”). Capitalized terms used in this Current Report on Form 8-K but not otherwise defined herein have the meanings given to them in the Business Combination Agreement.

 

Upon the terms and subject to the conditions of the Business Combination Agreement and in accordance with applicable law, as soon as practicable following the date hereof, (i) EBAC will form, or cause to be formed, (a) Oculis Holding AG, a public limited liability company incorporated and existing under the laws of Switzerland and that will be a direct wholly owned subsidiary of EBAC (“New Parent”), (b) a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 1”), (c) another new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 2”) and (d) a new limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and existing under the laws of Switzerland that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 3”) and (ii) EBAC will cause New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to become a party to the Business Combination Agreement.

 

In connection with the transactions contemplated by the Business Combination Agreement, among other things, (i) Merger Sub 1 will merge with and into EBAC, with EBAC surviving such merger as a wholly owned subsidiary of New Parent (the “First Merger”), (ii) as a result of the First Merger, (a) each issued and outstanding share of EBAC Common Stock will automatically convert into one class of ordinary shares of the surviving company in the First Merger (“Surviving EBAC Shares”), (b) each issued and outstanding warrant issued by EBAC to purchase Class A Common Stock of EBAC will be automatically converted into warrants of the surviving company in the First Merger (“Surviving EBAC Warrants”), and (c) EBAC will deposit or cause to be deposited with the Exchange Agent the Surviving EBAC Shares and Surviving EBAC Warrants, (iii) following the First Merger Effective Time but prior to the Second Merger Effective Time, the Exchange Agent will contribute the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent in exchange for New Parent Class A ordinary shares, nominal value CHF 0.01 per share (the “New Parent Shares”) and a right to acquire New Parent Shares (each, a “New Parent Warrant”), with both New Parent Shares and New Parent Warrants to be held by the Exchange Agent solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants (the “New Parent Interests Consideration, (iv) prior to the Second Merger Effective Time, the Exchange Agent will undertake to (a) distribute the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares and (b) distribute the New Parent Warrants as part of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants, (v) after the First Merger Effective Time and following the completion of the Exchange Agent Contribution Actions, EBAC will merge with and into Merger Sub 2, with Merger Sub 2 as the surviving company and remaining a wholly owned subsidiary of New Parent, (vi) consenting Oculis shareholders executing the Company Shareholders Support Agreements will contribute their shares of Oculis to New Parent in exchange for New Parent Shares and (vii) approximately 30 days after the Acquisition Closing Date, Oculis will merge with and into Merger Sub 3, with Merger Sub 3 as the surviving company.

 

The Business Combination Agreement and the transactions contemplated thereby were approved by the boards of directors of each of EBAC and Oculis.

 

 

 

Merger Consideration

 

The consideration payable to current Oculis equityholders in connection with the transactions will be comprised of New Parent Shares. Each New Parent Share shall entitle the holder thereof to one vote and such holder will be entitled to receive dividends if and when declared. The aggregate value of the consideration of New Parent Shares payable to existing Oculis equityholders, without considering any Earnout Shares (as defined below) equals $208,000,000 (subject to certain adjustments) (valuing each New Parent Share at $10 per share). Additionally, all unexercised Oculis options will be assumed by New Parent and converted into options to purchase New Parent Shares.

 

In addition to the consideration described above, existing equityholders of Oculis will also be entitled to receive at the Acquisition Closing additional consideration in the form of 4,000,000 newly issued shares of New Parent (the “Earnout Shares”), which will initially be unvested and will be subject to forfeiture, on the terms and subject to the conditions set forth in the Business Combination Agreement. The Earnout Shares will be issued in three tranches of (i) 1,500,000 shares, (ii) 1,500,000 shares, and (iii) 1,000,000 shares, vesting based on achievement of post-closing share price targets of New Parent of $15.00, $20.00 and $25.00, respectively, in each case for any 20 trading days within any 30 trading day period commencing on the Acquisition Closing Date and ending on the five-year anniversary thereafter (the “Vesting Period”). The achievement metrics described above are also deemed to be achieved if there is a Change of Control (to the extent an applicable share price target has not already occurred) during the Vesting Period. The Earnout Shares shall not be entitled to vote on matters submitted to the holders of New Parent Shares for approval or be entitled to receive dividends or distributions in respect of the New Parent Shares, if any, until such Earnout Shares vest. The Earnout Shares that have not vested by the end of the Vesting Period shall, automatically be forfeited and cancelled for no consideration.

 

The Sponsor has forfeited 727,096 of its shares of EBAC Class B Common Stock for no consideration, contingent upon the consummation of the Acquisition Closing. Furthermore, if as of the Acquisition Closing Date, (i) the amount of cash available in the Trust Account following the EBAC Shareholders’ Meeting (after deducting the amount required to satisfy the EBAC Share Redemption Amount but before payment of any Company Transaction Expenses or EBAC Transaction Expenses), plus (ii) the PIPE Investment Amount actually received by New Parent (or other financing, including through a convertible loan, in connection with the Acquisition Transactions) prior to or substantially concurrently with the Acquisition Closing from a PIPE Investor or other investor that in either case has been introduced to the Company following the date hereof by the Sponsor, is less than $25,500,000, then the Sponsor will forfeit for no consideration an additional number of EBAC Class B Common Stock (the “Additional At-Risk Shares”) proportional to the available cash relative to the $25,500,000 threshold (up to a maximum of 1,594,348 Additional At-Risk Shares forfeited); provided that such amount may be reduced by the number of Additional At-Risk Shares transferred by the Sponsor to EBAC Shareholders in connection with executing a Non-Redemption Agreement or similar arrangement after the date hereof; provided further that, the number of shares transferred to any such shareholder does not exceed 10% of the number of EBAC Class A Common Stock owned by such shareholder as of the date of such Non-Redemption Agreement or similar arrangement.

 

Covenants of the Parties

 

Pursuant to the terms and conditions set forth in the Business Combination Agreement, among other customary covenants, each of EBAC, New Parent, Merger Sub 1, Merger Sub 2, Merger Sub 3 and Oculis have agreed to use its respective commercially reasonable efforts to take all actions reasonably necessary or advisable to consummate and make effective as soon as practicable the closing of the Business Combination (the “Closing”), including using commercially reasonable efforts to obtain all material Governmental Authorizations to effect the Closing. The Business Combination Agreement also contains certain customary covenants by EBAC and Oculis during the period between the signing of the Business Combination Agreement and the Closing, including, among other things, the conduct of their respective businesses, publicity, provision of information, maintenance of books and records, notification of certain matters, terminating affiliate contracts, some of which may continue after the termination of the Business Combination Agreement. Each of EBAC and Oculis also agreed not to solicit or enter into any alternative competing transactions during the period from the date of the Business Combination Agreement and the Closing. EBAC and New Parent also agreed to cause New Parent Shares issuable in accordance with the Business Combination Agreement to be approved for listing on the Nasdaq as promptly as practicable after the date hereof. EBAC has also agreed to seek an extension (via shareholder approval) to amend its governing documents to extend the time period necessary for EBAC to consummate a business combination if EBAC and Oculis determine in good faith that it is probable the Closing will not occur prior to March 18, 2023 (the “Termination Date”).

 

 

 

Directors of New Parent

 

The parties agreed in the Business Combination Agreement to take all actions necessary or appropriate to cause the board of directors of New Parent as of the Closing to consist of up to seven directors, of which two individuals will be designated by the Sponsor and up to five individuals designated by Oculis, one whom shall be the chief executive of Oculis and at least three of whom, who in each case will be subject to the prior approval of the Sponsor (not to be unreasonably withheld), will qualify as independent directors under applicable SEC and Nasdaq listing rules.

 

Closing Conditions

 

The obligations of the parties to complete the Closing are subject to various conditions, including customary conditions of each party and the following mutual conditions of the parties unless waived:

 

·the New Parent Shares and New Parent Warrants contemplated to be listed pursuant to the Business Combination Agreement shall have been approved for listing on Nasdaq;

 

·there will not be in force any applicable Law or Governmental Order enjoining, prohibiting, or making illegal the Acquisition Transactions; provided that the Governmental Authority issuing such Governmental Order has jurisdiction over the parties to the Business Combination Agreement;

 

·the approval of the EBAC shareholders with respect to the transaction proposals identified in the Business Combination Agreement shall have been obtained;

 

·the registration statement on Form F-4 (as such filing is amended or supplemented, and including the proxy statement/prospectus contained therein, the “Registration Statement”) shall have become effective, no stop order shall have been issued by the SEC with respect to the Registration Statement and no action seeking such stop order shall have been threatened or initiated by the SEC and not withdrawn;

 

·EBAC shall have net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act (as defined below)) of at least $5,000,001; and

 

·the (i) amount of cash available in the account established by EBAC for the benefit of its public shareholders, pursuant to the Management Trust Agreement, dated March 15, 2021 by and between EBAC and Continental Stock Transfer & Trust Company following the EBAC Shareholders’ Meeting (after deducting the amount required to satisfy the EBAC Share Redemption Amount and payment of any Company Transaction Expenses or EBAC Transaction Expenses); plus (ii) (A) the cash actually received by New Parent pursuant to the Convertible Loan Agreement from the respective lender parties thereto and (B) the PIPE Investment Amount actually received by New Parent (or other financing in connection with the Acquisition Transactions) prior to or substantially concurrently with the Acquisition Closing being equal to or greater than $100 million.

 

Termination

 

The Business Combination Agreement may be terminated under certain customary and limited circumstances, including:

 

·by the mutual written consent of EBAC and Oculis;

 

·by either EBAC or Oculis if: (i) the representations, warranties, covenants or agreements of the other party, as set forth in the Business Combination Agreement, are breached such that there is a failure of the related closing condition at the Acquisition Closing (subject to a 45-day cure period); (ii) the Closing has not occurred by the Termination Date; provided, that if a proposal to amend EBAC’s governing documents to extend the time period necessary for EBAC to consummate a business combination is approved at an Extension Shareholders’ Meeting (if necessary), then the Termination Date will extend to the last day of such extended time period, (iii) any Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Governmental Order which has become final and nonappealable and has the effect of making consummation of any of the Acquisition Transactions illegal or otherwise preventing or prohibiting consummation of any of the Acquisition Transactions or if there shall be adopted any Law that permanently makes consummation of any of the

 

 

 

Acquisition Transactions illegal or otherwise prohibited; or (iv) the EBAC Shareholder Approval is not obtained upon a vote duly taken thereon at the relevant EBAC shareholders’ meeting (subject to any permitted adjournment or postponement thereof); or

 

·by Oculis in the event of a Modification in Recommendation.

 

Other General

 

The Business Combination Agreement contains representations, warranties and covenants that the respective parties made to each other as of the date of such agreement or other specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating such agreement. The Business Combination Agreement has been filed to provide investors with information regarding its terms. It is not intended to provide any other factual information about EBAC, Oculis or any other party to the Business Combination Agreement. In particular, the representations, warranties, covenants and agreements contained in the Business Combination Agreement, which were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Business Combination Agreement (or any entity that may become a party thereto after the date hereof), may be subject to limitations agreed upon by the contracting parties (including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Business Combination Agreement instead of establishing these matters as facts) and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors and reports and documents filed with the SEC. Investors should not rely on the representations, warranties, covenants and agreements, or any descriptions thereof, as characterizations of the actual state of facts or condition of any party (or future party) to the Business Combination Agreement. In addition, the representations, warranties, covenants and agreements and other terms of the Business Combination Agreement may be subject to subsequent waiver or modification. Moreover, information concerning the subject matter of the representations and warranties and other terms may change after the date of the Business Combination Agreement, which subsequent information may or may not be fully reflected in EBAC’s public disclosures.

 

The foregoing description of the Business Combination Agreement is not complete and is qualified in its entirety by reference to the Business Combination Agreement, which is attached as Exhibit 2.1 to this Current Report and incorporated herein by reference.

 

PIPE Subscription Agreements

 

In connection with the execution of the Business Combination Agreement, EBAC entered into subscription agreements (the “PIPE Subscription Agreements”) with certain investors, including an affiliate of the Sponsor and certain existing equity holders of Oculis (the “PIPE Investors”). Pursuant to the PIPE Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and EBAC agreed to issue and sell to such investors, on the Acquisition Closing Date, an aggregate of 6,330,391 EBAC ordinary shares for a purchase price of $10.00 per share, for aggregate gross proceeds of $63,303,910 (the “PIPE Financing”).

 

The foregoing description of the PIPE Subscription Agreements is subject to and qualified in its entirety by reference to the full text of the form of Subscription Agreement, a copy of which is included as Exhibit 10.1 hereto, and the terms of which are incorporated by reference.

 

Convertible Loan Agreement

 

In connection with the execution of the Business Combination Agreement, Oculis entered into a convertible loan agreement (the “Convertible Loan Agreement”) with certain of its existing equity holders (the “Lenders”). Pursuant to the Convertible Loan Agreement, the Lenders grant Oculis a right to receive a convertible loan with certain conversion rights, in an aggregate amount of $12,670,000. Following the Second Merger Effective Time, it is the intent of the parties thereto that New Parent shall assume the Convertible Loan Agreement, and that immediately after such assumption but before the Company Share Contribution, the Lenders will exercise their conversion rights in exchange for New Parent Shares at $10 per share.

 

 

 

The foregoing description of the Convertible Loan Agreements is subject to and qualified in its entirety by reference to the full text of the form of Convertible Loan Agreement, a copy of which is included as Exhibit 10.2 hereto, and the terms of which are incorporated by reference.

 

Non-Redemption Agreements

 

Concurrently with the execution of the Business Combination Agreement, certain shareholders of EBAC (the “EBAC Voting Shareholders”) entered into non-redemption agreements (the “Non-Redemption Agreements”) with EBAC and Sponsor.

 

Pursuant to the Non-Redemption Agreements, each EBAC Voting Shareholder agreed for the benefit of EBAC to not redeem and to vote all of their EBAC ordinary shares now owned or hereafter acquired (the “Subject EBAC Equity Securities”), representing 700,789 EBAC ordinary shares in the aggregate, in favor of the transaction proposals. In connection with these commitments from the EBAC Voting Shareholders, Sponsor has agreed to transfer to each Investor one New Parent Share for every ten EBAC ordinary shares owned by such investor, on or promptly following the Acquisition Closing Date. The EBAC Voting Shareholders also each agreed to a lock-up to not transfer any Subject EBAC Equity Securities for a period of 90 calendar days after the Acquisition Closing Date.

 

The foregoing description of the Non-Redemption Agreement is subject to and qualified in its entirety by reference to the full text of the form of Subscription Agreement, a copy of which is included as Exhibit 10.3 hereto, and the terms of which are incorporated by reference.

 

Oculis Shareholder Support Agreements

 

Concurrently with the execution of the Business Combination Agreement, certain equityholders of Oculis (the “Oculis Supporting Members”) entered into a support agreement (the “Oculis Shareholder Support Agreement”) in favor of EBAC and Oculis and their respective successors.

 

In the Oculis Shareholder Support Agreement, the Oculis Supporting Members agreed to, among other things (i) vote to adopt the Business Combination Agreement and approve and consent to the consummation of the Transactions, (ii) waive any rights of appraisal or dissenter’s rights and (iii) provide a release of claims against Oculis and its Subsidiaries.

 

The foregoing description of the Oculis Shareholder Support Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Oculis Shareholder Support Agreement, the form of which is filed as Exhibit 10.4 hereto and is incorporated herein by reference.

 

Sponsor Letter Agreement

 

Concurrently with the execution of the Business Combination Agreement, the Sponsor entered into a letter agreement (the “Sponsor Letter Agreement”) with EBAC and Oculis pursuant to which the Sponsor agreed, among other things, to (i) vote all of the EBAC Common Stock it beneficially owns in favor of the Business Combination and related transactions and to take certain other actions in support of the Business Combination Agreement and related transactions, (ii) not transfer its shares of EBAC Common Stock and EBAC Warrants, in each case until the consummation of the Acquisition Closing (subject to certain customary exceptions), (iii) waive certain anti-dilution adjustments and (iv) waive certain redemption rights.

 

The foregoing description of the Sponsor Letter Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Sponsor Letter Agreement, a copy of which is filed as Exhibit 10.5 hereto and is incorporated herein by reference.

 

Amended and Restated Registration Rights and Lock-Up Agreement

 

On the Acquisition Closing Date, the Sponsor and certain shareholders of Oculis (the “Holders”) and New Parent will enter into an amended and restated registration rights agreement and lock-up agreement (the “Amended and Restated Registration Rights and Lock-Up Agreement”) pursuant to which, among other

 

 

 

things, certain shareholders of New Parent will be granted certain customary demand and “piggy-back” registration rights with respect to their respective New Parent Shares.

 

The Amended and Restated Registration Rights and Lock-Up Agreement will contain certain restrictions on transfer of New Parent Shares and other Registrable Securities (as defined therein) to be held by the Holders immediately following the Acquisition Closing (the “Lock-up Securities”). Such restrictions begin on the Acquisition Closing Date and end on the earlier of (x) (i) for the Sponsor the 270 days after the Acquisition Closing Date and (ii) for the rest of the Holders 180 days from the Acquisition Closing Date and (y) the last reported trading price of the New Parent Shares on Nasdaq exceeds $15.00 for 20 trading days within any 30 trading day period commencing at least 150 days after the Acquisition Closing Date.

 

The foregoing description of the Amended and Restated Registration Rights and Lock-Up Agreement is subject to and qualified in its entirety by reference to the full text of the form of Subscription Agreement, a copy of which is included as Exhibit 10.6 hereto, and the terms of which are incorporated by reference.

 

Item 3.02Unregistered Sales of Equity Securities.

 

The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K with respect to the issuance of (i) EBAC Class A Common Stock to the PIPE Investors and (ii) New Parent Shares to the Oculis Supporting Members is incorporated by reference herein. The EBAC Class A Common Stock issuable to the PIPE Investors in connection with the transactions contemplated by the Business Combination Agreement will not be registered under the Securities Act, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.

 

Item 7.01.Regulation FD Disclosure.

 

On October 17, 2022, EBAC and Oculis issued a Joint Press Release (the “Joint Press Release”) announcing the execution of the Business Combination Agreement.

 

Also on October 17, 2022, EBAC released an investor presentation that will be used by EBAC and Oculis with respect to the Business Combination (the “Investor Presentation”).

 

Copies of the Joint Press Release and Investor Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report.

 

The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Forward-Looking Statements

 

The information in this Current Report includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “result,” “follow,” “to be,” “extend,” “shall,” “may” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, expectations and timing related to commercial product launches, potential benefits of the transaction and expectations related to the terms and timing of the transaction. These statements are based on various assumptions, whether or not identified in this Current Report, and on the current expectations of Oculis’s and EBAC’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Oculis and EBAC.

 

 

 

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; the inability of the parties to successfully or timely consummate the proposed business combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination or that the approval of the shareholders of Oculis or EBAC is not obtained; changes to the proposed structure of the proposed business combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the proposed business combination; the risk that the proposed business combination disrupts current plans and operations of Oculis as a result of the announcement and consummation of the proposed business combination; failure to realize the anticipated benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to Oculis; the ability for Oculis Holding AG to meet stock exchange listing standards following the consummation of the proposed business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; Oculis’s ability to manage future growth; the effects of competition on Oculis’ future business; the amount of redemption requests made by EBAC’s public shareholders; the ability of EBAC or the combined company to issue equity or equity-linked securities in connection with the proposed business combination or in the future; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries against Oculis or EBAC; and those factors discussed in EBAC’s Quarterly Report on Form 10-Q for the period ended June 30, 2022, under the heading “Risk Factors” filed with the SEC on August 15, 2022, its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 under the heading “Risk Factors,” and other documents of EBAC filed, or to be filed, with the SEC, including the proxy statement/prospectus to be filed on Form F-4 with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither EBAC nor Oculis presently know or that EBAC nor Oculis currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect EBAC’s or Oculis’s expectations, plans or forecasts of future events and views as of the date of this Current Report. EBAC and Oculis anticipate that subsequent events and developments will cause EBAC’s or Oculis’s assessments to change. However, while EBAC and Oculis may elect to update these forward-looking statements at some point in the future, EBAC and Oculis specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing EBAC’s or Oculis’s assessments as of any date subsequent to the date of this Current Report. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

Additional Information About the Proposed Business Combination and Where To Find It

 

The proposed business combination will be submitted to shareholders of EBAC for their consideration. EBAC intends to file the Registration Statement with the SEC which will include preliminary and definitive proxy statements to be distributed to EBAC’s shareholders in connection with EBAC’s solicitation for proxies for the vote by EBAC’s shareholders in connection with the proposed business combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to Oculis’s shareholders in connection with the completion of the proposed business combination. After the Registration Statement has been filed and declared effective, EBAC will mail a definitive proxy statement and other relevant documents to its shareholders as of the record date established for voting on the proposed business combination. EBAC’s shareholders and other interested persons are advised to read, once available, the preliminary proxy statement / prospectus and any amendments thereto and, once available, the definitive proxy statement / prospectus, in connection with EBAC’s solicitation of proxies for its special meeting of shareholders to be held to approve, among other things, the proposed business combination, because these documents will contain important information about EBAC, Oculis and the proposed business combination. Shareholders may also obtain a copy of the definitive proxy statement/prospectus, once available, as well as other documents filed with the SEC regarding the proposed business combination and other documents filed with the SEC by EBAC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to 660 Madison Ave Suite 1600, New York, NY 10065.

 

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

 

Participants in the Solicitation

 

EBAC, Oculis and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from EBAC’s shareholders in connection with the proposed business combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of EBAC’s shareholders in connection with the proposed business combination will be set forth in EBAC’s proxy statement / prospectus when it is filed with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement / prospectus when they become available. Shareholders, potential investors and other interested persons should read the proxy statement / prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

 

No Offer or Solicitation

 

This Current Report is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

Item 9.01Financial Statements and Exhibits.

 

                     (d) Exhibits

 

Exhibit No. 

Description 

2.1* Business Combination Agreement, dated October 17, 2022 by and among EBAC and Oculis SA.
10.1 Form of PIPE Subscription Agreement by and among EBAC and certain investors party thereto.
10.2 Convertible Loan Agreement, dated October 17, 2022 by and among Oculis SA and certain shareholders party thereto.
10.3 Form of Shareholder Non-Redemption Agreement, by and among Sponsor and certain investors party thereto.
10.4 Oculis Shareholder Support Agreement, dated October 17, 2022 by and among Oculis, EBAC and the other parties thereto.
10.5 Sponsor Support Agreement, dated October 17, 2022 by and among Sponsor, EBAC and Oculis.
10.6 Form of Amended and Restated Registration Rights and Lock-Up Agreement by and among New Parent and the other signatories to be a party thereto.
99.1 Joint Press Release, dated October 17, 2022.
99.2 Investor Presentation, dated October 17, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

______________

*Certain exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). EBAC agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 17, 2022

 

  EUROPEAN BIOTECH ACQUISITION CORP.
   
   
  By: /s/ Eduardo Bravo Fernandez de Araoz
    Name: Eduardo Bravo Fernandez de Araoz
    Title: Chief Executive Officer (Principal Executive Officer)

 

 

 

 

 

 

 

 

Exhibit 2.1

 

Execution Version 

 

 

 

BUSINESS COMBINATION AGREEMENT

 

by and among

 

EUROPEAN BIOTECH ACQUISITION CORP.

 

and

 

OCULIS SA

 

dated as of October 17, 2022

 

 

 

 

 

 

 

TABLE OF CONTENTS

 

 

Page

Article 1

Certain Definitions

Section 1.01.   Definitions 5
Section 1.02.   Construction 25
Section 1.03.   Knowledge 26

Article 2

the Mergers; Share Contribution; Closing

Section 2.01.   The Mergers; Exchange Agent Contribution; Contribution of Company Common Shares to New Parent 26
Section 2.02.   Effective Times; Sponsor Forfeiture; Closings 27
Section 2.03.   Closing Deliverables 30

Article 3

Effects of the Merger on EBAC Securities

Section 3.01.   Conversion of Securities 31
Section 3.02.   Equitable Adjustments 32
Section 3.03.   Delivery of Shares 32
Section 3.04.   Withholding 34
Section 3.05.   Earn Out Shares 35
Section 3.06.   Treatment of Company Options 36

Article 4

Representations and Warranties of the Company

Section 4.01.   Company Organization 38
Section 4.02.   Subsidiaries 38
Section 4.03.   Due Authorization 38
Section 4.04.   No Conflict 39
Section 4.05.   Governmental Authorities; Consents 40
Section 4.06.   Capitalization of the Company 40
Section 4.07.   Capitalization of Subsidiaries 42
Section 4.08.   Financial Statements 42
Section 4.09.   Undisclosed Liabilities 43
Section 4.10.   Litigation and Proceedings 44
Section 4.11.   Legal Compliance 44
Section 4.12.   Contracts; No Defaults 45
Section 4.13.   Company Benefit Plans 47
Section 4.14.   Labor Relations; Employees 49
Section 4.15.   Taxes 50
Section 4.16.   Brokers’ Fees 53

 

 

 

 

Section 4.17.   Insurance 53
Section 4.18.   Permits 53
Section 4.19.   Regulatory Compliance 54
Section 4.20.   Real Property 54
Section 4.21.   Intellectual Property 54
Section 4.22.   Privacy and Cybersecurity 57
Section 4.23.   Environmental Matters 58
Section 4.24.   Absence of Changes 58
Section 4.25.   Anti-Corruption Compliance 58
Section 4.26.   Anti-Money Laundering, Sanctions and National Security Compliance 59
Section 4.27.   Information Supplied 59
Section 4.28.   No Outside Reliance 59
Section 4.29.   No Additional Representation or Warranties 60

Article 5

Representations and Warranties Relating to New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3

Section 5.01.   Corporate Organization 60
Section 5.02.   Due Authorization 61
Section 5.03.   Capitalization 62
Section 5.04.   Consents and Requisite Governmental Approvals; No Violations 62
Section 5.05.   Business Activities 63
Section 5.06.   Brokers’ Fees 63
Section 5.07.   Tax Matters 63
Section 5.08.   Investment Company Act 64
Section 5.09.   Investigation; No Other Representations 64
Section 5.10.   No Outside Reliance 65
Section 5.11.   No Additional Representation or Warranties 65

Article 6

Representations and Warranties of EBAC

Section 6.01.   Company Organization 65
Section 6.02.   [Intentionally Omitted] 66
Section 6.03.   Due Authorization 66
Section 6.04.   No Conflict 67
Section 6.05.   Governmental Authorities; Consents 67
Section 6.06.   Litigation and Proceedings 67
Section 6.07.   SEC Filings 68
Section 6.08.   Internal Controls; Listing; Financial Statements 68
Section 6.09.   Trust Account 69
Section 6.10.   Investment Company Act; JOBS Act 70
Section 6.11.   Absence of Changes 70
Section 6.12.   No Undisclosed Liabilities 71
Section 6.13.   Capitalization of EBAC 71

 

 

 

 

Section 6.14.   Brokers’ Fee 72
Section 6.15.   Indebtedness 72
Section 6.16.   Taxes 72
Section 6.17.   Business Activities 74
Section 6.18.   Stock Market Quotation 75
Section 6.19.   Investigation; No Other Representations 75
Section 6.20.   No Outside Reliance 75
Section 6.21.   No Additional Representation or Warranties 76

Article 7

Covenants of the Company

Section 7.01.   Conduct of Business 76
Section 7.02.   Inspection 79
Section 7.03.   Preparation and Delivery of Additional Company Financial Statements 79
Section 7.04.   Affiliate Agreements 80
Section 7.05.   Acquisition Proposals 80
Section 7.06.   Subsidiary Member Approval 80
Section 7.07.   Stock Exchange Listing of New Parent Shares 81
Section 7.08.   EBAC D&O Indemnification and Insurance 81
Section 7.09.   Agent Deliverables 82

Article 8

Covenants of EBAC

Section 8.01.   Trust Account Proceeds and Related Available Equity 83
Section 8.02.   De-Listing 83
Section 8.03.   No Solicitation by EBAC 83
Section 8.04.   EBAC Conduct of Business 84
Section 8.05.   EBAC Public Filings 86
Section 8.06.   Shareholder Litigation 86
Section 8.07.   New Parent Corporate Documents 86
Section 8.08.   Corporate Formation 87
Section 8.09.   Agent Deliverables 97
Section 8.10.   Extension of Time to Consummate a Business Combination 88

Article 9

Joint Covenants

Section 9.01.   Efforts to Consummate 90
Section 9.02.   Preparation of Proxy Statement/Registration Statement; Shareholders’ Meeting and Approvals 91
Section 9.03.   Support of Transaction 94
Section 9.04.   Cooperation; Consultation 94
Section 9.05.   Additional Equity Financing 95

 

 

 

 

Section 9.06.   Section 16 Matters 95
Section 9.07.   Employee Matters 95
Section 9.08.   Director and Officer Appointments 96
Section 9.09.   Tax Matters 96
Section 9.10.   Third Merger 98
Section 9.11.   Engagement Letters; Subscription Agreements 98
Section 9.12.   Agent Deliverables 99

Article 10

Conditions to Obligations

Section 10.01.   Conditions to Obligations of the Parties 100
Section 10.02.   Conditions to Obligations of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 100
Section 10.03.   Conditions to the Obligations of the Company 101

Article 11

Termination/Effectiveness

Section 11.01.   Termination 102
Section 11.02.   Effect of Termination 103

Article 12

Miscellaneous

Section 12.01.   Trust Account Waiver 103
Section 12.02.   Waiver 104
Section 12.03.   Notices 104
Section 12.04.   Assignment 105
Section 12.05.   Rights of Third Parties 105
Section 12.06.   Expenses 106
Section 12.07.   Governing Law 106
Section 12.08.   Headings; Counterparts 106
Section 12.09.   Company and EBAC Disclosure Letters 106
Section 12.10.   Entire Agreement 107
Section 12.11.   Amendments 107
Section 12.12.   Publicity 107
Section 12.13.   Severability 108
Section 12.14.   Jurisdiction; Waiver of Jury Trial 108
Section 12.15.   Enforcement 108
Section 12.16.   Non-Recourse 109
Section 12.17.   Non-Survival of Representations, Warranties and Covenants 109
Section 12.18.   Conflicts and Privilege 109

 

Exhibits

 

Exhibit A Form of Non-Redemption Agreement
Exhibit B Form of Registration Rights Agreement

 

 

 

 

 

BUSINESS COMBINATION AGREEMENT

 

This Business Combination Agreement, dated as of October 17, 2022 (this “Agreement”), is made and entered into by and among European Biotech Acquisition Corp., a Cayman Islands exempted company (“EBAC”) and Oculis SA, a public limited liability company (société anonyme) incorporated and existing under the laws of Switzerland (the “Company”) that is wholly and directly owned by the Company Shareholders (as defined below). EBAC and the Company are collectively referred to herein as the “Parties” and each individually referred to herein as a “Party.”

 

RECITALS

 

WHEREAS, (a) EBAC is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities and (b) New Parent (as defined below) will be a newly formed entity, wholly owned by EBAC, and formed for the purpose of this Agreement and the transactions contemplated hereby (the “Transactions”) and the other documents and the transactions contemplated thereby, including to act as the publicly traded holding company for the Company and its businesses after the Acquisition Closing (as defined below);

 

WHEREAS, as soon as practicable following the execution of this Agreement, (a) EBAC shall form or cause to be formed (i) Oculis Holding AG, a public limited liability company incorporated and existing under the laws of Switzerland and that will be a direct wholly owned subsidiary of EBAC (“New Parent”), (ii) a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 1”), (iii) another new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 2”) and (iv) a new limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and existing under the laws of Switzerland that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 3”) and (b) EBAC shall cause New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to become a party hereto as a “Party” and “EBAC Party” by executing a joinder agreement;

 

WHEREAS, contemporaneously with the execution and delivery of this Agreement, in connection with the Transactions, EBAC and certain investors (the “PIPE Investors”) have entered into subscription agreements, dated on or around the date hereof (as amended or modified from time to time, the “Subscription Agreements”), pursuant to which the PIPE Investors who are parties thereto have committed, on the terms and subject to the conditions of the Subscription Agreements, to subscribe for and purchase a number of shares of EBAC Class A Common Stock (the “PIPE Shares”) equal to 6,330,391 before the First Merger Effective Time (as defined below);

 

1 

 

WHEREAS, as a condition and inducement to the Company’s willingness to enter into this Agreement, simultaneously with the execution and delivery of this Agreement, the Sponsor and certain of its Affiliates (as applicable) have executed and delivered to the Company a Sponsor Support Agreement, dated as of the date hereof (the “Sponsor Support Agreement”), pursuant to which the Sponsor and certain of its Affiliates (as applicable) have agreed to, among other things, on the terms, and subject to the conditions, set forth therein (i) vote to adopt and approve this Agreement and the other documents contemplated hereby and the transactions contemplated hereby and thereby, (ii) lock up their (a) shares of EBAC Common Stock and (b) EBAC Warrants, in each case, until the consummation of the Acquisition Closing, (iii) waive certain anti-dilution adjustments and (iv) waive certain redemption rights;

 

WHEREAS, subject to the terms and conditions hereof and as an inducement to EBAC’s and the Company’s willingness to enter into this Agreement, certain EBAC Shareholders have entered into non-redemption agreements with EBAC and New Parent in the form attached as Exhibit A hereto (the “Non-Redemption Agreements”);

 

WHEREAS, as a condition and inducement to EBAC’s willingness to enter into this Agreement, simultaneously with the execution and delivery of this Agreement, certain of the Company Shareholders have executed and delivered to EBAC a Company Shareholder support agreement, dated as of the date hereof (collectively, the “Company Shareholders Support Agreement”), pursuant to which such Company Shareholder has agreed to, among other things, on the terms, and subject to the conditions, set forth therein (i) adopt this Agreement and approve and consent to the Mergers and the consummation of the Transactions, (ii) execute and deliver the exchange notice contemplated by ‎Section 2.01, (iii) vote in favor of the Third Merger and the transactions contemplated thereby pursuant to ‎Section 9.10 and (iv) provide a release of claims against the Company and its Subsidiaries;

 

WHEREAS, subject to the terms and conditions hereof, on the day before the Acquisition Closing Date (as defined below) and at the First Merger Effective Time, Merger Sub 1 will merge with and into EBAC, the separate corporate existence of Merger Sub 1 will cease and EBAC will be the surviving company and wholly owned subsidiary of New Parent (the “First Merger”);

 

WHEREAS, as part of the First Merger, (i) each share of EBAC Common Stock (including those held by the PIPE Investors) shall be automatically converted into one class of common stock of EBAC, as the surviving company of the First Merger (the “Surviving EBAC Shares”), (ii) each EBAC Warrant outstanding immediately prior to the First Merger Effective time will be automatically converted into warrants of EBAC, as the surviving company of the First Merger (“Surviving EBAC Warrants”) and (iii) EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants on the terms, and subject to the conditions set forth herein and in the Ancillary Agreements;

 

2 

 

WHEREAS, on the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the Second Merger Effective Time (as defined below), the Exchange Agent will contribute the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent (the “Exchange Agent Contribution”) in exchange for (i) New Parent Class A Shares, nominal value CHF 0.01 per share (the “New Parent Shares”) and (ii) a right to acquire New Parent Shares (each, a “New Parent Warrant”), in each case of (i) and (ii), to be held by the Exchange Agent solely on behalf of the holders of Surviving EBAC Shares and Surviving EBAC Warrants (the “New Parent Interests Consideration”);

 

WHEREAS, in connection with the Exchange Agent Contribution, on the day before the Acquisition Closing Date and prior to the Second Merger Effective Time, the Exchange Agent will (i) undertake to distribute the New Parent Shares as part of the New Parent Interests Consideration to the holders of Surviving EBAC Shares on the terms as further specified in Section 3.03(b) and (ii) distribute the New Parent Warrants as part of the New Parent Interests Consideration to the holders of Surviving EBAC Warrants (the “Exchange Agent Contribution Actions”);

 

WHEREAS, on the day before the Acquisition Closing Date and following the completion of the Exchange Agent Contribution Actions, at the Second Merger Effective Time, EBAC will merge with and into Merger Sub 2, the separate corporate existence of EBAC will cease and Merger Sub 2 will be the surviving company and remain a wholly owned subsidiary of New Parent (the “Second Merger” and, together with the First Merger, the “EBAC Mergers”);

 

WHEREAS, at approximately 10:00am ET on the Acquisition Closing Date, those Company Shareholders executing Company Shareholders Support Agreements and the exchange notice contemplated by ‎Section 2.01 shall effect the Company Share Contribution (as defined below);

 

WHEREAS, approximately thirty (30) days after the Acquisition Closing Date, pursuant to a merger agreement to be entered into in accordance with ‎Section 9.10, the Company will merge with and into Merger Sub 3, the separate corporate existence of the Company will cease and Merger Sub 3 will be the surviving company and remain a wholly owned subsidiary of New Parent (the “Third Merger” and together with the EBAC Mergers, the “Mergers”)

 

WHEREAS, the Parties intend that, for U.S. federal income Tax purposes (i) the EBAC Mergers, taken together, will qualify as a “reorganization” within the meaning of Section 368(a)(1)(F) of the Internal Revenue Code of 1986 (the “Code”) and the applicable Treasury Regulations, (ii) the Company Share Contribution and the Third Merger, taken together, will qualify as a “reorganization” within the meaning of Section 368(a) of the Code and the applicable Treasury Regulations, (iii) with respect to each of the EBAC Mergers, the Company Share Contribution, and the Third Merger, this Agreement will constitute a “plan of reorganization” within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a) and for purposes of Sections 354, 361, and 368 of the Code and the applicable Treasury Regulations, and (iv) with respect to the Convertible Loans, (A) the Convertible Loans will be treated as issued solely by New

 

3 

 

Parent after the Second Merger Effective Time but before the Company Share Contribution on the Acquisition Closing Date and not at any other time or by any other Person or entity (including, for the avoindance of doubt, the Company), (B) the Convertible Loans will not be treated as issued until the receipt by New Parent of cash to fund the Convertible Loans from the respective lender parties thereto, (C) until such time as cash to fund the Convertible Loans has been paid to New Parent, the “Escrow Agent” (as defined in the Convertible Loan Agreement) will hold any such cash on behalf of the Lenders that funded such payment, and such Lenders will be treated as the owners of such cash unless and until such cash is delivered to New Parent pursuant to the Convertible Loan Agreement (together, the “Intended Tax Treatment”);

 

WHEREAS, the Board of Directors of the Company has (a) determined that it is advisable for and in the best interests of the Company and its shareholders to enter into this Agreement and the other documents to which the Company is a party contemplated hereby and (b) approved the execution and delivery of this Agreement and the other documents to which the Company is a party contemplated hereby and the transactions contemplated hereby and thereby;

 

WHEREAS, the EBAC Board has (a) determined that it is advisable and in the best interests of the EBAC Parties and their shareholders for the EBAC Parties to enter into this Agreement and the other documents to which the EBAC Parties are a party contemplated hereby and consummate the transactions contemplated hereby and thereby, (b) approved the execution, delivery and performance of this Agreement and the other documents to which the EBAC Parties are a party contemplated hereby and the transactions contemplated hereby and thereby, and (c) recommended the approval and adoption of this Agreement and the other documents to which the EBAC Parties are a party contemplated hereby and the transactions contemplated hereby and thereby by the EBAC Shareholders and sole shareholder of the other EBAC Parties;

 

WHEREAS, in furtherance of the Transactions and in accordance with the terms hereof, EBAC shall provide an opportunity to its shareholders to have their outstanding shares of EBAC Common Stock redeemed on the terms and subject to the conditions set forth in this Agreement and EBAC’s Governing Documents (as defined below) in connection with the Transactions;

 

WHEREAS, at the Acquisition Closing, New Parent, the EBAC Class B Holders and certain of their respective Affiliates shall enter into a Registration Rights Agreement (the “Registration Rights Agreement”) in substantially the form attached hereto as Exhibit B (with such changes as may be mutually agreed in writing by EBAC and the Company), which shall be effective as of the Acquisition Closing; and

 

NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth in this Agreement, the receipt and sufficiency of which are hereby acknowledged and, intending to be legally bound hereby, the Parties agree as follows:

 

4 

 

Article 1
Certain Definitions

 

Section 1.01.      Definitions. As used herein, the following terms shall have the following meanings:

 

Acquisition Closing” has the meaning specified in Section 2.02(d).

 

Acquisition Closing Date” has the meaning specified in Section 2.02(d).

 

Acquisition Proposal” means, with respect to the Company and its Subsidiaries, other than the Transactions and other than the acquisition or disposition of equipment or other tangible personal property in the ordinary course of business, any offer or proposal relating to: (a) any acquisition or purchase, direct or indirect, of (i) fifteen percent (15%) or more of the consolidated assets of the Company and its Subsidiaries or (ii) fifteen percent (15%) or more of any class of equity or voting securities of (x) the Company or (y) one (1) or more Subsidiaries of the Company holding assets or producing revenue constituting, individually or in the aggregate, fifteen percent (15%) or more of the consolidated assets or revenue of the Company and its Subsidiaries; (b) any tender offer (including a self-tender offer) or exchange offer that, if consummated, would result in any Person beneficially owning fifteen percent (15%) or more of any class of equity or voting securities of (i) the Company or (ii) one or more Subsidiaries of the Company holding assets or producing revenue constituting, individually or in the aggregate, fifteen percent (15%) or more of the consolidated assets or revenue of the Company and its Subsidiaries; or (c) a merger, consolidation, share exchange, business combination, sale of substantially all the assets, reorganization, recapitalization, liquidation, dissolution or other similar transaction involving the sale or disposition of (i) the Company or (ii) one or more Subsidiaries of the Company holding assets or producing revenue constituting, individually or in the aggregate, fifteen percent (15%) or more of the consolidated assets or revenue of the Company and its Subsidiaries.

 

Acquisition Transactions” means the transactions contemplated by the EBAC Mergers.

 

Action” means any claim, action, suit, audit, examination, assessment, arbitration, mediation, inquiry, proceeding or investigation by or before any Governmental Authority.

 

Additional At-Risk Sponsor Shares” means 1,594,348 shares of EBAC Class B Common Stock.

 

Additional At-Risk Sponsor Forfeit Amount” means a number equal to (x) the Additional At-Risk Sponsor Shares minus (y) the product of (i) the Additional At-Risk Sponsor Shares and (ii) a fraction, the numerator of which is equal to the Closing Trust Proceeds and the denominator of which is equal 25,500,000.

 

5 

 

Additional Proposal” has the meaning specified in ‎Section 9.02(c).

 

Additional Sponsor Incentive Shares” has the meaning specified in ‎Section 2.02(c)(ii).

 

Additional Subscription Agreement” means a subscription agreement in respect of the purchase or sale of EBAC Class A Common Stock, New Parent Shares, warrants or other securities in compliance with the exceptions set forth in Sections ‎7.01(k), ‎8.04(a)(vii) and ‎8.04(a)(viii).

 

Adjournment Proposal” has the meaning specified in ‎Section 9.02(c).

 

Affiliate” means, with respect to any specified Person, any Person that, directly or indirectly, controls, is controlled by, or is under common control with, such specified Person, whether through one or more intermediaries or otherwise. The term “Control” (including the terms “controlling,” “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by Contract or otherwise.

 

Affiliate Agreements” has the meaning specified in ‎Section 4.12(a)(vii).

 

Affiliated Group” means a group of Persons that elects, is required to, or otherwise files a Tax Return or pays a Tax as an affiliated, consolidated, combined, unitary or other group recognized by Law in respect of Tax.

 

Agent” means any Placement Agent or Financial Advisor.

 

Agent Deliverables” means the documents deliverable pursuant to Sections 7.09 and 8.09.

 

Agreement” has the meaning specified in the Preamble hereto.

 

Agreement End Date” has the meaning specified in ‎Section 11.01(b).

 

Ancillary Agreements” has the meaning specified in ‎Section 12.10.

 

Anti-Bribery Laws” means all applicable anti-corruption and bribery Laws (including, as applicable, the United Kingdom Bribery Act 2010, the U.S. Foreign Corrupt Practices Act, as amended, national laws governing bribery of private and public employees, and any rules or regulations promulgated thereunder or other Laws of other countries implementing the OECD Convention on Combating Bribery of Foreign Officials).

 

Anti-Money Laundering Laws” means all applicable Laws concerning or relating to the prevention of money laundering or countering the financing of terrorism, including applicable Laws governing customer due diligence, licensing and registration, financial recordkeeping, and suspicious activity reporting.

 

6 

 

At-Risk Sponsor Shares” means 797,174 shares of EBAC Class B Common Stock.

 

Audited Financial Statements” has the meaning specified in ‎Section 4.08(a)(i).

 

Business Combination” has the meaning set forth in Article 1.1 of EBAC’s Governing Documents as in effect on the date hereof.

 

Business Combination Proposal” means any offer, inquiry, proposal or indication of interest (whether written or oral, binding or non-binding, and other than an offer, inquiry, proposal or indication of interest with respect to the Transactions), relating to a Business Combination.

 

Business Day” means a day other than a Saturday, Sunday or any other day on which commercial banks in either New York, New York, or Lausanne, Switzerland or the Governmental Authorities in the Cayman Islands (for so long as EBAC remains domiciled in Cayman Islands) are authorized or required by Law to close.

 

CARES Act” means the Coronavirus Aid, Relief, and Economic Security Act (Pub. L. 116-136), together with all rules and regulations and guidance issued by any Governmental Authority with respect thereto.

 

Cayman Companies Act” means the Companies Act (as revised) of the Cayman Islands.

 

Cayman Plan of Merger” has the meaning specified in ‎Section 2.02(b)(i).

 

Change of Control” means any transaction or series of transactions (a) following which a Person or “group” (within the meaning of Section 13(d) of the Exchange Act), other than the Company and its Subsidiaries, has direct or indirect beneficial ownership of securities (or rights convertible or exchangeable into securities) representing fifty percent (50%) or more of the voting power of or economic rights or interests in New Parent and its Subsidiaries that, in the aggregate, constitute at least 50% of the consolidated assets of New Parent (excluding any “holding company” reorganizations or similar reorganizations that do not affect the ultimate beneficial ownership of New Parent), (b) constituting a merger, consolidation, reorganization or other business combination, however effected, following which the voting securities of New Parent immediately prior to such merger, consolidation, reorganization or other business combination do not continue to represent or are not converted into fifty percent (50%) or more of the combined voting power of the then outstanding voting securities of the Person resulting from such combination or, if the surviving company is a Subsidiary, the ultimate parent thereof, or (c) the result of which is a sale of all or substantially all of the assets of New Parent to any Person.

 

7 

 

Claim” has the meaning specified in ‎Section 12.01.

 

Closing Trust Proceeds” has the meaning specified in ‎Section 2.02(c)(ii).

 

Code” has the meaning specified in the Recitals hereto.

 

Collaboration Partners” means the Company’s or its Subsidiaries’ research, development, collaboration or similar commercialization partners with respect to Products.

 

Collective Bargaining Agreement” means any collective bargaining agreement or any similar labor-related agreement or arrangement with any labor or trade union, employee representative body, works council or labor organization, in each case to which the Company or its Subsidiaries is party or by which it is bound.

 

Commercial Register Zug” has the meaning specified in ‎Section 2.02(b)(ii).

 

Company” has the meaning specified in the Preamble hereto.

 

Company Benefit Plan” has the meaning specified in Section 4.13(a).

 

Company Common Shares” has the meaning specified in ‎Section 4.06(a).

 

Company Consideration” has the meaning specified in ‎Section 2.01.

 

Company Cure Period” has the meaning specified in ‎Section 11.01(f).

 

Company Disclosure Letter” has the meaning specified in the introduction to ‎Article 4.

 

Company Equity Plan” means the Company’s Stock Option and Incentive Plan Regulation 2018.

 

Company Equity Value” means an amount equal to (i) $208,000,000 plus (ii) the Equity Investment Amount, minus (iii) the aggregate value of the vested Company Options in accordance with ‎Section 3.06(c).

 

Company Fundamental Representations” means the representations and warranties made pursuant to the first and second sentences of ‎Section 4.01 (Company Organization), ‎Section 4.03 (Due Authorization), ‎Section 4.06(a) and (c) (Capitalization of the Company), ‎Section 4.07(b) (Capitalization of Subsidiaries) and ‎Section 4.16 (Brokers’ Fees).

 

Company Group” has the meaning specified in ‎Section 12.18(a).

 

Company IP” means the Company Owned IP and the Company Licensed IP.

 

8 

 

Company IT Systems” means any and all computers, hardware, software, firmware, middleware, systems, workstations, servers, routers, hubs, switches, networks, platforms, peripherals, data communication lines, and other information technology equipment and related systems and services, and all associated documentation, in each case, that are owned or controlled by (or purported to be owned or controlled by), or licensed or leased to (or purported to be licensed or leased to), the Company or any of its Subsidiaries.

 

Company Licensed IP” means any and all Intellectual Property owned by a third party and licensed or sublicensed (or purported to be licensed or sublicensed) to the Company or any of its Subsidiaries or for which the Company or any of its Subsidiaries has obtained (or purported to have obtained) a covenant not to be sued.

 

Company Material Adverse Effect” means any event, state of facts, development, circumstance, occurrence or effect (collectively, “Events”) that (a) has had, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, assets, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole or (b) does or would reasonably be expected to, individually or in the aggregate, prevent the ability of the Company to consummate the Transactions; provided, however, that in no event would any of the following, alone or in combination, be deemed to constitute, or be taken into account in determining whether there has been or will be, a “Company Material Adverse Effect”: (i) any change in applicable Laws or IFRS or any interpretation thereof following the date of this Agreement, (ii) any change in interest rates or economic, political, business or financial market conditions generally, (iii) the taking of any action required by this Agreement, (iv) any natural disaster (including hurricanes, storms, tornados, flooding, earthquakes, volcanic eruptions or similar occurrences) or change in climate, (v) any epidemic, pandemic or disease outbreak (including the COVID-19 pandemic), or any Law or mandate, directive, pronouncement or guideline issued by a Governmental Authority, the Centers for Disease Control and Prevention, the World Health Organization or industry group providing for business closures, “sheltering-in-place,” curfews or other restrictions that relate to, or arise out of, an epidemic, pandemic or disease outbreak (including the COVID-19 pandemic) or any change in such Law or directive, pronouncement or guideline or interpretation thereof after the date hereof or any material worsening of such conditions after the date hereof, (vi) any acts of terrorism or war, the outbreak or escalation of hostilities, geopolitical conditions, local, national or international political conditions, (vii) any failure of the Company to meet any projections or forecasts (provided that this clause (vii) shall not prevent a determination that any Event not otherwise excluded from this definition of Company Material Adverse Effect underlying such failure to meet projections or forecasts has resulted in a Company Material Adverse Effect), (viii) any Events generally applicable to the industries or markets in which the Company and its Subsidiaries operate (including increases in the cost of products, supplies, materials or other goods purchased from third-party suppliers), (ix) the announcement of this Agreement and consummation of the Transactions, including any termination of, reduction in or similar adverse impact (but in each case only to the extent attributable to such announcement or consummation) on relationships,

 

9 

 

contractual or otherwise, with any landlords, customers, suppliers, distributors, partners or employees of the Company and its Subsidiaries (it being understood that this clause (ix) shall be disregarded for purposes of the representation and warranty set forth in ‎Section 4.04 and the condition to Acquisition Closing with respect thereto), (x) any matter set forth on the Company Disclosure Letter that would not reasonably be expected to have a material adverse effect on the business, assets, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole, or (xi) any action taken by, or at the written request of, EBAC; provided, further, that any Event referred to in clauses (i), (ii), (iv), (v), (vi) or (viii) above may be taken into account in determining if a Company Material Adverse Effect has occurred to the extent it has a disproportionate and adverse effect on the business, assets, results of operations or financial condition of the Company and its Subsidiaries, taken as a whole, relative to similarly situated companies in the industry in which the Company and its Subsidiaries conduct their respective operations, but only to the extent of the incremental disproportionate effect on the Company and its Subsidiaries, taken as a whole, relative to similarly situated companies in the industry in which the Company and its Subsidiaries conduct their respective operations.

 

Company Options” means each outstanding and unexercised option to purchase Company Common Shares, whether issued pursuant to the Company Equity Plan or otherwise, whether then vested or fully exercisable, granted prior to the Acquisition Closing Date to any current or former Service Provider of the Company (each such Service Provider, a “Company Optionholder”).

 

Company Owned IP” means any and all Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries.

 

Company Preferred Shares” has the meaning specified in ‎Section 4.06(a).

 

Company Registered Intellectual Property” has the meaning specified in ‎Section 4.21(a).

 

Company Share Capital” has the meaning specified in ‎Section 4.06(a).

 

Company Share Contribution” has the meaning specified in ‎Section 2.01.

 

Company Shareholders” means, collectively, the holders of shares of Company Share Capital as of any applicable determination time prior to the Acquisition Closing.

 

Company Shareholders Support Agreement” has the meaning specified in the Recitals hereto.

 

Company Transaction Expenses” means the following out-of-pocket fees and expenses paid or payable by the Company or any of its Subsidiaries (whether or not billed or accrued for) as a result of or in connection with the negotiation, documentation and consummation of the transactions contemplated hereby: (a) all fees, costs, expenses,

 

10 

 

brokerage fees, commissions, finders’ fees and disbursements of the Company’s financial advisors, investment banks, data room administrators, attorneys, accountants, and other advisors and service providers; (b) the filing fees incurred in connection with making any filings under ‎Section 9.01; (c) the fees and expenses in connection with preparing and filing the Registration Statement, the Proxy Statement or the Proxy Statement/Registration Statement under ‎Section 9.02 and obtaining approval of the Stock Exchange under ‎Section 7.07; (d) change-in-control payments, transaction bonuses, retention payments, severance or similar compensatory payments payable by the Company or any of its Subsidiaries to any current or former Service Provider as a result of the transactions contemplated hereby (and not tied to any subsequent event or condition, such as a termination of employment), including the employer portion of any employment or payroll Taxes arising therefrom; (e) amounts owing or that may become owed, payable or otherwise due, directly or indirectly, by the Company or any of its Subsidiaries to any Affiliate of the Company or any of its Subsidiaries in connection with the consummation of the transactions contemplated hereby, including fees, costs and expenses related to the termination of any Affiliate Agreement; and (f) any other fees and expenses as a result of or in connection with the negotiation, documentation and consummation of the transactions contemplated hereby, in each case of clauses (a) through (f), solely to the extent such fees and expenses are incurred and unpaid as of the Acquisition Closing. Company Transaction Expenses shall not include any fees or expenses of the Company’s equityholders.

 

Confidentiality Agreement” has the meaning specified in ‎Section 12.10.

 

Contracts” means any written contracts, agreements, subcontracts, leases, and purchase orders.

 

Control” has the meaning specified in the definition of “Affiliate.”

 

Convertible Loan” or “Convertible Loans” means the “Loan” or “Loans” as defined in the Convertible Loan Agreement.

 

Convertible Loan Agreement” means the Convertible Loan Agreement, dated as of October 17, 2022, by and among the Company, Vischer, Earlybird Growth GmbH, Pivotal bioVenture Partners Fund I L.P., NFLS Beta Limited, and any other “Adhering Shareholders” (as defined in the Convertible Loan Agreement), including any successor or replacement agreement.

 

Cooley” has the meaning specified in ‎Section 12.18(b).

 

Cooley Privileged Communications” has the meaning specified in ‎Section 12.18(b).

 

COVID-19” means SARS-CoV-2 or COVID-19, and any evolutions or mutations thereof or related or associate epidemics, pandemic or disease outbreaks.

 

11 

 

COVID-19 Measures” means any quarantine, “shelter in place,” “stay at home,” workforce reduction, social distancing, shut down, closure, sequester or any similar Law, mandate, directive, guidelines or recommendations by any Governmental Authority in connection with or in response to COVID-19, including the CARES Act.

 

COVID-19 Reasonable Response” means any reasonable action or inaction, including the establishment of any policy, procedure or protocol, by the Company and its Subsidiaries that the Company determines in its reasonable discretion is necessary, advisable or prudent in connection with (i) mitigating the adverse effects of COVID-19 or applicable COVID-19 Measures, (ii) ensuring compliance by the Company and its Subsidiaries with COVID-19 Measures applicable to any of them and/or (iii) in respect of COVID-19, protecting the health and safety of employees or other persons with whom the Company and its Subsidiaries and their personnel come into contact with during the course of business operations.

 

Davis Polk” has the meaning specified in ‎Section 12.18(a).

 

Davis Polk Privileged Communications” has the meaning specified in ‎Section 12.18(a).

 

Disclosure Letter” means, as applicable, the Company Disclosure Letter or the EBAC Disclosure Letter.

 

Dollars” or “$” means lawful money of the United States; provided that any amount of currency that is calculated in accordance herewith or for purposes hereof that is not in U.S. dollars will be converted into U.S. dollars calculated using the spot currency exchange rate applicable to obligations payable in any foreign currency published by Bloomberg L.P. five (5) Business Days prior to the date hereof.

 

Earnout Achievement Date” means each of the First Earnout Achievement Date, Second Earnout Achievement Date, and Third Earnout Achievement Date.

 

“Earnout Options" has the meaning specified in Section 3.06.

 

Earnout Shares” means 4,000,000 New Parent Shares authorized for issuance by New Parent on the terms, and subject to the conditions set forth in Section 3.05.

 

EBAC” has the meaning specified in the Preamble hereto.

 

EBAC Articles” means the amended and restated memorandum and articles of association of EBAC, dated as of March 18, 2021, as in effect on the date of this Agreement.

 

EBAC Board” means the Board of Directors of EBAC.

 

EBAC Board Recommendation” has the meaning specified in ‎Section 9.02(d).

 

12 

 

EBAC Class A Common Stock” means Class A ordinary shares, par value $0.0001 per share, of EBAC.

 

EBAC Class B Common Stock” means Class B ordinary shares, par value $0.0001 per share, of EBAC.

 

EBAC Class B Holders” means holders of shares of EBAC Class B Common Stock.

 

EBAC Common Stock” means EBAC Class A Common Stock and EBAC Class B Common Stock.

 

EBAC Cure Period” has the meaning specified in ‎Section 11.01(g).

 

EBAC D&O Persons” has the meaning specified in ‎Section 7.08(a).

 

EBAC Disclosure Letter” has the meaning specified in the introduction to ‎Article 6.

 

EBAC Financial Statements” means (i) the audited balance sheet as of December 31, 2021, and the related audited statements of operations, changes in shareholder’s equity and cash flows of EBAC for the period ended December 31, 2021, together with the auditor’s reports thereon, and (ii) the unaudited balance sheet as of June 30, 2022, and the related unaudited statements of operations, changes in shareholder’s deficit and cash flows of EBAC for the six months ended June 30, 2022.

 

EBAC Fundamental Representations” means the representations and warranties set forth in ‎Section 6.01 (Company Organization), Section 6.03 (Due Authorization), ‎Section 6.13(b) and (c) (Capitalization) and ‎Section 6.14 (Brokers’ Fees).

 

EBAC Group” has the meaning specified in ‎Section 12.18(a).

 

EBAC Mergers” has the meaning specified in the Recitals hereto.

 

EBAC Parties” means, collectively, EBAC and, upon execution of a joinder to this Agreement pursuant to ‎Section 8.08(d), New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3.

 

EBAC Private Placement Warrant” means a warrant to purchase one (1) share of EBAC Class A Common Stock at an exercise price of eleven Dollars fifty cents ($11.50) issued to the Sponsor.

 

EBAC Public Warrant” means a warrant to purchase one (1) share of EBAC Class A Common Stock at an exercise price of eleven Dollars fifty cents ($11.50) that was included in the units sold as part of EBAC’s initial public offering.

 

EBAC SEC Filings” has the meaning specified in ‎Section 6.06.

 

13 

 

EBAC Securities” has the meaning specified in ‎Section 6.12(a).

 

EBAC Share Redemption” means the election of an eligible (as determined in accordance with EBAC’s Governing Documents) holder of shares of EBAC Class A Common Stock to redeem all or a portion of the shares of EBAC Class A Common Stock held by such holder at a per-share price, payable in cash, equal to a pro rata share of the aggregate amount on deposit in the Trust Account (including any interest earned on the funds held in the Trust Account) (as determined in accordance with EBAC’s Governing Documents) in connection with the Transactions.

 

EBAC Share Redemption Amount” means the aggregate amount payable with respect to all EBAC Share Redemptions.

 

EBAC Shareholder Approval” means the approval of those Transaction Proposals identified in clauses ‎(i) through ‎(iii) of ‎Section 9.02(c) by an affirmative vote of the applicable majority of the outstanding EBAC Common Stock entitled to vote, who attend and vote thereupon (as determined in accordance with EBAC’s Governing Documents), in each case, at an EBAC Shareholders’ Meeting duly called by the EBAC Board and held for such purpose.

 

EBAC Shareholders” means the shareholders of EBAC as of any applicable determination time prior to the Acquisition Closing.

 

EBAC Shareholders’ Meeting” has the meaning specified in ‎Section 9.02(c).

 

EBAC Transaction Expenses” means the following out-of-pocket fees and expenses paid or payable by EBAC or its Affiliates (whether or not billed or accrued for) (A) to the extent directly arising out of the negotiation, documentation and consummation of the transactions contemplated hereby or EBAC’s initial public offering: (a) all fees, costs, expenses, brokerage fees, commissions, finders’ fees and disbursements (“Expenses”) of EBAC’s financial advisors, investment banks, data room administrators, attorneys, accountants, auditors and other advisors and service providers (“Advisors”) (including any deferred underwriting commissions and placement fees incurred in connection with the PIPE Investment); (b) the filing fees incurred by EBAC in connection with making any filings under ‎Section 9.01; (c) the fees and expenses incurred in connection with preparing and filing the Registration Statement, the Proxy Statement or the Proxy Statement/Registration Statement under ‎Section 9.02; (d) repayment of any Working Capital Loans; and (e) any other fees and expenses to third-party advisors or third-party service providers as a result of or in connection with the negotiation, documentation and consummation of the transactions contemplated hereby, (B) to the extent arising out of the customary operations of EBAC (as a special purpose acquisition company, including expenses related to exploration of initial business combination opportunities) and related activities, including Expenses of Advisors; and (C) to the extent arising out of the customary operations of EBAC (as a special purpose acquisition company) and related activities, including Expenses of Advisors, in each case of clauses (A) through (C), solely to the extent such fees and expenses are incurred and unpaid as of the Acquisition Closing.

 

14 

 

EBAC Unit” means the units issued in EBAC’s initial public offering consisting of one share of EBAC Class A Common Stock and one-third of an EBAC Warrant.

 

EBAC Warrant Agreement” means the Warrant Agreement, dated as of March 15, 2021, between EBAC and Continental Stock Transfer & Trust Company, as warrant agent.

 

EBAC Warrants” means the EBAC Public Warrants and the EBAC Private Placement Warrants.

 

Equity Investment Agreement” means the Investment Agreement Extension, dated as of June 30, 2022, between the Company and LSP 7 Coöperatief U.A.

 

Equity Investment Amount” means the aggregate proceeds received by the Company pursuant to the Equity Investment Agreement, as adjusted in accordance with Schedule 2.01 of the Company Disclosure Letter.

 

Enforceability Exceptions” has the meaning specified in ‎Section 4.03(a).

 

Environmental Laws” means any and all applicable Laws relating to Hazardous Materials, pollution, or the protection or management of the environment or natural resources, or protection of human health (with respect to exposure to Hazardous Materials).

 

Equity Securities” means any share, share capital, capital stock, partnership, membership, joint venture or similar interest in any Person (including any stock appreciation, phantom stock, profit participation or similar rights) and any option, warrant, right or security (including debt securities) convertible, exchangeable or exercisable therefor.

 

Exchange Act” means the Securities Exchange Act of 1934.

 

Exchange Agent” has the meaning specified in ‎Section 3.04(a).

 

Exchange Agent Agreement” has the meaning specified in ‎Section 3.04(a).

 

Exchange Agent Contribution” has the meaning specified in the Recitals hereto.

 

Exchange Agent Contribution Actions” has the meaning specified in the Recitals hereto.

 

Exchange Fund” has the meaning specified in ‎Section 3.04(a).

 

15 

 

Extension Proposal” has the meaning set forth in Section 6.23(a).

 

Extension Proxy Statement” has the meaning set forth in Section 6.23(a).

 

Extension Shareholders’ Meeting” has the meaning set forth in Section 6.23(c).

 

FDCA” means the United States Federal Food, Drug and Cosmetic Act.

 

Financial Advisor” means BofA Securities, Inc. in its capacity as financial advisor to the Company.

 

Financial Advisor Engagement Letters” means, (i) that certain letter agreement dated as of May 27, 2022, by and between the Company and BofA Securities, Inc.; and (ii) that certain letter agreement dated as of October 16, 2022, by and between the Company and BofA Securities, Inc

 

Financial Statements” has the meaning specified in ‎Section 4.08(a)(ii).

 

First Earnout Achievement Date” has the meaning set forth in Section 3.05(b).

 

First Merger” has the meaning specified in the Recitals hereto.

 

First Merger Effective Time” means the time at which the First Merger becomes effective pursuant to the filing and registration of the Plan of Merger with the Cayman Registrar of Companies or at such later time as may be agreed by New Parent and the Company in writing and specified in such Plan of Merger.

 

Food and Drug Law” has the meaning specified in ‎Section 4.19(a).

 

GAAP” means generally accepted accounting principles in the United States as in effect from time to time.

 

Governing Documents” means the legal document(s) by which any Person (other than an individual) establishes its legal existence or which govern its internal affairs. For example, the “Governing Documents” of a corporation are its certificate of incorporation and bylaws, the “Governing Documents” of a limited partnership are its limited partnership agreement and certificate of limited partnership, the “Governing Documents” of a limited liability company are its operating agreement and certificate of formation and the “Governing Documents” of an exempted company are its memorandum and articles of association.

 

Government Funded IP” has the meaning specified in ‎Section 4.21(g).

 

16 

 

Governmental Authority” means any federal, state, provincial, municipal, local or foreign government, governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court or tribunal.

 

Governmental Authorization” has the meaning specified in ‎Section 4.05.

 

Governmental Order” means any order, judgment, injunction, decree, writ, stipulation, determination or award, in each case, entered by or with any Governmental Authority.

 

Hazardous Materials” means any (a) pollutant, contaminant, chemical, (b) industrial, solid, liquid or gaseous toxic or hazardous substance, material or waste, (c) petroleum or any fraction or product thereof, (d) asbestos or asbestos-containing material, (e) polychlorinated biphenyl, (f) chlorofluorocarbons, (g) per- and polyfluoroalkyl substances (including PFAs, PFOA, PFOS, Gen X, and PFBs) and (h) other substance, material or waste, in each case of (a) - (h), which are regulated under any Environmental Law because of its dangerous or deleterious properties or characteristics or as to which liability may be imposed pursuant to Environmental Law.

 

IFRS” means international financial reporting standards, consistently applied.

 

Indebtedness” means, with respect to any Person, without duplication, any obligations, contingent or otherwise, in respect of (a) the principal of and premium (if any) in respect of all indebtedness for borrowed money, including accrued interest and any per diem interest accruals, (b) amounts drawn (including any accrued and unpaid interest) on letters of credit, bank guarantees, bankers’ acceptances and other similar instruments (solely to the extent such amounts have actually been drawn), (c) the principal of and premium (if any) in respect of obligations evidenced by bonds, debentures, notes and similar instruments, (d) the marked to market value of interest rate protection agreements and currency obligation swaps, hedges or similar arrangements (without duplication of other indebtedness supported or guaranteed thereby), (e) the principal component of all obligations to pay the deferred and unpaid purchase price of property and equipment which have been delivered, including “earn outs” and “seller notes,” except in connection with the purchase of any business, any post-Acquisition Closing payment adjustments to which the Company may become entitled to the extent such payment is determined by a final Closing balance sheet or such payment depends on the performance of such business after the Acquisition Closing, (f) breakage costs, prepayment or early termination premiums, penalties, or other fees or expenses payable as a result of the consummation of the Transactions in respect of any of the items in the foregoing clauses (a) through (e), and (g) all Indebtedness of another Person referred to in clauses (a) through (f) above guaranteed directly or indirectly, jointly or severally.

 

17 

 

Intellectual Property” means any and all intellectual property or proprietary rights throughout the world, including any and all United States and foreign: (i) patents, patent applications, invention disclosures, and all provisionals, non-provisionals, continuations, continuations-in-part, divisionals, reissues, renewals, re-examinations, substitutions, and extensions thereof; (ii) trademarks, logos, service marks, trade dress, trade names, service names, slogans, internet domain names, and other similar designations of source or origin, together with all goodwill symbolized by or associated with any of the foregoing; (iii) copyrights and rights in copyrightable subject matter, including such corresponding rights in software and other works of authorship; (iv) rights in algorithms, databases, compilations and data; (v) trade secrets and all rights to other confidential and proprietary information, know-how, proprietary processes, inventions (whether or not patentable or reduced to practice), discoveries, specifications, improvements, methods, formulae, models, and methodologies (“Trade Secrets”); (vi) rights of publicity and privacy, (vii) moral rights and rights of attribution and integrity; (viii) social media addresses and accounts and usernames, account names and identifiers; and (ix) all applications and registrations, and any renewals, extensions and reversions, of the foregoing.

 

Intended Tax Treatment” has the meaning specified in the Recitals hereto.

 

Interim Period” has the meaning specified in ‎Section 7.01.

 

Investment Company Act” means the Investment Company Act of 1940.

 

IRS” means the United States Internal Revenue Service.

 

JOBS Act” has the meaning specified in ‎Section 6.07(a).

 

Knowledge” or “to the knowledge” has the meaning specified in ‎Section 1.03.

 

Labor Organization” has the meaning specified in ‎Section 4.14(a).

 

Law” means any statute, law, ordinance, rule, regulation or Governmental Order, in each case, of any Governmental Authority.

 

Leased Real Property” means all real property leased, licensed, subleased or otherwise used or occupied by the Company or any of its Subsidiaries.

 

Legal Proceedings” has the meaning specified in ‎Section 4.10.

 

Letter of Transmittal” has the meaning specified in ‎Section 3.04(b).

 

Licenses” means any approvals, authorizations, consents, licenses, registrations, permits or certificates of a Governmental Authority.

 

Lien” means all liens, mortgages, deeds of trust, pledges, hypothecations, encumbrances, licenses, security interests, options, restrictions, claims or other liens of any kind whether consensual, statutory or otherwise.

 

Local Counsels” has the meaning specified in ‎Section 12.18(a).

 

18 

 

Material Contracts” has the meaning specified in ‎Section 4.12(a).

 

Material Permits” has the meaning specified in ‎Section 4.18.

 

Mergers” has the meaning specified in the Recitals hereto.

 

Modification in Recommendation” has the meaning specified in ‎Section 9.02(d).

 

Modification in Recommendation Notice” has the meaning specified in ‎Section 9.02(d).

 

Modification in Recommendation Notice Period” has the meaning specified in ‎Section 9.02(d).

 

New Parent” has the meaning specified in the Recitals hereto.

 

New Parent Board of Directors” has the meaning specified in ‎Section 9.08.

 

New Parent Class A Shares” means Class A ordinary shares, nominal value CHF 0.01 per share of New Parent.

 

New Parent Equity Incentive Plan” has the meaning specified in ‎Section 9.07.

 

New Parent Interests Consideration” has the meaning specified in ‎the Recitals hereto.

 

New Parent Organizational Documents” has the meaning specified in ‎Section 2.02(e).

 

New Parent Share Capital Increase” has the meaning specified in ‎Section 2.02(b)(ii).

 

New Parent Shares” has the meaning specified in the Recitals hereto.

 

New Parent Squeeze-Out Shares” means, if applicable, a number of common shares of CHF 0.01 nominal value of New Parent to be issued in the Third Merger to Company Shareholders that do not exchange Company Share Capital for New Parent Shares pursuant to the Company Share Contribution.

 

New Parent Warrant” has the meaning specified in the Recitals hereto.

 

Option Exchange Ratio” shall have the meaning as set forth in Schedule 2.01 of the Company Disclosure Letter.

 

Owned Real Property” means all real property owned in fee simple by the Company or any of its Subsidiaries.

 

19 

 

Party” and “Parties” have the meaning specified in the Preamble hereto.

 

Permitted Liens” means (i) mechanic’s, materialmen’s and similar Liens arising in the ordinary course of business with respect to any amounts (A) not yet due and payable or which are being contested in good faith through appropriate proceedings and (B) for which adequate accruals or reserves have been established in accordance with IFRS or GAAP, as applicable, (ii) Liens for Taxes (A) not yet due and payable or which are being contested in good faith through appropriate proceedings and (B) for which adequate accruals or reserves have been established in accordance with IFRS or GAAP, as applicable, (iii) defects or imperfections of title, easements, encroachments, covenants, rights-of-way, conditions, matters that would be apparent from a physical inspection or current, accurate survey of such real property, restrictions and other similar charges or encumbrances that do not, individually or in the aggregate, materially impair the value or materially interfere with the present use of the Realty, (iv) with respect to any Leased Real Property, (A) the interests and rights of the respective lessors with respect thereto, including any Lien on the lessor’s interest therein and statutory landlord liens securing payments not yet due and (B) any Liens encumbering the underlying fee title of the real property of which the Leased Real Property is a part, (v) zoning, building, entitlement and other land use and environmental regulations promulgated by any Governmental Authority that do not, individually or in the aggregate, materially interfere with the current use of, or materially impair the value of, the Realty, (vi) non-exclusive licenses of Intellectual Property entered into in the ordinary course of business consistent with past practice, (vii) ordinary course purchase money Liens and Liens securing rental payments under operating or capital lease arrangements for amounts not yet due or payable, (viii) reversionary rights in favor of landlords under any real property leases with respect to any of the buildings or other improvements owned by the Company or any of its Subsidiaries and (ix) other Liens that do not materially and adversely affect (x) the value, use or operation of the asset subject thereto or (y) the operation of the businesses of the Company or any of its Subsidiaries, taken as a whole.

 

Person” means any individual, firm, corporation, partnership, limited liability company, incorporated or unincorporated association, joint venture, joint stock company, Governmental Authority or instrumentality or other entity of any kind.

 

PIPE Investment” means the purchase of any PIPE Shares pursuant to the Subscription Agreements and the purchase of any EBAC Class A Common Stock, warrants or other securities pursuant to any Additional Subscription Agreements.

 

PIPE Investment Amount” means the aggregate proceeds actually received by EBAC prior to or substantially concurrently with the Acquisition Closing for the shares in the PIPE Investment.

 

PIPE Investors” has the meaning specified in the Recitals hereto and shall include, for the avoidance of doubt, investors that are party to any Additional Subscription Agreements.

 

20 

 

PIPE Placement Agents” means Credit Suisse Securities (USA) LLC, Kempen & Co. USA, Inc., BofA Securities, Inc., SVB Securities LLC and Arctica Finance hf.

 

PIPE Placement Agent Engagement Letters” means, collectively, (1) that certain letter agreement dated as of June 3, 2022, by and between EBAC and Credit Suisse Securities (USA) LLC, (2) that certain letter agreement dated as of June 3, 2022, by and among, among others, EBAC and Kempen & Co. USA, Inc., (3) that certain letter agreement dated as of June 3, 2022, by and between EBAC and BofA Securities, Inc., (4) that certain consent letter dated as of June 3, 2022, by and between EBAC and BofA Securities, Inc., (5) that certain letter agreement dated as of June 3, 2022, by and between EBAC and SVB Securities LLC and (6) that certain letter agreement dated as of July 15, 2022, by and between EBAC and Arctica Finance hf.

 

PIPE Shares” has the meaning specified in the Recitals hereto.

 

Privacy and Cybersecurity Requirements” has the meaning specified in ‎Section 4.22(a).

 

Products” means any products or services under development, developed, manufactured, performed, out-licensed, sold, distributed other otherwise made available by or on behalf of the Company or any of the Company’s Subsidiaries, from which the Company or any of the Company’s Subsidiaries has derived previously, is currently deriving or is scheduled or intends to derive, revenue from the sale or provision thereof.

 

Prospectus” has the meaning specified in ‎Section 12.01.

 

Proxy Statement” means the proxy statement filed by EBAC as part of the Registration Statement with respect to the EBAC Shareholders’ Meeting for the purpose of soliciting proxies from EBAC Shareholders to approve the Transaction Proposals (which shall also provide the EBAC Shareholders with the opportunity to redeem their shares of EBAC Common Stock in conjunction with a stockholder vote on the Transactions).

 

Q2 2022 Financial Statements” has the meaning specified in ‎Section 4.08(a)(ii).

 

Q3 2022 Financial Statements” has the meaning specified in ‎Section 7.03(d).

 

Realty” means, collectively, the Owned Real Property and the Leased Real Property.

 

Registration Rights Agreement” has the meaning specified in the Recitals hereto.

 

Registration Statement” has the meaning specified in ‎Section 9.02(a).

 

21 

 

Sanctioned Country” means at any time, a country or territory which is itself the subject or target of any country-wide or territory-wide Sanctions Laws (at the time of this Agreement, the Crimea region, Cuba, Iran, Russia, North Korea and Syria).

 

Sanctioned Person” means (i) any Person identified in any sanctions-related list of designated Persons maintained by (a) the United States (including the Department of the Treasury’s Office of Foreign Assets Control or the United States Department of State); (b) the United Kingdom; (c) any committee of the United Nations Security Council; (d) the European Union or any European Union member state; or (e) any other jurisdiction where the Company or any of its Subsidiaries operates; (ii) any Person located, organized, or resident in a Sanctioned Country; (iii) a Governmental Authority or government instrumentality of any Sanctioned Country or Venezuela; and (iv) any Person directly or indirectly owned fifty percent (50%) or more, or controlled by, or acting for the benefit or on behalf of, a Person or Persons described in clauses (i) or (ii), either individually or in the aggregate.

 

Sanctions Laws” means any trade, economic or financial sanctions Laws administered, enacted or enforced from time to time by (i) the United States (including the Department of the Treasury’s Office of Foreign Assets Control or the United States Department of State) (ii) the European Union or any European Union member state, (iii) the United Nations, (iv) the United Kingdom or (v) any other jurisdiction where the Company or any of its Subsidiaries operates.

 

Sarbanes-Oxley Act” means the Sarbanes-Oxley Act of 2002.

 

SEC” means the United States Securities and Exchange Commission.

 

Second Earnout Achievement Date” has the meaning set forth in Section 3.05(c).

 

Second Merger” has the meaning specified in the Recitals hereto.

 

Second Merger Effective Time” means the time at which the Second Merger becomes effective pursuant to the filing and registration of the Plan of Merger with the Cayman Registrar of Companies or at such later time as may be agreed by New Parent and the Company in writing and specified in such Plan of Merger.

 

Securities Act” means the Securities Act of 1933.

 

Service Provider” means, as of any relevant time, any director, officer, employee, independent contractor or consultant of the Company or any of its Subsidiaries.

 

Sponsor” means LSP Sponsor EBAC B.V. a Dutch limited liability company.

 

Sponsor Incentive Shares” has the meaning specified in Section 2.02(c).

 

22 

 

Sponsor Nominee” has the meaning specified in ‎Section 9.08.

 

Sponsor Support Agreement” has the meaning specified in the Recitals hereto.

 

Staleness Date” has the meaning specified in ‎Section 7.03(d).

 

Stock Exchange” means the Nasdaq Stock Market.

 

Subscription Agreements” has the meaning specified in the Recitals hereto.

 

Subsidiary” means, with respect to a Person, a corporation or other entity of which (i) more than fifty percent (50%) of the voting power of the equity securities or equity interests is owned, directly or indirectly, by such Person or (ii) such Person otherwise directs the management policies or corporate direction whether by equity ownership, contract or otherwise.

 

Surviving EBAC Shares” has the meaning specified in the Recitals hereto.

 

Surviving EBAC Warrants” has the meaning specified in the Recitals hereto.

 

Swiss Code of Obligations” means the Swiss Federal Act on the Amendment of the Swiss Civil Code of 30 March 1911.

 

Tax Grant” means any Tax exemption, Tax holiday, reduced Tax rate or other Tax benefit granted by a Governmental Authority with respect to the Company or any of its Subsidiaries that is not generally available without specific application therefor.

 

Tax Return” means any return, declaration, report, statement, information statement or other document filed or required to be filed with any Governmental Authority with respect to Taxes, including any claims for refunds of Taxes, any information returns and any schedules, attachments, amendments or supplements of any of the foregoing.

 

Tax Sharing Agreement” means any agreement or arrangement (including any provision of a Contract) pursuant to which a Person is or may be obligated to indemnify another Person for, or otherwise pay, any Tax of or imposed on any Person, or indemnify, or pay over to, another Person any amount determined by reference to actual or deemed Tax benefits, Tax assets, or Tax savings.

 

Taxes” means any and all U.S. federal, state, and local and non-U.S. taxes, including all income, gross receipts, license, payroll, recapture, net worth, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, ad valorem, value added, ad valorem, inventory, franchise, profits, withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, transfer, registration, alternative or add-on minimum, estimated, and other taxes and all governmental charges, duties, fees, levies, and other similar charges in the nature of a tax, including any interest, penalty, or addition thereto.

 

23 

 

Terminating Company Breach” has the meaning specified in ‎Section 11.01(f).

 

Terminating EBAC Breach” has the meaning specified in ‎Section 11.01(g).

 

Third Earnout Achievement Date” has the meaning set forth in Section 3.05(d).

 

Third Merger” has the meaning specified in the Recitals hereto.

 

Third Merger Effective Time” means the time at which the Third Merger becomes effective pursuant to the filing and registration of the Plan of Merger in accordance with the provisions of the Swiss Code of Obligations or at such later time as may be agreed by New Parent and the Company in writing and specified in such Plan of Merger.

 

Trade Secrets” has the meaning specified in the definition of “Intellectual Property.”

 

Trading Day” means any day on which New Parent Shares are actually traded on the principal securities exchange or securities market on which New Parent Shares are then traded.

 

Transaction Expenses” means the EBAC Transaction Expenses and the Company Transaction Expenses.

 

Transaction Proposals” has the meaning specified in ‎Section 9.02(c).

 

Transactions” has the meaning specified in the Recitals hereto.

 

Transfer Tax” means any direct or indirect transfer (including real estate transfer), sales, value added, use, stamp, documentary, registration, conveyance, recording, or other similar Taxes payable as a result of the consummation of the Transactions.

 

Treasury Regulations” means the regulations promulgated under the Code by the United States Department of the Treasury (whether in final, proposed or temporary form).

 

Trust Account” has the meaning specified in ‎Section 12.01.

 

Trust Agreement” has the meaning specified in ‎Section 6.08.

 

Trustee” has the meaning specified in ‎Section 6.08.

 

Vischer” has the meaning specified in ‎Section 12.18(b).

 

24 

 

VWAP” means, for any security as of any day or multi-day period, the dollar volume-weighted average price for such security on the principal securities exchange or securities market on which such security is then traded during the period beginning at 9:30:01 a.m., New York time on such day or the first day of such multi-day period (as applicable), and ending at 4:00:00 p.m., New York time on such day or the last day of such multi-day period (as applicable), as reported by Bloomberg through its “HP” function (set to weighted average) or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time on such day or the first day of such multi-day period (as applicable), and ending at 4:00:00 p.m., New York time on such day or the last day of such multi-day period (as applicable), as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported by OTC Markets Group Inc. during such day or multi-day period (as applicable). If the VWAP cannot be calculated for such security for such day or multi-day period (as applicable) on any of the foregoing bases, the VWAP of such security shall be the fair market value per share at the end of such day or multi-day period (as applicable) as reasonably determined by the Board of Directors of New Parent.

 

Warrant Assumption Agreement” means a Warrant Assignment and Assumption Agreement to be entered into among EBAC, New Parent and the Exchange Agent, in a form to be agreed upon among EBAC, New Parent, the Exchange Agent and the Company, to be effective upon the Acquisition Closing.

 

Warrant Conversion” means the right of the EBAC Shareholders to receive a New Parent Warrant in exchange for EBAC Warrants to be transferred immediately to holders of EBAC Warrants pursuant to the Warrant Assumption Agreement, to be effective upon the Acquisition Closing.

 

Working Capital Loans” means any loan made to EBAC by any of the Sponsor, an Affiliate of the Sponsor, or any of EBAC’s officers or directors, and evidenced by a promissory note, for the purpose of financing costs incurred in connection with a Business Combination.

 

Section 1.02.      Construction.

 

(a)            Unless the context of this Agreement otherwise requires, (i) words of any gender include each other gender; (ii) words using the singular or plural number also include the plural or singular number, respectively; (iii) the terms “hereof,” “herein,” “hereby,” “hereto” and derivative or similar words refer to this entire Agreement; (iv) the terms “Article” or “Section” refer to the specified Article or Section of this Agreement; (v) the word “including” shall mean “including, without limitation”; and (vi) the word “or” shall be disjunctive but not exclusive.

 

25 

 

(b)            Unless the context of this Agreement otherwise requires, references to statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation.

 

(c)            Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified.

 

(d)            All accounting terms used herein and not expressly defined herein shall have the meanings given to them under IFRS or GAAP, as applicable.

 

(e)            The term “actual fraud” means, with respect to a party to this Agreement, any actual and intentional fraud with respect to the making of the representations and warranties pursuant to Article 4, Article 5 or Article 6 (as applicable); provided that such actual and intentional fraud of such Person shall only be deemed to exist if any of the individuals included on Section 1.03 of the Company Disclosure Letter (in the case of the Company) or Section 1.03 of the EBAC Disclosure Letter (in the case of EBAC) had knowledge that a representation or warranty made by such Person pursuant to, in the case of the Company, Article 4 and Article 5 as qualified by the Company Disclosure Letter, or, in the case of EBAC, Article 6 as qualified by the EBAC Disclosure Letter, were false when made, with the intention that any of the other Parties to this Agreement rely thereon to its detriment, and such other Party actually did rely thereon to its detriment and incurred a loss as a result of such reliance.

 

(f)             Except as otherwise specifically provided herein, to the extent this Agreement refers to information or documents having been “made available” (or words of similar import) by or on behalf of one or more Parties to another Party hereto, such obligation shall be deemed satisfied if (i) such one or more Parties hereto or a Person acting on its behalf made such information or document available (or delivered or provided such information or document) in the electronic data rooms hosted by Intralinks, Inc. and labeled “Oculis” prior to 6:00 p.m. Eastern time on the date that is one Business Day prior to the date of this Agreement or (ii) such information or document is publicly available prior to 6:00 p.m. Eastern time on the date that is one Business Day prior to the date of this Agreement in the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database of the SEC and not subject to any redactions or omissions.

 

Section 1.03.      Knowledge. As used herein, (i) the word “knowledge” or the phrase “to the knowledge” of the Company shall mean the knowledge of the individuals identified on Section 1.03 of the Company Disclosure Letter, and (ii) the word “knowledge” or the phrase “to the knowledge” of EBAC shall mean the knowledge of the individuals identified on Section 1.03 of the EBAC Disclosure Letter.

 

26 

 

Article 2
the Mergers; Share Contribution; Closing

 

Section 2.01.      The Mergers; Exchange Agent Contribution; Contribution of Company Common Shares to New Parent.

 

(a)            The EBAC Mergers and Exchange Agent Contribution.

 

(i)            Upon the terms and subject to the conditions set forth in this Agreement, on the day before the Acquisition Closing Date and at the First Merger Effective Time, Merger Sub 1 shall be merged with and into EBAC in the First Merger. Following the First Merger, the separate corporate existence of Merger Sub 1 shall cease and EBAC shall continue as the surviving company.

 

(ii)            Upon the terms and subject to the conditions set forth in this Agreement, as part of the First Merger, EBAC shall deposit, or cause to be deposited, with the Exchange Agent (held solely on behalf of the holders of EBAC Common Stock and EBAC Warrants) the Surviving EBAC Shares and Surviving EBAC Warrants.

 

(iii)            Upon the terms and subject to the conditions set forth in this Agreement, on the day before the Acquisition Closing Date and following the First Merger Effective Time but prior to the Second Merger Effective Time the Exchange Agent shall effect the Exchange Agent Contribution, and immediately thereafter shall perform the Exchange Agent Contribution Actions.

 

(iv)            Upon the terms and subject to the conditions set forth in this Agreement, on the day before the Acquisition Closing Date and at the Second Merger Effective Time, which shall be approximately 30 minutes after the First Merger Effective Time, EBAC shall be merged with and into Merger Sub 2 in the Second Merger. Following the Second Merger, the separate corporate existence of EBAC shall cease and Merger Sub 2 shall continue as the surviving company. Following the consummation of the EBAC Mergers, all New Parent Shares shall be of the same class of shares and consist only of New Parent Class A Shares. Following the Acquisition Closing, Merger Sub 2 shall be liquidated, and its assets shall be distributed in the framework of the liquidation procedure to New Parent.

 

(b)            Company Share Contribution.

 

(i)            As soon as reasonably practicable following the date hereof, the Company shall cause the Company Shareholders to sign an exchange notice, pursuant to which such Company Shareholders agree, subject to the substantially concurrent satisfaction or waiver of all of the conditions set forth in Article 10 of this Agreement, to transfer, assign and surrender to the Exchange Agent all Company Share Capital held by such Company Shareholder free and clear of all

 

27 

 

Liens (other than general restrictions on transfer under applicable securities Laws or the articles of association of the Company), in exchange for New Parent Shares on the terms, and subject to the conditions set forth in this Agreement, including the Company Share Contribution ratios set forth in Schedule 2.01 of the Company Disclosure Letter. All such transferring Company Shareholders authorize the Exchange Agent as its lawful attorney-in-fact to do any and all things and to take any and all actions reasonably necessary to effect the exchange of Company Share Capital into New Parent Shares. All such transferring Company Shareholders shall undertake all such further steps, including executing an ad hoc contribution agreement, as are necessary to effect the contribution of the full legal and beneficial ownership of the applicable Company Share Capital to New Parent (and, in exchange, New Parent shall issue New Parent Shares to Company Shareholders, the “Company Share Contribution”) (the number of New Parent Shares so issued, the “Company Consideration”). The aggregate value of the Company Consideration shall be deemed to be equal to the Company Equity Value, and shall be subscribed for by the Company Shareholders at a value of $10.00 per New Parent Share. For the avoidance of doubt, any New Parent Shares to be issued as Company Consideration to the Company Shareholders shall be of the same class, with equal rights and privileges, as any New Parent Shares to be issued as part of the New Parent Interests Consideration to the EBAC Shareholders and PIPE Investors.

 

(ii)            At approximately 10:00 am ET on the Acquisition Closing Date, such transferring Company Shareholders and New Parent shall consummate the Company Share Contribution.

 

(c)            The Third Merger. Upon the terms and subject to the conditions set forth in this Agreement and as an integrated part of the Transactions, approximately thirty (30) days after the Acquisition Closing Date and at the Third Merger Effective Time, the Company shall be merged with and into Merger Sub 3 in the Third Merger. Following the Third Merger, the separate corporate existence of the Company shall cease, and Merger Sub 3 shall continue as the surviving company.

 

Section 2.02.      Effective Times; Sponsor Forfeiture; Closings.

 

(a)            First Merger and Second Merger. Subject to the satisfaction or waiver of all of the conditions set forth in Article 10 of this Agreement, and provided this Agreement has not theretofore been terminated pursuant to its terms, on the Acquisition Closing Date, the Parties shall cause the First Merger and Second Merger to be consummated by filing with the Cayman Registrar of Companies a Plan of Merger (the “Cayman Plan of Merger”), duly executed and completed in accordance with the relevant provisions of the Cayman Companies Act.

 

28 

 

(b)            First Merger Capital Increase by New Parent. New Parent shall undertake all corporate steps required to increase its share capital to reflect the issuance of the New Parent Shares to be transferred to (i) the Exchange Agent (held solely on behalf of the holders of Surviving EBAC Shares, including the PIPE Investors) in connection with the distribution of New Parent Shares as part of the New Parents Interests Consideration to such holders following the Exchange Agent Contribution in accordance with the Exchange Agent Contribution Actions performed prior to the consummation of the transactions contemplated by the Second Merger and (ii) the Company Shareholders in connection with the Company Share Contribution (together, clauses (i) and (ii), the “New Parent Share Capital Increase”) and to register on the Acquisition Closing Date in one single application the New Parent Share Capital Increase in the Commercial Register of the Canton of Zug, Switzerland (“Commercial Register Zug”), which registration shall be made using the express procedure allowing for same-day registration (Hyperexpressverfahren). Upon registration of the New Parent Share Capital Increase in the Commercial Register Zug pursuant to this Section 2.02(b), New Parent shall issue to (x) the Exchange Agent, New Parent Shares to be distributed to holders of Surviving EBAC Shares following the consummation of the Exchange Agent Contribution and in accordance with the Exchange Agent Contribution Actions performed prior to the consummation of the transactions contemplated by the Second Merger and (y) to the Company Shareholders, the New Parent Shares constituting the Company Consideration for the Company Share Contribution on the terms, and subject to the conditions of, this Agreement and the Ancillary Agreements. Unless otherwise agreed by New Parent and the relevant recipient of the New Parent Shares, all New Parent Shares shall be uncertificated, with record ownership reflected on the books and records of New Parent. Immediately following the New Parent Share Capital Increase, the Exchange Agent and the Company Shareholders shall hold all New Parent Shares, with the exception of any New Parent Shares held by New Parent as treasury shares, and immediately thereafter, the New Parent Shares as part of the New Parent Interests Consideration shall be delivered by the Exchange Agent to the EBAC Shareholders, including the PIPE Investors.

 

(c)            Sponsor Forfeiture Events.

 

(i)            All of the At-Risk Sponsor Shares are hereby forfeited for no consideration, contingent upon the consummation of the Acquisition Closing; provided, that the number of At-Risk Sponsor Shares forfeited pursuant to this Section 2.02(c)(i) is reduced by the number of At-Risk Sponsor Shares that the Sponsor or its affiliates has agreed to transfer to any EBAC Shareholder in connection with such EBAC Shareholder’s execution of a Non-Redemption Agreement (the “Sponsor Incentive Shares”); provided, further, that the number of Sponsor Incentive Shares granted to any EBAC Shareholder does not exceed ten percent (10%) of the number of shares of EBAC Class A Common Stock owned or controlled by such EBAC Shareholder as of the date of the appliable Non-Redemption Agreement.

 

(ii)            Notwithstanding anything to the contrary herein, if, as of the Acquisition Closing Date, (A) the amount of cash or cash equivalents available in the Trust Account following the EBAC Shareholders’ Meeting (after deducting the amount required to satisfy the EBAC Share Redemption Amount but before payment of any Company Transaction Expenses or EBAC Transaction Expenses);

 

29 

 

plus (B) the PIPE Investment Amount actually received by New Parent (or other financing, including through a convertible loan, in connection with the Acquisition Transactions) prior to or substantially concurrently with the Acquisition Closing from a PIPE Investor or other investor that in either case has been introduced to the Company following the date hereof by the Sponsor or its affiliates as set forth on Section 2.02(c)(i) of the EBAC Disclosure Letter (which, subject to the Company’s prior approval (not to be unreasonably withheld, conditioned or delayed), schedule EBAC may update from time to time after the date hereof) (collectively, the “Closing Trust Proceeds”) is less than $25,500,000, then a number of Additional At-Risk Sponsor Shares equal to the Additional At-Risk Sponsor Forfeit Amount shall be forfeited for no consideration concurrently with the consummation of the Company Share Contribution; provided, that the number of Additional At-Risk Sponsor Shares forfeited pursuant to this Section 2.02(c)(ii) shall be reduced by the number of Additional At-Risk Sponsor Shares to be transferred by the Sponsor or its affiliates (such transfer as reasonably evidenced to the Company) to any EBAC Shareholder in connection with a Non-Redemption Agreement or similar arrangement executed after the date of this Agreement (the “Additional Sponsor Incentive Shares”); provided, further, that the number of Additional Sponsor Incentive Shares that may be granted to any EBAC Shareholder shall not exceed ten percent (10%) of the number of shares of EBAC Class A Common Stock owned or controlled by such EBAC Shareholder as of the date of such Non-Redemption Agreement or similar arrangement.

 

(d)            Closings. On the next Business Day (unless otherwise agreed between EBAC and the Company) following the date which is three (3) Business Days after the date on which all conditions set forth in Article 10 shall have been satisfied or waived (other than those conditions that by their terms are to be satisfied at the Acquisition Closing (as defined below), but subject to the satisfaction or waiver thereof) or such other time and place as EBAC and the Company may mutually agree in writing, the closing of the First Merger, Second Merger and Company Share Contribution (collectively, the “Acquisition Closing”) shall take place electronically through the exchange of documents via email. The date on which the Acquisition Closing is completed is referred to herein as the “Acquisition Closing Date.” The New Parent Share Capital Increase shall be made contemporaneously with the filing of the Cayman Plan of Merger.

 

(e)            Effects of the EBAC Mergers and New Parent Capital Increase. The EBAC Mergers shall have the effects set forth in this Agreement and the Cayman Companies Act, and the New Parent Share Capital Increase shall have the effect set forth in the Swiss Code of Obligations. Without limiting the generality of the foregoing and subject thereto, by virtue of the (i) First Merger and without further act or deed, at the First Merger Effective Time, all of the property, rights, privileges, powers and franchises of Merger Sub 1 shall vest in EBAC, as the surviving company of the First Merger, and all of the debts, liabilities and duties of Merger Sub 1 shall become the debts, liabilities and duties of EBAC and (ii) Second Merger and without further act or deed, at the Second Merger

 

30 

 

Effective Time, all of the property, rights, privileges, powers and franchises of EBAC shall vest in Merger Sub 2, as the surviving company of the First Merger, and all of the debts, liabilities and duties of EBAC shall become the debts, liabilities and duties of Merger Sub 2.

 

(f)             Articles of Association of New Parent. In connection with the Acquisition Transactions, on the Acquisition Closing Date, New Parent will take all requisite action to adopt the articles of association (the “New Parent Organizational Documents”) amended in accordance with their terms and Swiss Law.

 

(g)            Directors and Officers of the Surviving Company. Persons constituting the directors and officers of Merger Sub 2 prior to the Second Merger Effective Time shall continue to be the directors and officers of Merger Sub 2 following the consummation of the EBAC Mergers until the earlier of their resignation or removal or until their respective successors are duly appointed.

 

Section 2.03.      Closing Deliverables.

 

(a)            At the Acquisition Closing, the Company will deliver or cause to be delivered:

 

(i)            to EBAC, a certificate signed by an executive officer of the Company, dated as of the Acquisition Closing Date, certifying that, to the knowledge and belief of such officer, the conditions specified in Section 10.02(a), Section 10.02(b) and Section 10.02(c) have been fulfilled; and

 

(ii)            to EBAC, the Registration Rights Agreement, duly executed by certain Affiliates of the Company party thereto.

 

(b)            At the Acquisition Closing, EBAC will deliver or cause to be delivered:

 

(i)            to the Company, a certificate signed by an officer of EBAC, dated as of the Acquisition Closing Date, certifying that, to the knowledge and belief of such officer, the conditions specified in Section 10.03(a) through Section 10.03(d) have been fulfilled;

 

(ii)            to the Company, the Registration Rights Agreement, duly executed by the EBAC Class B Holders and New Parent; and

 

(iii)            to the Company, the written resignations of all of the directors and officers of EBAC and New Parent, effective as of the Second Merger Effective Time.

 

31 

 

Article 3
Effects of the Merger on EBAC Securities

 

Section 3.01.      Conversion of Securities. Treatment of Securities of EBAC in the First Merger. At the First Merger Effective Time, by virtue of the Merger and without any action on the part of EBAC, Merger Sub 1, New Parent or the holder of any shares of capital stock of any of the foregoing:

 

(a)            EBAC Units. Each EBAC Unit outstanding immediately prior to the First Merger Effective Time shall be automatically detached and the holder thereof shall be deemed to hold one share of EBAC Class A Common Stock and one-third of an EBAC Warrant in accordance with the terms of the applicable EBAC Unit, which underlying shares of EBAC Class A Common Stock and EBAC Warrants shall be adjusted in accordance with the applicable terms of this Section 3.01.

 

(b)            EBAC Capital Stock. Immediately following the separation of each EBAC Unit in accordance with Section 3.01 and in connection with the First Merger, the shares of EBAC Common Stock shall be automatically converted into the Surviving EBAC Shares, and in connection therewith, EBAC shall deposit, or cause to be deposited, each Surviving EBAC Share with the Exchange Agent (solely on behalf of the EBAC Shareholders, including the PIPE Investors). As of the First Merger Effective Time, each EBAC Shareholder shall cease to have any other rights in and to EBAC and each share of EBAC Class A Common Stock issued and outstanding immediately prior to the First Merger Effective Time shall automatically be cancelled and cease to exist.

 

(c)            Exchange of EBAC Warrants. Each EBAC Warrant outstanding immediately prior to the First Merger Effective Time shall, at the First Merger Effective Time, be automatically converted into the Surviving EBAC Warrants and such Surviving EBAC Warrants shall be deposited with the Exchange Agent (solely on behalf of the holders of EBAC Warrants) in exchange for the right of each holder of EBAC Warrants to receive New Parent Warrants pursuant to the Warrant Conversion on the terms, and subject to the conditions of, the Warrant Assumption Agreement. Each EBAC Warrant outstanding immediately prior to the First Merger Effective Time shall, at the First Merger Effective Time, cease to be a warrant with respect to EBAC Common Stock and shall be assumed by New Parent pursuant to the Warrant Assumption Agreement on substantially the same terms as were in effect immediately prior to the Merger Effective Time under the terms of the EBAC Warrant Agreement (including any repurchase rights and cashless exercise provisions). EBAC and New Parent shall take all lawful action to effect the aforesaid provisions of this Section 3.01, including entering into the Warrant Assumption Agreement.

 

(d)            New Parent Shares Held by EBAC. The New Parent Shares held by EBAC shall be cancelled for no consideration immediately prior to the implementation of the Second Merger.

 

32 

 

(e)            EBAC Treasury Stock. Notwithstanding clause (a) above or any other provision of this Agreement to the contrary, if there are any shares of EBAC Common Stock that are owned by EBAC as treasury stock or any EBAC Common Stock owned by any direct or indirect Subsidiary of EBAC immediately prior to the First Merger Effective Time, such EBAC Common Stock shall be cancelled and shall cease to exist without any conversion thereof or payment or other consideration therefor.

 

(f)             EBAC Redeeming Shares. Notwithstanding clause (a) above or any other provision of this Agreement to the contrary, if there are any shares of EBAC Common Stock that are required to be redeemed pursuant to the EBAC Share Redemption, such EBAC Common Stock shall not be exchanged pursuant to clause (a) above but shall, immediately prior to the First Merger Effective Time, be cancelled and shall cease to exist and shall thereafter be redeemed for the consideration, and on the terms and subject to the conditions and limitations, set forth in this Agreement, EBAC’s Governing Documents, the Trust Agreement and the Proxy Statement.

 

Section 3.02.      Equitable Adjustments. If, between the date of this Agreement and the First Merger Effective Time, the outstanding shares of any class or series of Company Share Capital or EBAC Common Stock shall have been changed into a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares, or any similar event shall have occurred, then, without duplication, any number, value (including dollar value) or amount contained herein which is based upon the number of shares of any class or series of Company Share Capital or EBAC Common Stock will be appropriately adjusted to provide to the holders of Company Share Capital and the holders of EBAC Common Stock the same economic effect as contemplated by this Agreement; provided, however, that this Section 3.02 shall not be construed (i) to permit any party to take any action with respect to its respective securities that is prohibited by the terms and conditions of this Agreement or would reasonably be expected to prevent, impair or impede the Intended Tax Treatment or (ii) to apply to any adjustment made with respect to the New Parent Warrants in the Warrant Conversion.

 

Section 3.03.      Delivery of Shares.

 

(a)            Prior to the First Merger Effective Time, New Parent, the Company and EBAC shall, with the Company’s prior consent, (i) appoint a Person authorized to act as exchange agent in connection with the Transactions, which Person shall be selected by New Parent, the Company and EBAC (the “Exchange Agent”) and shall act on behalf of the Company and the Company Shareholders and on behalf of EBAC and holders of the Surviving EBAC Shares and Surviving EBAC Warrants, as the case may be, and (ii) enter into an exchange agent agreement with the Exchange Agent reasonably acceptable to New Parent, the Company and EBAC for the purpose of, among other things, (A) contributing the Surviving EBAC Shares and Surviving EBAC Warrants to New Parent in exchange for New Parent Shares and New Parent Warrants, (B) effecting the distribution of such New Parent Shares and New Parent Warrants to the holders of Surviving EBAC Shares (including the PIPE Investors) and Surviving EBAC Warrants,

 

33 

 

(C) exchanging the Company Share Capital for New Parent Shares and (D) effecting the distribution of such New Parent Shares to the Company Shareholders, all in accordance with this Agreement (the “Exchange Agent Agreement”). New Parent Shares deposited with the Exchange Agent shall be referred to as the “Exchange Fund.”

 

(b)            As soon as reasonably practicable after the registration of the New Parent Share Capital Increase with the Commercial Register Zug, the Exchange Agent shall mail or otherwise deliver to (i) each holder of record of EBAC Common Stock who has the right to receive the New Parent Shares delivered by the Exchange Agent as part of the New Parent Interests Consideration hereunder and (ii) each Company Shareholder who has the right to receive the New Parent Shares delivered by the Exchange Agent as part of the Company Consideration hereunder, a letter of transmittal in customary form to be approved by New Parent, the Company and EBAC (such approval not to be unreasonably withheld, conditioned, or delayed) prior to the Acquisition Closing (the “Letter of Transmittal”), which shall be in such form and have such other customary provisions as New Parent, the Company and EBAC may reasonably specify. In the event a holder of EBAC Common Stock or a Company Shareholder does not deliver to the Exchange Agent a duly executed and completed Letter of Transmittal, where applicable, such Person shall not be entitled to receive such uncertificated New Parent Shares as part of the New Parent Interests Consideration unless and until such Person delivers a duly executed and completed Letter of Transmittal, as applicable, to the Exchange Agent. Each uncertificated share of EBAC Common Stock (and each resulting Surviving EBAC Share) or uncertificated share of Company Share Capital represents only the right to receive, upon compliance with these requirements, the New Parent Shares as part of the New Parent Interests Consideration or as part of the Company Consideration in accordance with this Agreement.

 

(c)            If applicable, upon receipt of a Letter of Transmittal duly, completely and validly executed in accordance with the instructions thereto, and such other documents as may reasonably be required by New Parent, the holder of such EBAC Common Stock (and resulting Surviving EBAC Shares) or the Company Shareholder shall be entitled to receive, pursuant to the terms of this Agreement, in exchange therefor the New Parent Shares as part of the New Parent Interests Consideration or as part of the Company Consideration in book-entry form. Until surrendered as contemplated by this Section 3.03(c), each EBAC Common Stock (and resulting Surviving EBAC Shares) or share of Company Share Capital shall be deemed to represent only the right to receive upon such surrender the New Parent Shares as part of the New Parent Interests Consideration or as part of the Company Consideration which the holders of Surviving EBAC Shares or the Company Shareholder were entitled to receive in respect of such shares pursuant to the terms of this Article 3.

 

(d)            Immediately after registration of the New Parent Share Capital Increase with the Commercial Register Zug, without any action of the EBAC Shareholders and the Company Shareholder, (x) New Parent, the Company and EBAC shall cause the Exchange Agent to deliver to the Depository Trust Company book-entry shares representing the New Parent Shares to be issued as part of the New Parent Interests Consideration and as part of the Company Consideration and (y) all Surviving EBAC Warrants held by New Parent will be cancelled for no consideration;

 

34 

 

(e)            All New Parent Shares distributed by the Exchange Agent upon the surrender of EBAC Common Stock or shares of Company Share Capital in accordance with the terms of this Article 3 shall be deemed to have been exchanged and paid in full satisfaction of all rights pertaining to the securities represented by such EBAC Common Stock (and resulting Surviving EBAC Shares) or shares of Company Share Capital, as applicable, and there shall be no further registration of transfers on the stock transfer books of EBAC of the shares of EBAC Common Stock or the Company of the shares of Company Share Capital that were issued and outstanding immediately prior to the First Merger Effective Time. From and after the First Merger Effective Time, holders of EBAC Common Stock shall cease to have any rights as shareholders of EBAC, except as provided in this Agreement or by applicable Law.

 

(f)             Any portion of the Exchange Fund payable to EBAC Shareholders as part of the New Parent Interests Consideration that remains unclaimed by the holders of EBAC Common Stock who were entitled to receive a portion of the Exchange Fund in accordance with Section 2.02 and this Section 3.03 twelve (12) months after the Acquisition Closing Date shall be returned to New Parent for no consideration and any such holder of EBAC Common Stock who has not received its portion of the Exchange Fund in accordance with Section 2.02 and this Section 3.03 prior to that time, shall thereafter look only to New Parent (subject to abandoned property, escheat or other similar Laws), as general creditors thereof, for the delivery of the New Parent Shares to which they are entitled, subject to New Parent receiving a Letter of Transmittal duly, completely and validly executed in accordance with the instructions thereto, and such other documents as may reasonably be required by New Parent. Notwithstanding the foregoing, New Parent shall not be liable to any holder or former holder of EBAC Common Stock for any amounts paid to any Governmental Authority pursuant to applicable abandoned property, escheat or similar Laws. Any New Parent Shares remaining unclaimed by holders of EBAC Common Stock twenty-four (24) months after the Acquisition Closing Date shall become, to the extent permitted by applicable Law, the property of New Parent free and clear of any claims or interest of any Person previously entitled thereto and New Parent.

 

Section 3.04.      Withholding. Notwithstanding any other provision to this Agreement, each of the Parties, their respective Affiliates, and the Exchange Agent, as applicable, shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement such amounts as are required to be deducted and withheld from the making of such payments under applicable Law. In the event that any Person reasonably determines in good faith that any payment hereunder in subject to deduction or withholding (other than compensatory payments to employees of the Company or any of its Subsidiaries), such Person shall use commercially reasonable efforts to (a) notify the Company as soon as is reasonably practicable after such determination and (b) cooperate with the Company and its shareholders to reduce or eliminate any applicable deduction or withholding. To the extent that any amounts are so

 

35 

 

deducted and withheld, such deducted and withheld amounts shall be (i) timely remitted to the appropriate Governmental Authority and (ii) treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made.

 

Section 3.05.      Earn Out Shares.

 

(a)               Subject to and conditioned upon the occurrence of the Acquisition Closing, New Parent shall issue the Earnout Shares to the Company Shareholders in accordance with the Company Share Contribution ratios set forth in Schedule 2.01 of the Company Disclosure Letter,which shall initially be unvested and shall be subject to the following transfer restrictions, vesting and forfeiture provisions:

 

(i)                 If, at any time during the five (5) years following the Acquisition Closing Date (the “Vesting Period”), the VWAP of New Parent Shares is greater than or equal to $15.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days (the date when the foregoing is first satisfied, the “First Earnout Achievement Date”), then 1,500,000 Earnout Shares; minus any Earnout Options granted in replacement of vested Company Options pursuant to Section 3.06, shall automatically become vested, shall no longer be subject to forfeiture the transfer restrictions provided for in Section 3.05(d).

 

(ii)              If, at any time during the Vesting Period, the VWAP of New Parent Shares is greater than or equal to $20.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days (the date when the foregoing is first satisfied, the “Second Earnout Achievement Date”), then an additional 1,500,000 Earnout Shares; minus any Earnout Options granted in replacement of vested Company Options pursuant to Section 3.06, shall automatically become vested, shall no longer be subject to forfeiture the transfer restrictions provided for in Section 3.05(d).

 

(iii)            If, at any time during the Vesting Period, the VWAP of New Parent Shares is greater than or equal to $25.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days (the date when the foregoing is first satisfied, the “Third Earnout Achievement Date”), then the remaining 1,000,000 Earnout Shares; minus any Earnout Options granted in replacement of vested Company Options pursuant to Section 3.06, shall automatically become vested, shall no longer be subject to forfeiture the transfer restrictions provided for in Section 3.05(d).

 

(b)               For the avoidance of doubt, the Earnout Shares shall be entitled to vesting described in Section 3.05(a)(i), Section 3.05(a)(ii) and Section 3.05(a)(iii), respectively, only upon the occurrence of the respective Earnout Achievement Date; provided, however, that each such date shall only occur once, if at all, and in no event shall such Company Shareholders be collectively entitled to receive more than an aggregate of 4,000,000 shares of New Parent Shares as Earnout Shares; minus any Earnout Options granted in replacement of vested Company Options pursuant to Section 3.06.

 

36 

 

(c)               The Earnout Shares that do not vest in accordance with Section 3.05(i), Section 3.05(ii) and Section 3.05(iii) during the Vesting Period shall automatically be forfeited by the Company Shareholders back to New Parent for no consideration and without any encumbrance, third party right, further right, obligation or liability of any kind or nature on the part of New Parent or any of the Company Shareholders. New Parent shall pay any stamp, transfer, documentary or similar taxes imposed upon the forfeiture of any Earnout Shares. Similarly, any Earnout Options that do not vest in accordance with Section 3.05(i), Section 3.05(ii) and Section 3.05(iii) during the Vesting Period shall automatically expire.

 

(d)               For the avoidance of doubt, it is understood and agreed that the Earnout Shares shall not be entitled to vote on matters submitted to the holders of New Parent Shares for approval or be entitled to receive dividends or distributions in respect of the New Parent Shares, if any, until such Earnout Shares vest pursuant to Section 3.05(a)(i), Section 3.05(a)(ii), Section 3.05(a)(iii) or Section 3.05(e) and may not be offered, sold, transferred, redeemed, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) by such Person or be subject to execution, attachment or similar process without the consent of New Parent, and shall bear a customary legend with respect to such transfer restrictions. Any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of such Earnout Shares shall be null and void; provided, that, notwithstanding the foregoing, transfers, assignments and sales by the holders of the Earnout Shares are permitted (i) in the case of a holder who is an individual, by bona fide gift to a member of such holder’s immediate family or to a trust created and controlled by such holder, the beneficiary of which is a member of one of the individual’s immediate family, an Affiliate of such person or to a charitable organization; (ii) in the case of a holder who is an individual, by virtue of laws of descent and distribution upon death of the individual; (iii) in the case of a holder who is an individual, pursuant to a qualified domestic relations order; (iv) to New Parent for a price not exceeding the nominal value of such Earnout Shares; and (v) in the event of completion of a liquidation, merger, share exchange or other similar transaction which results in all of New Parent shareholders having the right to exchange their New Parent Shares for cash, securities or other property subsequent to the completion of the Transactions; provided, however, that in the case of clauses (i) through (iii) these permitted transferees must enter into a written agreement agreeing to be bound by the restrictions herein.

 

(e)               In the event that there is a Change of Control during the Vesting Period, to the extent an applicable Earnout Achievement Date has not already occurred, each respective Earnout Achievement Date shall be deemed to occur on the day prior to the closing of such Change of Control, and (A) all Earnout Shares shall automatically become vested on the date prior to the closing of such Change of Control (to the extent such Earnout Shares has not previously been issued) and (B) thereafter, the obligations in this Section 3.05 shall terminate and no longer apply.

 

37 

 

(f)                The New Parent Shares price targets set forth in this Section 3.05 shall be equitably adjusted for stock splits, reverse stock splits, stock dividends, reorganizations, recapitalizations, reclassifications, combinations, exchanges of shares or other like changes or transactions with respect to the New Parent Shares occurring on or after the Acquisition Closing (other than the Transactions).

 

Section 3.06.      Treatment of Company Options.

 

(a)               At the Acquisition Closing, all of the Company Options outstanding and unexercised immediately prior to the Acquisition Closing, automatically and without any action on the part of any Company Optionholder or beneficiary thereof, will be assumed by New Parent and each such Company Option shall be replaced by a stock option (each, a “Converted Option”) to purchase New Parent Shares and the option to acquire Earnout Shares (each, an “Earnout Option”) at the same proportion as a holder of Company Common Shares receives New Parent Shares and Earnout Shares pursuant to Schedule 2.01 of the Company Disclosure Letter.

 

(b)               Each such Converted Option as so assumed and replaced shall continue to have and be subject to substantially the same terms and conditions (other than the vesting and transfer restrictions applicable to each Earnout Option) as were applicable to such Company Option immediately before the Acquisition Closing (including vesting (if applicable), expiration date and exercise provisions), except that, as of the Acquisition Closing, each such Converted Option as so assumed and replaced shall be exercisable for that number of New Parent Shares and Earnout Shares determined by multiplying the number of Company Common Shares subject to such Company Option immediately prior to the Acquisition Closing by the Option Exchange Ratio, which product shall be mathemathically rounded to the nearest whole number of shares at a per share exercise price determined by dividing the per share exercise price of such Company Option immediately prior to the Acquisition Closing by the Option Exchange Ratio, which quotient shall be mathematically rounded to the nearest whole cent; provided, that the exercise price and the number of New Parent Shares purchasable under each Converted Option shall, in the case of any Company Option to which Section 409A of the Code applies, be determined in a manner consistent with the requirements of Section 409A of the Code and the applicable regulations promulgated thereunder; provided, further, that in the case of any Company Option to which Section 422 of the Code applies, the exercise price and the number of New Parent Shares purchasable under such Converted Option shall be determined in accordance with the foregoing in a manner that satisfies the requirements of Section 424(a) of the Code; provided, that the exercise price shall not be lower than CHF 0.01. As of the Acquisition Closing, all Company Options shall no longer be outstanding and each holder of Converted Options shall cease to have any rights with respect to such Company Options, except as set forth in this ‎Section 3.06. For any unvested Company Option, the Company may replace any Earnout Option with another option of economically similar value.

 

38 

 

(c)               Solely for purposes of determining the Company Equity Value (as defined herein), all Company Options that are vested and not exercised at the Acquisition Closing Date shall be treated as if they had been exercised on a cashless basis. The value of the total number of Company Common Shares resulting from such deemed cashless exercise, as determined in accordance with Section 2.01 of the Disclosure Letter, shall be deducted from determining the Company Equity Value in accordance with the definition thereof for purposes of calculating the number of New Parent Shares to be issued to the Company Shareholders.

 

(d)               Notwithstanding anything to the contrary herein, absent the exercise of a vested Company Option, no New Parent Share shall be issued to Company Optionholders and all vested Company Options shall be replaced by vested New Parent Options and Earnout Options which reflect economically the terms of replaced vested Company Options as outlined in this Section 3.05. For the avoidance of doubt, this Section 3.05 shall not create any rights to any Company Optionholder.

 

Article 4
Representations and Warranties of the Company

 

Except as set forth in the disclosure letter delivered to EBAC by the Company on the date of this Agreement (the “Company Disclosure Letter”) (each section of which, subject to ‎Section 12.09, qualifies the correspondingly numbered and lettered representations in this ‎Article 4), the Company represents and warrants to EBAC as follows:

 

Section 4.01.      Company Organization. The Company has been duly incorporated and is validly existing as a public limited liability company (société anonyme) incorporated and existing under the laws of Switzerland and has all power and authority necessary to own, lease or operate all of its properties and assets and to conduct its business as it is now being conducted. The Governing Documents of the Company as previously made available by or on behalf of the Company to EBAC, are true, correct and complete. The Company is lawfully licensed or qualified and in good standing as a foreign or extra-provincial corporation (or other entity, if applicable) in each jurisdiction in which its ownership of property or the character of its activities is such as to require it to be so licensed or qualified or in good standing, as applicable, except where the failure to be so licensed or qualified or in good standing has not been, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole.

 

Section 4.02.      Subsidiaries. A complete list of each Subsidiary of the Company and its jurisdiction of incorporation, formation or organization, as applicable, is set forth on Section 4.02 of the Company Disclosure Letter. All Subsidiaries of the Company have been duly formed or organized and are validly existing under the Laws of their jurisdiction of incorporation or organization and have the requisite power and authority to own, lease or operate all of their respective properties and assets and to conduct their respective businesses as they are now being conducted. True, correct and complete copies of the Governing Documents of the Subsidiaries of the Company, in each case, as

 

39 

 

amended to the date of this Agreement, have been previously made available to EBAC by or on behalf of the Company. Each Subsidiary of the Company is duly licensed or qualified and in good standing as a foreign or extra-provincial corporation (or other entity, if applicable) in each jurisdiction in which its ownership of property or the character of its activities is such as to require it to be so licensed or qualified or in good standing, as applicable, except where the failure to be so licensed or qualified or in good standing has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect.

 

Section 4.03.      Due Authorization.

 

(a)            The Company has all requisite company or corporate power, as applicable, and authority to execute and deliver this Agreement and the other documents to which it is a party contemplated hereby and to consummate the transactions contemplated hereby and thereby and to perform all of its obligations hereunder and thereunder. The execution and delivery of this Agreement and the other documents to which the Company is a party contemplated hereby and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized and approved by the Board of Directors of the Company, and no other company or corporate proceeding on the part of the Company is necessary to authorize this Agreement and the other documents to which the Company is a party contemplated hereby. This Agreement has been, and on or prior to the Acquisition Closing, the other documents to which the Company is a party contemplated hereby will be, duly and validly executed and delivered by the Company and this Agreement constitutes, and on or prior to the Acquisition Closing, the other documents to which the Company is a party contemplated hereby will constitute, a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and subject, as to enforceability, to general principles of equity (the “Enforceability Exceptions”).

 

(b)            On or prior to the date of this Agreement, the Board of Directors of the Company has duly adopted resolutions (i) determining that this Agreement and the other documents to which the Company is a party contemplated hereby and the transactions contemplated hereby and thereby are advisable and fair to, and in the best interests of, the Company and its shareholders, as applicable, (ii) approving the transfer of the Company Common Shares to New Parent, and (iii) authorizing and approving the execution, delivery and performance by the Company of this Agreement, the Transactions and the other documents to which the Company is a party contemplated hereby and the transactions contemplated hereby and thereby. No other corporate action is required on the part of the Company or any of its shareholders to enter into this Agreement or the other documents to which the Company is a party contemplated hereby or to approve the transactions contemplated hereby and thereby. The Governing Documents of the Company have been duly and validly approved in accordance with applicable Law.

 

40 

 

Section 4.04.      No Conflict. Subject to the receipt of the Governmental Authorizations set forth in Section 4.05 of the Company Disclosure Letter and except as set forth on Section 4.04 of the Company Disclosure Letter, the execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement and the other documents to which the Company is a party contemplated hereby and the consummation of the Transactions and thereby do not and will not (a) violate or conflict with any provision of, or result in the breach of, or default under, the Governing Documents of the Company or any of its Subsidiaries, (b) violate or conflict with any provision of, or result in the breach of, or default under, any Law, License or Governmental Order applicable to the Company or any of its Subsidiaries, (c) violate or conflict with any provision of, or result in the breach of, result in the loss of any right or benefit, or cause acceleration, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, cancellation or acceleration) under any Material Contract to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries may be bound, or terminate or result in the termination of any such foregoing Contract or (d) result in the creation of any Lien (other than Permitted Liens) upon any of the properties or assets of the Company or any of its Subsidiaries, except, in the case of clauses (b) through (d), to the extent that the occurrence of the foregoing which (i) has not had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or (ii) would not be, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole.

 

Section 4.05.      Governmental Authorities; Consents. No action by, notice, consent, approval, waiver or authorization of, or designation, declaration or filing with, any Governmental Authority is required on the part of the Company or its Subsidiaries with respect to the Company’s execution, delivery and performance of this Agreement and the other Ancillary Agreements to which the Company is a party and the consummation of the transactions contemplated hereby and thereby (each, a “Governmental Authorization”), except for (i) the filings and approvals set forth in Section 4.05 of the Company Disclosure Letter, (ii) the filing with the SEC of (A) the Registration Statement and the declaration of the effectiveness thereof by the SEC and (B) such reports under Section 13(a) or 15(d) of the Exchange Act as may be required in connection with this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby, (iii) such filings with and approvals of the Stock Exchange to permit New Parent Shares to be issued in accordance with this Agreement to be listed on the Stock Exchange, (iv) filing of the Cayman Plan of Merger and, if applicable, the plan of merger under the applicable law of the Swiss Code of Obligations, as appropriate, (v) such filings with the relevant Swiss commercial register as per Section 2.02(b), Section 8.07 or Section 9.10 or (vi) any actions, notices, consents, approvals, waiver or authorizations, designations, declarations or filings, the absence of which has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole.

 

41 

 

Section 4.06.      Capitalization of the Company.

 

(a)            The issued share capital of the Company consists of CHF 1,690,661.40, divided into (i) 3,402,771 registered shares with a nominal value of CHF 0.10 each (the “Company Common Shares”), (ii) 1,623,793 registered Series A preferred shares (the “Series A Preferred Shares”) with a nominal value of CHF 0.10 each, (iii) 2,486,188 registered Series B-1 preferred shares (the “Series B-1 Preferred Shares”) with a nominal value of CHF 0.10 each, (iv) 2,705,324 registered Series B-2 preferred shares (the “Series B-2 Preferred Shares”) with a nominal value of CHF 0.10 each, (v) 5,699,813 registered Series C-1(a) preferred shares (the “Series C-1(a) Preferred Shares”) with a nominal value of CHF 0.10 each and (vi) 197,745 registered Series C-1(b) preferred shares (the “Series C-1(b) Preferred Shares”) with a nominal value of CHF 0.50 each (collectively, the Series A Preferred Shares, the Series B-1 Preferred Shares, the Series B-2 Preferred Shares, the Series C-1(a) Preferred Shares and the Series C-1(b) Preferred Shares, the “Company Preferred Shares” and, together with the Company Common Shares, “Company Share Capital”), and there are no other authorized Equity Securities of the Company that are issued and outstanding. All of the issued and outstanding shares of Company Share Capital (i) have been duly authorized and validly issued and are fully paid and non-assessable; (ii) have been offered, sold and issued in compliance with applicable Law and all requirements set forth in (1) the Governing Documents of the Company and (2) any other applicable Contracts governing the issuance of such securities; (iii) are not subject to, nor have they been issued in violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law, the Governing Documents of the Company or any Contract to which the Company is a party or otherwise bound (other than the Company's shareholders' agreement dated April 1, 2021 (and any prior version thereof)); (iv) are fully vested and nonforfeitable; and (v) are free and clear of any Liens (other than restrictions under applicable securities Laws or the articles of association of the Company or the Company's shareholders' agreement dated April 1, 2021 (and any prior version thereof). As of the date of this Agreement, 1,543,829 (including conditional capital of 1,443,829 and 100,000 treasury shares) are reserved for future common share issuance pursuant to the Company Equity Plan, of which 1,538,297 Company Common Shares are subject to outstanding Company Options.

 

(b)            Except as otherwise set forth on Section 4.02 of the Company Disclosure Letter, neither the Company nor any of its Subsidiaries owns or holds (of record, beneficially, legally or otherwise), directly or indirectly, any Equity Securities in any other Person or the right to acquire any such Equity Security, and, without limiting the foregoing, none of the Company or any of its Subsidiaries are a partner or member of any partnership, limited liability company or joint venture.

 

42 

 

(c)            Except as otherwise set forth on Section 4.06(c) of the Company Disclosure Letter, the Company has not granted any outstanding subscriptions, options, stock appreciation rights, warrants, rights or other securities (including debt securities) convertible into or exchangeable or exercisable for shares of Company Share Capital, any other commitments, calls, conversion rights, rights of exchange or privilege (whether pre-emptive, contractual or by matter of Law), plans or other agreements of any character providing for the issuance of additional Equity Securities, the sale of Equity Securities, or for the repurchase or redemption of Equity Securities of the Company or the value of which is determined by reference to shares of Company Share Capital or other Equity Securities of the Company, and there are no voting trusts, proxies or agreements of any kind which may obligate the Company to issue, purchase, register for sale, redeem or otherwise acquire any shares of Company Share Capital or other Equity Securities of the Company or vote any Equity Securities of the Company in any manner.

 

(d)            Section 4.06(d) of the Company Disclosure Letter sets forth the following information with respect to each Company Option outstanding, if applicable: (i) the name of the Company Optionholder and whether such Company Optionholder is a current or former employee of the Company or any of its Subsidiaries; (ii) the number of shares of the Company Common Shares outstanding with respect to such Company Option; (iii) the exercise price of such Company Option; (iv) the date on which such Company Option was granted; and (v) the date on which such Company Option expires. The Company has made available to EBAC an accurate and complete copy of the Company Equity Plan and all forms of award agreements evidencing all outstanding Company Option. No Company Option was granted with an exercise price per share less than the fair market value of the underlying Company Common Shares as of the date such Company Option was granted, as determined in accordance with Section 409A of the Code. All Company Common Shares subject to issuance as aforesaid, upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, will be duly authorized, validly issued, fully paid and nonassessable. All Company Options may, by their respective terms, be treated as set forth in Section 3.07 of this Agreement.

 

Section 4.07.      Capitalization of Subsidiaries.

 

(a)            The outstanding shares of capital stock or Equity Securities of each Subsidiary of the Company (i) have been duly authorized and validly issued and are, to the extent applicable, fully paid and non-assessable; (ii) have been offered, sold and issued in compliance with applicable Law, including federal and state securities Laws, and all requirements set forth in (1) the Governing Documents of each such Subsidiary of the Company, and (2)any other applicable Contracts governing the issuance of such securities; (iii) are not subject to, nor have they been issued in violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law, the Governing Documents of each such Subsidiary or any Contract to which each such Subsidiary is a party or otherwise bound; and (iv) are free and clear of any Liens (other than restrictions under applicable securities Laws).

 

43 

 

(b)            The Company owns of record and beneficially all the issued and outstanding shares of capital stock or Equity Securities of such Subsidiaries of the Company free and clear of any Liens other than Permitted Liens.

 

(c)            Except as set forth on Section 4.07(c) of the Company Disclosure Letter, there are no outstanding subscriptions, options, warrants, rights or other securities (including debt securities) exercisable or exchangeable for any capital stock of such Subsidiaries of the Company, any other commitments, calls, conversion rights, rights of exchange or privilege (whether pre-emptive, contractual or by matter of Law), plans or other agreements of any character providing for the issuance of additional shares, the sale of treasury shares or other Equity Securities, or for the repurchase or redemption of shares or other Equity Securities of such Subsidiaries or the value of which is determined by reference to shares or other Equity Securities of the Company Subsidiaries, and there are no voting trusts, proxies or agreements of any kind which may obligate any Subsidiary of the Company to issue, purchase, register for sale, redeem or otherwise acquire any of its Equity Securities or vote its Equity Securities in any manner.

 

Section 4.08.      Financial Statements.

 

(a)            Attached as Section 4.08(a) of the Company Disclosure Letter are:

 

(i)            true and complete copies of the audited consolidated statement of financial position as of December 31, 2021 and December 31, 2020, and the related audited statements of comprehensive income, changes in equity and cash flows for the years ended December 31, 2021, and December 31, 2020, of the Company and its Subsidiaries, together with the auditor’s reports thereon (the “Audited Financial Statements”); and

 

(ii)            true and complete copies of the unaudited interim consolidated statement of financial position as of June 30, 2022, and the related unaudited interim statements of comprehensive income, changes in equity, and cash flows for the 6-month period ended June 30, 2022 of the Company and its Subsidiaries (the “Q2 2022 Financial Statements” and, together with the Audited Financial Statements, and Q3 2022 Financial Statements (if delivered pursuant to Section 7.03) the “Financial Statements”).

 

(b)            Except as set forth on Section 4.08(b) of the Company Disclosure Letter, the Financial Statements (i) fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries, as at the respective dates thereof, and the consolidated results of their operations, their consolidated comprehensive incomes or losses, their consolidated changes in shareholders’ equity and their consolidated cash flows for the respective periods then ended (except for, in the case of the Q2 2022 Financial Statements and Q3 2022 Financial Statements (if delivered), any normal year-end adjustments and any absence of footnotes), and (ii) were prepared in conformity with IFRS applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto and, in the case of the Q2 2022 Financial Statements and Q3 2022 Financial Statements (if delivered), the absence of footnotes or the inclusion of limited footnotes).

 

44 

 

(c)            Neither the Company (including, to the knowledge of the Company, any employee thereof) nor any independent auditor of the Company has identified or been made aware of (i) any significant deficiency or material weakness in the system of internal accounting controls utilized by the Company, (ii) any fraud, whether or not material, that involves the Company’s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii) any written claim or allegation regarding any of the foregoing.

 

Section 4.09.      Undisclosed Liabilities. Except as set forth on Section 4.09 of the Company Disclosure Letter, as of the date of this Agreement, there is no other liability, debt (including Indebtedness) or obligation of, or claim or judgment against, the Company or any of the Company’s Subsidiaries (whether direct or indirect, absolute or contingent, accrued or unaccrued, known or unknown, liquidated or unliquidated, or due or to become due) of the type required to be set forth on a balance sheet in accordance with IFRS, except for liabilities, debts, obligations, claims or judgments (a) reflected or reserved for on the Financial Statements or disclosed in the notes thereto, (b) that have arisen since the date of the most recent balance sheet included in the Financial Statements in the ordinary course of business, consistent with past practice, of the Company and its Subsidiaries (none of which results from, arises out of or was caused by any tortious conduct, breach of Contract, or infringement or violation of applicable Law), (c) that will be discharged or paid off prior to or at the Acquisition Closing or (d) which has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole. This Section 4.09 shall not apply to Tax matters.

 

Section 4.10.      Litigation and Proceedings. Except as set forth on Section 4.10 of the Company Disclosure Letter or which has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or has not had, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, (a) there are no pending or, to the knowledge of the Company, threatened, lawsuits, actions, suits, judgments, claims, proceedings or any other Actions (including any investigations or inquiries initiated, pending or threatened by any Governmental Authority), or other proceedings at law or in equity (collectively, “Legal Proceedings”), against the Company or any of the Company’s Subsidiaries or their respective properties or assets; and (b) there is no outstanding Governmental Order imposed upon the Company or any of the Company’s Subsidiaries; nor are any properties or assets of the Company or any of its Subsidiaries’ respective businesses bound or subject to any Governmental Order. This Section 4.10 shall not apply to Tax matters.

 

45 

 

Section 4.11.      Legal Compliance.

 

(a)            Except where the failure to be, or to have been, in compliance with such Laws has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, each of the Company, its Subsidiaries and, to the knowledge of the Company, Collaboration Partners, is, and for the prior three (3) years has been, in compliance with all applicable Laws.

 

(b)            Except where the failure to maintain such program has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, the Company and its Subsidiaries maintain a program of policies, procedures and internal controls reasonably designed and implemented to (i) prevent the use of the products and services of the Company and its Subsidiaries in a manner that violates applicable Law (including money laundering or fraud), and (ii) otherwise provide reasonable assurance that violation of applicable Law by any of the Company’s or its Subsidiaries’ directors, officers, employees or its or their respective agents, representatives or other Persons, acting on behalf of the Company or any of the Company’s Subsidiaries, will be prevented, detected and deterred.

 

(c)            For the past three (3) years, neither the Company nor any of its Subsidiaries or any of the officers or directors of its Subsidiaries acting in such capacity, or to the knowledge of the Company, Collaboration Partners, has received any written notice of, or been charged with, the violation of any Laws, except where such violation has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement or is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole.

 

(d)            This Section 4.11 shall not apply to Tax matters.

 

Section 4.12.      Contracts; No Defaults.

 

(a)            True, correct and complete copies of the Contracts listed described in clauses (i) through (xi) below to which, as of the date of this Agreement, the Company or any Subsidiary of the Company is a party or by which they are bound, other than a Company Benefit Plan, (the “Material Contracts”) have previously been delivered to or made available to EBAC or its agents or representatives, together with all amendments thereto. Section 4.12(a) of the Company Disclosure Letter contains a listing of all Material Contracts.

 

(i)            Each Contract, excluding leases, subleases or other occupancy agreements related to real property, pursuant to which Company or any of the Company’s Subsidiaries is obligated to pay, or entitled to receive, payments in excess of $500,000 in the twelve (12) month period following the date hereof;

 

46 

 

(ii)            Each note, debenture, other evidence of Indebtedness, guarantee, loan, credit or financing agreement or instrument or other Contract for money borrowed by the Company or any of the Company’s Subsidiaries, including any agreement or commitment for future loans, credit or financing, in each case, in excess of $50,000;

 

(iii)            Each Contract for the acquisition of any Person or any business unit thereof or the disposition of any material assets of the Company or any of its Subsidiaries in the last three (3) years, in each case, involving payments in excess of $50,000 other than Contracts (A) in which the applicable acquisition or disposition has been consummated and there are no material obligations ongoing or (B) between the Company and its Subsidiaries;

 

(iv)            Each lease, rental or occupancy agreement, installment and conditional sale agreement, and other Contract that provides for the ownership of, leasing of, title to, use of, or any leasehold or other interest in any real or personal property that involves aggregate payments in excess of $50,000 in any calendar year;

 

(v)            Each Contract that is material to the Company and its Subsidiaries, taken as a whole, involving the formation of a (A) joint venture, (B) partnership, or (C) limited liability company, in each case providing for the sharing of revenues, profits, losses or costs (excluding, in the case of clauses (B) and (C), any Subsidiary of the Company);

 

(vi)            Contracts (other than employment agreements, employee confidentiality and invention assignment agreements, equity or incentive equity documents and Governing Documents) that are material to the Company and its Subsidiaries, taken as a whole, between the Company and any Subsidiary of the Company, on the one hand, and Affiliates of the Company or any of the Company’s Subsidiaries (other than the Company or any of the Company’s Subsidiaries), the officers and managers (or equivalents) of the Company or any of the Company’s Subsidiaries, the members or shareholders of the Company or any of the Company’s Subsidiaries, any employee of the Company or any of the Company’s Subsidiaries or a member of the immediate family of the foregoing Persons, on the other hand (collectively, the “Affiliate Agreements”);

 

(vii)            Each employment Contract with each executive officer of the Company or any of its Subsidiaries;

 

(viii)            Material Contracts containing covenants of the Company or any of the Company’s Subsidiaries (or, after the Acquisition Closing, that would reasonably be expected to bind, in any material respect, the operations of New

 

47 

 

Parent or any of its Affiliates) (A) prohibiting or limiting the right of the Company or any of the Company’s Subsidiaries to engage in or compete with any Person in any line of business in any material respect, (B) prohibiting or restricting the Company’s and the Company’s Subsidiaries’ ability to conduct their business with any Person in any geographic area in any material respect, (C) prohibiting the Company or any of the Company’s Subsidiaries from soliciting any strategic partner or (D) granting exclusive or preferential rights or “most favored nations” status to any person;

 

(ix)            Any Collective Bargaining Agreement;

 

(x)            Contracts with any Governmental Authority;

 

(xi)            Each Contract involving any resolution or settlement of any actual or threatened Action under which the Company or any of its Subsidiaries has any ongoing non-monetary obligations (other than customary confidentiality or similar provisions) or monetary obligations in excess of $50,000;

 

(xii)            Each Contract pursuant to which the Company or any of its Subsidiaries licenses or sublicenses from or to any third party (or receives from or grants to any third party a covenant not to sue with respect to) any Intellectual Property that is material to the business of the Company and its Subsidiaries taken as a whole, other than off-the-shelf software licenses that are commercially available on reasonable terms to the public generally;

 

(xiii)            Each Contract requiring capital expenditures by the Company or any of the Company’s Subsidiaries after the date of this Agreement in an amount in excess of $50,000 in any calendar year; and

 

(xiv)            Contracts granting to any Person (other than the Company or its Subsidiaries) a right of first refusal, first offer or similar preferential right to purchase or acquire Equity Securities in the Company or any of the Company’s Subsidiaries that are material to the Company and its Subsidiaries, taken as a whole.

 

(b)            Except for any Contract that will terminate upon the expiration of the stated term thereof prior to the Acquisition Closing Date, all of the Material Contracts listed pursuant to Section 4.12(a) in the Company Disclosure Letter are (i) in full force and effect and (ii) represent the legal, valid and binding obligations of the Company or the Subsidiary of the Company party thereto and, to the knowledge of the Company, represent the legal, valid and binding obligations of the counterparties thereto. Except where such breach, receipt of claim or notice or occurrence of an event has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, (1) neither the Company, the Subsidiaries of the

 

48 

 

Company, nor, to the knowledge of the Company, any other party thereto is in breach of or default under any such Contract, (2) during the last twelve (12) months, neither the Company nor any of the Subsidiaries of the Company has received any written claim or written notice of termination or breach of or default under any such Contract, and (3) to the knowledge of the Company, no event has occurred which individually or together with other events, would reasonably be expected to result in a breach of or a default under any such Contract by the Company or any Subsidiary of the Company or, to the knowledge of the Company, any other party thereto (in each case, with or without notice or lapse of time or both).

 

Section 4.13.      Company Benefit Plans.

 

(a)            Section 4.13(a) of the Company Disclosure Letter sets forth a complete list, as of the date hereof, of each Company Benefit Plan. For purposes of this Agreement, a “Company Benefit Plan” means any plan, policy, program or agreement (including any “employee benefit plan” as defined in Section 3(3) of the U.S. Employee Retirement Income Security Act of 1974, as amended (“ERISA”), whether or not subject to ERISA, and all other employment, bonus, incentive or deferred compensation, Service Provider loan, note or pledge agreements, equity or equity-based compensation, severance, retention, retirement, change in control or similar plan, policy, program or agreement) providing compensation or other benefits to any current or former Service Provider, which are maintained, sponsored or contributed to by the Company or any of its Subsidiaries, or to which the Company or any of the its Subsidiaries is a party or has any liability, and in each case whether or not (i) in writing or (ii) funded, but excluding in each case any statutory plan, program or arrangement that is maintained by any Governmental Authority. The Company has made available to EBAC true, complete and correct copies of such Company Benefit Plan (or, if not written a written summary of its material terms).

 

(b)            Except as set forth on Section 4.13(b) of the Company Disclosure Letter or which has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, (i) each Company Benefit Plan has been operated and administered in compliance with its terms and all applicable Laws; and (ii) in all material respects, all contributions required to be made with respect to any Company Benefit Plan on or before the date hereof have been made and all obligations in respect of each Company Benefit Plan as of the date hereof have been accrued and reflected in the Company’s financial statements to the extent required by IFRS.

 

(c)            Except as has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole, no employee has previously transferred to the Company or any of its subsidiaries pursuant to

 

49 

 

the United Kingdom Transfer of Undertakings (Protection of Employment) Regulations 1981 or 2006 (as amended), and there are no such employees who prior to such transfer participated in a defined benefit pension scheme that made provision for benefits other than related to old age, invalidity or on death.

 

(d)            With respect to each Company Benefit Plan, no material actions, suits or claims (other than routine claims for benefits in the ordinary course) are pending or, to the knowledge of the Company, threatened, and to the knowledge of the Company, no facts or circumstances exist that would reasonably be expected to give rise to any such actions, suits or claims.

 

(e)            Except as set forth on Section 4.13(e) of the Company Disclosure Letter, the consummation of the Transactions will not, either alone or in combination with another event (such as termination following the consummation of the Transactions), (i) entitle any current or former Service Provider to any severance pay or any other compensation or benefits payable or to be provided by the Company or any Subsidiary of the Company, (ii) accelerate the time of payment, funding or vesting, or increase the amount of compensation or benefits due any such Service Provider or (iii) result in the forgiveness of any Indebtedness of any Service Provider.

 

(f)             Neither the Company nor any of its Subsidiaries has incurred any current or projected liability in respect of post-employment or post-retirement health, medical or life insurance benefits for current or former or retired Service Providers, except as required by applicable Law.

 

(g)            Each Company Benefit Plan that constitutes a “nonqualified deferred compensation plan” (as defined in Section 409A(d)(1) of the Code) has been documented and operated in compliance with Section 409A of the Code. There is no agreement, plan, or arrangement, or other contract by which the Company or any of its Subsidiaries is bound to compensate any Service Provider for any Taxes.

 

Section 4.14.      Labor Relations; Employees.

 

(a)            (i) Neither the Company nor any of its Subsidiaries is a party to or bound by any Collective Bargaining Agreement with any labor or trade union, works council, employee representative body or labor organization or association (collectively, a “Labor Organization”), (ii) no such Collective Bargaining Agreement is being negotiated by the Company or any of its Subsidiaries, (iii) no employees of the Company or any of its Subsidiaries are represented by any Labor Organization with respect to their employment with the Company or its Subsidiaries and (iv) no Labor Organization has, to the knowledge of the Company, requested or made a pending demand for recognition or certification or sought to organize or represent any of the employees of the Company or any of its Subsidiaries with respect to their employment with the Company or its Subsidiaries.

 

50 

 

(b)            In the past three (3) years, there has been no actual or, to the knowledge of the Company, threatened material unfair labor practice charge, grievance, arbitration, strike, slowdown, work stoppage, lockout, picketing, hand billing, or similar labor dispute against or affecting the Company or its Subsidiaries.

 

(c)            The execution of this Agreement and the consummation of the Transactions will not result in any breach or other violation of any Collective Bargaining Agreement and will not require the approval of any Labor Organizations.

 

(d)            Each of the Company and its Subsidiaries are, and have been for the past three (3) years, in compliance in all material respects with all applicable Laws respecting labor and employment, including, but not limited to, all Laws respecting terms and conditions of employment, health and safety, wages and hours, holiday pay and the calculation of holiday pay, working time, employee classification (with respect to exempt vs. non-exempt status and employee vs. independent contractor and worker status), child labor, immigration, employment discrimination, disability rights or benefits, equal opportunity and equal pay, workers’ compensation, labor relations, employee leave issues and unemployment insurance.

 

(e)            Except as set forth on Section 4.14(e) of the Company Disclosure Letter or would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole, in the past three (3) years, the Company and its Subsidiaries have not received (i) notice of any unfair labor practice charge or complaint pending or threatened before any Governmental Authority against them, (ii) notice of any complaints, grievances or arbitrations arising out of any Collective Bargaining Agreement or any other complaints, grievances or arbitration procedures against them, (iii) notice of any charge or complaint with respect to or relating to them pending before the Equal Employment Opportunity Commission or any other Governmental Authority responsible for the prevention of unlawful employment practices, (iv) notice of the intent of any Governmental Authority responsible for the enforcement of labor, employment, wages and hours of work, child labor, immigration, or occupational safety and health Laws to conduct an investigation with respect to or relating to them or notice that such investigation is in progress, or (v) notice of any complaint, lawsuit or other proceeding pending or threatened in any forum by or on behalf of any present or former employee of such entities, any applicant for employment or classes of the foregoing alleging breach of any express or implied Contract of employment, any applicable Law governing employment or the termination thereof or other discriminatory, wrongful or tortious conduct in connection with the employment relationship.

 

(f)             To the knowledge of the Company, no current Service Provider is in violation of any term of any employment agreement, restrictive covenant, nondisclosure obligation or fiduciary duty (i) to the Company or any of its Subsidiaries or (ii) to a former employer or engager of any such individual relating to (A) the right of any such individual to work for or provide services to the Company or any of its Subsidiaries or (B) the knowledge or use of trade secrets or proprietary information, except as has not

 

51 

 

had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole.

 

(g)            Neither the Company nor any of its Subsidiaries is party to a material settlement agreement with a current or former officer Service Provider that involves allegations relating to sexual harassment, sexual misconduct or any form of illegal discrimination by an officer of the Company or any of its Subsidiaries. To the knowledge of the Company, in the last three (3) years, no material allegations of sexual harassment, sexual misconduct or any form of illegal discrimination have been made against any employee of the Company or any of its Subsidiaries.

 

(h)            In the past three (3) years, the Company and the its Subsidiaries are and have been in compliance in all material respects with all notice and other requirements under all applicable Laws relating to layoffs and individual and collective dismissals. The Company and its Subsidiaries have not engaged in broad-based layoffs, furloughs, employment terminations (other than for cause) or effected any broad-based salary or other compensation or benefits reductions, in each case, whether temporary or permanent, since January 1, 2021, through the date hereof. The Company, taken as a whole with its Subsidiaries, has sufficient employees to operate the business of the Company and its Subsidiaries as currently conducted.

 

Section 4.15.      Taxes. Except as disclosed on Schedule 4.15 of the Company Disclosure Letter:

 

(a)            All income and other material Tax Returns required to be filed by or with respect to the Company or any of its Subsidiaries have been timely filed (taking into account any applicable extensions), all such Tax Returns (taking into account all amendments thereto) are true, complete and accurate in all material respects and all material amounts of Taxes of the Company or any of its Subsidiaries that are due and payable (whether or not shown on any Tax Return) have been fully and timely paid, other than Taxes being contested in good faith and for which adequate reserves have been established in accordance with IFRS.

 

(b)            The Company and each of its Subsidiaries have withheld from amounts owing to any employee, creditor or other Person all material Taxes required by Law to be withheld, paid over to the proper Governmental Authority in a timely manner all such withheld amounts required to have been so paid over and complied in all material respects with all applicable withholding and related reporting requirements with respect to such Taxes.

 

(c)            Neither the Company nor any of its Subsidiaries has any liability for unpaid Taxes which has not been accrued for or reserved on the Financial Statements, other than any liability for unpaid Taxes that has been incurred since the end of the most recent fiscal year in the ordinary course of business.

 

52 

 

(d)            There are no Liens for any material Taxes (other than Permitted Liens) upon the property or assets of the Company or any of its Subsidiaries.

 

(e)            No claim, assessment, deficiency or proposed adjustment for any material amount of Tax has been asserted or assessed by any Governmental Authority against the Company or any of its Subsidiaries that remains unpaid except for claims, assessments, deficiencies or proposed adjustments being contested in good faith and for which adequate reserves have been established in accordance with IFRS.

 

(f)             There are no ongoing or pending Legal Proceedings with respect to any Taxes of the Company or any of its Subsidiaries and neither the Company nor any of its Subsidiaries has received written notice from any Governmental Authority that any such Legal Proceeding is contemplated or pending. There are no waivers, extensions or requests for any waivers or extensions of any statute of limitations currently in effect with respect to any material Taxes of the Company or any of its Subsidiaries (other than pursuant to an extension of time to file a Tax Return of not more than seven months obtained in the ordinary course of business).

 

(g)            Neither the Company nor any of its Subsidiaries has made a request for an advance Tax ruling, a request for administrative Tax relief, a request for technical Tax advice, a request for a change of any method of accounting or any similar request with respect to Taxes that is in progress or pending with any Governmental Authority.

 

(h)            Neither the Company nor any of its Subsidiaries is a party to any Tax Sharing Agreement other than (i) any such agreement solely among the Company and its Subsidiaries and (ii) customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes.

 

(i)             Neither the Company nor any of its Subsidiaries has ever been a member of an Affiliated Group (other than an Affiliated Group the common parent of which is the Company or any of its Subsidiaries and which consists only of the Company and its Subsidiaries). Neither the Company nor any of its Subsidiaries is liable for Taxes of any other Person (other than the Company and its Subsidiaries) under Treasury Regulation Section 1.1502-6 or any similar provision of state, local or non-U.S. Tax Law or as a transferee or successor or by Contract (other than (i) any such agreement solely among the Company and its Subsidiaries and (ii) customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes).

 

(j)             No written claim has been made by any Governmental Authority in a jurisdiction where the Company or any of its Subsidiaries does not pay a particular type of Tax or file a particular type of Tax Return that it is or may be required to pay such type of Tax or file such type of Tax Return in such jurisdiction.

 

53 

 

(k)            To the Company’s Knowledge, neither the Company nor any of its Subsidiaries has, or has ever had, a permanent establishment in any country other than the country of its organization, or is, or has ever been, subject to income Tax in a jurisdiction outside the country of its organization.

 

(l)             Neither the Company nor any of its Subsidiaries has constituted either a “distributing corporation” or a “controlled corporation” in a distribution of stock qualifying for tax-free treatment under Section 355 of the Code in the prior two (2) years.

 

(m)             Neither the Company nor any of its Subsidiaries has participated in a “listed transaction” within the meaning of Treasury Regulations Section 1.6011-4(b)(2).

 

(n)            Neither the Company nor any of its Subsidiaries will be required to include any material amount in taxable income or exclude any material item of deduction or loss from taxable income for any taxable period ending after the Acquisition Closing Date as a result of any (i) installment sale or open transaction disposition made prior to the Acquisition Closing outside the ordinary course of business, (ii) prepaid amount received or deferred revenue recognized prior to the Acquisition Closing outside the ordinary course of business, (iii) change in method of accounting for a taxable period ending on or prior to the Acquisition Closing Date, (iv) “closing agreement” as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or non-U.S. Tax Law) executed on or prior to the Acquisition Closing Date or (v) binding agreement with respect to Taxes with a Governmental Authority executed prior to the Acquisition Closing.

 

(o)            Neither the Company nor any of its Subsidiaries has any obligation to make any payment described in Section 965(h) of the Code.

 

(p)            To the Company’s Knowledge, the Company and its Subsidiaries have complied in all material respects with the conditions stipulated in each Tax Grant that the Company and its Subsidiaries have utilized.

 

(q)            The Company reasonably believes it was not a “passive foreign investment company” within the meaning of Section 1297 of the Code for its taxable year ended December 31, 2021, and reasonably does not expect to be a “passive foreign investment company” within the meaning of Section 1297 of the Code for its taxable year ending December 31, 2022.

 

(r)             Neither the Company nor any of its Subsidiaries has taken any action or agreed to take any action not contemplated by the Transactions, and to the knowledge of the Company there are no facts or circumstances, that would reasonably be expected to prevent, impair or impede the Intended Tax Treatment.

 

(s)            The Company has not and will not exercise any rights to cause funding to occur under the Convertible Loan Agreement.

 

54 

 

Section 4.16.      Brokers’ Fees. No broker, finder, investment banker or other Person (except the Person(s) set forth on Section 4.16 of the Company Disclosure Letter) is entitled to any brokerage fee, finders’ fee or other commission in connection with the Transactions based upon arrangements made by the Company, any of the Company’s Subsidiaries’ or any of their Affiliates for which EBAC, the Company or any of the Company’s Subsidiaries has any obligation.

 

Section 4.17.      Insurance. Except as has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole: (i) all the material policies or binders of property, fire and casualty, product liability, workers’ compensation, and other forms of insurance (other than any such policies relating to a Company Benefit Plan) held by, or for the benefit of, the Company or any of its Subsidiaries as of the date of this Agreement are in full force and effect and (ii) there is no existing default or event that, with notice or lapse of time or both, would constitute a default by any insured thereunder.

 

Section 4.18.      Permits. Each of the Company and its Subsidiaries holds all permits (the “Material Permits”) that are required to own, lease or operate its properties and assets and to conduct its business as currently conducted, except as has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole. Except as is not and would not reasonably be expected to be material to the Company and its Subsidiaries, taken as a whole, (i) each Material Permit is in full force and effect in accordance with its terms and (ii) no written notice of revocation, cancellation or termination of any Material Permit has been received by the Company and its Subsidiaries. The Company is, and since January 1, 2019, has been, in compliance with the terms of all the Material Permits except as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Company and its Subsidiaries, taken as a whole. To the Company’s knowledge, no event, circumstance, or state of facts has occurred which (with or without due notice or lapse of time or both) would reasonably be expected to result in the failure of the Company or any of its Subsidiaries to be in compliance in all material respects with the terms of the Material Permits.

 

Section 4.19.      Regulatory Compliance.

 

(a)            Each of the Company and each Subsidiary of the Company is, and for the past three (3) years has been, in material compliance with the FDCA, the Federal Trade Commission Act, and the Fair Packaging and Labeling Act (collectively “Food and Drug Law”). Neither the Company nor any Subsidiary of the Company has received any claim (and, to the Company’s knowledge, no claim has been filed, commenced or threatened against the Company or any Subsidiary of the Company) alleging a material violation under any Food and Drug Law that has not been duly cured, and there are no pending or, to the Company’s knowledge, threatened legal proceedings, investigations, subpoenas, or civil investigative demands by any Governmental Authority, or other entity or individual, with respect to any alleged violation by the Company or any Subsidiary of the Company of any Food and Drug Law.

 

55 

 

(b)            The Products are not adulterated or misbranded within the meaning of the FDCA. All of the claims the Company and any Subsidiary of the Company makes or has made for its Products are and have been adequately supported and are otherwise compliant with Food and Drug Laws.

 

(c)            Since the date of the most recent balance sheet included in the Financial Statements, neither the Company nor any Subsidiary of the Company has received any warning letter, notice of violation, seizure, recall request, injunction, regulatory enforcement action, or criminal action issued, initiated, threatened in writing, or to the Company’s knowledge, otherwise threatened, by the FDA. Neither the Company nor any Subsidiary of the Company has made an untrue statement of material fact or fraudulent statement to the FDA or any other similar Governmental Authority.

 

Section 4.20.      Real Property. Except as had not had, and would not reasonably be expected to have, a Company Material Adverse Effect, the Company and its Subsidiaries have title, in fee or valid leasehold, easement or other rights, in each case, free and clear of all Liens other than Permitted Liens, to the land, buildings, structures and other improvements thereon and fixtures thereto necessary to permit the Company and its Subsidiaries to conduct their business as currently conducted.

 

Section 4.21.      Intellectual Property. Except as has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and except as is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole:

 

(a)            Section 4.21(a) of the Company Disclosure Letter lists, in a true and complete manner, each item of Intellectual Property that is registered or applied-for with a Governmental Authority or other applicable registrar and, as of the date hereof, is owned by, or exclusively licensed to, the Company or any of its Subsidiaries, whether applied for or registered in the United States or internationally (“Company Registered Intellectual Property”), in each case listing, as applicable, (i) the owner, (ii) the jurisdiction where the application/registration is located (or, for domain names, the applicable registrar), (iii) the title, (iv) the application or registration number, (v) the filing date or issuance/registration/grant date, and (vi) for each item of Company Registered Intellectual Property that is exclusively licensed to the Company or any of its Subsidiaries, the applicable agreement pursuant to which such item of Company Registered Intellectual Property is so licensed.

 

(b)            The Company or one of its Subsidiaries is the sole and exclusive owner, and with respect to Company Registered Intellectual Property, record owner, of all of Company Owned IP, and the Company and its Subsidiaries hold their respective rights under all Company Licensed IP, in each case, free and clear of all Liens (other than

 

56 

 

Permitted Liens). All Company Registered Intellectual Property (i) has been duly maintained (including the timely payment of registration, maintenance and renewal fees and timely filing of statements of use), (ii) is subsisting, in full force and effect and not expired, abandoned or cancelled, (iii) to the knowledge of the Company, is valid and enforceable, and (iv) has not been adjudged invalid or unenforceable, in whole or in part. With respect to each item of Company Registered Intellectual Property that is held by the Company or any of its Subsidiaries or any of their respective licensors by assignment, such assignment has been duly recorded with the applicable Government Authority from which such Company Registered Intellectual Property was issued or granted or before which such Company Registered Intellectual Property is pending.

 

(c)            The Company and its Subsidiaries and, to the knowledge of the Company, the Company’s and its Subsidiaries’ licensors, have complied with all necessary and applicable Laws regarding the duty of disclosure, candor and good faith in connection with each issued patent or pending patent application included in the Company Registered Intellectual Property. To the knowledge of the Company, there is no relevant prior art revealed, disclosed or discovered after the issuance of any patent included in the Company IP that was not cited during the prosecution of such patent.

 

(d)            The Company and each of its Subsidiaries owns, or has a valid and enforceable written license to use, all Intellectual Property used or held for use in, or otherwise necessary for, the continued conduct of the business of the Company and its Subsidiaries as currently conducted and in substantially the same manner as such business has been conducted during the twelve (12) months prior to the date hereof.

 

(e)            Neither the Company nor any of its Subsidiaries have infringed, misappropriated or otherwise violated, or are infringing upon, misappropriating or otherwise violating, any Intellectual Property of any Person. There is no Action pending, or, to the knowledge of the Company, threatened (including by way of a cease and desist letter or offer or invitation to take a license), (i) alleging the Company’s or any of its Subsidiaries’ infringement, misappropriation or other violation of any Intellectual Property of any Person, or (ii) challenging the scope, use, registrability, validity, or enforceability of, or the Company’s or any of its Subsidiaries’ right, title or interest in, to, or under, any Company IP, and there has not been any such Action brought or threatened in writing. Neither the Company nor any of its Subsidiaries is a party to or bound by any decree, judgment, order, or arbitral award that requires the Company or any of its Subsidiaries to grant to any Person any license, covenant not to sue, immunity or other right with respect to any Intellectual Property.

 

(f)             To the knowledge of the Company, no Person is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Company Owned IP or any of the Company’s or any of its Subsidiaries’ rights under any Company Licensed IP. Neither the Company nor any of its Subsidiaries has commenced or threatened any Action with respect to any such infringement, misappropriation or other violation against any Person.

 

57 

 

(g)            Section 4.21(g) of the Company Disclosure Letter contains a true and complete list of any and all Company IP that was created, developed or reduced to practice, or is being created, developed or reduced to practice, (i) pursuant to, or in connection with, any Contract with any Governmental Authority or Governmental Authority-affiliated entity, or university, college or other educational institution, or (ii) using any funding or facilities of any Governmental Authority or Governmental Authority-affiliated entity, or university, college or other educational institution (collectively, “Government Funded IP”).  The Company and its Subsidiaries and, to the knowledge of the Company, the Company’s and its Subsidiaries’ licensors, have taken any and all actions necessary to obtain, secure, maintain, enforce and protect the Company’s or its applicable Subsidiary’s, or such licensors’, as applicable, right, title and interest in, to and under all Government Funded IP, and the Company and its Subsidiaries and, to the knowledge of the Company, the Company’s and its Subsidiaries’ licensors, have complied with any and all any Intellectual Property disclosure and/or licensing obligations under any applicable Contract referenced in clause (i) above.

 

(h)            The Company and each of its Subsidiaries has taken reasonable steps, in accordance with normal industry practice, to maintain, defend and enforce all Company Owned IP and their respective rights in all Company Licensed IP, including reasonable actions to maintain and protect the confidentiality of any Trade Secrets included in the Company IP, and no such Trade Secrets have been disclosed other than pursuant to written and enforceable confidentiality agreements, which have not been breached or otherwise violated. Each current and former employee, consultant and contractor of the Company and its Subsidiaries, and each other Person currently or formerly engaged in the development or creation of any Company IP, has executed a written agreement whereby such employee, consultant, contractor or other Person presently assigns to the Company or one of its Subsidiaries or their respective licensors all right, title and interest in and to any and all Intellectual Property developed or created by such employee, consultant, contractor or other Person during the term of employment or engagement with the Company or its Subsidiaries or licensors, as applicable, and, to the knowledge of the Company, no such agreement has been breached or otherwise violated.

 

(i)             The execution and delivery of this Agreement and the consummation of the Transactions will not alter, encumber, impair or extinguish any Company IP. There exist no restrictions on the disclosure, use, licensing or transfer of any of the Company IP.

 

Section 4.22.      Privacy and Cybersecurity. Except as has not had, and would not reasonably be expected to have, a material adverse effect on the ability of the Company to enter into and perform its obligations under this Agreement and except as is not, and would not reasonably be expected to be, material to the business of the Company and its Subsidiaries, taken as a whole:

 

(a)            The Company and its Subsidiaries are presently in compliance with, and have at all times been in compliance with, all applicable (i) Laws, (ii) internal and posted or publicly facing rules, policies, and procedures, (iii) contractual obligations and (iv) industry standards, in each case, relating to the collection, storage, use, privacy,

 

58 

 

security or other processing of the Company IT Systems or Personal Data (the foregoing clauses (i) through (iv), “Privacy and Cybersecurity Requirements”). There currently are not, and historically have not been, any Actions pending or, to the knowledge of the Company, threatened, against the Company or any of its Subsidiaries alleging any breach or violation of any Privacy and Cybersecurity Requirement, and, to the knowledge of the Company, there exists no reasonable basis for any such Action.

 

(b)            The Company IT Systems are fully functional and operate and perform in all respects in accordance with their documentation and functional specifications and otherwise in the manner as is necessary for the business of each of the Company and each of its Subsidiaries as currently conducted, and do not contain any faults, viruses, bugs, worms, defects, similar corruptants or hardware components designed to permit unauthorized access to or to disable or otherwise harm any computer systems or software.

 

(c)            There have been no breaches (including any ransomware attack), violations, outages or unlawful, accidental, unauthorized uses, interruptions, exfiltrations, destructions, losses, disclosures, thefts, corruptions, compromises, disablements, modifications or transmissions of or accesses to any Company IT Systems or to any Personal Data otherwise in the possession, custody or control of the Company or any of its Subsidiaries or held or processed by any vendor, processor or other Person for or on behalf of the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries has notified or been required to notify any Governmental Authority or any other Person of any of the foregoing.

 

(d)            The Company IT Systems are adequate for and meet the needs of the business and operations of the Company and each of its Subsidiaries as currently conducted. The Company and each of its Subsidiaries have established and maintain, and use reasonable efforts to ensure that all Persons operating any Company IT Systems or otherwise processing Personal Data on behalf of the Company or any of its Subsidiaries have established and maintain, commercially reasonable and legally compliant policies, safeguards and procedures to maintain and protect the Company’s and its Subsidiaries’ Trade Secrets and other confidential information and the operation, integrity, redundancy, continuity and security of the Company IT Systems (including any and all information and data (including Personal Data) stored thereon or transmitted thereby), including the implementation, maintenance, monitoring and periodic testing of (i) data back-up, (ii) disaster avoidance, disaster recovery and business continuity plans, policies and procedures and (iii) encryption, redaction and other reasonable and appropriate organizational, administrative, technical and physical safeguards. Neither the Company nor any of its Subsidiaries, nor, to the knowledge of the Company, any such Person, has received any written notice or complaint from any other Person with respect to any of the foregoing, nor, to the knowledge of the Company, has any such notice or complaint been threatened in writing against the Company or any of its Subsidiaries or any such Person.

 

(e)            The consummation of the Transactions shall not breach or otherwise cause any violation of any Privacy and Cybersecurity Requirements or result in the Company or any of its Subsidiaries being prohibited from receiving or using any Personal Data in the manner currently received or used by the Company or its Subsidiaries.

 

59 

 

Section 4.23.      Environmental Matters. Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect:

 

(a)            The Company and its Subsidiaries are and, except for matters which have been fully resolved, have been in compliance with all Environmental Laws.

 

(b)            There has been no release of any Hazardous Materials by the Company or its Subsidiaries in quantities or concentrations that require remediation by the Company or its Subsidiaries under Environmental Laws (i) at, in, on or under any Realty or in connection with the Company’s and its Subsidiaries’ operations off-site of the Realty or (ii) to the knowledge of the Company, at, in, on or under any former Realty during the time that the Company owned or leased such property or at any other location where Hazardous Materials generated by the Company or any of the Company’s Subsidiaries have been transported to, sent, placed or disposed of.

 

(c)            Neither the Company nor its Subsidiaries are subject to any current Governmental Order relating to any non-compliance with Environmental Laws by the Company or its Subsidiaries or the investigation, sampling, monitoring, treatment, remediation, removal or cleanup of Hazardous Materials.

 

(d)            No Legal Proceeding is pending or, to the knowledge of the Company, threatened with respect to the Company’s and its Subsidiaries’ compliance with or liability under Environmental Laws, and there are no facts or circumstances which could reasonably be expected to form the basis of such a Legal Proceeding.

 

Section 4.24.      Absence of Changes. From the date of the most recent balance sheet included in the Financial Statements to the date of this Agreement, there has not been any Company Material Adverse Effect.

 

Section 4.25.      Anti-Corruption Compliance.

 

(a)            For the past four (4) years, neither the Company nor any of its Subsidiaries, nor any director, officer, or, to the knowledge of the Company, employee or agent, in each case acting on behalf of the Company or any of the Company’s Subsidiaries, has offered or given anything of value to: (i) any official or employee of a Governmental Authority, any political party or official thereof, or any candidate for political office, (ii) any other Person, in any such case while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to any official or employee of a Governmental Authority or candidate for political office, or (iii) any director, officer, employee, or agent of a commercial enterprise, in each case, in material violation of applicable Anti-Bribery Laws.

 

60 

 

(b)            To the knowledge of the Company, there are no pending or threatened, material claims, complaints, charges, investigations, voluntary disclosures or Legal Proceedings against the Company or any of the Company’s Subsidiaries related to any Anti-Bribery Laws.

 

Section 4.26.      Anti-Money Laundering, Sanctions and National Security Compliance.

 

(a)            The Company and its Subsidiaries are, and have been for the past four (4) years, in compliance with all Anti-Money Laundering Laws and Sanctions Laws in all material respects. To the knowledge of the Company, there are no pending or threatened claims, complaints, charges, investigations, voluntary disclosures or Legal Proceedings against the Company or any of the Company’s Subsidiaries related to any Anti-Money Laundering Laws or Sanctions Laws.

 

(b)            Neither the Company nor any of its Subsidiaries nor any of their respective directors or officers, employees, agents, representatives or other Persons acting on behalf of the Company or any of the Company’s Subsidiaries, (i) is a Sanctioned Person, or (ii) has during the past four (4) years been a Sanctioned Person with whom the Company or any Subsidiary was prohibited from dealing pursuant to applicable Sanctions Laws. Neither the Company nor any of its Subsidiaries nor any of their respective directors or officers, or, to the knowledge of the Company, employees, agents, representatives (in each case acting in their capacity as such) or other Persons acting on behalf of the Company or any of the Company’s Subsidiaries, has transacted material business in the past four (4) years directly or knowingly indirectly with any Sanctioned Person or Sanctioned Country.

 

Section 4.27.      Information Supplied. None of the information supplied or to be supplied by the Company or any of the Company’s Subsidiaries specifically in writing for inclusion in the Registration Statement will, at the date on which the Proxy Statement/Registration Statement is first mailed to the EBAC Shareholders or at the time of the EBAC Shareholders’ Meeting, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading.

 

Section 4.28.      No Outside Reliance. Notwithstanding the delivery or disclosure (except in Article 6 and the EBAC Disclosure Letter) to the Company or any of their respective representatives of any documentation or other information (including any financial projections or other supplemental details), the Company and its directors, managers, officers, employees, equityholders, partners, members or representatives, acknowledge and agree that the Company has made its own investigation of EBAC and that none of EBAC nor any of its Affiliates, agents or representatives is making any representation or warranty whatsoever, express or implied, beyond those expressly given by EBAC in ‎‎ ‎Article 6, including any implied warranty or representation as to condition, merchantability, suitability or fitness for a particular purpose or trade as to any of the

 

61 

 

assets of EBAC, the prospects (financial or otherwise) or the viability or likelihood of success of the business of EBAC as conducted after the Acquisition Closing, as contained in any materials provided by EBAC or any of its Affiliates or any of their respective directors, officers, employees, shareholders, partners, members or representatives or otherwise, and no statement contained in any of such materials made or made in any such presentation of the business and affairs of EBAC shall be deemed a representation or warranty hereunder or otherwise or deemed to be relied upon by the Company in executing, delivery or performing this Agreement or the Transactions. Except as otherwise expressly set forth in this Agreement, the Company understands and agrees that any assets, properties and business of EBAC are furnished “as is,” “where is” and subject to and except as otherwise provided in the representations and warranties contained in Article 6, with all faults and without any other representation or warranty of any nature whatsoever.

 

Section 4.29.      No Additional Representation or Warranties. Except as provided in this Article 4, neither the Company nor any of its Affiliates, nor any of their respective directors, managers, officers, employees, equityholders, partners, members or representatives has made, or is making, any representation or warranty whatsoever to EBAC or their Affiliates and no such party shall be liable in respect of the accuracy or completeness of any other information provided to EBAC or their Affiliates. Except for the representations and warranties expressly set forth in this Article 4, it is understood that any cost estimates, projections or other predictions, any data, any financial information or any memoranda or offering materials or presentations, including any offering memorandum or similar materials made available by or on behalf of the Company are not and shall not be deemed to be or to include representations or warranties of the Company or any of its Subsidiaries or any other person, and are not and shall not be deemed to be relied upon by EBAC in executing, delivering or performing this Agreement or the Transactions.

 

Article 5
Representations and Warranties Relating to New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3

 

Except as set forth in the disclosure letter delivered to the Company by EBAC on the date of this Agreement (each section of which, subject to ‎Section 12.09, qualifies the correspondingly numbered and lettered representations in this ‎Article 5), each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 hereby represents and warrants to the Company (each upon execution of a joinder agreement) as follows:

 

Section 5.01.      Corporate Organization. At the time of formation, each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 will be a corporation, exempted company, limited liability company or other applicable business entity duly organized, incorporated or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its

 

62 

 

jurisdiction of formation, incorporation or organization (as applicable) and has the requisite company or corporate power, as applicable, and authority to own, lease or operate all of its properties and assets and to conduct its business as it is now being conducted. The Governing Documents of each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, as amended to the date of this Agreement and as previously made available to the Company, are true, correct and complete. New Parent is duly licensed or qualified and in good standing as a foreign or extra-provincial corporation (or other entity, if applicable) in each jurisdiction in which its ownership of property or the character of its activities is such as to require it to be so licensed or qualified or in good standing, as applicable, except where the failure to be so licensed or qualified or in good standing is not and would not reasonably be expected to be material to its business and the business of EBAC and its Subsidiaries, taken as a whole.

 

Section 5.02.      Due Authorization.

 

(a)            New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 will have, the requisite company or corporate power, as applicable, and authority to execute and deliver this Agreement and the other documents to which it is a party contemplated hereby and to consummate the transactions contemplated hereby and thereby and to perform all of its obligations hereunder and thereunder. Subject to the receipt of the approvals and consents to be obtained by New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 pursuant to Section 7.06, the execution and delivery of this Agreement and other documents to which either of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 is a party contemplated hereby and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized and approved by all necessary corporate (or other similar) action on the part of each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 and no other company or corporate proceeding on the part of each of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, as the case may be, is necessary to authorize this Agreement and the other documents to which any of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 is a party contemplated hereby. This Agreement has been, and on or prior to the Acquisition Closing, the other documents to any of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, as the case may be, is a party contemplated hereby will constitute a legal, valid and binding obligation of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, as the case may be, enforceable against New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, as the case may be, in accordance with its terms, subject to the Enforceability Exceptions.

 

(b)            On or prior to the Acquisition Closing Date, the Board of Directors of New Parent shall duly adopt resolutions (i) determining that this Agreement and the other documents to which New Parent is a party contemplated hereby and the transactions contemplated hereby and hereby are advisable and fair to, and in the best interests of, New Parent and its stockholders and (ii) authorizing and approving the execution, delivery and performance by New Parent of this Agreement and the other documents to which it is a party contemplated hereby and the transactions contemplated hereby and thereby. No other corporate action is required on the part of New Parent or any of its stockholders to enter into this Agreement or the other documents to which New Parent is a party contemplated hereby or to approve the transactions contemplated hereby and thereby.

 

63 

 

Section 5.03.      Capitalization.

 

(a)            On the Acquisition Closing Date, immediately prior to the Acquisition Closing, the issued share capital of New Parent consists of CHF 100,000 divided into 10,000,000 registered shares (Namenaktien/actions nominatives) with a nominal value of CHF 0.01, which shall be duly authorized and validly issued. Except as set forth in the first sentence of this Section 5.03(a), immediately prior to the issuance of New Parent Shares in accordance with this Agreement, there shall be no other New Parent Shares or other Equity Securities of New Parent authorized, reserved, issued or outstanding.

 

(b)            (i) As of the date of formation of New Parent, the sole stockholder of New Parent will be EBAC and (ii) upon consummation of the transactions set forth in Section 8.08, the sole stockholder of each of Merger Sub 1, Merger Sub 2 and Merger Sub 3 will be New Parent. As of the date its formation, New Parent will have no Subsidiaries and will not own, directly or indirectly, any Equity Securities in any Person.

 

(c)            Immediately prior to the issuance of New Parent Shares in accordance with this Agreement, there shall be (i) no subscriptions, calls, options, warrants, rights or other securities convertible into or exchangeable or exercisable for New Parent Shares or any other Contracts to which New Parent is a party or by which New Parent is bound obligating New Parent to issue or sell any shares of capital stock of, other Equity Securities in or debt securities of, New Parent, (ii) no equity equivalents, stock appreciation rights, phantom stock ownership interests or similar rights in New Parent and (iii) no voting trusts, proxies or other Contracts with respect to the voting or transfer of New Parent Shares, in each case except as expressly provided for in this Agreement or the Transactions.

 

Section 5.04.      Consents and Requisite Governmental Approvals; No Violations.

 

(a)            No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Authority is required on the part of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 and, upon executing a joinder in accordance with Section 8.08(d) hereto, New Parent’s, Merger Sub 1’s, Merger Sub 2’s or Merger Sub 3’s execution, delivery or performance of its obligations under this Agreement or the other Ancillary Agreements to which it is or will be party or the consummation of the transactions contemplated hereby or by the Ancillary Agreements, except for (i) the filing with the SEC of (A) the Registration Statement and the declaration of the effectiveness thereof by the SEC and (B) such reports under Section 13(a) or 15(d) of the Exchange Act as may be required in connection with this Agreement, the Ancillary Agreements or the transactions contemplated by hereby or thereby, (ii) such filings with and approvals of the Stock Exchange to permit New Parent Shares to be issued in accordance with this Agreement to be listed on the Stock Exchange, (iii) filing of the Cayman Plan of Merger and, if applicable, the plan of merger under the applicable law of the Swiss Code of

 

64 

 

Obligations, (iv) the approvals and consents to be obtained by New Parent pursuant to Section 7.06 and Merger Sub 1, Merger Sub 2 and Merger Sub 3 pursuant to Section 8.08(e), or (v) any consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not reasonably be expected to be, individually or in the aggregate, material to EBAC and its Subsidiaries, taken as a whole.

 

(b)            The execution and delivery by New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 of this Agreement and other documents to which each will be a party as contemplated hereby and the consummation of the transactions contemplated hereby and thereby will not (i) violate or conflict with any provision of, or result in the breach of, or default under, the Governing Documents of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, (ii) violate or conflict with any provision of, or result in the breach of, or default under, any Law, License or Governmental Order applicable to New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 or (iii) result in the creation of any Lien (other than Permitted Liens) upon any of the properties or assets of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3, except, in the case of clauses (i) through (iii), to the extent that the occurrence of the foregoing would not reasonably be expected to be material to the business of EBAC and its Subsidiaries, taken as a whole.

 

Section 5.05.      Business Activities. Each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 will be organized or formed solely for the purpose of entering into this Agreement, the Ancillary Agreements and consummating the transactions contemplated hereby and thereby and will not have engaged in any activities or business, other than those incident or related to or incurred in connection with its organization or formation, as applicable, or the negotiation, preparation or execution of this Agreement or any Ancillary Agreements, as applicable, the performance of its covenants or agreements in this Agreement or any Ancillary Agreements or the consummation of the transactions contemplated hereby or thereby. At all times prior to the Acquisition Closing Date, none of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 shall have, except as expressly contemplated by the Transaction Agreements and the Transactions, any assets, properties, liabilities or obligations of any kind other than those incident to its formation and this Agreement, and will not conduct any business or operations except as expressly contemplated by the Transaction Agreements and the Transactions.

 

Section 5.06.      Brokers’ Fees. No broker, finder, investment banker or other Person is entitled to any brokerage fee, finders’ fee or other commission in connection with the Transactions based upon arrangements made by or on behalf of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 or any of their Affiliates for which New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 have any obligation.

 

Section 5.07.      Tax Matters.

 

(a)            For U.S. federal income Tax purposes, each of New Parent, Merger Sub 1 and Merger Sub 3 will be treated as an association taxable as a corporation since the date of its formation.

 

65 

 

(b)            As of the Acquisition Closing, Merger Sub 2 will have timely filed an initial entity classification election on a valid IRS Form 8832 to be treated as an entity disregarded as separate from New Parent for U.S. federal income Tax purposes effective as of the day of its formation and will not subsequently change such classification.

 

(c)            As of immediately prior to the First Merger Effective Time, the Second Merger Effective Time and the Third Merger Effective Time, respectively, Merger Sub 1, Merger Sub 2 and Merger Sub 3 shall be direct wholly owned Subsidiaries of New Parent.

 

(d)            None of New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 has taken or agreed to take any action not contemplated by the Transactions, and to the knowledge of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 there are no facts or circumstances, that would reasonably be expected to prevent, impair or impede the Intended Tax Treatment.

 

Section 5.08.      Investment Company Act. New Parent is not an “investment company” or a Person directly or indirectly “controlled” by or acting on behalf of a person subject to registration and regulation as an “investment company,” in each case, within the meaning of the Investment Company Act of 1940, as amended.

 

Section 5.09.      Investigation; No Other Representations.

 

(a)            Each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, on its own behalf and on behalf of its representatives, acknowledges, represents, warrants and agrees that (i) it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of the Company and (ii) it has been furnished with or given access to such documents and information about the Company and its businesses and operations as it and its representatives have deemed necessary to enable it to make an informed decision with respect to the execution, delivery and performance of this Agreement, the Ancillary Agreements and the transactions contemplated hereby and thereby.

 

(b)            In entering into this Agreement and the other Ancillary Agreements to which it is a party, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 will have relied solely on its own investigation and analysis and the representations and warranties expressly set forth in ‎‎Article 4 and in the Ancillary Agreements to which it is a party and no other representations or warranties of EBAC or any other Person, either express or implied, and each of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, on its own behalf and on behalf of its representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in Article 6 and in the Ancillary Agreements to which it is a party, neither the Company nor any other Person makes or has made any representation or warranty, either express or implied, in connection with or related to this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby.

 

66 

 

Section 5.10.      No Outside Reliance. Notwithstanding anything contained in this Article 5 or any other provision hereof, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, and their directors, managers, officers, employees, equityholders, partners, members or representatives, acknowledge and agree that they and their Affiliates have made their own investigation of the Company and that none of the Company nor any of its Affiliates, agents or representatives is making any representation or warranty whatsoever, express or implied, beyond those expressly given by the Company in ‎‎‎Article 4, including any implied warranty or representation as to condition, merchantability, suitability or fitness for a particular purpose or trade as to any of the assets of the Company, the prospects (financial or otherwise) or the viability of likelihood of success of the business of the Company as conducted after the Acquisition Closing, as contained in any materials provided by the Company or any of its Affiliates or any of their respective directors, officers, employees, shareholders, partners, members or representatives or otherwise. Except as otherwise expressly set forth in this Agreement, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 each understands and agrees that any assets, properties and business of the Company furnished “as is,” “where is” and subject to and except as otherwise provided in the representations and warranties contained in Article 4, with all faults and without any other representation or warranty of any nature whatsoever.

 

Section 5.11.      No Additional Representation or Warranties. Except as provided in this Article 5, neither New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3 nor any of its and their Affiliates, nor any of their respective directors, managers, officers, employees, equityholders, partners, members or representatives has made, or is making, any representation or warranty whatsoever to the Company or their Affiliates and no such party shall be liable in respect of the accuracy or completeness of any other information provided to the Company or their Affiliates.

 

Article 6
Representations and Warranties of EBAC

 

Except as set forth in (a) any EBAC SEC Filings filed or submitted on or prior to the date hereof (excluding (i) any disclosures in any risk factors section that do not constitute statements of fact, disclosures in any forward-looking statements disclaimer and other disclosures that are generally cautionary, predictive or forward-looking in nature and (ii) any exhibits or other documents appended thereto) (it being acknowledged that nothing disclosed in such EBAC SEC Filings will be deemed to modify or qualify the representations and warranties set forth in Section 6.08, ‎Section 6.12 and ‎Section 6.15), or (b) in the disclosure letter delivered by EBAC to the Company on the date of this Agreement (the “EBAC Disclosure Letter”) (each section of which, subject to ‎Section 12.09, qualifies the correspondingly numbered and lettered representations in this ‎Article 6), EBAC represents and warrants to the Company as follows:

 

67 

 

Section 6.01.      Company Organization. EBAC has been duly formed or organized and is validly existing under the Laws of its jurisdiction of incorporation or organization, and has the requisite company or corporate power, as applicable, and authority to own, lease or operate all of its properties and assets and to conduct its business as it is now being conducted. The Governing Documents of EBAC, as amended to the date of this Agreement and as previously made available by or on behalf of EBAC to the Company, are true, correct and complete. EBAC is duly licensed or qualified and in good standing as a foreign or extra-provincial corporation (or other entity, if applicable) in each jurisdiction in which its ownership of property or the character of its activities is such as to require it to be so licensed or qualified, except where the failure to be so licensed or qualified or in good standing is not and would not reasonably be expected to be material to the business of the EBAC.

 

Section 6.02.      [Intentionally Omitted].

 

Section 6.03.      Due Authorization.

 

(a)            Other than the EBAC Shareholder Approval, EBAC has all requisite company or corporate power, as applicable, and authority to execute and deliver this Agreement and the other documents to which it is a party contemplated hereby and to consummate the transactions contemplated hereby and thereby and to perform all of its obligations hereunder and thereunder. The execution and delivery of this Agreement and the other documents to which EBAC is a party contemplated hereby and the consummation of the transactions contemplated hereby and thereby have been (A) duly and validly authorized and approved by the EBAC Board and (B) determined by the EBAC Board as advisable to and in the best interests of EBAC and the EBAC Shareholders, and recommended for approval by the EBAC Shareholders. No other company or corporate proceeding on the part of EBAC is necessary to authorize this Agreement and the other documents to which EBAC is a party contemplated hereby (other than the EBAC Shareholder Approval). This Agreement has been, and at or prior to the Acquisition Closing, the other documents to which EBAC is a party contemplated hereby will be, duly and validly executed and delivered by EBAC and this Agreement constitutes, and on or prior to the Acquisition Closing, the other documents to which EBAC is a party contemplated hereby will constitute, assuming the due authorization, execution and delivery by the other parties hereto, a legal, valid and binding obligation of EBAC, enforceable against EBAC in accordance with its terms, subject to the Enforceability Exceptions.

 

(b)            Assuming that a quorum (as determined pursuant to EBAC’s Governing Documents) is present, each of those Transaction Proposals identified in clauses (i), (ii) and (iii) of Section 9.02(c), in each case, shall require approval by an affirmative vote of the holders of at least a majority of the outstanding EBAC Common Stock entitled to vote, who attend and vote thereupon (as determined in accordance with EBAC’s Governing Documents) at a shareholders’ meeting duly called by the EBAC Board and held for such purpose.

 

68 

 

(c)            The foregoing votes are the only votes of any of EBAC’s share capital necessary in connection with entry into this Agreement by EBAC and the consummation of the Transactions, including the Acquisition Closing.

 

(d)            At a meeting duly called and held, the EBAC Board has unanimously approved the Transactions as a Business Combination.

 

Section 6.04.      No Conflict. Subject to the EBAC Shareholder Approval and the receipt of the Governmental Authorizations set forth in Section 6.04, the execution and delivery of this Agreement by EBAC and the other documents to which EBAC is a party contemplated hereby by EBAC and the consummation of the transactions contemplated hereby and thereby do not and will not (a) violate or conflict with any provision of, or result in the breach of or default under the Governing Documents of EBAC, (b) violate or conflict with any provision of, or result in the breach of, or default under any applicable Law or Governmental Order applicable to EBAC, (c) violate or conflict with any provision of, or result in the breach of, result in the loss of any right or benefit, or cause acceleration, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, cancellation or acceleration) under any Contract to which EBAC is a party or by which EBAC may be bound, or terminate or result in the termination of any such foregoing Contract or (d) result in the creation of any Lien upon any of the properties or assets of EBAC, except, in the case of clauses (b) through (d), to the extent that the occurrence of the foregoing would not (i) have, or would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to enter into and perform its obligations under this Agreement or (ii) be, and would not be reasonably expected to be, material to EBAC.

 

Section 6.05.      Governmental Authorities; Consents. Assuming the truth and completeness of the representations and warranties of the Company contained in this Agreement, no Governmental Authorization is required on the part of EBAC with respect to EBAC’s execution, delivery and performance of this Agreement and the other Ancillary Agreements to which EBAC is a party and the consummation of the transactions contemplated hereby and thereby, except for the filing of the plan of merger under the Cayman Companies Act and Swiss Code of Obligations (if applicable).

 

Section 6.06.      Litigation and Proceedings. There are no pending or, to the knowledge of EBAC, threatened Legal Proceedings against EBAC or its properties or assets, or, to the knowledge of EBAC, any of their respective directors, managers, officers or employees (in their capacity as such). There are no investigations or other inquiries pending or, to the knowledge of EBAC, threatened by any Governmental Authority, against EBAC or its properties or assets, or, to the knowledge of EBAC, any of its directors, managers, officers or employees (in their capacity as such). There is no outstanding Governmental Order imposed upon EBAC, nor are any assets of EBAC’s business bound or subject to any Governmental Order the violation of which would have, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. As of the date hereof, EBAC is in compliance with all applicable Laws, except as would not have, or

 

69 

 

would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. For the past three (3) years, EBAC has not received any written notice of or been charged with the violation of any Laws, except where such violation would not have, or would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. This Section 6.06 shall not apply to Tax matters.

 

Section 6.07.      SEC Filings. EBAC has timely filed or furnished all statements, prospectuses, registration statements, forms, reports and documents required to be filed by it with the SEC since August 15, 2022, pursuant to the Exchange Act or the Securities Act (collectively, as they have been amended since the time of their filing through the date hereof, the “EBAC SEC Filings”). Each of the EBAC SEC Filings, as of the respective date of its filing (or if amended or superseded by a filing prior to the date of this Agreement or the Acquisition Closing Date, then on the date of such amendment or superseding filing), complied in all material respects with the applicable requirements of the Securities Act, the Exchange Act, the Sarbanes-Oxley Act and any rules and regulations promulgated thereunder applicable to the EBAC SEC Filings. As of the respective date of its filing (or if amended or superseded by a filing prior to the date of this Agreement or the Acquisition Closing Date, then on the date of such amendment or superseding filing), the EBAC SEC Filings did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading. As of the date hereof, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the EBAC SEC Filings. To the knowledge of EBAC, none of the EBAC SEC Filings filed on or prior to the date hereof is subject to ongoing SEC review or investigation as of the date hereof.

 

Section 6.08.      Internal Controls; Listing; Financial Statements.

 

(a)            Except as not required in reliance on exemptions from various reporting requirements by virtue of EBAC’s status as an “emerging growth company” within the meaning of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”), EBAC has established and maintains disclosure controls and procedures (as defined in Rule 13a-15 under the Exchange Act). Such disclosure controls and procedures are designed to ensure that material information relating to EBAC, including its consolidated Subsidiaries, if any, is made known to EBAC’s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared. To EBAC’s knowledge, such disclosure controls and procedures are effective in timely alerting EBAC’s principal executive officer and principal financial officer to material information required to be included in EBAC’s periodic reports required under the Exchange Act. EBAC has established and maintained a system of internal controls over financial reporting (as defined in Rule 13a-15 under the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of EBAC’s financial reporting and the preparation of EBAC Financial Statements for external purposes in accordance with GAAP, except as would not have, or would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions.

 

70 

 

(b)            Each director and executive officer of EBAC has filed with the SEC on a timely basis all statements required by Section 16(a) of the Exchange Act and the rules and regulations promulgated thereunder. EBAC has not taken any action prohibited by Section 402 of the Sarbanes-Oxley Act.

 

(c)            EBAC has complied in all material respects with the applicable listing and corporate governance rules and regulations of the Nasdaq. The EBAC Class A Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed for trading on the Nasdaq. There is no Legal Proceeding pending or, to the knowledge of EBAC, threatened against EBAC by the Nasdaq or the SEC with respect to any intention by such entity to deregister the EBAC Class A Common Stock or prohibit or terminate the listing of EBAC Class A Common Stock on the Nasdaq. EBAC has taken no action that would reasonably be likely to result in the termination of the registration of the EBAC Class A Common Stock under the Exchange Act. EBAC has not received any written or, to the knowledge of EBAC, oral deficiency notice from the Nasdaq relating to the continued listing requirements of the EBAC Class A Common Stock.

 

(d)            Except as disclosed in the EBAC SEC Filings, the EBAC Financial Statements (i) in all material respects fairly present the financial position of EBAC, as at the respective dates thereof, and the results of operations and consolidated cash flows for the respective periods then ended, (ii) were prepared in all material respects in conformity with GAAP applied on a consistent basis during the periods involved (except as may be indicated therein or in the notes thereto), and (iii) comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof. The books and records of EBAC have been, and are being, maintained in accordance with GAAP and any other applicable legal and accounting requirements in all material respects. Since the consummation of the initial public offering of EBAC’s securities, EBAC has timely filed all certifications and statements required by (i) Rule 13a-14 or Rule 15d-14 under the Exchange Act or (ii) 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act) with respect to any EBAC SEC Filing. Each such certification is correct and complete in all material respects.

 

(e)            There are no outstanding loans or other extensions of credit made by EBAC to any executive officer (as defined in Rule 3b-7 under the Exchange Act) or director of EBAC. EBAC has not taken any action prohibited by Section 402 of the Sarbanes-Oxley Act.

 

(f)             Neither EBAC (including any employee thereof) nor EBAC’s independent auditors has identified or been made aware of (i) any fraud, whether or not material, that involves EBAC’s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by EBAC or (ii) any claim or allegation regarding any of the foregoing.

 

71 

 

Section 6.09.      Trust Account. As of the date of this Agreement, EBAC has at least $127,741,378 in the Trust Account (including, if applicable, an aggregate of approximately $4,944,024 of deferred underwriting commissions and other fees being held in the Trust Account), such monies invested in United States government securities or money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act pursuant to the Investment Management Trust Agreement, dated as of March 15, 2021, between EBAC and Continental Stock Transfer & Trust Company, as trustee (the “Trustee”) (the “Trust Agreement”). The Trust Agreement is in full force and effect and is a legal, valid and binding obligation of EBAC, enforceable in accordance with its terms. The Trust Agreement has not been terminated, repudiated, rescinded, amended, supplemented or modified, in any respect by EBAC or the Trustee, and no such termination, repudiation, rescission, amendment, supplement or modification is contemplated by EBAC. There are no separate Contracts, side letters or other arrangements or understandings (whether written or unwritten, express or implied) that would cause the description of the Trust Agreement in the EBAC SEC Filings to be inaccurate or that would entitle any Person (other than shareholders of EBAC holding EBAC Common Stock sold in EBAC’s initial public offering who shall have elected to redeem their shares of EBAC Common Stock pursuant to EBAC’s Governing Documents and the underwriters of EBAC’s initial public offering with respect to deferred underwriting commissions) to any portion of the proceeds in the Trust Account. Prior to the Acquisition Closing, none of the funds held in the Trust Account may be released other than to pay Taxes and payments with respect to all EBAC Share Redemptions. There are no material claims or material proceedings pending or, to the knowledge of EBAC, threatened with respect to the Trust Account. EBAC has performed all material obligations required to be performed by it to date under, and is not in default, breach or delinquent in performance or any other respect (claimed or actual) in connection with, the Trust Agreement, and no event has occurred which, with due notice or lapse of time or both, would constitute such a default or breach thereunder. As of the First Merger Effective Time, the obligations of EBAC to dissolve or liquidate pursuant to EBAC’s Governing Documents shall terminate, and as of the First Merger Effective Time, EBAC shall have no obligation whatsoever pursuant to EBAC’s Governing Documents to dissolve and liquidate the assets of EBAC by reason of the consummation of the Transactions. To EBAC’s knowledge, as of the date hereof, following the First Merger Effective Time, no EBAC Shareholder shall be entitled to receive any amount from the Trust Account except to the extent such EBAC Shareholder is exercising an EBAC Share Redemption. As of the date hereof, assuming the conditions set forth in Section 10.01 and Section 10.02 are satisfied, EBAC does not have any reason to believe that any of the conditions to the use of funds in the Trust Account will not be satisfied or funds available in the Trust Account will not be available to EBAC on the Acquisition Closing Date.

 

Section 6.10.      Investment Company Act; JOBS Act. EBAC is not an “investment company” or a Person directly or indirectly “controlled” by or acting on behalf of an “investment company,” in each case within the meaning of the Investment Company Act. EBAC constitutes an “emerging growth company” within the meaning of the JOBS Act.

 

72 

 

Section 6.11.      Absence of Changes. Since March 31, 2022, (a) there has not been any event or occurrence that has had, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions and (b) EBAC has, in all material respects, conducted its business and operated its properties in the ordinary course of business consistent with past practice.

 

Section 6.12.      No Undisclosed Liabilities. Except for any fees and expenses payable by EBAC as a result of or in connection with the consummation of the Transactions, as of the date of this Agreement, there is no liability, debt or obligation of or claim or judgment against EBAC (whether direct or indirect, absolute or contingent, accrued or unaccrued, known or unknown, liquidated or unliquidated, or due or to become due), except for liabilities and obligations (a) reflected or reserved for on the financial statements or disclosed in the notes thereto included in EBAC SEC Filings, (b) that have arisen since the date of the most recent balance sheet included in the EBAC SEC Filings in the ordinary course of business of EBAC, or (c) which would not have, or would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions. This Section 6.12 shall not apply to Tax matters.

 

Section 6.13.      Capitalization of EBAC.

 

(a)            As of the date of this Agreement, the authorized share capital of EBAC is consists of (i) 200,000,000 shares of EBAC Class A Common Stock, of which 13,209,880 shares are issued and outstanding (including those underlying the EBAC Units), (ii) 20,000,000 shares of EBAC Class B Common Stock, of which 3,188,696 shares are issued and outstanding, and (iii) 1,000,000 preferred shares, par value $0.0001 per share, of which no shares are issued and outstanding (the foregoing clauses (i), (ii) and (iii) collectively, the “EBAC Securities”). The foregoing represents all of the issued and outstanding EBAC Securities as of the date of this Agreement. All issued and outstanding EBAC Securities (i) have been duly authorized and validly issued and are fully paid and non-assessable; (ii) have been offered, sold and issued in compliance with applicable Law, including federal and state securities Laws, and all requirements set forth in (A) EBAC’s Governing Documents, and (B) any other applicable Contracts governing the issuance of such securities; and (iii) are not subject to, nor have they been issued in violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law, EBAC’s Governing Documents or any Contract to which EBAC is a party or otherwise bound.

 

73 

 

(b)            As of the date of this Agreement, 4,251,595 EBAC Public Warrants (including those underlying the EBAC Units) and 151,699 EBAC Private Placement Warrants are issued and outstanding. All outstanding EBAC Warrants (i) have been duly authorized and validly issued and constitute valid and binding obligations of EBAC, enforceable against EBAC in accordance with their terms, subject to the Enforceability Exception; (ii) have been offered, sold and issued in compliance with applicable Law, including federal and state securities Laws, and all requirements set forth in (1) EBAC’s Governing Documents and (2) any other applicable Contracts governing the issuance of such securities; and (iii) are not subject to, nor have they been issued in violation of, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of any applicable Law, EBAC’s Governing Documents or any Contract to which EBAC is a party or otherwise bound. Except for the Subscription Agreements, any Additional Subscription Agreements, EBAC’s Governing Documents and this Agreement, there are no outstanding Contracts of EBAC to repurchase, redeem or otherwise acquire any EBAC Securities.

 

(c)            Other than in connection with the PIPE Investment or the Transactions, and except as set forth in this Section 6.13 as contemplated by this Agreement or the other documents contemplated hereby, or with the written consent of the Company, EBAC has not granted any outstanding options, stock appreciation rights, warrants, phantom stock, stock-based performance unit, profit participation, restricted stock, restricted stock unit, rights or other securities convertible into or exchangeable or exercisable for EBAC Securities, or any other commitments or agreements providing for the issuance of additional shares, the sale of treasury shares, for the repurchase or redemption of any EBAC Securities or the value of which is determined by reference to the EBAC Securities, and there are no Contracts of any kind which may obligate EBAC to issue, purchase, redeem or otherwise acquire any of its EBAC Securities.

 

Section 6.14.      Brokers’ Fee. No broker, finder, investment banker or other Person (except the Person(s) set forth on Section 6.13 of the EBAC Disclosure Letter) is entitled to any brokerage fee, finders’ fee or other commission in connection with the Transactions based upon arrangements made by EBAC or any of its Affiliates.

 

Section 6.15.      Indebtedness. EBAC does not have any Indebtedness other than Working Capital Loans. As of the date hereof, the balance of the Working Capital Loans is $0.00.

 

Section 6.16.      Taxes.

 

(a)            All income and other material Tax Returns required to be filed by or with respect to EBAC have been timely filed (taking into account any applicable extensions), all such Tax Returns (taking into account all amendments thereto) are true, complete and accurate in all material respects and all material amounts of Taxes of EBAC that are due and payable (whether or not shown on any Tax Return) have been fully and timely paid, other than Taxes being contested in good faith and for which adequate reserves have been established in accordance with GAAP.

 

(b)            EBAC has withheld from amounts owing to any employee, creditor or other Person all material Taxes required by Law to be withheld, paid over to the proper Governmental Authority in a timely manner all such withheld amounts required to have been so paid over and complied in all material respects with all applicable withholding and related reporting requirements with respect to such Taxes.

 

74 

 

(c)            EBAC does not have any liability for unpaid Taxes which has not been accrued for or reserved on the EBAC Financial Statements, other than any liability for unpaid Taxes that has been incurred since the end of the most recent fiscal year in the ordinary course of business.

 

(d)            There are no Liens for any material Taxes (other than Permitted Liens) upon the property or assets of EBAC.

 

(e)            No claim, assessment, deficiency or proposed adjustment for any material amount of Tax has been asserted or assessed by any Governmental Authority against EBAC that remains unpaid except for claims, assessments, deficiencies or proposed adjustments being contested in good faith and for which adequate reserves have been established in accordance with GAAP.

 

(f)             There are no ongoing or pending Legal Proceedings with respect to any material Taxes of EBAC and EBAC has not received written notice from any Governmental Authority that any such Legal Proceeding is contemplated or pending. There are no waivers, extensions or requests for any waivers or extensions of any statute of limitations currently in effect with respect to any material Taxes of EBAC (other than pursuant to an extension of time to file a Tax Return of not more than seven months obtained in the ordinary course of business).

 

(g)            EBAC has not made a request for an advance Tax ruling, a request for administrative Tax relief, a request for technical Tax advice, a request for a change of any method of accounting or any similar request with respect to Taxes that is in progress or pending with any Governmental Authority.

 

(h)            EBAC is not a party to any Tax Sharing Agreement other than customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes.

 

(i)             EBAC has never been a member of an Affiliated Group and is not liable for Taxes of any other Person (other than EBAC) under Treasury Regulations Section 1.1502-6 or any similar provision of state, local or non-U.S. Tax Law or as a transferee or successor or by Contract (other than customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes).

 

(j)             No written claim has been made by any Governmental Authority in a jurisdiction where the EBAC does not pay a particular type of Tax or file a particular type of Tax Return that it is or may be required to pay such type of Tax or file such type of Tax Return in such jurisdiction.

 

75 

 

(k)            To EBAC’s Knowledge, EBAC does not have, nor has ever had, a permanent establishment in any country other than the country of its organization and is not, nor has ever been, subject to income Tax in a jurisdiction outside the country of its organization.

 

(l)             EBAC has not constituted either a “distributing corporation” or a “controlled corporation” in a distribution of stock qualifying for tax-free treatment under Section 355 of the Code in the prior two (2) years.

 

(m)             EBAC has not participated in a “listed transaction” within the meaning of Treasury Regulation Section 1.6011-4(b)(2).

 

(n)            EBAC will not be required to include any material amount in taxable income or exclude any material item of deduction or loss from taxable income for any taxable period ending after the Acquisition Closing Date as a result of any (i) installment sale or open transaction disposition made prior to the Acquisition Closing outside the ordinary course of business, (ii) prepaid amount received or deferred revenue recognized prior to the Acquisition Closing outside the ordinary course of business, (iii) change in method of accounting for a taxable period ending on or prior to the Acquisition Closing Date, (iv) “closing agreement” as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or non-U.S. Tax Law) executed on or prior to the Acquisition Closing Date or (v) binding agreement with respect to Taxes with a Governmental Authority executed prior to the Acquisition Closing.

 

(o)            EBAC has not taken any action or agreed to take any action not contemplated by the Transactions, and to the knowledge of EBAC there are no facts or circumstances, that would reasonably be expected to prevent, impair or impede the Intended Tax Treatment.

 

Section 6.17.      Business Activities.

 

(a)            Since formation, EBAC has not conducted any business activities other than activities related to EBAC’s initial public offering or directed toward the accomplishment of a Business Combination. Except as set forth in EBAC’s Governing Documents or as otherwise contemplated by this Agreement or the Ancillary Agreements and the transactions contemplated hereby and thereby, there is no agreement, commitment, or Governmental Order binding upon EBAC or to which EBAC is a party which has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of EBAC or any acquisition of property by EBAC or the conduct of business by EBAC or as currently conducted or as contemplated to be conducted as of the Acquisition Closing.

 

(b)            Except for the transactions contemplated by this Agreement and the Ancillary Agreements, EBAC does not own or have a right to acquire, directly or indirectly, any interest or investment (whether equity or debt) in any corporation, partnership, joint venture, business, trust or other entity. Except for this Agreement and

 

76 

 

the Ancillary Agreements and the transactions contemplated hereby and thereby, EBAC has no material interests, rights, obligations or liabilities with respect to, and is not party to, bound by or has its assets or property subject to, in each case whether directly or indirectly, any Contract or transaction which is, or would reasonably be interpreted as constituting, a Business Combination (other than confidentiality agreements, term sheets, letters of intent or other customary agreements entered into in connection with review of potential initial business combinations conducted by EBAC, in each case which were entered into prior to the date hereof and which do not contain binding terms with respect to liabilities or obligations to effect a Business Combination).

 

(c)            As of the date hereof and except for this Agreement, the Ancillary Agreements and the other documents and transactions contemplated hereby and thereby (including with respect to expenses and fees incurred in connection therewith), EBAC is not a party to any Contract with any other Person that would require payments by EBAC or any of its Subsidiaries after the date hereof in excess of $500,000 in the aggregate with respect to any individual Contract, other than Working Capital Loans.

 

Section 6.18.      Stock Market Quotation. As of the date hereof, the shares of EBAC Class A Common Stock are registered pursuant to Section 12(b) of the Exchange Act and is listed for trading on the Nasdaq under the symbol “EBAC.” As of the date hereof, the EBAC Warrants are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq under the symbol “EBACW.” EBAC is in compliance with the rules of the Nasdaq and there is no Action or proceeding pending or, to the knowledge of EBAC, threatened against EBAC by the Nasdaq or the SEC with respect to any intention by such entity to deregister the shares of EBAC Class A Common Stock or EBAC Warrants or terminate the listing of shares of EBAC Class A Common Stock or EBAC Warrants on the Nasdaq. Neither EBAC nor its Affiliates has taken any action in an attempt to terminate the registration of the shares of EBAC Class A Common Stock or EBAC Warrants under the Exchange Act except as contemplated by this Agreement.

 

Section 6.19.      Investigation; No Other Representations.

 

(a)            EBAC, on its own behalf and on behalf of its representatives, acknowledges, represents, warrants and agrees that (i) it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of the Company and its Subsidiaries and (ii) it has been furnished with or given access to such documents and information about Company, its Subsidiaries and their respective businesses and operations as they and their respective representatives have deemed necessary to enable it to make an informed decision with respect to the execution, delivery and performance of this Agreement, the Ancillary Agreements and the transactions contemplated hereby and thereby.

 

77 

 

(b)            In entering into this Agreement and the other Ancillary Agreements to which it is a party, EBAC has relied solely on its own investigation and analysis and the representations and warranties expressly set forth in Article 6 and in the Ancillary Agreements to which it is a party and no other representations or warranties of the Company, its Subsidiaries or any other Person, either express or implied, and EBAC, on its own behalf and on behalf of its representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in Article 6 and in the Ancillary Agreements to which it is a party, neither EBAC nor any other Person makes or has made any representation or warranty, either express or implied, in connection with or related to this Agreement, the Ancillary Agreements or the transactions contemplated hereby or thereby.

 

Section 6.20.      No Outside Reliance. Notwithstanding the delivery or disclosure (except in Article 4 or the Company Disclosure Letter) to EBAC or any of its respective representatives of any documentation or other information (including any financial projections or other supplemental details), EBAC and its directors, managers, officers, employees, equityholders, partners, members or representatives, acknowledge and agree that EBAC has made its own investigation of the Company and that neither the Company nor any of its Affiliates, agents or representatives is making any representation or warranty whatsoever, express or implied, beyond those expressly given by the Company in Article 4, including any implied warranty or representation as to condition, merchantability, suitability or fitness for a particular purpose or trade as to any of the assets of the Company or its Subsidiaries, the prospects (financial or otherwise) or the viability or likelihood of success of the business of the Company as conducted after the Acquisition Closing, as contained in any materials provided by Company or any of its Affiliates or any of their respective directors, officers, employees, shareholders, partners, members or representatives or otherwise, and no statement contained in any of such materials made or made in any such presentation of the business and affairs of the Company shall be deemed a representation or warranty hereunder or otherwise or deemed to be relied upon by EBAC in executing, delivery or performing this Agreement or the Transactions. Except as otherwise expressly set forth in this Agreement, EBAC understands and agrees that any assets, properties and business of the Company and its Subsidiaries are furnished “as is,” “where is” and subject to and except as otherwise provided in the representations and warranties contained in Article 4, with all faults and without any other representation or warranty of any nature whatsoever.

 

Section 6.21.      No Additional Representation or Warranties. Except as provided in this Article 6, neither EBAC nor its Affiliates, nor any of its directors, managers, officers, employees, equityholders, partners, members or representatives has made, or is making, any representation or warranty whatsoever to the Company or its Affiliates and no such party shall be liable in respect of the accuracy or completeness of any other information provided to the Company or its Affiliates. Except for the representations and warranties expressly set forth in this Article 6, it is understood that any cost estimates, projections or other predictions, any data, any financial information or any memoranda or offering materials or presentations, including any offering memorandum or similar materials made available by or on behalf of the EBAC are not and shall not be deemed to be or to include representations or warranties of EBAC or any other person, and are not and shall not be deemed to be relied upon by the Company in executing, delivering or performing this Agreement or the Transactions.

 

78 

 

Article 7
Covenants of the Company

 

Section 7.01.      Conduct of Business. From the date of this Agreement through the earlier of the Acquisition Closing or valid termination of this Agreement pursuant to Article 11 (the “Interim Period”), the Company shall, and shall cause its Subsidiaries to, except as explicitly contemplated by this Agreement or the Ancillary Agreements, as required by Law (including any COVID-19 Measures), for any COVID-19 Reasonable Response, as consented to by EBAC in writing (which consent shall not be unreasonably conditioned, withheld, delayed or denied) or as set forth on Section 7.01 of the Company Disclosure Letter, use commercially reasonable efforts to (x) operate the business of the Company in the ordinary course of business consistent with past practice and (y) preserve intact the Company’s present business organization, retain the Company’s current officers, and preserve the Company’s relationships with its key suppliers and customers (if applicable). Without limiting the generality of the foregoing, except as explicitly contemplated by this Agreement or the Ancillary Agreements, as required by Law (including any COVID-19 Measures), for any COVID-19 Reasonable Response, as consented to by EBAC in writing (which consent shall not be unreasonably conditioned, withheld, delayed or denied) or as set forth on Section 7.01 of the Company Disclosure Letter, the Company shall not, and the Company shall cause its Subsidiaries not to:

 

(a)            change or amend the Governing Documents of the Company or any Subsidiary of the Company, in each case, in a manner adverse in any material respect to EBAC, New Parent, Merger Sub 1, Merger Sub 2 or Merger Sub 3;

 

(b)            make or declare any dividend or distribution to the equityholders of Company or make any other distributions in respect of any shares of the Company Share Capital or the Equity Securities of the Company or any Subsidiary of the Company (other than any dividends or distributions between or among the Company and any of its Subsidiaries);

 

(c)            split, combine, reclassify, recapitalize or otherwise amend any terms of any shares or series of the Company or any Subsidiary of the Company’s capital stock or Equity Securities, except with respect to any split, combination, reclassification or recapitalization of any shares or series of any Subsidiary of the Company’s capital stock or Equity Securities, in a manner not adverse in any material respect to the Company or any Subsidiary of the Company;

 

(d)            purchase, repurchase, redeem or otherwise acquire any issued and outstanding share capital, outstanding shares of capital stock, membership interests or other Equity Securities of the Company or any Subsidiary of the Company, except for (i) the acquisition by the Company or any of its Subsidiaries of any shares of capital stock, membership interests or other Equity Securities of the Company or its Subsidiaries, or (ii) transactions between the Company and any wholly owned Subsidiary of the Company or between wholly owned Subsidiaries of the Company;

 

79 

 

(e)            acquire by merger or consolidation with, or merge or consolidate with, or purchase substantially all or a material portion of the assets of, any corporation, partnership, association, joint venture or other business organization or division thereof;

 

(f)             sell, assign, transfer, convey, lease or otherwise dispose of any material tangible assets or properties of the Company or its Subsidiaries, except for (i) dispositions of obsolete or worthless equipment, (ii) transactions among the Company and its Subsidiaries or among its Subsidiaries, (iii) transactions in the ordinary course of business consistent with past practice or (iv) transactions involving assets or properties that are sold, assigned, transferred, conveyed, leased or otherwise disposed of at or above fair market value (as reasonably determined by EBAC) and that in the aggregate generate less than 5% of the consolidated EBITDA of the Company and its Subsidiaries for the most recent four completed consecutive fiscal quarters ending prior to the consummation of such transaction;

 

(g)            (i) issue or sell any debt securities of the Company or any Subsidiary of the Company or otherwise incur or assume any Indebtedness, or (ii) guarantee any Indebtedness of another Person, in each case, except (x) in the ordinary course of business consistent with past practice or (y) for the issuance, sale, or incurrence of debt securities or Indebtedness used to refinance existing Indebtedness;

 

(h)            (i) fail to timely pay all material Taxes that become due and payable, (ii) make, change or revoke any election in respect of material Taxes, (iii) adopt or request permission of any Governmental Authority to change any material method of accounting in respect of Taxes, (iv) settle or compromise any material Tax liability, (v) enter into any material agreement in respect of Taxes with a Governmental Authority, (vi) enter into any Tax Sharing Agreement (other than any such agreement solely among the Company and its Subsidiaries and customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes) or (vii) amend, modify or otherwise change in a material respect any filed Tax Return unless required by applicable Law, or (viii) consent to any extension or waiver of the statute of limitations regarding any material amount of Taxes;

 

(i)             take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to prevent, impair or impede the Intended Tax Treatment;

 

(j)             (i) issue, sell, or otherwise dispose of any existing or additional shares of Company Share Capital or securities exercisable for or convertible into shares of Company Share Capital, other than (1) in respect of the PIPE Investment, including for the avoidance of doubt, the issuance of New Parent Shares, warrants or other securities pursuant to a Subscription Agreement or an Additional Subscription Agreement or (2) in connection with the exercise of Company Options outstanding on the date of this Agreement or (ii) grant any Company Options or other equity or equity-based compensation;

 

80 

 

(k)            Except (w) as required under the existing terms of any Company Benefit Plan, as in effect on the date of this Agreement, (x) as required by this Agreement, (y) as required by any applicable Law or (z) in the ordinary course of business consistent with past practice, (i) adopt, enter into, terminate or materially amend or modify any material Company Benefit Plan, (ii) increase the compensation payable to any Service Provider, (iii) accelerate any payment, right to payment, vesting or benefit, or the funding of any payment, right to payment, vesting or benefit, payable or to become payable to any Service Provider or (iv) waive or release any noncompetition, non-solicitation, no-hire, nondisclosure or other restrictive covenant obligation of any Service Provider;

 

(l)             adopt a plan of, or otherwise enter into or effect a, complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization of the Company or any Subsidiary of the Company (other than the Acquisition Transactions);

 

(m)             terminate without replacement or fail to use commercially reasonable efforts to maintain any License material to the conduct of the business of the Company and its Subsidiaries, taken as a whole;

 

(n)            enter into, modify in any material respect or terminate (other than expiration in accordance with its terms) any Affiliate Agreements, other than as required by Law

 

(o)            sell, assign, transfer, abandon, permit to lapse, dispose of, license, sublicense, modify, terminate, create or incur any Lien on, or otherwise fail to take any action necessary to maintain, enforce or protect, any Company IP, other than granting non-exclusive licenses in the ordinary course of business consistent with past practice; or

 

(p)            enter into any agreement to do any action prohibited under this Section 7.01.

 

Section 7.02.      Inspection. Subject to confidentiality obligations (whether contractual, imposed by applicable Law or otherwise) that may be applicable to information furnished to the Company or any of the Company’s Subsidiaries by third parties that may be in the Company’s or any of its Subsidiaries’ possession from time to time, and except for any information that is subject to attorney-client privilege (provided that, to the extent possible, the parties shall cooperate in good faith to permit disclosure of such information in a manner that preserves such privilege or compliance with such confidentiality obligation), and to the extent permitted by applicable Law, the Company shall, and shall cause its Subsidiaries to, afford to EBAC and its accountants, counsel and other representatives reasonable access during the Interim Period (for purposes of consummating the Transactions), during normal business hours and with reasonable advance notice, in such manner as to not materially interfere with the ordinary course of business of the Company and its Subsidiaries, to all of their respective properties, books, Contracts, commitments, Tax Returns, records and appropriate officers and employees of

 

81 

 

the Company and its Subsidiaries; provided that such access shall not include any unreasonably invasive or intrusive investigations or other testing, sampling or analysis of any properties, facilities or equipment of the Company or its Subsidiaries without the prior written consent of the Company. All information obtained by EBAC or its representatives pursuant to this Section 7.02 shall be subject to the Confidentiality Agreement.

 

Section 7.03.      Preparation and Delivery of Additional Company Financial Statements.

 

(a)            If the First Merger Effective Time has not occurred prior to the date the Audited Financial Statements become stale for purposes of Regulation S-X of the Securities Act (the “Staleness Date”), the Company shall use its commercially reasonable efforts to deliver to EBAC, as soon as reasonably practicable following the Staleness Date, the unaudited interim consolidated statement of financial position as of September 30, 2022 and the related unaudited interim statements of comprehensive income, changes in equity, and cash flows for the 9-month period ended September 30, 2022 of the Company and its Subsidiaries (the “Q3 2022 Financial Statements”), together with the auditor’s reports thereon, which comply in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act applicable to a registrant; provided that upon delivery of such Q3 2022 Financial Statements, the representations and warranties set forth in Section 4.08 shall be deemed to apply to the Q3 2022 Financial Statements with the same force and effect as if made as of the date of this Agreement.

 

(b)            The Company shall use its commercially reasonable efforts to cause its independent auditors to provide any necessary consents to the inclusion of the financial statements set forth in Section 4.08 and this Section 7.03 in EBAC’s filings with the SEC in accordance with the applicable requirements of federal securities Laws.

 

Section 7.04.      Affiliate Agreements. At or prior to the Acquisition Closing, the Company shall terminate or settle, or cause to be terminated or settled, without further liability to EBAC or any of its Affiliates, the Company or any of the Company’s Subsidiaries, all Affiliate Agreements of the Company (other than any such agreements set forth in Section 7.04 of the Company Disclosure Letter) and provide EBAC with evidence of such termination or settlement reasonably satisfactory to EBAC.

 

Section 7.05.      Acquisition Proposals. From the date hereof until the Acquisition Closing Date or, if earlier, the termination of this Agreement in accordance with Article 11, the Company and its Subsidiaries shall not, and the Company shall instruct and use its commercially reasonable efforts to cause its representatives, not to (a) initiate any negotiations with any Person with respect to, or provide any non-public information or data concerning the Company or any of the Company’s Subsidiaries to any Person relating to, an Acquisition Proposal or afford to any Person access to the business, properties, assets or personnel of the Company or any of the Company’s Subsidiaries in connection with an Acquisition Proposal, (b) enter into any acquisition agreement,

 

82 

 

merger agreement or similar definitive agreement, or any letter of intent, memorandum of understanding or agreement in principle, or any other agreement relating to an Acquisition Proposal, (c) grant any waiver, amendment or release under any confidentiality agreement or the anti-takeover laws of any state relating to an Acquisition Proposal, or (d) otherwise knowingly facilitate any such inquiries, proposals, discussions, or negotiations or any effort or attempt by any Person to make an Acquisition Proposal. From and after the date hereof, the Company shall, and shall instruct its Subsidiaries, officers and directors and representatives acting on its behalf or on behalf of its Subsidiaries (as applicable) to, immediately cease and terminate all discussions and negotiations with any Persons that may be ongoing with respect to any Acquisition Proposal (other than the Parties and their respective representatives).

 

Section 7.06.      Subsidiary Member Approval. As promptly as reasonably practicable following the consummation of the transactions contemplated by Section 8.08, New Parent, as the sole shareholder of each of Merger Sub 1, Merger Sub 2 and Merger Sub 3 will approve and adopt this Agreement, the Ancillary Agreements to which New Parent is or will be a party and the transactions contemplated hereby and thereby (including the Acquisition Transactions).

 

Section 7.07.      Stock Exchange Listing of New Parent Shares. EBAC shall cause New Parent to, and New Parent shall, use its commercially reasonable efforts to cause New Parent Shares issuable in accordance with this Agreement to be approved for listing on the Stock Exchange (and EBAC and the Company shall reasonably cooperate in connection therewith), subject to official notice of issuance, as promptly as practicable after the date of this Agreement, and in any event prior to the Acquisition Closing Date and to cause New Parent to satisfy any applicable initial and continuing listing requirements of the Stock Exchange, subject to any available exemptions or phase-in periods.

 

Section 7.08.      EBAC D&O Indemnification and Insurance.

 

(a)            Each Party agrees that (i) all rights to indemnification or exculpation now existing in favor of past or present directors, officers, members, managers and employees of EBAC, as provided in an EBAC’s Governing Documents or otherwise in effect as of the date of the Acquisition Closing, in either case, solely with respect to any matters occurring on or prior to the Acquisition Closing, shall survive the Transactions and shall continue in full force and effect from and after the Acquisition Closing for a period of six years and (ii) New Parent will perform and discharge all obligations to provide such indemnity and exculpation during such six-year period. To the maximum extent permitted by applicable Law, during such six-year period, New Parent shall advance expenses in connection with such indemnification as provided in EBAC’s Governing Documents or other applicable agreements. The indemnification and liability limitation or exculpation provisions of EBAC’s Governing Documents or other applicable agreements shall not, during such six-year period, be amended, repealed or otherwise modified after the Acquisition Closing in any manner that would materially and adversely affect the rights thereunder of individuals who, as of the Acquisition Closing or at any

 

83 

 

time prior to the Acquisition Closing, were or are directors, officers, members, managers or employees of EBAC (the “EBAC D&O Persons”) to be so indemnified, have their liability limited or be exculpated with respect to any matters occurring on or prior to Acquisition Closing and relating to the fact that such EBAC D&O Person was a director, officer, member, manager or employee of EBAC at or prior to the Acquisition Closing, unless such amendment, repeal or other modification is required by applicable Law.

 

(b)            New Parent shall not have any obligation under this Section 7.08 to any EBAC D&O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and non-appealable) that the indemnification of such EBAC D&O Person in the manner contemplated hereby is prohibited by applicable Law.

 

(c)            New Parent shall purchase, at or prior to the Acquisition Closing, and maintain in effect for a period of six (6) years after the Acquisition Closing Date, without lapses in coverage, a “tail” insurance policy(ies) providing directors’ and officers’ liability and fiduciary liability insurance coverage for the benefit of those Persons who are covered by any comparable insurance policy(ies) of EBAC as of the date hereof with respect to matters occurring on or prior to the Acquisition Closing. Such “tail” insurance policy(ies) shall provide coverage on terms (including with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided under EBAC’s directors’ and officers’ liability and fiduciary liability insurance policy(ies) as of the Acquisition Closing; provided that New Parent shall not be required to pay a premium for such “tail” insurance policy(ies) in excess of 250% of the most recent annual premium paid by EBAC prior to the date of this Agreement and, in such event, New Parent shall purchase the maximum coverage available for 250% of the most recent annual premium paid by EBAC prior to the date of this Agreement.

 

(d)            If New Parent or any of its respective successors or assigns (i) shall merge or consolidate with or merge into any other corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii) shall transfer all or substantially all of their respective properties and assets as an entity in one or a series of related transactions to any Person, then in each such case, proper provisions shall be made so that the successors or assigns of New Parent or the Company or any of its Subsidiaries shall assume all of the obligations set forth in this Section 7.08.

 

(e)            The EBAC D&O Persons entitled to the indemnification, liability limitation, exculpation and insurance set forth in this Section 7.08 are intended to be third-party beneficiaries of this Section 7.08. This Section 7.08 shall survive the consummation of the Transactions and shall be binding on all successors and assigns of New Parent, the Company and the Company’s Subsidiaries.

 

84 

 

Section 7.09.      Agent Deliverables. The Company shall: (a) cause its chief executive officer or the president of the Company and the chief financial or chief accounting officer of the Company to deliver to the Placement Agents and the Financial Advisor a certificate on behalf of the Company certifying that (I) the representations and warranties of the Company contained in this Agreement are true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case, such representations and warranties shall be true and correct in all respects) as of the date when made and as of the date of such certificate, as though made on and as of such date, except for such representations and warranties that speak as of a specific date, except to the extent otherwise disclosed in the Proxy Statement/Registration Statement and (II) the Registration Statement and any amendments thereto conformed in all material respects to the requirements of the Securities Act and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, (b) use reasonable best efforts to cause its independent auditors to deliver to the PIPE Placement Agents and Financial Advisor a comfort letter in a form that is generally provided to underwriters in connection with underwritten public offerings of securities, and (c) use reasonable best efforts to cause its counsel to deliver a customary negative assurance letter in respect of the Proxy Statement/Registration Statement in a form that is generally provided to underwriters in connection with underwritten public offerings of securities, in each case in form and substance reasonably satisfactory to the Placement Agents and Financial Advisor, with each of the deliverables set forth in clauses (a), (b) and (c) to be provided: (1) on the date of the effectiveness of the Registration Statement and (2) on the date of the EBAC Shareholders’ Meeting, each dated the date of delivery.

 

Article 8
Covenants of EBAC

 

Section 8.01.      Trust Account Proceeds and Related Available Equity.

 

(a)            EBAC shall take all necessary and appropriate actions to release and make available all of the remaining funds from the Trust Account, after payments for any deferred underwriting commissions and the EBAC Share Redemptions, including (1) providing notice to the Trustee of the anticipated Acquisition Closing Date for the purpose of unwinding any non-cash assets in the Trust Account, sufficiently in advance of the Acquisition Closing Date and in accordance with the terms of the Trust Agreement, (2) upon satisfaction or waiver of the conditions set forth in Article 10, (i) in accordance with and pursuant to the Trust Agreement, at the Acquisition Closing, EBAC (A) shall cause any documents, opinions and notices required to be delivered to the Trustee pursuant to the Trust Agreement to be so delivered and (B) shall use its commercially reasonable efforts to cause the Trustee to, and the Trustee shall thereupon be obligated to (I) pay as and when due all amounts payable to EBAC Shareholders pursuant to the EBAC Share Redemptions (II) pay any deferred underwriting commissions, and (III) pay all remaining amounts then available in the Trust Account to New Parent for immediate use, subject to this Agreement and the Trust Agreement, and (ii) thereafter, the Trust Account shall terminate, except as otherwise provided therein.

 

85 

 

Section 8.02.      De-Listing. Prior to the Acquisition Closing, EBAC shall cooperate with the Company and, with respect to EBAC, shall use its commercially reasonable efforts to take, or cause to be taken, all actions reasonably necessary to de-list all securities of EBAC from the Stock Exchange and de-register such securities under the Exchange Act as soon as practicable following the First Merger Effective Time.

 

Section 8.03.      No Solicitation by EBAC. From the date hereof until the Acquisition Closing Date or, if earlier, the termination of this Agreement in accordance with Article 11, EBAC shall not, and shall cause its Subsidiaries not to, and EBAC shall instruct its and their representatives acting on its and their behalf, not to, (a) make any proposal or offer that constitutes a Business Combination Proposal, (b) initiate any discussions or negotiations with any Person with respect to a Business Combination Proposal, (c) enter into any acquisition agreement, business combination, merger agreement or similar definitive agreement, or any letter of intent, memorandum of understanding or agreement in principle, or any other agreement relating to a Business Combination Proposal or (d) otherwise knowingly facilitate any such inquiries, proposals, discussions, or negotiations or any effort or attempt by any Person to make a Business Combination Proposal, in each case, other than to or with the Company and its respective representatives. From and after the date hereof, EBAC shall, and shall instruct and cause its officers and directors and representatives acting on its behalf, its Subsidiaries and their respective representatives (acting on their behalf) to, immediately cease and terminate all discussions and negotiations with any Persons that may be ongoing with respect to a Business Combination Proposal (other than the Company and its representatives).

 

Section 8.04.      EBAC Conduct of Business.

 

(a)            During the Interim Period, EBAC shall, except as explicitly contemplated by this Agreement (including as contemplated by any of the Subscription Agreements, any of the Additional Subscription Agreements or in connection with the PIPE Investment) or the Ancillary Agreements, as required by Law or as consented to by the Company in writing (which consent shall not be unreasonably conditioned, withheld, delayed or denied), operate its business in the ordinary course and consistent with past practice. Without limiting the generality of the foregoing, except as explicitly contemplated by this Agreement (including as contemplated by any of the Subscription Agreements, any of the Additional Subscription Agreements or in connection with the PIPE Investment) or the Ancillary Agreements, as required by Law or as consented to by the Company in writing (which consent, except with respect to clause (xii), shall not be unreasonably conditioned, withheld, delayed or denied), EBAC shall not:

 

(i)            change, modify, amend or terminate (or seek any approval from the EBAC Shareholders to) the Trust Agreement, the Subscription Agreements, the Non-Redemption Agreements or the Governing Documents of EBAC, except as contemplated by the Transaction Proposals or Extension Proposal;

 

(ii)            withdraw any funds from the Trust Account, other than as permitted by the Trust Agreement;

 

86 

 

(iii)            except as contemplated by the Transaction Proposals (including any adjustment made with respect to the New Parent Warrants in the Warrant Conversion), (A) make or declare any dividend or distribution to the shareholders of EBAC or make any other distributions in respect of any of EBAC’s capital stock, share capital or equity interests, (B) split, combine, reclassify or otherwise amend any terms of any shares or series of EBAC’s capital stock or equity interests, or (C) purchase, repurchase, redeem or otherwise acquire any issued and outstanding share capital, outstanding shares of capital stock, share capital or membership interests, warrants or other equity interests of EBAC, other than a redemption of shares of EBAC Class A Common Stock made as part of the EBAC Share Redemptions;

 

(iv)            enter into, renew or amend in any material respect, any transaction or Contract with an Affiliate of EBAC (including, for the avoidance of doubt, (x) the Sponsor and (y) any Person in which the Sponsor has a direct or indirect legal, contractual or beneficial ownership interest of five percent (5%) or greater);

 

(v)            (i) fail to timely pay all material Taxes that become due and payable, (ii) make, change or revoke any election in respect of material Taxes, (iii) adopt or request permission of any Governmental Authority to change any material method of accounting in respect of Taxes, (iv) settle or compromise any material Tax liability, (v) enter into any material agreement in respect of Taxes with a Governmental Authority, (vi) enter into any Tax Sharing Agreement (other than customary commercial Contracts entered into in the ordinary course of business not primarily related to Taxes) or (vii) amend, modify or otherwise change in a material respect any filed Tax Return unless required by applicable Law, or (viii) consent to any extension or waiver of the statute of limitations regarding any material amount of Taxes;

 

(vi)            take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to prevent, impair or impede the Intended Tax Treatment;

 

(vii)            issue or sell any debt securities or warrants or other rights to acquire any debt securities of EBAC or otherwise incur or assume any Indebtedness, or guarantee any Indebtedness of another Person, other than (x) fees and expenses incurred in support of the transactions contemplated by this Agreement and the Ancillary Agreements, (y) any adjustment made with respect to the New Parent Warrants in the Warrant Conversion or (z) in support of the ordinary course operations of EBAC (which the parties agree shall include any Indebtedness in respect of any Working Capital Loan incurred in the ordinary course of business, subject to Section 8.04(a)(xii) below);

 

87 

 

(viii)            (A) issue any EBAC Securities or securities exercisable for or convertible into EBAC Securities, other than (x) in respect of the PIPE Investment, including for the avoidance of doubt, EBAC Class A Common Stock, warrants or other securities pursuant to an Additional Subscription Agreement, and (y) to effect a transfer or agreement to transfer (which may be effectuated as a forfeiture to EBAC and reissuance by EBAC) of EBAC Class A Common Stock or EBAC Class B Common Stock by Sponsor to an investor pursuant to a Subscription Agreement or an Additional Subscription Agreement, in the case of an Additional Subscription Agreement, entered into with the prior written consent of the Company, not to be unreasonably withheld, conditioned or delayed, (B) grant any options, warrants or other equity-based awards with respect to EBAC Securities not outstanding on the date hereof, except as provided for in clause (x) and (y) above, or (C) amend, modify or waive any of the material terms or rights set forth in any EBAC Warrant or the EBAC Warrant Agreement, including any amendment, modification or reduction of the warrant price set forth therein except for any adjustment made with respect to the New Parent Warrants in the Warrant Conversion;

 

(ix)            acquire by merger or consolidation with, or merge or consolidate with, or purchase substantially all or a material portion of the assets of, any corporation, partnership, association, joint venture or other business organization or division thereof;

 

(x)            adopt a plan of, or otherwise enter into or effect a, complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization;

 

(xi)            change EBAC’s methods of accounting in any material respect, other than changes that are required by any securities Law or any order, directive, guideline, recommendation, statement, comment or guidance issued, passed, approved, published, promulgated or released by, the SEC, following reasonable prior consultation with the Company;

 

(xii)            incur Working Capital Loans other than the incurrence of Working Capital Loans such that the aggregate outstanding Working Capital Loans (including those incurred prior to the date of this Agreement) do not exceed $1,000,000 in the aggregate after such incurrence; or

 

(xiii)            enter into any agreement to do any action prohibited under this Section 8.04.

 

(b)            During the Interim Period, EBAC shall use commercially reasonably efforts to materially comply with, and continue materially performing under, as applicable, the Trust Agreement and all other agreements or Contracts to which EBAC may be a party.

 

Section 8.05.      EBAC Public Filings. From the date hereof through the First Merger Effective Time, EBAC will keep current and timely file all reports required to be filed or furnished with the SEC (including any amendment or restatement of any report previously filed or furnished to the extent necessary to respond to comments or other guidance, whether formal or informal from the SEC) and otherwise comply in all material respects with its reporting obligations under applicable Laws. Any report filed by EBAC with the SEC after the date hereof shall be considered an EBAC SEC Filing for the purposes of this Agreement.

 

88 

 

Section 8.06.      Shareholder Litigation. In the event that any litigation related to this Agreement, any Ancillary Agreement or the transactions contemplated hereby or thereby is brought, or, to the knowledge of EBAC, threatened in writing, against EBAC or the EBAC Board by any of the EBAC Shareholders prior to the Acquisition Closing, EBAC shall promptly notify the Company of any such litigation and keep the Company reasonably informed with respect to the status thereof. EBAC shall provide the Company the opportunity to participate in (subject to a customary joint defense agreement), but not control, the defense of any such litigation, shall give due consideration to the Company’s advice with respect to such litigation and shall not settle any such litigation without the prior written consent of the Company, such consent not to be unreasonably withheld, conditioned or delayed.

 

Section 8.07.      New Parent Corporate Documents. As soon as reasonably practical after the date hereof, EBAC shall cause all Swiss corporate documents of New Parent to be submitted for formal positive pre-clearance (Vorprüfung / examen préliminaire) from the commercial register of the Canton of Zug. EBAC and New Parent shall use their commercially reasonable efforts to procure that the relevant corporate documents will be pre-registered (vorerfasst / pré-enregistrés) by the commercial register of the Canton of Zug in the expedited pre-registration procedure (Vorerfassungsverfahren / procédure de pré-enregistrement) when submitted to the commercial register of the Canton of Zug on the Acquisition Closing Date.

 

Section 8.08.      Corporate Formation. The following shall occur as soon as practicable following the execution of this Agreement as set forth below:

 

(a)            EBAC shall form New Parent as a public limited liability company (société anonyme) incorporated and existing under the laws of Switzerland that will be a direct wholly owned subsidiary of EBAC;

 

(b)            New Parent shall form Merger Sub 1 as a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent;

 

(c)            New Parent shall form Merger Sub 2 as a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent;

 

(d)            New Parent shall form Merger Sub 3 as a new public limited liability company (société anonyme) incorporated and existing under the laws of Switzerland that will be a direct wholly owned subsidiary of New Parent;

 

(e)            Following the formation of New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, EBAC, in the case of New Parent, and New Parent, in the case of Merger Sub 1, Merger Sub 2 and Merger Sub 3, shall cause New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3, as applicable, to become a party to this Agreement by executing a joinder agreement, in form and substance reasonably satisfactory to each of New Parent and the Company; and

 

89 

 

(f)             New Parent shall cause each of Merger Sub 1, Merger Sub 2 and Merger Sub 3 to approve and adopt resolutions similar in substance to those resolutions of New Parent contemplated by Section 5.02(b).

 

Section 8.09.      Agent Deliverables. EBAC shall: (a) cause its chief executive officer or the president of EBAC and the chief financial or chief accounting officer of EBAC to deliver to the Placement Agents and Financial Advisor a certificate certifying that (I) the representations and warranties of EBAC contained in this Agreement are true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case, such representations and warranties shall be true and correct in all respects) as of the date when made and as of the date of such certificate, as though made on and as of such date, except for such representations and warranties that speak as of a specific date, except to the extent otherwise disclosed in the Proxy Statement/Registration Statement and (II) the Registration Statement and any amendments thereto conformed in all material respects to the requirements of the Securities Act and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, (b) use reasonable best efforts to cause its independent auditors to deliver to the PIPE Placement Agents and Financial Advisor a comfort letter in a form that is generally provided to underwriters in connection with underwritten public offerings of securities, (c) use reasonable best efforts to cause its counsel to deliver a customary negative assurance letter in respect of the Proxy Statement/Registration Statement in a form that is generally provided to underwriters in connection with underwritten public offerings of securities, in each case in form and substance reasonably satisfactory to the Placement Agents and Financial Advisor, and (d) use reasonable best efforts to obtain from counsel to the Placement Agents delivery of a customary negative assurance letter in respect of the Proxy Statement/Registration Statement, in each case in form and substance satisfactory to the Placement Agents and Financial Advisor, with each of the deliverables set forth in clauses (a), (b) and (c) to be provided: (1) on the date of the effectiveness of the Registration Statement and (2) on the date of the EBAC Shareholders’ Meeting, each dated the date of delivery.

 

Section 8.10.      Extension of Time to Consummate a Business Combination.

 

(a)            If EBAC and the Company determine in good faith by December 15, 2022 that it is probable the Acquisition Closing will not occur prior to the Agreement End Date, EBAC and the Company shall cooperate to prepare and, not later than fifteen (15) Business Days after the date of such mutual determination (or such other date as the parties may agree in writing), shall file with the SEC a mutually acceptable proxy statement (such proxy statement, together with any amendments or supplements thereto, the “Extension Proxy Statement”) to amend the EBAC Articles, on terms and conditions

 

90 

 

agreed by the parties, to (i) extend the period of time EBAC is afforded under the EBAC Articles and the Prospectus to consummate an initial business combination for an additional three months, from March 18, 2023 to June 18, 2023 (or such earlier date as the parties may agree in writing) (the “Initial Extension Date”) and (ii) provide that EBAC may extend the Initial Extension Date one time by an additional three months (for a total of up to 30 months to complete an initial business combination) if the Sponsor provides five (5) days’ advance notice prior to the applicable deadline (the “Extension Proposal”). EBAC shall cooperate and provide the Company (and its counsel) with a reasonable opportunity to review and comment on the Extension Proxy Statement, and any amendment or supplement thereto, and any responses to comments from the SEC or its staff or the provision of additional information in connection therewith, prior to filing or delivery of the same with or to the SEC. The EBAC Parties, with the assistance of the Company, will promptly respond to any SEC comments on the Extension Proxy Statement and will use all commercially reasonable efforts to cause the Extension Proxy Statement to be cleared by the SEC as promptly as practicable after such filing. The EBAC Parties will advise the Company reasonably promptly after: (A) the time when the Extension Proxy Statement has been filed; (B) in the event the Extension Proxy Statement is not reviewed by the SEC, the expiration of the waiting period in Rule 14a-6(a) under the Exchange Act; (C) in the event the preliminary Extension Proxy Statement is reviewed by the SEC, receipt of oral or written notification of the completion of the review by the SEC; (D) the filing of any supplement or amendment to the Extension Proxy Statement; (E) any request by the SEC for amendment of the Extension Proxy Statement; (F) any comments from the SEC relating to the Extension Proxy Statement and responses thereto (and shall provide the Company with a copy or, in the case of oral communications, summary of such comments); (G) requests by the SEC for additional information (and shall provide the Company with a copy or, in the case of oral communications, summary of such request); and (H) any other communication, whether written or oral, from the SEC (and shall provide the Company with a copy or, in the case of oral communications, summary of such communication).

 

(b)            Each party shall promptly correct any information provided by it for use in the Extension Proxy Statement if and to the extent that such information is determined to have become false or misleading in any material respect or as otherwise required by applicable Laws.

 

(c)            As promptly as practicable after the Extension Proxy Statement is cleared by the SEC, EBAC shall distribute the Extension Proxy Statement to the EBAC Shareholders and (x) shall duly call and give notice of special meeting of the EBAC Shareholders (the “Extension Shareholders’ Meeting”) in accordance with the EBAC Articles and the Cayman Companies Act for a date no later than forty-five (45) days after such notice, subject to EBAC’s right to adjourn the Extension Shareholders’ Meeting as provided in this Agreement, (y) subject to the other provisions of this Agreement, shall solicit proxies from the EBAC Shareholders to vote in favor of the Extension Proposal, and shall duly convene and hold the Extension Shareholders’ Meeting, and (z) shall provide its shareholders with the opportunity to elect to convert their EBAC Common Stock into a pro rata portion of the Trust Account in connection with the extension as

 

91 

 

provided for in the EBAC Articles. EBAC may only adjourn the Extension Shareholders’ Meeting (i) to solicit additional proxies for the purpose of obtaining approval of the Extension Proposal or to take steps to reduce the number of shares of EBAC Common Stock issued in the IPO as to which the holders thereof elect to convert such shares into a pro rata portion of the Trust Account in connection with the extension as provided for in the EBAC Articles, (ii) if a quorum is not present at the Extension Shareholders’ Meeting, (iii) to amend the Extension Proposal, subject to the Company’s consent, not to be unreasonably withheld, conditioned or delayed, or (iv) to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosure that EBAC has determined in good faith after consultation with outside legal counsel is required under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by the EBAC Shareholders prior to the Extension Shareholders’ Meeting; provided that the Extension Shareholders’ Meeting is reconvened as promptly as practical thereafter. EBAC agrees that if the approval of the Extension Proposal shall not have been obtained at any such Extension Shareholders’ Meeting, then EBAC shall continue until the Agreement End Date to take all such necessary actions and hold additional Extension Shareholders’ Meetings in order to obtain the approval of the Extension Proposal by the Agreement End Date.

 

(d)            The EBAC Parties shall comply with all applicable provisions of and rules under the Exchange Act and all applicable provisions of the Cayman Companies Act in the preparation, filing and distribution of the Extension Proxy Statement, the solicitation of proxies thereunder, and the calling and holding of the Extension Shareholders’ Meeting. Without limiting the foregoing, EBAC Parties and the Company shall each ensure that the Extension Proxy Statement does not, as of the date on which it is first distributed to EBAC Shareholders and the holders of the Company Securities, and as of the date of the Extension Shareholders’ Meeting, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made in light of the circumstances under which they were made, not misleading (provided that no party shall be responsible for the accuracy or completeness of any information relating to another party or any other information furnished by another party for inclusion in the Extension Proxy Statement).

 

(e)            EBAC, acting through the EBAC Board, shall include in the Extension Proxy Statement the EBAC Board’s recommendation that EBAC Shareholders vote in favor of the Extension Proposal, and shall otherwise use reasonable best efforts to obtain approval thereof. Neither the EBAC Board nor any committee or agent or representative thereof shall withdraw (or modify in a manner adverse to the Company), or propose to withdraw (or modify in a manner adverse to the Company) the EBAC Board’s recommendation that the EBAC Shareholders vote in favor of the adoption of the Extension Proposal.

 

92 

 

Article 9
Joint Covenants

 

Section 9.01.      Efforts to Consummate.

 

(a)            Subject to the terms and conditions herein provided, each of EBAC, New Parent, Merger Sub 1, Merger Sub 2, Merger Sub 3 and the Company shall, and the Company shall cause its Subsidiaries to: (i) use commercially reasonable efforts to assemble, prepare and file any information (and, as needed, to supplement such information) as may be reasonably necessary to obtain as promptly as practicable all Governmental Authorizations required to be obtained in connection with the Transactions, (ii) use commercially reasonable efforts to take, or cause to be taken, and to do, or cause to be done, all things reasonably necessary or advisable to consummate and make effective as promptly as practicable the Transactions, including using commercially reasonable efforts to obtain all material Governmental Authorizations that any of EBAC, the Company, or their respective Affiliates are required to obtain in order to consummate the Transactions; provided that in no event shall New Parent, EBAC, the Merger Sub 1, Merger Sub 2, Merger Sub 3, the Company or its Subsidiaries be obligated to bear any material expense, pay any material fee or grant any material concession in connection with obtaining any such approvals (other than any required filing fees in connection therewith); provided, however, that each Party shall bear its out-of-pocket costs and expenses in connection with the preparation of any such approvals, and (iii) take such other action as may reasonably be necessary or as any other Party may reasonably request to satisfy the conditions of the other Parties set forth in Article 10 or otherwise to comply with this Agreement. The Parties shall promptly inform the other of any substantive communication between any itself, and any Governmental Authority regarding any of the Transactions. Without limiting the foregoing, each Party and their respective Affiliates shall not enter into any agreement with any Governmental Authority not to consummate the Transactions, except with the prior consent of the other Parties. Nothing in this Section 9.01 obligates any Party or any of its Affiliates to agree to (i) sell, license or otherwise dispose of, or hold separate and agree to sell, license or otherwise dispose of, any entities, assets or facilities of the Company or any of its Subsidiaries or any entity, facility or asset of such Party or any of its Affiliates, (ii) terminate, amend or assign existing relationships and contractual rights or obligations, (iii) amend, assign or terminate existing licenses or other agreements, or (iv) enter into new licenses or other agreements. Without limiting in any respect the Parties’ obligations under this Section 9.01, the Company shall have the right to direct, devise and implement the strategy with respect to obtaining Governmental Authorizations in accordance with this Section 9.01; provided EBAC is provided prompt notice by the Company of material communications and developments with respect to such process; provided, further, that the Company shall not be permitted to consent to any action, omission, undertaking, commitment or agreement with any Governmental Authority to the extent that such action, omission, undertaking, commitment or agreement requires any action, omission, commitment, undertaking or agreement by EBAC or its Affiliates without the prior written consent of EBAC.

 

93 

 

(b)            From and after the date of this Agreement until the earlier of the Acquisition Closing or termination of this Agreement in accordance with its terms, the Parties shall give counsel for the other Parties a reasonable opportunity to review in advance, and consider in good faith the views of the other in connection with, any proposed material written communication to any Governmental Authority relating to the Transactions, including in respect of any Tax rulings related thereto. Each of the Parties agrees not to participate in any substantive meeting or discussion, either in person, videoconference, or by telephone with any Governmental Authority in connection with the Transactions, including in respect of any Tax rulings related thereto, unless, to the extent not prohibited by such Governmental Authority, it consults with the other Parties, in advance. Each of the Parties shall use commercially reasonable efforts to provide (or use commercially reasonable efforts to cause its Affiliates provide) to the other Parties reasonable information or documents in such Party’s possession and within its control as are necessary or required for the preparation of any filings, notifications or submissions in connection with all Governmental Authorizations required to be obtained in connection with the Transactions. Notwithstanding the foregoing, any materials shared may be redacted before being provided to the other Parties (i) to remove references concerning the valuation of the Company, (ii) as necessary to comply with contractual arrangements and (iii) as necessary to avoid disclosure of other competitively sensitive information or to address reasonable privilege or confidentiality concerns.

 

Section 9.02.      Preparation of Proxy Statement/Registration Statement; Shareholders’ Meeting and Approvals.

 

(a)            As promptly as practicable following the execution and delivery of this Agreement, the Company, New Parent and EBAC shall prepare, with the assistance of the Company, and cause to be filed with the SEC by New Parent a registration statement on Form F-4 (as amended or supplemented from time to time, and including the Proxy Statement contained therein, the “Registration Statement”) in connection with the registration under the Securities Act of the New Parent Shares to be issued under this Agreement as part of the New Parent Interests Consideration and Company Consideration and the New Parent Warrants (and the New Parent Shares issuable upon exercise thereof). Each of EBAC and the Company shall use its commercially reasonable efforts to cause the Registration Statement to comply with the rules and regulations promulgated by the SEC, to have the Registration Statement declared effective under the Securities Act as promptly as practicable after such filing and to keep the Registration Statement effective as long as is necessary to consummate the Acquisition Transactions. Each of EBAC and the Company shall furnish all information concerning it as may reasonably be requested by the other party in connection with such actions and the preparation of the Registration Statement. Promptly after the Registration Statement is declared effective under the Securities Act, EBAC will cause the Proxy Statement to be mailed to shareholders of EBAC. The Company and EBAC shall each pay one half of all fees and expenses incurred in connection with the preparation and filing of the Registration Statement and the receipt of stock exchange approval in connection with the listing of New Parent Shares to be issued as part of the New Parent Interests Consideration and the New Parent Warrants (and the New Parent Shares issuable upon exercise thereof), other than fees and expenses of advisors (which shall be borne by the party incurring such fees).

 

94 

 

(b)            Each of EBAC, New Parent and the Company shall cooperate and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed) any response to comments of the SEC or its staff with respect to the Registration Statement and any amendment to the Registration Statement filed in response thereto. If EBAC, New Parent or the Company becomes aware that any information contained in the Registration Statement shall have become false or misleading in any material respect or that the Registration Statement is required to be amended in order to comply with applicable Law, then (i) such party shall promptly inform the other parties and (ii) EBAC and New Parent, on the one hand, and the Company, on the other hand, shall reasonably cooperate and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed) an amendment or supplement to the Registration Statement. EBAC, New Parent and the Company shall use commercially reasonable efforts to cause the Registration Statement as so amended or supplemented, to be filed with the SEC and to be disseminated to the holders of shares of EBAC Common Stock pursuant to applicable Law and subject to the terms and conditions of this Agreement and EBAC’s Governing Documents. Each of the Company, New Parent and EBAC shall provide the other parties with copies of any written comments, and shall inform such other parties of any oral comments, that New Parent receives from the SEC or its staff with respect to the Registration Statement promptly after the receipt of such comments and shall give the other Parties a reasonable opportunity to review and comment on any proposed written or oral responses to such comments prior to responding to the SEC or its staff.

 

(c)            EBAC, New Parent and the Company agree to include provisions in the Proxy Statement and to take reasonable action related thereto, with respect to (i) approval of the Transactions, including the Business Combination (as defined in EBAC’s Governing Documents) and the adoption and approval of this Agreement (the “Transaction Proposal”), (ii) adjournment of the special meeting (the “EBAC Shareholders’ Meeting”), if necessary, to permit further solicitation of proxies because there are not sufficient votes to approve and adopt any of the foregoing proposals (the “Adjournment Proposal”) and (iii) approval of any other proposals required by applicable securities Laws or Nasdaq listing rules or reasonably agreed by EBAC and the Company to be necessary or appropriate in connection with the Transactions (the “Additional Proposal” and together with the Transaction Proposal and the Adjournment Proposal, the “Transaction Proposals”). Without the prior written consent of the Company, the Transaction Proposals shall be the only matters (other than procedural matters) which EBAC shall propose to be voted on by the EBAC Shareholders at the EBAC Shareholders’ Meeting.

 

95 

 

(d)            EBAC shall use commercially reasonable efforts to, as promptly as practicable after the Registration Statement is declared effective under the Securities Act, (i) duly call, give notice of, convene and hold the EBAC Shareholders’ Meeting, (ii) cause the Proxy Statement to be disseminated to EBAC Shareholders in compliance with applicable Law and (iii) solicit proxies from the holders of EBAC Common Stock to vote in accordance with the recommendation of the EBAC Board with respect to each of the Transaction Proposals. EBAC shall, through the EBAC Board, recommend to its shareholders that they approve the Transaction Proposals (the “EBAC Board Recommendation”) and shall include the EBAC Board Recommendation in the Proxy Statement. The EBAC Board shall not (and no committee or subgroup thereof shall) change, withdraw, withhold, qualify or modify, or publicly propose to change, withdraw, withhold, qualify or modify, the EBAC Board Recommendation (together with any withdrawal, amendment, qualification or modification of its recommendation to the shareholders of EBAC described in the Recitals hereto, a “Modification in Recommendation”); provided that the EBAC Board may make a Modification in Recommendation prior to receipt of the EBAC Shareholder Approval if, and only if, the EBAC Board determines in consultation with EBAC’s outside legal counsel that failure to make a Modification in Recommendation would be inconsistent with the fiduciary duties of the EBAC Board under applicable Laws; provided, further, that the EBAC Board shall not be entitled to make, or agree or resolve to make, a Modification in Recommendation unless (x) EBAC has provided the Company with a written notice (a “Modification in Recommendation Notice”) advising the Company that the EBAC Board proposes to take such action and containing the material facts underlying the EBAC Board’s determination that a Modification in Recommendation is required hereunder (in each case, it being acknowledged that such Modification in Recommendation Notice shall not itself constitute a breach of this Agreement), and (y) at or after 5:00 p.m. on the fourth (4th) Business Day immediately following the day on which EBAC delivered the Modification in Recommendation Notice (such period from the time the Modification in Recommendation Notice is provided until 5:00 p.m. on the fourth (4th) Business Day immediately following the day on which EBAC delivered the Modification in Recommendation Notice  (the “Modification in Recommendation Notice Period”)), the EBAC Board reaffirms in good faith (after consultation with its outside counsel) that the failure to make a EBAC Modification in Recommendation would be inconsistent with its fiduciary duties under applicable Law. If requested by the Company, EBAC will and will use its reasonable best efforts to cause its Representatives to, during the Modification in Recommendation Notice Period, engage in good faith negotiations with the Company and its Representatives to make such adjustments in the terms and conditions of this Agreement so as to obviate the need for a Modification in Recommendation.  EBAC’s obligations under Section 9.02(c) to call and hold the EBAC Shareholders’ Meeting with respect to all Transaction Proposals shall not be affected by any Modification in Recommendation.  For the avoidance of doubt, in the event of a Modification in Recommendation, EBAC shall continue to submit this Agreement to the EBAC Shareholders for approval at the EBAC Shareholders’ Meeting unless this Agreement shall have been terminated in accordance with its terms prior to the EBAC Shareholders’ Meeting.

 

96 

 

(e)            EBAC may postpone the EBAC Shareholders’ Meeting, or adjourn the EBAC Shareholders’ Meeting opened in accordance with EBAC’s Governing Documents, on one or more occasions for up to twenty (20) Business Days in the aggregate after the date for which the EBAC Shareholders’ Meeting was originally scheduled upon the good faith determination by the EBAC Board that such postponement or adjournment, as the case may be, is necessary to (i) solicit additional proxies to obtain the EBAC Shareholder Approval, (ii) obtain a quorum if one is not present at any then scheduled EBAC Shareholders’ Meeting, (iii) ensure that any supplement or amendment to the Proxy Statement that is required by applicable Law is provided to the EBAC Shareholders with adequate time for review prior to the EBAC Shareholders’ Meeting, or (iv) otherwise take actions consistent with EBAC’s obligations under Section 9.03.

 

Section 9.03.      Support of Transaction. Without limiting any covenant contained in Article 7, or Article 8, EBAC and the Company shall each, and each shall cause its respective Subsidiaries to (a) use commercially reasonable efforts to obtain as soon as practicable all material consents and approvals of third parties (including any Governmental Authority) that any of EBAC, or the Company or their respective Affiliates are required to obtain in order to consummate the Acquisition Transactions, and (b) take such other action as soon as practicable as may be reasonably necessary or as another party hereto may reasonably request to satisfy the conditions to the obligations of the other parties set forth in Article 10 or otherwise to comply with this Agreement and to consummate the Transactions as soon as practicable and in accordance with all applicable Law.

 

Section 9.04.      Cooperation; Consultation.

 

(a)            Prior to Acquisition Closing, each of the Company, New Parent and EBAC shall, and each of them shall cause its respective Subsidiaries and Affiliates (as applicable) and its and their officers, directors, managers, employees, consultants, counsel, accounts, agents and other representatives to, reasonably cooperate in a timely manner in connection with the PIPE Investment or any other financing arrangement the parties may mutually agree to seek in connection with the Transactions (it being understood and agreed that the consummation of any such financing by the Company, New Parent or EBAC shall be subject to the parties’ mutual agreement), including (i) by providing such information and assistance as the other party may reasonably request (including the Company and EBAC providing such financial statements and other financial data relating to the Company or EBAC and their Subsidiaries, as applicable, and as would be required (x) if New Parent were filing a general form for registration of securities under Form 10 following the consummation of the Transactions, (y) for a registration statement on Form F-1 for the resale of the securities issued in the PIPE Investment following the Acquisition Closing), (ii) granting such access to the other party and its representatives as may be reasonably necessary for their due diligence, and (iii) participating in a reasonable number of meetings, presentations, road shows, drafting sessions and due diligence sessions with respect to such financing efforts (including direct contact between senior management and other representatives of the Company and its Subsidiaries at reasonable times and locations) and (iv) taking, or to causing to be taken, all actions required, necessary or advisable to consummate such financing transactions, including using commercially reasonable efforts to enforce its rights under any Subscription Agreement or Additional Subscription Agreement. All such cooperation, assistance and access shall be granted during normal business hours and shall be granted under conditions that shall not unreasonably interfere with the business and operations of the Company, EBAC, or their respective auditors.

 

97 

 

(b)            From the date of the announcement of this Agreement or the date of the Transactions (pursuant to any applicable public communication made in compliance with Section 12.12), until the Acquisition Closing Date, EBAC and the Company shall use their commercially reasonable efforts to, and shall instruct their respective financial advisors to, keep each other and each other’s financial advisors reasonably informed with respect to the PIPE Investment and the rotation of the EBAC Common Stock during such period, including by (i) providing regular updates and (ii) consulting and cooperating with, and considering in good faith any feedback from, each other and each other’s financial advisors with respect to such matters.

 

Section 9.05.      Additional Equity Financing. For the avoidance of doubt, during the Interim Period and subject to Sections 7.01(j) and 8.04(a)(viii), EBAC and the Company and/or New Parent may execute Additional Subscription Agreements with investors with the prior written consent of the other Parties hereto.

 

Section 9.06.      Section 16 Matters. Prior to the First Merger Effective Time, upon request of EBAC, each of the Company and New Parent shall use commercially reasonable efforts to take all such steps (to the extent permitted under applicable Law) to cause any acquisitions or dispositions of the New Parent Shares or of EBAC Common Stock (including, in each case, securities deliverable upon exercise, vesting or settlement of any derivative securities) resulting from the Transactions by each individual who is or may become subject to the reporting requirements of Section 16(a) of the Exchange Act in connection with the Transactions to be exempt under Rule 16b-3 promulgated under the Exchange Act.

 

Section 9.07.      Employee Matters. Prior to the Acquisition Closing and with the prior written consent of EBAC (not to be unreasonably withheld, conditioned or delayed), the Company shall approve and adopt an incentive award plan (the “New Parent Equity Incentive Plan”), which shall provide for an aggregate share reserve thereunder equal to sixteen percent (16%) of the New Parent Shares on a fully diluted basis plus (inclusive of the Converted Options). Within two (2) Business Days following the expiration of the sixty (60) day period following the date New Parent has filed a current Form 10 information with the SEC reflecting its status as an entity that is not a shell company, New Parent shall use its commercially reasonable efforts to file an effective registration statement on Form S-8 (or other applicable form, including Form F-3) with respect to the New Parent Shares issuable under the New Parent Equity Incentive Plan, and New Parent shall use commercially reasonable efforts to maintain the effectiveness of such registration statement(s) (and maintain the current status of the prospectus or prospectuses contained therein) for so long as awards granted pursuant to the New Parent Equity Incentive Plan remain outstanding.

 

98 

 

Section 9.08.      Director and Officer Appointments. Except as otherwise agreed in writing by the Company and EBAC prior to the Acquisition Closing, and conditioned upon the occurrence of the Acquisition Closing, subject to any limitation imposed under applicable Laws and Nasdaq listing requirements, EBAC and the Company shall take all actions necessary or appropriate to cause the individuals set forth on Section 9.08 of the Company Disclosure Letter to be elected as members of the Board of Directors of New Parent (the “New Parent Board of Directors”) and/or officers of New Parent, as indicated thereon, in each case effective as of the Acquisition Closing. Such New Parent Board of Directors will, at the Acquisition Closing, include: (i) two (2) individuals designated as the Sponsor director nominees (individually, the “Sponsor Nominee”) and (ii) up to five (5) individuals designated by the Company, one of whom shall be the chief executive of the Company and at least three of whom, who in each case will be subject to the prior approval of the Sponsor (not to be unreasonably withheld) shall qualify as “independent” under applicable SEC and Nasdaq listing rules. If any of the individuals set forth on Section 9.08 of the Company Disclosure Letter is prohibited by applicable Law from acting as a director or officer of New Parent or does not meet any regulatory fit and proper requirements or the Company (acting reasonably) determines that any such individual is in breach of any applicable Laws (including Anti-Bribery Laws and Sanctions Laws but excluding any other minor offenses that do not have an effect on the reputation or fit and proper status of such individual), a replacement individual shall be selected by the Company, or in the case of the Sponsor Nominee by the Sponsor, to act as a member of the New Parent Board of Directors and/or officer of New Parent, as applicable. On the Acquisition Closing Date, New Parent shall enter into customary indemnification agreements reasonably satisfactory to the Sponsor with the Sponsor Nominees, which indemnification agreements shall continue to be effective following the Acquisition Closing.

 

Section 9.09.      Tax Matters.

 

(a)            The Parties intend that the EBAC Mergers, taken together, the Company Share Contribution and the Third Merger, taken together, and the Convertible Loans qualify for the Intended Tax Treatment. This Agreement is intended to constitute and hereby is adopted as a “plan of reorganization” with respect to each of the EBAC Mergers, the Company Share Contribution, and the Third Merger within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a) and for purposes of Sections 354, 361, and 368 of the Code and the applicable Treasury Regulations. The Parties (i) shall use commercially reasonable efforts to cause the Transactions to qualify for the Intended Tax Treatment, (ii) shall not take any action that could reasonably be expected to prevent, impair, or impede the Intended Tax Treatment, and (iii) shall not take any position for Tax purposes inconsistent with the Intended Tax Treatment unless otherwise required by a “determination” within the meaning of Section 1313 of the Code.

 

(b)            All Transfer Taxes shall be borne and paid by New Parent. Unless otherwise required by applicable Law, New Parent shall timely file any Tax Return or other document with respect to Transfer Taxes (and the other Parties shall reasonably cooperate with respect thereto as necessary). The Parties shall reasonably cooperate to reduce or eliminate the amount of any Transfer Taxes.

 

99 

 

(c)            The Parties shall use commercially reasonable efforts to cooperate fully, as and to the extent reasonably requested by the other Party or its counsel, in connection with filing relevant Tax Returns, conducting and defending relevant Legal Proceedings with respect to Taxes, and documenting and supporting the Intended Tax Treatment, including by providing customary representation letters. Such cooperation shall include the reasonable provision of records and information that are reasonably relevant to any such matters and within such Party’s possession or obtainable by such Party without material cost or expense, and the use of commercially reasonable efforts to make employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder.

 

(d)            EBAC shall (i) cause Merger Sub 2 to timely file an initial entity classification election on a valid IRS Form 8832 to be treated for U.S. federal income Tax purposes as an entity disregarded as separate from New Parent, effective as of the date of its formation (and shall not thereafter change such classification), (ii) take no action that would result in New Parent, Merger Sub 1, or Merger Sub 3 being treated as anything other than an association taxable as a corporation for U.S. federal income Tax purposes, and (iii) take no action that would result in Merger Sub 1, Merger Sub 2, or Merger Sub 3 being other than a wholly owned direct Subsidiary of New Parent as of immediately prior to the First Merger Effective Time, the Second Merger Effective Time, and the Third Merger Effective Time, respectively.

 

(e)            In the event that EBAC is treated as a “passive foreign investment company” within the meaning of Section 1297 of the Code, New Parent shall make available to the pre-closing EBAC shareholders information that is reasonably required to make a timely and valid “Qualifying Electing Fund” election under Section 1295 of the Code and the Treasury Regulations promulgated thereunder with respect to EBAC for the taxable year that includes the Acquisition Closing Date and the immediately preceding taxable year (including through provision of a PFIC Annual Information Statement described in Treasury Regulations Section 1.1295-1(g)), including, at New Parent’s election, by making such information publicly available on New Parent’s website.

 

(f)             Each of the Parties shall promptly notify the other Parties in writing if, before the Acquisition Closing, it determines that it is not reasonable for the Transactions to qualify for the Intended Tax Treatment. Following such notice, the notifying Party may propose amendments to the terms of this Agreement (including, without limitation, having Merger Sub 3 timely file an entity classification election on a valid IRS Form 8832 to be treated as an entity disregarded as separate from New Parent for U.S. federal income Tax purposes, effective prior to the Acquisition Closing) that such Party reasonably believes could facilitate such qualification without an adverse effect on any other Party. In that case, each other Party shall consider in good faith the proposed amendments and, if it determines in good faith that such amendments would not have an adverse effect on such Party, the Parties shall use commercially reasonable efforts to effect such amendments.

 

100 

 

(g)            The Company shall not call, request, receive, or otherwise take possession in cash of any amounts pursuant to the Convertible Loan Agreement. In the event that cash to fund the Convertible Loans is funded by the lender parties thereto prior to the assumption of the Company’s rights and obligations under the Convertible Loan Agreement by New Parent, such cash shall only be funded to the “Escrow Agent” (as defined in the Convertible Loan Agreement), which the Escrow Agent shall hold on behalf of the Lenders that funded such cash, and such Lenders shall be treated as the owners of such cash for U.S. federal income Tax purposes unless and until such cash is distributed to New Parent pursuant to the Convertible Loan Agreement. No person other than the Escrow Agent shall be entitled to receive any cash funded pursuant to the Convertible Loan Agreement until after the Second Merger Effective Time.

 

(h)            The Company, EBAC, and New Parent will use commercially reasonable efforts to ensure that the intended Tax treatment set forth in clause (iv) of the definition of Intended Tax Treatment is obtained. In furtherance of the foregoing, following the Second Merger Effective Time but prior to the Company Share Contribution, the Company shall agree with New Parent for the assumption by New Parent of all rights and obligations of the Company under the Convertible Loan Agreement pursuant to documentation and/or instruments reasonably satisfactory to New Parent and the Company.

 

Section 9.10.      Third Merger.

 

(a)            On the Acquisition Closing Date, and after the Company Share Contribution, the New Parent Board of Directors shall hold a meeting to implement the issuance of the New Parent Squeeze-Out Shares, if any, and take any other actions required in order to effect the Third Merger. The New Parent Board of Directors shall execute the application to the commercial register for an expedited pre-registration procedure (Vorerfassungsverfahren / procédure de pré-enregistrement), and any other actions that may be required in connection with such meeting of the New Parent Board of Directors.

 

(b)            Immediately after conducting such meeting of the New Parent Board of Directors, but in any event not later than 11:00 a.m. Swiss time on the Acquisition Closing Date, the New Parent Board of Directors shall file the application for registration in the expedited pre-registration procedure (Vorerfassungsverfahren / procédure de pré-enregistrement) of the matters covered in such meeting with the commercial register of the Canton of Zug.

 

(c)            On or prior to the Acquisition Closing Date, New Parent, the Company, and Merger Sub 3 shall prepare a merger agreement, on mutually agreeable terms, to effect the Third Merger. New Parent, the Company and Merger Sub 3 shall also adopt a merger report in accordance with the Swiss Code of Obligations in connection with the Third Merger.

 

101 

 

(d)            No less than three (3) and no more than five (5) Business Days following the Acquisition Closing Date, the Company shall invite all Company Shareholders that did not execute a Company Shareholders Support Agreement and the exchange notice contemplated by Section 2.01 to effect the Company Share Contribution to an Extraordinary Shareholders’ Meeting (“Company EGM”) with the resolutions required for the Third Merger.

 

(e)            The Company and Merger Sub 3 shall each hold the Company EGM and the Merger Sub 3 extraordinary shareholders’ meeting, respectively, on or about thirty-two (32) calendar days after the Acquisition Closing Date before a Swiss notary public, to approve the Third Merger. The Company shall file the application for registration with the commercial register of the Canton of Vaud. Upon registration of the Third Merger, and with no further action required on the part of any Person, (i) New Parent shall issue to the Company Shareholders that did not execute a Company Shareholders Support Agreement or the exchange notice contemplated by Section 2.01 an amount of New Parent Squeeze-Out Shares, using the applicable ratios set forth in Schedule 2.01 of the Company Disclosure Letter and (ii) following such payment, each interest of Company Share Capital held by such Company Shareholders shall be cancelled and cease to exist.

 

(f)             The New Parent Board of Directors shall file the transfer of New Parent’s registered seat to Lausanne with the commercial register of the Canton of Vaud on or about forty-five (45) calendar days after the Acquisition Closing Date.

 

Section 9.11.      Engagement Letters; Subscription Agreements. As of the Acquisition Closing, New Parent will assume all of the obligations of EBAC under the PIPE Placement Agent Engagement Letters and the Subscription Agreements, and of the Company under the Financial Advisor Engagement Letters.

 

Section 9.12.      Agent Deliverables. EBAC and the Company shall not allow any of the following events to occur without delivering the Agent Deliverables to the Agents, in form agreed to (but unexecuted) by the Agents at least two (2) Business Days prior to the date of the following events, in each case, dated as of the respective dates of the following events: (i) the Registration Statement to be declared effective or (ii) the EBAC Shareholders’ Meeting to take place (with any such failure of delivery, a “Delivery Default”), in each case, unless the Agents, after being notified by EBAC and the Company in writing in reasonable detail of an expected Delivery Default, have had a reasonable period of time but no less than three (3) Business Days (the “Resignation Period”) prior to the occurrence of the relevant event to take any action the Agents deem appropriate, including without limitation, to elect to (A) resign from their respective roles, (B) disclose such resignation publicly, and/or (C) disclose such resignation to the SEC or otherwise (in each case above at their sole and absolute discretion) as is deemed necessary by the Agents. Notwithstanding the foregoing, nothing in this Agreement shall limit the right of any Agent to take any action it deems appropriate, including without limitation, to resign from any or all of its capacities at any time and for any reason, in its sole and absolute discretion.

 

102 

 

Article 10
Conditions to Obligations

 

Section 10.01.  Conditions to Obligations of the Parties. The obligations of the Parties to consummate, or cause to be consummated, the Transactions is subject to the satisfaction of the following conditions, any one or more of which may be waived in writing by all of such parties:

 

(a)            The EBAC Shareholder Approval shall have been obtained;

 

(b)            The Registration Statement shall have become effective under the Securities Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose shall have been initiated or threatened by the SEC and not withdrawn;

 

(c)            There shall not be in force any Governmental Order enjoining or prohibiting the consummation of either or both of the Acquisition Transactions or any Law that makes the consummation of either or both of the Acquisition Transactions illegal or otherwise prohibited; provided that the Governmental Authority issuing such Governmental Order has jurisdiction over the parties hereto with respect to the Transactions;

 

(d)            EBAC having net tangible assets of at least $5,000,001;

 

(e)            The New Parent Shares and New Parent Warrants to be issued in connection with the Acquisition Transactions shall have been approved for listing on the Stock Exchange; and

 

(f)             (i) The amount of cash or cash equivalents available in the Trust Account following the EBAC Shareholders’ Meeting (after deducting the amount required to satisfy the EBAC Share Redemption Amount and payment of any Company Transaction Expenses or EBAC Transaction Expenses); plus (ii) (A) the cash actually received by New Parent pursuant to the Convertible Loan Agreement from the respective lender parties thereto and (B) the PIPE Investment Amount actually received by New Parent (or other financing in connection with the Acquisition Transactions) prior to or substantially concurrently with the Acquisition Closing is equal to or greater than $100 million.

 

Section 10.02.  Conditions to Obligations of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3. The obligations of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to consummate, or cause to be consummated, the Acquisition Transactions are subject to the satisfaction of the following additional conditions, any one or more of which may be waived in writing by EBAC:

 

103 

 

(a)            (i) The representations and warranties of the Company contained in the first sentence of Section 4.06(a) shall be true and correct in all respects as of the date hereof and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all respects at and as of such date, except for changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements, (ii) the Company Fundamental Representations (other than the first sentence of Section 4.06(a)) shall be true and correct in all material respects, in each case as of the as of the date hereof and Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all material respects at and as of such date, except for changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements, and (iii) each of the representations and warranties of the Company contained in this Agreement other than the Company Fundamental Representations (disregarding any qualifications and exceptions contained therein relating to materiality, material adverse effect and Company Material Adverse Effect or any similar qualification or exception) shall be true and correct as of the date hereof and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct at and as of such date, except for, in each case, inaccuracies or omissions that have not had, and would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect;

 

(b)            Each of the covenants of the Company set forth in this Agreement to be performed as of or prior to the Acquisition Closing shall have been performed in all material respects; and

 

(c)            There shall not have occurred a Company Material Adverse Effect after the date of this Agreement.

 

Section 10.03.  Conditions to the Obligations of the Company. The obligation of the Company to consummate, or cause to be consummated, the Acquisition Transactions is subject to the satisfaction of the following additional conditions, any one or more of which may be waived in writing by the Company:

 

(a)            (i) the EBAC Fundamental Representations shall be true and correct in all material respects as of the date of this Agreement and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all material respects at and as of such date, except for changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements, (ii) the representations and warranties set forth in the first sentence of each of the first sentence of each of Section 5.03(a) and Section 6.13(a) shall be true and correct in all respects as of the date hereof and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct in all respects at and as of such date, except for changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements and (iii) the representations and warranties of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 in ‎‎ ‎Article 5 and Article 6 (other

 

104 

 

than the EBAC Fundamental Representations and the representations and warranties set forth in the first sentence of the first sentence of each of Section 5.03(a) and Section 6.13(a)) (disregarding any qualifications and exceptions contained therein relating to materiality, material adverse effect or any similar qualification or exception) shall be true and correct as of the date hereof and as of the Acquisition Closing Date, except with respect to such representations and warranties which speak as to an earlier date, which representations and warranties shall be true and correct as of such date, except for, in each case, inaccuracies or omissions that have not had, and would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of EBAC to consummate the Transactions in accordance with the terms of this Agreement and changes after the date of this Agreement which are contemplated or expressly permitted by this Agreement or the Ancillary Agreements;

 

(b)            Each of the covenants of EBAC, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 set forth in this Agreement to be performed as of or prior to the Acquisition Closing shall have been performed in all material respects; and

 

(c)            There shall not have occurred a material adverse effect of the EBAC after the date of this Agreement.

 

Article 11
Termination/Effectiveness

 

Section 11.01.  Termination. This Agreement may be terminated and the Transactions abandoned:

 

(a)            by mutual written consent of the Company and EBAC;

 

(b)            by the Company or EBAC if the Acquisition Closing Date has not occurred by March 18, 2023 (the “Agreement End Date”); provided, that if an Extension Proposal shall be approved at an Extension Shareholders’ Meeting, then the Agreement End Date shall be the last day of the extended time period for EBAC to consummate a business combination; provided, further, however, that a party shall not be entitled to terminate this Agreement pursuant to this Section 11.01(b) if such party’s breach of this Agreement has prevented the consummation of the Acquisition Closing Date at or prior to such time;

 

(c)            by the Company or EBAC if any Governmental Authority, shall have enacted, issued, promulgated, enforced or entered any Governmental Order which has become final and nonappealable and has the effect of making consummation of either or both of the Acquisition Transactions illegal or otherwise preventing or prohibiting consummation of either or both of the Acquisition Transactions or if there shall be adopted any Law that permanently makes consummation of either or both of the Acquisition Transactions illegal or otherwise prohibited;

 

(d)            by the Company if there has been a Modification in Recommendation;

 

105 

 

(e)            by the Company or EBAC if the EBAC Shareholder Approval shall not have been obtained by reason of the failure to obtain the required vote at the EBAC Shareholders’ Meeting duly convened therefor or at any adjournment or postponement thereof;

 

(f)             by written notice to the Company from EBAC if (i) there is any breach of any representation, warranty, covenant or agreement on the part of the Company set forth in this Agreement, such that the conditions specified in Section 10.02(a) through Section 10.02(d) would not be satisfied at the Acquisition Closing (a “Terminating Company Breach”), except that, if such Terminating Company Breach is curable by the Company prior to the end of the period ending on the date that is the earlier of (A) forty-five (45) days after receipt by the Company of notice from EBAC of such breach or (B) the Agreement End Date (the “Company Cure Period”), such termination shall not be effective, and such termination shall become effective only if the Terminating Company Breach is not cured within the Company Cure Period; provided, however, that EBAC is not then in material breach of this Agreement; or

 

(g)            by written notice to EBAC from the Company if there is any breach of any representation, warranty, covenant or agreement on the part of EBAC set forth in this Agreement, such that the conditions specified in Section 10.03(a) through Section 10.03(c) would not be satisfied at the Acquisition Closing (a “Terminating EBAC Breach”), except that, if any such Terminating EBAC Breach is curable by EBAC prior to the end of the period ending on the date that is the earlier of (A) forty-five (45) days after receipt by EBAC of notice from the Company of such breach or (B) the Agreement End Date (the “EBAC Cure Period”), such termination shall not be effective, and such termination shall become effective only if the Terminating EBAC Breach is not cured within the EBAC Cure Period provided, however, that the Company is not then in material breach of this Agreement.

 

Section 11.02.  Effect of Termination. In the event of the termination of this Agreement pursuant to Section 11.01, this Agreement shall forthwith become void and have no effect, without any liability on the part of any party hereto or its respective Affiliates, officers, directors or shareholders, other than liability of the Company or EBAC, as the case may be, for actual fraud or any willful and material breach (meaning an action or omission that at the time taken or made is both deliberate and known to be a material breach) of this Agreement occurring prior to such termination except that the provisions of this Section 11.02 and Article 12 and the Confidentiality Agreement shall survive any termination of this Agreement.

 

Article 12
Miscellaneous

 

Section 12.01.  Trust Account Waiver. The Company understands and acknowledges that EBAC is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company further

 

106 

 

acknowledges that, as described in the final prospectus relating to EBAC’s initial public offering filed with the SEC on March 18, 2021 (File No. 333-23220) (the “Prospectus”), substantially all of EBAC’s assets consist of the cash proceeds of such initial public offering and private placement of securities, and substantially all of those proceeds have been deposited into a trust account (the “Trust Account”) for the benefit of EBAC and EBAC’s public shareholders. As further described in the Prospectus, the funds held from time to time in the Trust Account may only be released upon certain conditions. The Company acknowledges and agrees that, prior to the Acquisition Closing and subject in all respects to the Trust Agreement, it has no right of set-off or any right, title, interest or claim of any kind (“Claim”) to, or to any monies or other assets in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies or other assets in, the Trust Account that it may have now or in the future prior to Acquisition Closing. In the event the Company has any Claim against EBAC under this Agreement or otherwise, the Company shall pursue such Claim solely against EBAC and EBAC’s assets outside the Trust Account and not against the Trust Account or any monies or other assets in the Trust Account.

 

Section 12.02.  Waiver. Any Party to this Agreement may, at any time prior to the Acquisition Closing, by action taken by its Board of Directors, Board of Managers, Managing Member or other officers or Persons thereunto duly authorized, (a) extend the time for the performance of the obligations or acts of the other parties hereto, (b) waive any inaccuracies in the representations and warranties (of another party hereto) that are contained in this Agreement or (c) waive compliance by the other parties hereto with any of the agreements or conditions contained in this Agreement, but such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party granting such extension or waiver.

 

Section 12.03.  Notices. All notices and other communications among the parties shall be in writing and shall be deemed to have been duly given (i) when delivered in person, (ii) when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested, postage prepaid,(iii) when delivered by FedEx or other nationally recognized overnight delivery service, or (iv) when delivered by email (in each case in this clause (iv), solely if receipt is confirmed, but excluding any automated reply, such as an out-of-office notification), addressed as follows:

 

(a)    If to EBAC prior to the Acquisition Closing, or to Merger Sub 2 after the Second Merger Effective Time, to:

 

European Biotech Acquisition Corp.
EPFL Innovation Park Building
1015 Lausanne
Switzerland
Attention: Eduardo Bravo
Email: eduardo.bravo@eqtpartners.com

 

107 

 

with copies to (which shall not constitute notice):

 

Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, New York 10017

 

Attention: Michael Davis
  Derek Dostal
Email: michael.davis@davispolk.com
  derek.dostal@davispolk.com

 

(b)     If to the Company prior to the Acquisition Closing, or to New Parent after the Acquisition Closing, to:

 

Oculis SA
EPFL Innovation Park Building D
1015 Lausanne

 

Switzerland

 

Attention: Riad Sherif
Email: riad.sherif@oculis.com

 

with copies to (which shall not constitute notice):

 

Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ, UK


 

Attention: Michal Berkner
  Divakar Gupta
  Ryan Sansom
E-mail: mberkner@cooley.com
  dgupta@cooley.com
  rsansom@cooley.com

 

or to such other address or addresses as the parties may from time to time designate in writing. Copies delivered solely to outside counsel shall not constitute notice.

 

Section 12.04.  Assignment. No party hereto shall assign this Agreement or any part hereof without the prior written consent of the other parties and any such transfer without prior written consent shall be void. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.

 

Section 12.05.  Rights of Third Parties. This Agreement shall be binding upon and inure solely to the benefit of each Party and its successors and permitted assigns and, except as provided in Section 7.08, the last two sentences of this Section 12.05, Section 12.16 and Section 12.17, nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. Legal counsel identified in Section 12.18 shall be express third-party beneficiaries of Section 12.18. The PIPE Placement Agents and the Financial Advisor shall be express third-party beneficiaries of the provisos to Section 12.11.

 

108 

 

Section 12.06.  Expenses. Except as otherwise set forth in this Agreement, each party hereto shall be responsible for and pay its own expenses incurred in connection with this Agreement and the Transactions, including all fees of its legal counsel, financial advisers and accountants. If the Acquisition Closing shall not occur, the Company shall be responsible for the Company Transaction Expenses, and EBAC shall be responsible for the EBAC Transaction Expenses. If the Acquisition Closing shall occur, New Parent shall (x) pay or cause to be paid, the Company Transaction Expenses, and (y) pay or cause to be paid, the EBAC Transaction Expenses. For the avoidance of doubt, any payments to be made (or to cause to be made) by New Parent pursuant to this Section 12.06 shall be paid upon consummation of the Acquisition Transactions and release of proceeds from the Trust Account.

 

Section 12.07.  Governing Law. This Agreement, and all claims or causes of action based upon, arising out of, or related to this Agreement or the Transactions, shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without giving effect to principles or rules of conflict of Laws to the extent such principles or rules would require or permit the application of Laws of another jurisdiction (except that Swiss Law shall apply to the New Parent Share Capital Increase).

 

Section 12.08.  Headings; Counterparts. The headings in this Agreement are for convenience only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signatures to this Agreement may be delivered by email (including by .pdf, .tif, .gif, .jpeg or similar formatted attachment thereto) by any Party and such signature will be deemed binding for all purposes hereof without delivery of an original signature being thereafter required. This Agreement shall become effective when each Party hereto shall have received one or more counterparts hereof signed by each of the other Parties hereto and unless and until such receipt, this Agreement shall have no effect and no Party hereto shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication).

 

Section 12.09.  Company and EBAC Disclosure Letters. The Company Disclosure Letter and the EBAC Disclosure Letter (as the EBAC Disclosure Letter may be supplemented from time to time after the date hereof in accordance with Section 2.02(c)(ii)) (including, in each case, any section thereof) referenced herein are a part of this Agreement as if fully set forth herein. All references herein to the Company Disclosure Letter and/or the EBAC Disclosure Letter (including, in each case, any section thereof) shall be deemed references to such parts of this Agreement, unless the context shall otherwise require. Any disclosure made by a party in the applicable Disclosure Letter, or any section thereof, with reference to any section of this Agreement or section

 

109 

 

of the applicable Disclosure Letter shall be deemed to be a disclosure with respect to such other applicable sections of this Agreement or sections of applicable Disclosure Letter if it is reasonably apparent on the face of such disclosure that such disclosure is responsive to such other section of this Agreement or section of the applicable Disclosure Letter. Certain information set forth in the Disclosure Letters is included solely for informational purposes and may not be required to be disclosed pursuant to this Agreement. The disclosure of any information shall not be deemed to constitute an acknowledgment that such information is required to be disclosed in connection with the representations and warranties made in this Agreement, nor shall such information be deemed to establish a standard of materiality.

 

Section 12.10.  Entire Agreement. (a) This Agreement (together with the Company Disclosure Letter and the EBAC Disclosure Letter), (b) the Sponsor Support Agreement, (c) the Confidentiality Agreement, dated as of February 22, 2022, by and between EBAC and the Company (the “Confidentiality Agreement”), (d) the Company Shareholders Support Agreement and (e) when entered into at the Acquisition Closing, (i) the Registration Rights Agreement and (ii) the Warrant Assumption Agreement (the foregoing clauses (b) through (e), collectively, the “Ancillary Agreements”) constitute the entire agreement among the parties to this Agreement relating to the Transactions and supersede any other agreements, whether written or oral, that may have been made or entered into by or among any of the parties hereto or any of their respective Subsidiaries relating to the Transactions. No representations, warranties, covenants, understandings, agreements, oral or otherwise, relating to the Transactions exist between such parties except as expressly set forth in this Agreement and the Ancillary Agreements.

 

Section 12.11.  Amendments. This Agreement may be amended or modified in whole or in part, only by a duly authorized agreement in writing executed by the Parties hereto in the same manner as this Agreement and which makes reference to this Agreement, provided that Section 7.09, Section 8.09, Section 9.11, Section 9.12, the last sentence of Section 12.05 and Section 12.11 of this Agreement may not be amended, modified or waived without the prior written consent of the Placement Agents; provided further that Section 7.09, Section 8.09, Section 9.12, the last sentence of Section 12.05 and Section 12.11 of this Agreement may not be amended, modified or waived without the prior written consent of the Financial Advisor.

 

Section 12.12.  Publicity.

 

(a)            All press releases or other public communications relating to the Transactions, and the method of the release for publication thereof, shall prior to the Acquisition Closing be subject to the prior mutual approval of EBAC and the Company, which approval shall not be unreasonably withheld by any party; provided that no party shall be required to obtain consent pursuant to this Section 12.12(a) to the extent any proposed release or statement is substantially equivalent to the information that has previously been made public without breach of the obligation under this Section 12.12(a).

 

110 

 

(b)            The restriction in Section 12.12(a) shall not apply to the extent the public announcement is required by applicable securities Law, any Governmental Authority or stock exchange rule; provided, however, that in such an event, the party making the announcement shall use its commercially reasonable efforts to consult with the other party in advance as to its form, content and timing. Disclosures resulting from the parties’ efforts to obtain approval or early termination under any regulatory approvals needed in connection with this Agreement, and to make any relating filing shall be deemed not to violate this Section 12.12.

 

Section 12.13.  Severability. If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. The parties further agree that if any provision contained herein is, to any extent, held invalid or unenforceable in any respect under the Laws governing this Agreement, they shall take any actions necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent permitted by Law and, to the extent necessary, shall amend or otherwise modify this Agreement to replace any provision contained herein that is held invalid or unenforceable with a valid and enforceable provision giving effect to the intent of the parties.

 

Section 12.14.  Jurisdiction; Waiver of Jury Trial.

 

(a)            Any proceeding or Action based upon, arising out of or related to this Agreement or the Transactions must be brought in the Court of Chancery of the State of Delaware (or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware), or, if it has or can acquire jurisdiction, in the United States District Court for the District of Delaware, and each of the parties irrevocably (i) submits to the exclusive jurisdiction of each such court in any such proceeding or Action, (ii) waives any objection it may now or hereafter have to personal jurisdiction, venue or to convenience of forum, (iii) agrees that all claims in respect of the proceeding or Action shall be heard and determined only in any such court, and (iv) agrees not to bring any proceeding or Action arising out of or relating to this Agreement or the Transactions in any other court. Nothing herein contained shall be deemed to affect the right of any party to serve process in any manner permitted by Law or to commence Legal Proceedings or otherwise proceed against any other party in any other jurisdiction, in each case, to enforce judgments obtained in any Action, suit or proceeding brought pursuant to this Section 12.14.

 

(b)            EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY BE BASED ON, ARISE UNDER OR RELATE TO THIS AGREEMENT AND THE TRANSACTIONS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY, UNCONDITIONALLY AND VOLUNTARILY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, SUIT OR PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS.

 

111 

 

Section 12.15.  Enforcement. The parties hereto agree that irreparable damage could occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent any breach, or threatened breach, of this Agreement and to specific enforcement of the terms and provisions of this Agreement, in addition to any other remedy to which any party is entitled at law or in equity. In the event that any Action shall be brought in equity to enforce the provisions of this Agreement, no party shall allege, and each party hereby waives the defense, that there is an adequate remedy at law, and each party agrees to waive any requirement for the securing or posting of any bond in connection therewith.

 

Section 12.16.  Non-Recourse. Except in the case of claims against a Person in respect of such Person’s actual fraud:

 

(a)            Solely with respect to the Company and EBAC, this Agreement may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement or the Transactions may only be brought against, the Company and EBAC as named parties hereto; and

 

(b)            except to the extent a party hereto (and then only to the extent of the specific obligations undertaken by such party hereto), (i) no past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate, agent, attorney, advisor or representative or Affiliate of the Company or EBAC and (ii) no past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate, agent, attorney, advisor or representative or Affiliate of any of the foregoing shall have any liability (whether in Contract, tort, equity or otherwise) for any one or more of the representations, warranties, covenants, agreements or other obligations or liabilities of any one or more of the Company or EBAC under this Agreement for any claim based on, arising out of, or related to this Agreement or the Transactions.

 

Section 12.17.  Non-Survival of Representations, Warranties and Covenants. Except (x) as expressly otherwise contemplated by Section 11.02, none of the representations, warranties, covenants, obligations or other agreements in this Agreement or in any certificate, statement or instrument delivered pursuant to this Agreement, including any rights arising out of any breach of such representations, warranties, covenants, obligations, agreements and other provisions, shall survive the Acquisition Closing and shall terminate and expire upon the occurrence of the First Merger Effective Time (and there shall be no liability after the Acquisition Closing in respect thereof), except for (a) those covenants and agreements contained herein that by their terms expressly apply in whole or in part after the Acquisition Closing and then only with respect to any breaches occurring after the Acquisition Closing and (b) this Article 12.

 

Section 12.18.  Conflicts and Privilege.

 

112 

 

(a)            Each of the Parties to this Agreement, on its own behalf and on behalf of its successors and assigns, hereby agree that, in the event a dispute with respect to this Agreement or the Transactions arises after the Acquisition Closing between or among (i) the Sponsor, the shareholders or holders of other equity interests of EBAC, New Parent, Merger Sub 1, Merger Sub 2, Merger Sub 3 or the Sponsor, or any of their respective directors, members, partners, officers, employees or Affiliates (collectively, the “EBAC Group”), on the one hand, and (ii) the Company or the shareholders or holders of other equity interests of the Company, or any of their respective directors, members, partners, officers, employees or Affiliates (collectively, the “Company Group”), on the other hand, Davis Polk & Wardwell LLP (“Davis Polk”), and Maples Group (collectively, the “Local Counsels”) may represent the Sponsor or any other member of the EBAC Group in such dispute even though the interests of such Persons may be directly adverse to New Parent, Merger Sub 2 or Merger Sub 3, and even though such counsel may have represented EBAC, New Parent, Merger Sub 2 or Merger Sub 3 in a matter substantially related to such dispute, or may be handling ongoing matters for the Company or the Sponsor. The Parties, on behalf of their respective successors and assigns, further agree that, as to all communications prior to the Acquisition Closing (made in connection with the negotiation, preparation, execution, delivery and performance under, or any dispute or Action arising out of or relating to, this Agreement, any Ancillary Agreements or the transactions contemplated hereby or thereby) between or among EBAC, the Sponsor or any other member of the EBAC Group, on the one hand, and Davis Polk and/or Local Counsels, on the other hand, shall be deemed subject to attorney client privilege (the “Davis Polk Privileged Communications”), and the attorney/client privilege and the expectation of client confidence shall survive the Transactions and belong to the members of the EBAC Group after the Acquisition Closing, and shall not pass to or be claimed or controlled by the Company. Any privileged communications or information shared by the Company prior to the Acquisition Closing with EBAC or the Sponsor under a common interest agreement shall remain the privileged communications or information of the Company. The Parties, together with any of their respective Affiliates, Subsidiaries, successors or assigns, agree that the EBAC Group may restrict access to the Davis Polk Privileged Communications, whether located in the records or email server of any Party or its respective Subsidiaries, in any Action against or involving any of the Parties after the Acquisition Closing, and the Parties agree not to assert that any privilege has been waived as to the Davis Polk Privileged Communications, by virtue of the Transactions.

 

(b)            Each of the Parties to this Agreement, on its own behalf and on behalf of its respective directors, managers, members, partners, officers, Affiliates, successors and assigns, hereby agree that, in the event a dispute with respect to this Agreement or the Transactions arises after the Acquisition Closing between or among (i) the members of the Company Group, on the one hand, and (ii) Company or any member of the EBAC Group, on the other hand, any legal counsel, including Cooley (UK) LLP (“Cooley”) and Vischer AG (“Vischer”) that represented the Company prior to the Acquisition Closing may represent any member of the Company Group in such dispute even though the interests of such Persons may be directly adverse to the Company, and even though such counsel may have represented the Company in a matter substantially related to such dispute, or may be handling ongoing matters for the Company, further agree that, as to all

 

113 

 

communications prior to the Acquisition Closing (made in connection with the negotiation, preparation, execution, delivery and performance under, or any dispute or Action arising out of or relating to, this Agreement, any Ancillary Agreements or the transactions contemplated hereby or thereby) between or among Company or any member of the Company Group, on the one hand, and Cooley or Vischer, on the other hand, shall be deemed subject to attorney client privilege (the “Cooley Privileged Communications”), and the attorney/client privilege and the expectation of client confidence shall survive the Transactions and belong to the members of the Company Group after the Acquisition Closing, and shall not pass to or be claimed or controlled by New Parent. Any privileged communications or information shared by EBAC or the Sponsor prior to the Acquisition Closing with the Company or Company Group under a common interest agreement shall remain the privileged communications or information of the EBAC Group. The Parties, together with any of their respective Affiliates, Subsidiaries, successors or assigns, agree that the Company Group may restrict access to the Cooley Privileged Communications, whether located in the records or email server of any Party or its respective Subsidiaries, in any Action against or involving any of the Parties after the Acquisition Closing, and the Parties agree not to assert that any privilege has been waived as to the Cooley Privileged Communications, by virtue of the Transactions.

 

[Remainder of page intentionally left blank]

 

114 

 

IN WITNESS WHEREOF the parties have hereunto caused this Agreement to be duly executed as of the date first above written.

 

  OCULIS SA
   
   
  By:  
    Name:
    Title:

 

 

  EUROPEAN BIOTECH ACQUISITION CORP.
   
   
  By:  
    Name:
    Title:
     
     

 

 

[Signature Page to Business Combination Agreement]

 

 

 

 

 

EXHIBIT A

 

Form of Non-Redemption Agreement

 

[Attached]

 

 

 

 

 

EXHIBIT B

 

Form of Registration Rights Agreement

 

[Attached]

 

 

 

 

 

Exhibit 10.1 

 

SUBSCRIPTION AGREEMENT

 

This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into this 17th day of October 2022, by and between European Biotech Acquisition Corp., a Cayman Islands exempted company (the “Issuer”), and the undersigned (“Subscriber” or “you”). Defined terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Business Combination Agreement (as defined below).

 

WHEREAS, the Issuer and Oculis SA, a public limited liability company (société anonyme) incorporated and existing under the laws of Switzerland (“Oculis”) will, immediately following the execution of this Subscription Agreement, enter into that certain Business Combination Agreement, dated as of the date hereof (as amended, modified, supplemented or waived from time to time in accordance with its terms, the “Business Combination Agreement”).

 

WHEREAS, as soon as practicable following the execution of the Business Combination Agreement, (a) the Issuer shall form or cause to be formed (i) Oculis Holding AG, a public limited liability company incorporated and existing under the laws of Switzerland and that will be a direct wholly owned subsidiary of EBAC (“New Parent”), (ii) a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 1”), (iii) another new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 2”) and (iv) a new limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and existing under the laws of Switzerland that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 3”) and (b) EBAC shall cause New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to become a party to the Business Combination Agreement as a “Party” and “EBAC Party” by executing a joinder agreement;

 

WHEREAS, pursuant to the Business Combination Agreement, among other things, (a) on the day before the Acquisition Closing Date (the “Closing Start Date”), Merger Sub 1 will merge with and into the Issuer, with the Issuer as the surviving corporation (the “First SPAC Merger”), (b) approximately 30 minutes after the consummation of the First SPAC Merger, the Issuer will merge with and into Merger Sub 2, with Merger Sub 2 as the surviving company and remaining a wholly owned subsidiary of New Parent (the “Second SPAC Merger”), (c) after consummation of the Second SPAC Merger, consenting Oculis shareholders will contribute their shares of Oculis to New Parent in exchange for New Parent common shares (the “Company Share Contribution”, together with the First SPAC Merger and the Second SPAC Merger, the “Primary Transactions” and the closing of the Primary Transactions, the “Acquisition Closing”) and (d) Oculis will merge with and into Merger Sub 3, with Merger Sub 3 as the surviving company and remaining a wholly owned subsidiary of New Parent (the “Third Merger” and together with the other transactions contemplated by the Business Combination Agreement, the “Transactions”);

 

WHEREAS, in connection with the Transactions, Subscriber desires to subscribe for and purchase from the Issuer, immediately preceding the First SPAC Merger, that number of the Issuer’s ordinary shares (the “Ordinary Shares”) set forth on the signature page hereto (the

 

 

 

Subscribed Shares”) for a purchase price of $10.00 per share (the “Per Share Price”), and for the aggregate purchase price set forth on the signature page hereto (the “Purchase Price”), and the Issuer desires to issue and sell to Subscriber the Subscribed Shares in consideration of the payment of the Purchase Price therefor by or on behalf of Subscriber to the Issuer, all on the terms and subject to the conditions set forth herein;

 

WHEREAS, certain other “qualified institutional buyers” (as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”)) or institutional “accredited investors” (within the meaning of Rule 501(a)(1), (2), (3) or (7) under the Securities Act) (each, an “Other Subscriber”) have, severally and not jointly, entered into separate subscription agreements with the Issuer (the “Other Subscription Agreements”), pursuant to which such Other Subscribers have agreed to purchase Ordinary Shares on the Closing Date (as defined below) at the Per Share Price, and the aggregate amount of securities to be sold by the Issuer pursuant to this Subscription Agreement and the Other Subscription Agreements equals, as of the date hereof, 6,330,031 Ordinary Shares.

 

NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties and covenants, and subject to the conditions, herein contained, and intending to be legally bound hereby, the parties hereto hereby agree as follows:

 

For ease of administration, this single Subscription Agreement is being executed so as to enable each Subscriber identified on the signature page to enter into a Subscription Agreement, severally, but not jointly. The parties agree that (i) this Subscription Agreement shall be treated as if it were a separate agreement with respect to each Subscriber listed on the signature page, as if each Subscriber entity had executed a separate Subscription Agreement naming only itself as Subscriber, and (ii) no Subscriber listed on the signature page shall have any liability under the Subscription Agreement for the obligations of any Other Subscriber so listed. The decision of Subscriber to purchase the Subscribed Shares pursuant to this Subscription Agreement has been made by Subscriber independently of any Other Subscriber or any other investor and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Issuer, Oculis or any of their respective subsidiaries which may have been made or given by any Other Subscriber or investor or by any agent or employee of any Other Subscriber or investor, and neither Subscriber nor any of its agents or employees shall have any liability to any Other Subscriber or investor (or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein or in any Other Subscription Agreement, and no action taken by Subscriber or investor pursuant hereto or thereto, shall be deemed to constitute Subscriber and Other Subscribers or other investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that Subscriber and Other Subscribers or other investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Subscription Agreement and the Other Subscription Agreements. Subscriber acknowledges that no Other Subscriber has acted as agent for Subscriber in connection with making its investment hereunder and no Other Subscriber will be acting as agent of Subscriber in connection with monitoring its investment in the Subscribed Shares or enforcing its rights under this Subscription Agreement. Subscriber shall be entitled to independently protect and enforce its rights, including without

 

2 

 

limitation the rights arising out of this Subscription Agreement, and it shall not be necessary for any Other Subscriber or investor to be joined as an additional party in any proceeding for such purpose.

 

1.   Subscription. Subject to the terms and conditions hereof, at the Closing (as defined below), Subscriber hereby agrees, to subscribe for and purchase, and the Issuer hereby agrees to issue and sell to Subscriber, upon the payment of the Purchase Price, the Subscribed Shares (such subscription and issuance, the “Subscription”). Notwithstanding anything herein to the contrary, the consummation of the Subscription is contingent upon the substantially concurrent occurrence of the Acquisition Closing as further described herein. Each of the parties hereto acknowledge and agree that the Subscribed Shares to be issued pursuant hereto shall initially be shares of a Cayman Islands exempted company and that such shares shall, in connection with the Acquisition Closing, be exchanged for ordinary shares in a Swiss corporation.

 

2.   Representations, Warranties and Agreements.

 

2.1.   Subscriber’s Representations, Warranties and Agreements. To induce the Issuer to issue the Subscribed Shares, Subscriber hereby represents and warrants to the Issuer and acknowledges and agrees with the Issuer, as of the date hereof and as of the Closing Date, as follows:

 

2.1.1.   Subscriber has been duly formed or incorporated and is validly existing in good standing under the laws of its jurisdiction of incorporation or formation, with power and authority to enter into, deliver and perform its obligations under this Subscription Agreement.

 

2.1.2.   This Subscription Agreement has been duly authorized, validly executed and delivered by Subscriber. Assuming that this Subscription Agreement constitutes the valid and binding agreement of the Issuer, this Subscription Agreement is the valid and binding obligation of Subscriber, and is enforceable against Subscriber in accordance with its terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii) principles of equity, whether considered at law or equity.

 

2.1.3.   The execution, delivery and performance by Subscriber of this Subscription Agreement and the consummation of the transactions contemplated herein do not and will not (i) result in any violation of the provisions of the organizational documents of Subscriber or any of its subsidiaries, (ii) result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over Subscriber that would reasonably be expected to have a material adverse effect on the legal authority and ability of Subscriber to enter into and timely perform its obligations under this Subscription Agreement (a “Subscriber Material Adverse Effect”) or (iii) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of Subscriber or any of its subsidiaries pursuant to the terms of any indenture,

 

3 

 

mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which Subscriber or any of its subsidiaries is a party or by which Subscriber or any of its subsidiaries is bound or to which any of the property or assets of Subscriber or any of its subsidiaries is subject, which would reasonably be expected to have a Subscriber Material Adverse Effect.

 

2.1.4.   Subscriber (i) (a) is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an institutional “accredited investor” (within the meaning of Rule 501(a)(1), (2), (3), or (7) under the Securities Act), (b) is an Institutional Account as defined in FINRA Rule 4512(c) and (c) is a sophisticated institutional investor, experienced in investing in transactions of the type contemplated by this Subscription Agreement and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities, including its participation in the Subscription, in each case, satisfying the applicable requirements set forth on Schedule I, (ii) has exercised independent judgment in evaluating its participation in the purchase of the Subscribed Shares, (iii) is acquiring the Subscribed Shares only for its own account and not for the account of others, or if Subscriber is subscribing for the Subscribed Shares as a fiduciary or agent for one or more investor accounts, each owner of such account is a qualified institutional buyer, and Subscriber has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations, warranties and agreements herein on behalf of each owner of each such account, for investment purposes only and not with a view to any distribution of the Subscribed Shares in any manner that would violate the securities laws of the United States or any other applicable jurisdiction and (iv) is not acquiring the Subscribed Shares with a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act (and shall provide the requested information on Schedule I following the signature page hereto). Subscriber has determined based on its own independent review and such professional advice as it deems appropriate that its purchase of the Subscribed Shares and participation in the Subscription (i) are fully consistent with its financial needs, objectives and condition, and (ii) comply and are fully consistent with all investment policies, guidelines and other restrictions applicable to it (if any). Subscriber is not an entity formed for the specific purpose of acquiring the Subscribed Shares. Subscriber understands that the offering of the Subscribed Shares meets (i) the exemptions from filing under FINRA Rule 5123(b)(1)(A) and (C) or (J) and (ii) the institutional customer exemption under FINRA Rule 2111(b).

 

2.1.5.   Subscriber understands that the Subscribed Shares are being offered in a transaction not involving any public offering within the meaning of the Securities Act and that the Subscribed Shares have not been registered under the Securities Act or the securities laws of any other jurisdiction. Except in respect of any stock lending program, Subscriber understands that the Subscribed Shares may not be resold, transferred, pledged or otherwise disposed of by Subscriber absent an effective registration statement under the Securities Act, except (i) to the Issuer or a subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales that occur solely outside the United States within the meaning of Regulation S under the Securities Act or (iii)

 

4 

 

pursuant to another applicable exemption from the registration requirements of the Securities Act, and in each of cases (i) and (iii), in accordance with any applicable securities laws of the states and other jurisdictions of the United States, and that the Subscribed Shares shall be subject to a legend to such effect (provided that such legends will be eligible for removal upon compliance with the relevant resale provisions of Rule 144 and as set forth in this Subscription Agreement). Subscriber acknowledges that the Subscribed Shares will not be immediately eligible for offer, resale, transfer, pledge or disposition pursuant to Rule 144 promulgated under the Securities Act until at least one year from the filing by the Issuer of the “Form 10 information” after the closing of the Business Combination and that the provisions of Rule 144(i) will generally apply to the Subscribed Shares. Subscriber understands and agrees that the Subscribed Shares will be subject to the foregoing restrictions and, as a result, Subscriber may not be able to readily resell the Subscribed Shares and may be required to bear the financial risk of an investment in the Subscribed Shares for an indefinite period of time. Subscriber understands that it has been advised to consult independent legal counsel prior to making any offer, resale, pledge or transfer of any of the Subscribed Shares. Subscriber has determined based on its own independent review and such professional advice as it deems appropriate that the Subscribed Shares are a suitable investment for Subscriber, notwithstanding the substantial risks inherent in investing in or holding the Subscribed Shares, and that Subscriber is able at this time and in the foreseeable future to bear the economic risk of a total loss of Subscriber’s investment in the Issuer.

 

2.1.6.   Subscriber understands and agrees that Subscriber is purchasing the Subscribed Shares directly from the Issuer. Subscriber further acknowledges that there have been no representations, warranties, covenants or agreements made to Subscriber by the Issuer or Oculis or any of their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives, expressly or by implication, other than, in the case of the Issuer only, those representations, warranties, covenants and agreements expressly set forth in this Subscription Agreement. Subscriber understands that certain financial information (whether historical or in the form of financial forecasts or projections) of the Issuer and Oculis have been prepared and reviewed solely by the Issuer, Oculis and their respective officers, directors and employees, as applicable, and have not been reviewed by any outside party or, except for the financial statements as expressly set forth in the Registration Statement (as defined below), certified or audited by an independent third-party auditor or audit firm.

 

2.1.7.   Subscriber does not have, as of the date hereof, and during the 30-day period immediately prior to the date hereof such Subscriber has not, and during the period beginning as of the date hereof until and including the date that is two trading days following the Closing such Subscriber will not have, entered into, any “put equivalent position” as such term is defined in Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or short sale positions with respect to the securities of the Issuer.

 

2.1.8.   If Subscriber is an employee benefit plan that is subject to Title I of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),

 

5 

 

Subscriber represents and warrants that its acquisition and holding of the Subscribed Shares will not constitute or result in a non-exempt prohibited transaction under Section 406 of ERISA, Section 4975 of the Internal Revenue Code of 1986, as amended (the “Code”), or any applicable other federal, state, local, non-U.S. or other laws or regulations that are similar to such provisions of ERISA or the Code (collectively, “Similar Laws”).

 

2.1.9.   In making its decision to purchase the Subscribed Shares, Subscriber represents that it has relied solely upon independent investigation made by Subscriber and the representations, warranties and covenants of the Issuer contained in this Subscription Agreement. Without limiting the generality of the foregoing, Subscriber has not relied on any statements or other information provided by anyone, other than the Issuer and its representatives concerning the Issuer or the Subscribed Shares or the offer and sale of the Subscribed Shares. Subscriber acknowledges and agrees that Subscriber has received access to and has had an adequate opportunity to review such information as Subscriber deems necessary in order to make an investment decision with respect to the Subscribed Shares, including with respect to the Issuer, Oculis, and the Transactions. Subscriber represents and agrees that Subscriber and Subscriber’s professional advisor(s), if any, received, reviewed and understood the offering materials made available to them in connection with the Subscription and the Transactions, have had the full opportunity to ask such questions, including on the financial information, receive such answers and obtain such information as Subscriber and Subscriber’s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Subscribed Shares. Subscriber represents and warrants it is relying exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the Subscription, the Transactions, the Subscribed Shares and the business, condition (financial and otherwise), management, operations, properties and prospects of the Issuer and Oculis including but not limited to all business, legal, regulatory, accounting, credit and tax matters.

 

2.1.10.   Subscriber acknowledges that (i) none of Credit Suisse Securities (USA) LLC, Kempen & Co. USA, Inc., BofA Securities, Inc., SVB Securities LLC or Arctica Finance hf. (collectively, the “Placement Agents”) is acting as placement agent, as an underwriter or in any other capacity in connection with the sale of Subscribed Shares pursuant to this Subscription Agreement, nor is any of them making any recommendation to the Subscriber in respect of the purchase of the Subscribed Shares and (ii) the Placement Agents shall not deem the Subscriber to be “retail investors” or “retail customers” of any Placement Agent for purposes of either Securities and Exchange Commission Form CRS or Regulation Best Interest.

 

2.1.11.   Subscriber became aware of this offering of the Subscribed Shares solely by means of direct contact between Subscriber and the Issuer or one of their respective representatives. Subscriber did not become aware of this offering of the Subscribed Shares, nor were the Subscribed Shares offered to Subscriber, by any general solicitation or general advertising. Subscriber acknowledges that the Issuer represents and warrants that the Subscribed Shares were not offered by any form of general solicitation

 

6 

 

or general advertising, including methods described in section 502(c) of Regulation D under the Securities Act.

 

2.1.12.   Subscriber acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the Subscribed Shares, including those set forth in the SEC Documents (as defined below) and the investor presentation provided by the Issuer. Subscriber is able to fend for itself in the transactions contemplated herein, has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Subscribed Shares, and has sought accounting, legal and tax advice as Subscriber has considered necessary to make an informed investment decision.

 

2.1.13.   Subscriber understands and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the Subscribed Shares or made any findings or determination as to the fairness of an investment in the Subscribed Shares.

 

2.1.14.   Subscriber represents and warrants that none of Subscriber or any of its officers, directors, managers, managing members, general partners or any other person acting in a similar capacity or carrying out a similar function on its behalf is (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”) or in any Executive Order issued by the President of the United States and administered by OFAC or any similar list of sanctioned persons administered by the United Nations Security Council, the European Union, Switzerland, Her Majesty’s Treasury (“HMT”), any individual European Union member state or the United Kingdom or any other relevant sanctions authority (collectively, “Sanctions Lists”) or a person or entity designated by any OFAC sanctions program, (ii) directly or indirectly 50% or more owned or otherwise controlled by, or acting on behalf of, one or more persons on a Sanctions List, (iii) organized, incorporated, established, located, resident or born in, a country or territory that is the target of country-wide or territory-wide economic or trade sanctions (currently Cuba, Iran, North Korea, Syria, Venezuela, the Crimea region of Ukraine, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic and any other Covered Region of Ukraine identified pursuant to Executive Order 14065), or (iv) a non-U.S. shell bank or providing banking services indirectly to a non-U.S. shell bank. Subscriber agrees to provide law enforcement agencies, if requested thereby, such records as required by applicable law, provided that Subscriber is permitted to do so under applicable law. The representations, warranties and undertakings in this Section 2.1.14 will not apply to any party hereto to which Council Regulation (EC) No. 2271/96, as amended (the “Blocking Regulation”) applies, if and to the extent that such representation, warranty or undertaking is or would be invalid or unenforceable by reason of breach of any provision of the Blocking Regulation (or any law or regulation implementing such Blocking Regulation in any member state of the European Union or the United Kingdom). If Subscriber is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.), as amended by the USA PATRIOT Act of 2001, and its implementing regulations (collectively, the “BSA/PATRIOT Act”), Subscriber

 

7 

 

represents that it maintains policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. Subscriber also represents that, to the extent required, it maintains policies and procedures reasonably designed to ensure compliance with sanctions programs administered by OFAC, the United Nations Security Council, the European Union, Switzerland, HMT, any European Union member state and the United Kingdom, including for the screening of its investors against the Sanctions Lists and the OFAC sanctions programs. Subscriber further represents and warrants that, to the extent required, it maintains policies and procedures reasonably designed to ensure that the funds held by Subscriber and used to purchase the Subscribed Shares were legally derived.

 

2.1.15.   If Subscriber is an employee benefit plan that is subject to Title I of ERISA, a plan, an individual retirement account or other arrangement that is subject to section 4975 of the Code or an employee benefit plan that is a governmental plan (as defined in section 3(32) of ERISA), a church plan (as defined in section 3(33) of ERISA), a non-U.S. plan (as described in section 4(b)(4) of ERISA) or other plan that is not subject to the foregoing but may be subject to provisions under any other Similar Laws or an entity whose underlying assets are considered to include “plan assets” of any such plan, account or arrangement (each, a “Plan”), Subscriber represents and warrants that neither the Issuer, nor any of their respective affiliates (the “Transaction Parties”) has acted as the Plan’s fiduciary, or has been relied on for advice, with respect to its decision to acquire and hold the Subscribed Shares, and none of the Transaction Parties shall at any time be relied upon as the Plan’s fiduciary with respect to any decision to acquire, continue to hold or transfer the Subscribed Shares.

 

2.1.16.   [Reserved.]

 

2.1.17.   On each date the Purchase Price would be required to be funded to the Issuer pursuant to Section 3.1, Subscriber will have sufficient immediately available funds to pay the Purchase Price pursuant to Section 3.1 and will be able to consummate the subscription of the Subscribed Shares.

 

2.1.18.   No broker, finder or other financial consultant has acted on behalf of Subscriber in connection with this Subscription Agreement or the transactions contemplated hereby in such a way as to create any liability on the Issuer.

 

2.1.19.   Subscriber agrees that, from the date of this Subscription Agreement until the Closing or the earlier termination of this Subscription Agreement, none of Subscriber, its controlled affiliates, or any person or entity acting on behalf of Subscriber or any of its controlled affiliates or pursuant to any understanding with Subscriber or any of its controlled affiliates will engage in any Short Sales with respect to securities of the Issuer. For the purposes hereof, “Short Sales” shall include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect stock pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on

 

8 

 

a total return basis), including through non-U.S. broker dealers or foreign regulated brokers. Notwithstanding the foregoing, (a) nothing herein shall prohibit any entities under common management or that share an investment advisor with Subscriber (including Subscriber’s controlled affiliates and/or affiliates) from entering into any Short Sales and (b) in the case of a Subscriber that is a multimanaged investment vehicle whereby separate portfolio managers manage separate portions of such Subscriber’s assets, this Section 2.1.19 shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Subscribed Shares covered by this Subscription Agreement. For the avoidance of doubt, this Section 2.1.19 shall not apply to (i) any sale (including the exercise of any redemption right) of securities of the Issuer (A) held by Subscriber, its controlled affiliates or any person or entity acting on behalf of Subscriber or any of its controlled affiliates prior to the execution of this Subscription Agreement or (B) purchased by Subscriber, its controlled affiliates or any person or entity acting on behalf of Subscriber or any of its controlled affiliates in an open market transaction after the execution of this Subscription Agreement or (ii) ordinary course, non-speculative hedging transactions.

 

2.2.   Issuer’s Representations, Warranties and Agreements. To induce Subscriber to purchase the Subscribed Shares, the Issuer hereby represents and warrants to Subscriber and agrees with Subscriber, as of the date hereof and as of the Closing Date, as follows:

 

2.2.1.   The Issuer has been duly incorporated and (i) is validly existing and in good standing under the laws of its jurisdiction of incorporation or formation, (ii) is duly licensed or qualified to conduct its business and, if applicable, in good standing under the laws of each jurisdiction (other than its jurisdiction of incorporation) in which the conduct of its business or the ownership of its properties or assets requires such license or qualification, except, with respect to the foregoing clause (ii), where the failure to be in good standing would not reasonably be expected to have an Issuer Material Adverse Effect (as defined below), (iii) has all requisite power and authority to own, lease and operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement. As of the Closing Date, the Issuer will be duly incorporated, validly existing and in good standing under the laws of the Cayman Islands.

 

2.2.2.   At the Closing Date, the Subscribed Shares will be duly authorized and, when issued and delivered to Subscriber against full payment for the Subscribed Shares, will be free and clear of all liens or other restrictions (other than arising under applicable securities laws) in accordance with the terms of this Subscription Agreement and registered with the Issuer’s transfer agent, the Subscribed Shares will be validly issued, fully paid and non-assessable and will not have been issued in violation of or subject to any preemptive or similar rights under the Issuer’s constitutive agreements, under any agreement or instrument to which the Issuer is a party or by which the Issuer is bound, or under applicable law. There are no (and as of the Closing there will not be any) securities or instruments issued by or to which the Issuer is a party containing anti-dilution or similar provisions that will be triggered by the issuance of (i) the Subscribed

 

9 

 

Shares or (ii) the Ordinary Shares to be issued pursuant to any Other Subscription Agreement, in each case, that have not been or will not be validly waived on or prior to the Closing Date.

 

2.2.3.   This Subscription Agreement, the Other Subscription Agreements and the Business Combination Agreement (collectively, the “Transaction Documents”) have been duly authorized, validly executed and delivered by the Issuer and, assuming that the Transaction Documents constitute valid and binding obligations of the other parties thereto, are valid and binding obligation of the Issuer, and are enforceable against Issuer in accordance with their terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (ii) principles of equity, whether considered at law or equity.

 

2.2.4.   The execution, delivery and performance of the Transaction Documents (including compliance by the Issuer with all of the provisions hereof), the issuance and sale of the Subscribed Shares and the consummation of the other transactions contemplated under the Transaction Documents, including the Transactions, do not and will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of the Issuer or any of its subsidiaries pursuant to the terms of any indenture, mortgage, charge, deed of trust, loan agreement, lease, license or other agreement or instrument to which the Issuer or any of its subsidiaries is a party or by which the Issuer or any of its subsidiaries is bound or to which any of the property or assets of the Issuer or any of its subsidiaries is subject, which would reasonably be expected to have a material adverse effect on the business, properties, financial condition, stockholders’ equity or results of operations of the Issuer and Oculis and their respective subsidiaries, taken as a whole or materially and adversely affects the ability of the Issuer to timely perform its obligations under this Subscription Agreement, in each case subject to the exceptions in the definition of Company Material Adverse Effect in the Business Combination Agreement mutatis mutandis (collectively, an “Issuer Material Adverse Effect”), (ii) result in any violation of the provisions of the organizational documents of the Issuer or any of its subsidiaries or (iii) result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over the Issuer or any of its subsidiaries or any of its properties that would reasonably be expected to have an Issuer Material Adverse Effect.

 

2.2.5.   Neither the Issuer, nor any person acting on its behalf has, directly or indirectly, made any offers or sales of any security of the Issuer nor solicited any offers to buy any security under circumstances that would adversely affect reliance by the Issuer on Section 4(a)(2) of the Securities Act for the exemption from registration for the transactions contemplated hereby or would require registration of the issuance of the Subscribed Shares under the Securities Act.

 

10 

 

2.2.6.   No broker or finder is entitled to any brokerage or finder’s fee or commission from the Issuer solely in connection with the sale of the Subscribed Shares to the Subscriber.

 

2.2.7.   Neither the Issuer, nor any person acting on its behalf has conducted any general solicitation or general advertising, including methods described in section 502(c) of Regulation D under the Securities Act, in connection with the offer or sale of any of the Subscribed Shares and neither the Issuer, nor any person acting on its behalf has offered any of the Subscribed Shares in a manner involving a public offering under, or in a distribution in violation of, the Securities Act or any state securities laws.

 

2.2.8.   Concurrently with the execution and delivery of this Subscription Agreement, the Issuer is entering into the Other Subscription Agreements providing for the sale of an aggregate of 6,330,031 Ordinary Shares for an aggregate purchase price of $63,300,310 (including the Subscribed Shares purchased and sold under this Subscription Agreement). Other than the Other Subscription Agreements and any other subscription agreements entered into after the date hereof on economic terms substantially consistent with the terms hereof, the Issuer has not entered into any side letter or agreement (written or oral) with any Other Subscriber or any other investor relating to or modifying such Other Subscriber’s or investor’s direct or indirect investment in the Issuer. The Other Subscription Agreements contain terms (including the Per Share Price term) that are not more favorable from an economic perspective to any similarly situated Other Subscriber thereunder than the terms of this Subscription Agreement. The Other Subscription Agreements have not been amended in any material respect following the date of this Subscription Agreement.

 

2.2.9.   As of the date of this Subscription Agreement, the authorized share capital of the Issuer consists of 200,000,000 Class A ordinary shares, 20,000,000 Class B ordinary shares and 1,000,000 preference shares, $0.0001 par value each and as of the date immediately prior to the Transactions, the authorized share capital of the Issuer will consist of 200,000,000 Class A ordinary shares, 20,000,000 Class B ordinary shares and 1,000,000 preference shares, $0.0001 par value each. All issued and outstanding ordinary shares of the Issuer have been duly authorized and validly issued, are fully paid, non-assessable and are not subject to preemptive or similar rights. There are no shareholder agreements, voting trusts or other agreements or understandings to which the Issuer is a party or by which it is bound relating to the voting of any securities of the Issuer, other than as contemplated by the Business Combination Agreement and the Ancillary Agreements (as defined in the Business Combination Agreement). There are no securities or instruments issued by or to which the Issuer is a party containing anti-dilution or similar provisions that will be triggered by the issuance of (i) the Subscribed Shares or (ii) the shares to be issued pursuant to any Other Subscription Agreement that have not been or will not be validly waived on or prior to the Acquisition Closing.

 

2.2.10.   Assuming the accuracy of Subscriber’s representations and warranties set forth in Section 2.1 of this Subscription Agreement, (i) no registration under the Securities Act is required for the offer and sale of the Subscribed Shares by the

 

11 

 

Issuer to Subscriber and (ii) no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Issuer in connection with the consummation of the transactions contemplated by this Subscription Agreement, except for filings pursuant to Regulation D of the Securities Act and applicable state securities laws and filings required to consummate the Transactions as provided under the Business Combination Agreement.

 

2.2.11.   There are no pending or, to the knowledge of the Issuer, threatened, suits, claims, actions, or proceedings, which, if determined adversely, would, individually or in the aggregate, reasonably be expected to have an Issuer Material Adverse Effect. There is no unsatisfied judgment, any open injunction, or any decree, ruling or order of any governmental authority or arbitrator outstanding against or binding upon the Issuer, which would, individually or in the aggregate, reasonably be expected to have an Issuer Material Adverse Effect.

 

2.2.12.   The Issuer is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or other person in connection with the execution, delivery and performance by the Issuer of this Subscription Agreement (including, without limitation, the issuance of the Subscribed Shares), other than (i) filings with the Securities and Exchange Commission (the “SEC”), (ii) filings required by applicable state or federal securities laws, (iii) filings required in accordance with Section ‎‎4, (iv) those required by The Nasdaq Stock Market LLC (the “Nasdaq”) or the New York Stock Exchange, and (v) filings, the failure of which to obtain would not be reasonably be expected to have, individually or in the aggregate, an Issuer Material Adverse Effect.

 

2.2.13.   At Closing, each of Issuer and New Parent will be classified as a corporation for U.S. federal income tax purposes.

 

2.2.14.   The Issuer made available to Subscriber (including via the Commission’s EDGAR system) a true, correct and complete copy of each form, report, statement, schedule, prospectus, proxy, registration statement and other documents filed by the Issuer with the Commission prior to the date of this Subscription Agreement (the “SEC Documents”), which SEC Documents, as of their respective filing dates, complied in all material respects with the requirements of the Exchange Act applicable to the SEC Documents and the rules and regulations of the Commission promulgated thereunder and applicable to the SEC Documents. As of their respective dates, all SEC Documents required to be filed by the Issuer with the Commission prior to the date hereof complied in all material respects with the applicable requirements of the Securities Act and the Exchange Act and the rules and regulations of the Commission promulgated thereunder. None of the SEC Documents filed under the Exchange Act, contained, when filed or, if amended prior to the date of this Subscription Agreement, as of the date of such amendment with respect to those disclosures that are amended, any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary

 

12 

 

to make the statements therein, in light of the circumstances under which they were made, not misleading. The Issuer has timely filed each report, statement, schedule, prospectus, and registration statement that the Issuer was required to file with the Commission since its inception and through the date hereof. There are no material outstanding or unresolved comments in comment letters from the Commission staff with respect to any of the SEC Documents. The financial statements of Issuer included in the SEC Documents complied in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing and fairly present in all material respects the financial condition of Issuer as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments, and such financial statements have been prepared in conformity with GAAP applied on a consistent basis during the periods involved (except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP); except, in each case, as set forth in any subsequent SEC Document filed or furnished with the SEC on or prior to the date hereof.

 

2.2.15.   No broker, finder or other financial consultant has acted on behalf of the Issuer in connection with this Subscription Agreement or the transactions contemplated hereby in such a way as to create any liability on Subscriber.

 

2.2.16.   The Issuer is not, and immediately after receipt of payment for the Subscribed Shares will not be, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

2.2.17.   The Issuer is not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by OFAC or in any Executive Order issued by the President of the United States and administered by OFAC, on any Sanctions List, or a person or entity designated by any OFAC sanctions program, (ii) directly or indirectly 50% or more owned or otherwise controlled by, or acting on behalf of, one or more persons on a Sanctions List, (iii) organized, incorporated, established or located in Cuba, Iran, North Korea, Syria, Venezuela, the Crimea region of Ukraine, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic, any other Covered Region of Ukraine identified pursuant to Executive Order 14065, or any other country or territory embargoed or subject to substantial trade restrictions by the United States, the United Nations Security Council, the European Union, Switzerland, HMT, any individual European member state or the United Kingdom, or (iv) a non-U.S. shell bank or providing banking services indirectly to a non-U.S. shell bank (each person described in clauses (i) to (v), a “Blocked Person”). The representations, warranties and undertakings in this Section 2.2.17 will not apply to any party hereto to which the Blocking Regulation applies, if and to the extent that such representation, warranty or undertaking is or would be invalid or unenforceable by reason of breach of any provision of the Blocking Regulation (or any law or regulation implementing such Blocking Regulation in any member state of the European Union or the United Kingdom). If the Issuer is a financial institution subject to the BSA/PATRIOT Act, Issuer represents that it maintains policies and procedures reasonably designed to

 

13 

 

comply with applicable obligations under the BSA/PATRIOT Act. The Issuer also represents that, to the extent required, it maintains policies and procedures reasonably designed to ensure compliance with sanctions programs administered by OFAC, the United Nations Security Council, the European Union, Switzerland, HMT, any European Union member state and the United Kingdom, including for the screening of its investors against the Sanctions List and the OFAC sanctions programs. Issuer further represents and warrants that, to the extent required, it maintains policies and procedures reasonably designed to ensure that the funds held by Issuer were legally derived.

 

2.2.18.   No part of the proceeds from the Subscription constitutes or will constitute funds obtained on behalf of any Blocked Person or will otherwise be used by the Issuer, directly or indirectly, (i) in connection with any unauthorized investment in, or any unauthorized transactions or dealings with, any Blocked Person, or (ii) otherwise in violation of sanctions enforced by the United States, the European Union, Switzerland, Her Majesty’s Treasury (HMT) or any other relevant sanctions authority.

 

2.2.19.   Neither the Issuer and its executives and directors, nor any of its subsidiaries and their respective officers and directors, is or has been (i) charged with, or convicted of bribery or any other anticorruption related activity under any applicable law or regulation in any applicable country or jurisdiction, including but not limited to, the U.S. Foreign Corrupt Practices Act (collectively, “Anti-Corruption Laws”), (ii) under investigation by any governmental authority for possible violation of Anti-Corruption Laws, (iii) assessed civil or criminal penalties under any Anti-Corruption Laws or (iv) the target of sanctions imposed by the United Nations, the European Union, Switzerland or the United Kingdom.

 

2.2.20.   Neither the Issuer and its officers and directors, nor any of its subsidiaries and their respective officers and directors, within the last five years, directly or indirectly offered, promised, given, paid or authorized the offer, promise, giving or payment of anything of value to any governmental authority official or a commercial counterparty for the purposes of: (i) influencing any act, decision or failure to act by such governmental authority official in his or her official capacity or such commercial counterparty, (ii) inducing a governmental authority official to do or omit to do any act in violation of the governmental authority official’s lawful duty, or (iii) inducing a governmental authority official or a commercial counterparty to use his or her influence with a government or instrumentality to affect any act or decision of such government or entity; in each case in order to obtain, retain or direct business or to otherwise secure an improper advantage in violation of any applicable law or regulation or which would cause any such person to be in violation of any law or regulation applicable to such person.

 

2.2.21.   No part of the proceeds from the Subscription will be used, directly or indirectly, for any improper payments, including bribes, to any governmental authority official or commercial counterparty in order to obtain, retain or direct business or obtain any improper advantage. The Issuer has established procedures and controls which it reasonably believes are adequate (and otherwise comply with applicable law) to

 

14 

 

ensure that the Issuer is and will continue to be in compliance with all applicable current and future Anti-Corruption Laws.

 

2.2.22.   The Issuer is not in default or violation (and no event has occurred which, with notice or the lapse of time or both, would constitute a default or violation) of any term, condition or provision of (i) the organizational documents of the Issuer, (ii) any loan or credit agreement, guarantee, note, bond, mortgage, indenture, lease or other agreement, permit, franchise or license to which, as of the date of this Subscription Agreement, the Issuer is a party or by which the Issuer’s properties or assets are bound or (iii) any statute or any judgment, order, rule or regulation of any court or governmental agency, taxing authority or regulatory body, domestic or foreign, having jurisdiction over the Issuer or any of its properties, except, in the case of clauses (ii) and (iii), for defaults or violations that have not had and would not be reasonably likely to have, individually or in the aggregate, an Issuer Material Adverse Effect.

 

2.2.23.   The Issuer is in compliance with all applicable laws, except where such non-compliance would not be reasonably likely to have an Issuer Material Adverse Effect. The Issuer has not received any written communication from a governmental entity that alleges that the Issuer is not in compliance with or is in default or violation of any applicable law, except where such non- compliance, default or violation would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

2.2.24.   As of the date hereof, the issued and outstanding Class A ordinary shares, $0.0001 par value, of the Issuer (the “Class A Shares”) are registered pursuant to Section 12(b) of the Exchange Act, and are listed for trading on Nasdaq under the symbol “EBAC”. There is no suit, action, proceeding or investigation pending or, to the knowledge of the Issuer, threatened against the Issuer by Nasdaq or the Commission with respect to any intention by such entity to deregister the Class A Shares or prohibit or terminate the listing of the Class A Shares on Nasdaq. The Issuer has taken no action that is designed to terminate the registration of the Class A Shares under the Exchange Act or the listing of the Class A Shares on Nasdaq.

 

2.2.25.   The Business Combination Agreement has been or will be, as applicable, duly and validly authorized, executed and delivered by the Issuer, Oculis, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 and, assuming due authorization, execution and delivery by the other parties thereto, constitutes or will constitute, as applicable, a valid and binding agreement of the Issuer, Oculis, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 enforceable against the Issuer, Oculis, New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors’ rights generally or by equitable principles relating to enforceability. The representations and warranties of the Issuer set forth in the Business Combination Agreement are true and correct in all material respects (or, if any such representations or warranties are qualified by materiality, material adverse effect or similar language, true and correct in all respects). To the knowledge of the Issuer, the

 

15 

 

representations and warranties of Oculis contained in the Business Combination Agreement are true and accurate in all material respects (or, if any such representations or warranties are qualified by materiality, material adverse effect or similar language, true and correct in all respects).

 

3.   Settlement Date and Delivery.

 

3.1.   Closing. The closing of the Subscription contemplated hereby (the “Closing”) shall occur on the Closing Start Date, but subject to, the Acquisition Closing (the date of the Closing, the “Closing Date”). Upon written notice from (or on behalf of) the Issuer to Subscriber (the “Closing Notice”) at least five (5) Business Days prior to the date that the Issuer reasonably expects all conditions to the Acquisition Closing to be satisfied (the “Expected Closing Date”), Subscriber shall deliver to the Issuer no later than two (2) Business Days prior to the Expected Closing Date (i) the Purchase Price for the Subscribed Shares by wire transfer of United States dollars in immediately available funds to the account specified by the Issuer in the Closing Notice, such funds to be held by the Issuer in escrow until the Closing and (ii) any other information that is reasonably requested in the Closing Notice in order for Issuer to issue the Subscribed Shares including, without limitation, the legal name of the person in whose name such Subscribed Shares are to be issued, and if applicable, and a duly executed Internal Revenue Service Form W-9 or the applicable Internal Revenue Service Form W-8, as applicable. On the Closing Date, the Issuer shall issue to Subscriber (or the funds and accounts designated by Subscriber if so designated by Subscriber, or its nominee in accordance with its delivery instructions) or to a custodian designated by Subscriber, as applicable, the Subscribed Shares, free and clear of any liens or other restrictions whatsoever (other than those arising under state or federal securities laws), which Subscribed Shares, unless otherwise determined by the Issuer, shall be uncertificated, with record ownership reflected only in the register of shareholders of the Issuer and shall provide evidence of such issuance from the Issuer’s transfer agent showing Subscriber as the owner of the Subscribed Shares within two (2) Business Days of the Closing Date. If the Acquisition Closing is not consummated within two (2) Business Days after the Expected Closing Date, the Issuer shall promptly (but no later than one (1) Business Day thereafter) return the Purchase Price to Subscriber by wire transfer of United States dollars in immediately available funds to an account specified by Subscriber, and the Subscribed Shares shall be cancelled. Notwithstanding such return, (i) a failure to close on the Expected Closing Date shall not, by itself, be deemed to be a failure of any of the conditions to Closing set forth in this Section 3 to be satisfied or waived on or prior to the Closing Date, and (ii) unless and until this Subscription Agreement is terminated in accordance with Section 5 hereof, Subscriber shall remain obligated (A) to redeliver funds on the new Closing Date to the Issuer following the Issuer’s delivery to Subscriber of a new Closing Notice and (B) to consummate the Closing upon satisfaction of the conditions set forth in this Section 3. For purposes of this Subscription Agreement, “Business Day” means any day that, in New York, New York and Lausanne, Switzerland, is neither a legal holiday nor a day on which banking institutions are generally authorized or required by law or regulation to close.

 

3.2.   Conditions to Closing of the Issuer.

 

16 

 

The Issuer’s obligations to sell and issue the Subscribed Shares at the Closing are subject to the fulfillment or (to the extent permitted by applicable law) written waiver by the Issuer, on or prior to the Closing Date, of each of the following conditions:

 

3.2.1.   Representations and Warranties Correct. The representations and warranties made by Subscriber in Section 2.1 hereof shall be true and correct in all material respects when made (unless they specifically speak as of another date in which case they shall be true and correct in all material respects as of such date) (other than representations and warranties that are qualified as to materiality or Subscriber Material Adverse Effect, which representations and warranties shall be true and correct in all respects), and shall be true and correct in all material respects on and as of the Closing Date (unless they specifically speak as of another date in which case they shall be true and correct in all material respects as of such date) (other than representations and warranties that are qualified as to materiality or Subscriber Material Adverse Effect, which representations and warranties shall be true in all respects) with the same force and effect as if they had been made on and as of said date, but in each case without giving effect to consummation of the Transactions.

 

3.2.2.   Compliance with Covenants. Subscriber shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied with by Subscriber at or prior to the Closing.

 

3.2.3.   Closing of the Transactions. All conditions precedent to each of the Issuer’s and Oculis’s obligations to consummate, or cause to be consummated, the Acquisition Closing shall have been satisfied or waived by the party entitled to the benefit thereof under the Business Combination Agreement (other than those conditions that may only be satisfied at the consummation of the Acquisition Closing, but subject to satisfaction or waiver by such party of such conditions as of the consummation of the Acquisition Closing), and the Primary Transactions will be consummated immediately following the Closing (or in the case of the Company Share Contribution, upon the timing set forth in the Business Combination Agreement).

 

3.2.4.   Legality. There shall not be in force any order, judgment, injunction, decree, writ, stipulation, determination or award, in each case, entered by or with any governmental authority, statute, rule or regulation enjoining or prohibiting the consummation of the transactions contemplated by this Subscription Agreement or the Transactions and no such governmental authority shall have instituted or threatened in writing a proceeding seeking to impose any such restraint or prohibition.

 

3.3.   Conditions to Closing of Subscriber.

 

Subscriber’s obligation to purchase the Subscribed Shares at the Closing is subject to the fulfillment or (to the extent permitted by applicable law) written waiver by Subscriber, on or prior to the Closing Date, of each of the following conditions:

 

17 

 

3.3.1.   Representations and Warranties Correct. The representations and warranties made by the Issuer in Section 2.2 hereof shall be true and correct in all material respects when made (unless they specifically speak as of another date in which case they shall be true and correct in all material respects as of such date) (other than representations and warranties that are qualified as to materiality or Issuer Material Adverse Effect, which representations and warranties shall be true and correct in all respects), and shall be true and correct in all material respects on and as of the Closing Date (unless they specifically speak as of another date in which case they shall be true and correct in all material respects as of such date) (other than representations and warranties that are qualified as to materiality or Issuer Material Adverse Effect, which representations and warranties shall be true and correct in all respects) with the same force and effect as if they had been made on and as of said date, but in each case without giving effect to consummation of the Transactions.

 

3.3.2.   Compliance with Covenants. The Issuer shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied with by the Issuer at or prior to the Closing, except where the failure of such performance or compliance would not or would not reasonably be expected to prevent, materially delay, or materially impair the ability of the Issuer to consummate the Closing.

 

3.3.3.   Closing of the Transactions. All conditions precedent to the consummation of the Acquisition Closing shall have been satisfied or waived by the party entitled to the benefit thereof under the Business Combination Agreement (other than those conditions that may only be satisfied at the consummation of the Acquisition Closing, but subject to satisfaction or waiver by such party of such conditions as of the consummation of the Acquisition Closing), and the Primary Transactions will be consummated immediately following the Closing (or in the case of the Company Share Contribution, upon the timing set forth in the Business Combination Agreement). Except to the extent consented to in writing by Subscriber, the Business Combination Agreement (as filed with the Commission on or shortly after the date hereof) shall not have been amended, modified, supplemented or waived in a manner that would reasonably be expected to materially and adversely affect the economic benefits that Subscriber would reasonably expect to receive under this Subscription Agreement. New Parent shall have assumed, or shall have agreed to assume, all of the obligations of the Issuer hereunder (including, for the avoidance of doubt, standing in the place of the “Issuer” for purposes of Section 4 hereunder). There shall have been no amendment, waiver or modification to the Other Subscription Agreements that materially benefits any such Other Subscriber thereunder (other than terms particular to the legal or regulatory requirements of such Other Subscriber or its affiliates or related persons) unless Subscriber has been offered substantially the same benefits.

 

3.3.4.   Legality. There shall not be in force any order, judgment, injunction, decree, writ, stipulation, determination or award, in each case, entered by or with any governmental authority, statute, rule or regulation enjoining or prohibiting consummation of the transactions contemplated by this Subscription Agreement or the

 

18 

 

Transactions and no such governmental authority shall have instituted or threatened in writing a proceeding seeking to impose any such restraint or prohibition.

 

3.3.5.   Listing. No suspension of the qualification of the Ordinary Shares for offering or sale or trading in any jurisdiction, and no suspension or removal from listing of the Ordinary Shares on Nasdaq, and no initiation or threatening of any proceedings for any of such purposes or delisting, shall have occurred, and the Subscribed Shares shall be approved for listing on Nasdaq, as applicable, subject to official notice of issuance.

 

3.4.   From the date hereof until the Closing Date, the Issuer shall provide prompt written notice to Subscriber of any (i) amendment, modification or waiver of any provision of the Business Combination Agreement that would reasonably be expected to materially and adversely affect the economic benefits that Subscriber or the Issuer would reasonably expect to receive under this Subscription Agreement or (ii) any declaration by the Issuer of a Material Adverse Effect (as defined in the Business Combination Agreement) under the Business Combination Agreement.

 

4.   Registration Statement. The Issuer and the Subscriber hereby agree as follows, and the Issuer shall cause New Parent to, and acknowledges and agrees that, following the Acquisition Closing, New Parent shall, assume all of the Issuer’s obligations under the following Section 4 of this Subscription Agreement (including, for the avoidance of doubt, standing in the place of the “Issuer” for purposes of the following Section 4 hereunder):

 

4.1.   The Issuer agrees that, within thirty (30) Business Days after the Acquisition Closing Date (the “Filing Date”), the Issuer will file with the Commission (at the Issuer’s sole cost and expense) a registration statement (the “Registration Statement”) registering the resale of the Subscribed Shares and/or any other equity security (of the Issuer, any successor entity or otherwise) issued or issuable with respect to the Subscribed Shares by way of share split, dividend, distribution, recapitalization, merger, exchange, replacement or similar event or otherwise (the “Registrable Securities”), and the Issuer shall use its commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i) the 60th calendar day (or 90th calendar day if the Commission notifies the Issuer that it will “review” the Registration Statement) following the Closing Date and (ii) the tenth (10th) Business Day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the Commission that the Registration Statement will not be “reviewed” or will not be subject to further review (such earlier date, the “Effectiveness Date”); provided, however, that the Issuer’s obligations to include the Registrable Securities in the Registration Statement are contingent upon Subscriber furnishing a completed and executed selling shareholders questionnaire in customary form to the Issuer that contains the information required by Commission rules for a Registration Statement regarding Subscriber, the securities of the Issuer held by Subscriber and the intended method of disposition of the Registrable Securities to effect the registration of the Registrable Securities, and Subscriber shall execute such documents in connection with such registration as the Issuer may reasonably request that are customary of a selling stockholder in similar situations, including providing that the Issuer shall be entitled to postpone and suspend the effectiveness or use of the

 

19 

 

Registration Statement, if applicable, as permitted hereunder; provided, that Subscriber shall not in connection with the foregoing be required to execute any lock-up or similar agreement or otherwise be subject to any contractual restriction on the ability to transfer the Registrable Securities. For purposes of clarification, any failure by the Issuer to file the Registration Statement by the Filing Date or to effect such Registration Statement by the Effectiveness Date shall not otherwise relieve the Issuer of its obligations to file or effect the Registration Statement as set forth above in this Section 4. For purposes of this Section 4, “Registrable Securities” shall include, as of any date of determination, the Subscribed Shares and any other equity security issued or issuable with respect to the Subscribed Shares by way of share split, dividend, distribution, recapitalization, merger, exchange, replacement or similar event or otherwise, including, for the avoidance of doubt, any equity securities of New Parent issued in exchange for such Subscribed Shares or such other equity securities, and “Subscriber” shall include any person to which the rights under this Section 4 shall have been duly assigned. The Issuer will provide a draft of the Registration Statement to Subscriber for review at least two (2) Business Days in advance of filing the Registration Statement. In no event shall Subscriber be identified as a statutory underwriter in the Registration Statement unless requested by the Commission and consented to by Subscriber. If the Commission requests that Subscriber be identified as a statutory underwriter in the Registration Statement, Subscriber will have an opportunity to withdraw from the Registration Statement. Notwithstanding the foregoing, if the Commission prevents the Issuer from including any or all of the Registrable Securities proposed to be registered for resale under the Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of the Registrable Securities by the applicable shareholders or otherwise, (i) such Registration Statement shall register for resale such number of Subscribed Shares which is equal to the maximum number of Subscribed Shares as is permitted by the Commission and (ii) the number of Subscribed Shares to be registered for each selling shareholder named in the Registration Statement shall be reduced pro rata among all such selling shareholders; and as promptly as practicable after being permitted to register additional Subscribed Shares under Rule 415 under the Securities Act, the Issuer shall amend the Registration Statement or file a new Registration Statement to register such Subscribed Shares not included in the initial Registration Statement and cause such amendment or Registration Statement to become effective as promptly as practicable.

 

4.2.   In the case of the registration effected by the Issuer pursuant to this Subscription Agreement, the Issuer shall, upon reasonable request, inform Subscriber as to the status of such registration. At its expense the Issuer shall:

 

4.2.1.   except for such times as the Issuer is permitted hereunder to suspend the use of the prospectus forming part of a Registration Statement, use its commercially reasonable efforts to keep such registration, and any qualification, exemption or compliance under state securities laws which the Issuer determines to obtain, continuously effective, and to keep the applicable Registration Statement or any subsequent shelf registration statement free of any material misstatements or omissions, until the earlier of the following: (i) the third anniversary of the effectiveness of the Registration Statement, (ii) when Subscriber has sold all of its Registrable Securities pursuant to the Registration Statement or Rule 144 and (iii) the date all Registrable Securities held by the Subscriber may be sold without restriction under Rule 144,

 

20 

 

including without limitation, any volume and manner of sale restrictions which may be applicable to affiliates under Rule 144 and without the requirement for the Issuer to be in compliance with the current public information required under Rule 144(c)(1) (or Rule 144(i)(2), if applicable); provided, that for as long as the Registration Statement shall remain effective pursuant to the immediately preceding sentence, the Issuer will (a) use commercially reasonable efforts to file all reports, and (b) provide all customary and reasonable cooperation, necessary to (x) enable Subscriber to resell the Registrable Securities pursuant to the Registration Statement or Rule 144, as applicable, and (y) update or amend the Registration Statement as necessary to include the Registrable Securities.

 

4.2.2.   advise Subscriber, as promptly as practicable but in any event within five (5) Business Days:

 

(a)   when a Registration Statement or any post-effective amendment thereto has become effective;

 

(b)   of any request by the Commission for amendments or supplements to any Registration Statement or the prospectus included therein or for additional information;

 

(c)   of the issuance by the Commission of any stop order suspending the effectiveness of any Registration Statement or the initiation of any proceedings for such purpose;

 

(d)   of the receipt by the Issuer of any notification with respect to the suspension of the qualification of the Registrable Securities included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

 

(e)   subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any changes in any Registration Statement or prospectus so that, as of such date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus, in the light of the circumstances under which they were made) not misleading.

 

Notwithstanding anything to the contrary set forth herein, the Issuer shall not, when so advising Subscriber of such events, provide Subscriber with any material, non-public information regarding the Issuer or subject Subscriber to any duty of confidentiality;

 

4.2.3.   use its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as soon as reasonably practicable;

 

21 

 

4.2.4.   upon the occurrence of any event contemplated in Section 4.2.2(e), except for such times as the Issuer is permitted hereunder to suspend, and has suspended, the use of a prospectus forming part of a Registration Statement, the Issuer shall use its commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to such Registration Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Registrable Securities included therein, such prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;

 

4.2.5.   use its commercially reasonable efforts to cause all Subscribed Shares to be listed on each securities exchange or market, if any, on which the Issuer’s Ordinary Shares are then listed;

 

4.2.6.   allow Subscriber to review and consent to disclosure specifically regarding Subscriber in the Registration Statement on reasonable advance notice (which consent shall not be unreasonably withheld); and

 

4.2.7.   use its commercially reasonable efforts to take all other steps reasonably necessary to effect the registration of the Registrable Securities and to enable the sale of the Registrable Securities under Rule 144; and

 

4.2.8.   cause the Issuer’s transfer agent to remove any restrictive legend, at Subscriber’s request, when the Registrable Securities are sold pursuant to Rule 144 under the Securities Act or the Registration Statement or may be sold without restriction under Rule 144. In connection therewith, if required by the Issuer’s transfer agent and upon receipt of any customary certifications or other documentation reasonably requested by the Issuer, the Issuer will promptly cause an opinion of counsel to be delivered to and maintained with its transfer agent, together with any other authorizations, certificates and directions required by the transfer agent that authorize and direct the transfer agent to issue such Registrable Securities without any such legend.

 

4.3.   Notwithstanding anything to the contrary in this Subscription Agreement, the Issuer shall be entitled to delay or postpone the effectiveness of the Registration Statement, and from time to time to require Subscriber not to sell under the Registration Statement or to suspend the effectiveness thereof, (i) as may be necessary in connection with the preparation and filing of a post-effective amendment to the Registration Statement following the filing of the Issuer’s Annual Report on Form 10-K or 20-F, as applicable, or (ii) if the filing, effectiveness or continued use of any Registration Statement would require the Issuer to make any public disclosure of material non-public information, which disclosure, in the good faith determination of the board of directors of the Issuer, after consultation with counsel to the Issuer, (a) would be required to be made in any Registration Statement in order for the applicable Registration Statement not to contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein not misleading, (b) would not be required to be made at such time if the Registration Statement were not being filed, and (c) the Issuer has a

 

22 

 

bona fide business purpose for not making such information public (each such circumstance, a “Suspension Event”); provided, however, that the Issuer may not delay or suspend the Registration Statement on more than two occasions or for more than sixty (60) consecutive calendar days, or more than one hundred twenty (120) total calendar days, in each case, during any three hundred sixty (360) day period. Upon receipt of any written notice from the Issuer (which notice shall not contain any material non-public information regarding the Issuer and which notice shall not be subject to any duty of confidentiality) of the happening of any Suspension Event during the period that the Registration Statement is effective or if as a result of a Suspension Event the Registration Statement or related prospectus contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made (in the case of the prospectus) not misleading, Subscriber agrees that it will immediately discontinue offers and sales of the Subscribed Shares under the Registration Statement (excluding, for the avoidance of doubt, sales conducted pursuant to Rule 144) until Subscriber receives copies of a supplemental or amended prospectus (which the Issuer agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to above and receives notice that any post-effective amendment has become effective or unless otherwise notified by the Issuer that it may resume such offers and sales (which notice shall not contain any material non-public information regarding the Issuer and which notice shall not be subject to any duty of confidentiality). If so directed by the Issuer, Subscriber will deliver to the Issuer or, in Subscriber’s sole discretion destroy, all copies of the prospectus covering the Subscribed Shares in Subscriber’s possession; provided, however, that this obligation to deliver or destroy all copies of the prospectus covering the Subscribed Shares shall not apply (i) to the extent Subscriber is required to retain a copy of such prospectus (a) in order to comply with applicable legal, regulatory, self-regulatory or professional requirements or (b) in accordance with a bona fide pre-existing document retention policy or (ii) to copies stored electronically on archival servers as a result of automatic data back-up. Subscriber may deliver written notice (an “Opt-Out Notice”) to the Issuer requesting that Subscriber not receive notices from the Issuer otherwise required by this Section 4; provided, however, that Subscriber may later revoke any such Opt-Out Notice in writing. Following receipt of an Opt-Out Notice from Subscriber (unless subsequently revoked), (i) the Issuer shall not deliver any such notices to Subscriber and Subscriber shall no longer be entitled to the rights associated with any such notice and (ii) each time prior to Subscriber’s intended use of an effective Registration Statement, Subscriber will notify the Issuer in writing at least two (2) business days in advance of such intended use, and if a notice of a Suspension Event was previously delivered (or would have been delivered but for the provisions of the preceding sentence) and the related suspension period remains in effect, the Issuer will so notify Subscriber, within one (1) business day of Subscriber’s notification to the Issuer, by delivering to Subscriber a copy of such previous notice of Suspension Event, and thereafter will provide Subscriber with the related notice of the conclusion of such Suspension Event promptly following its availability.

 

4.4.   The parties agree that:

 

4.4.1.   The Issuer shall, notwithstanding the termination of this Subscription Agreement, indemnify and hold harmless, to the extent permitted by law, Subscriber (to the extent a selling shareholder under any Registration Statement), the

 

23 

 

officers, directors, agents, partners, members, managers, shareholders, affiliates, employees and investment advisers of each Subscriber, each person who controls such Subscriber (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), and the officers, directors, partners, members, managers, shareholders, agents, affiliates, employees and investment advisers of each such controlling person from and against any and all losses, claims, damages, liabilities, costs and expenses (including, without limitation, any reasonable and documented attorneys’ fees of one law firm and one local counsel in each applicable jurisdiction and expenses incurred in connection with defending or investigating any such action or claim) (collectively, “Losses”), as incurred, that arise out of or are based upon (i) any untrue or alleged untrue statement of material fact contained in any Registration Statement (or incorporated by reference therein), prospectus included in any Registration Statement or preliminary prospectus or any amendment thereof or supplement thereto or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading or (ii) any violation or alleged violation by the Issuer of the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder, in connection with the performance of its obligations under this Section 4, except insofar as the same are caused by or contained in any information furnished in writing to the Issuer by or on behalf of Subscriber expressly for use therein or Subscriber has omitted a material fact from such information; provided, however, that the indemnification contained in this Section 4.4 shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent of the Issuer (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Issuer be liable for any Losses to the extent they arise out of or are based upon a violation which occurs (A) in reliance upon and in conformity with written information furnished by Subscriber expressly for use in such Registration Statement or preliminary prospectus or any amendment thereof or supplement thereto, (B) in connection with any failure of such person to deliver or cause to be delivered a prospectus made available by the Issuer in a timely manner, (C) as a result of offers or sales effected by or on behalf of any person by means of a “free writing prospectus” (as defined in Rule 405 under the Securities Act) that was not authorized by the Issuer or (D) in connection with any offers or sales effected by or on behalf of Subscriber in violation of Section 4.3 hereof. The Issuer shall notify Subscriber promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this Section 4 of which the Issuer is aware.

 

4.4.2.   Subscriber agrees, severally and not jointly with any person that is a party to the Other Subscription Agreements, to indemnify and hold harmless, to the extent permitted by law, the Issuer and each of the Issuer’s directors, officers, employees and agents and each person who controls the Issuer (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act) against any and all Losses, as incurred, that arise out of or result from any untrue or alleged untrue statement of material fact contained in any Registration Statement, prospectus included in any Registration Statement or preliminary prospectus or any amendment thereof or

 

24 

 

supplement thereto or any omission of a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, but only to the extent that such untrue statement or omission is contained in any information or affidavit so furnished in writing by such Subscriber expressly for use therein; provided, however, that the indemnification contained in this Section 4.4 shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent of Subscriber (which consent shall not be unreasonably withheld, conditioned or delayed). Notwithstanding anything to the contrary herein, in no event shall the liability of Subscriber be greater in amount than the dollar amount of the net proceeds received by Subscriber upon the sale of the Subscribed Shares purchased pursuant to this Subscription Agreement giving rise to such indemnification obligation.

 

4.4.3.   Any person entitled to indemnification herein shall (1) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person’s right to indemnification hereunder to the extent such failure has not prejudiced the indemnifying party) and (2) unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent. An indemnifying party who elects not to assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of legal counsel to any indemnified party a conflict of interest exists between such indemnified party and any other of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party (which consent shall not be unreasonably withheld, conditioned or delayed), consent to the entry of any judgment or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms of such settlement) or which settlement includes a statement or admission of fault and culpability on the part of such indemnified party or which settlement does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.

 

4.4.4.   The indemnification provided for under this Subscription Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party and shall survive the transfer of the Subscribed Shares purchased pursuant to this Subscription Agreement. The Issuer shall cause New Parent to, and acknowledges and agrees that, following the Acquisition Closing, New Parent shall assume the Issuer’s obligations under Section 4.4 of this Subscription Agreement.

 

4.4.5.   If the indemnification provided under this Section 4.4 from the indemnifying party is unavailable or insufficient to hold harmless an indemnified party in

 

25 

 

respect of any Losses referred to herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by, or relates to information supplied by, such indemnifying party or indemnified party, and the indemnifying party’s and indemnified party’s relative intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the Losses or other liabilities referred to above shall be deemed to include, subject to the limitations set forth above, any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution pursuant to this Section 4.4 from any person who was not guilty of such fraudulent misrepresentation. Each indemnifying party’s obligation to make a contribution pursuant to this Section 4.4 shall be individual, not joint and several, and in no event shall the liability of Subscriber be greater in amount than the dollar amount of the net proceeds received by Subscriber upon the sale of the Subscribed Shares purchased pursuant to this Subscription Agreement giving rise to such contribution obligation.

 

5.   Termination. This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest to occur of (i) such date and time as the Business Combination Agreement is validly terminated in accordance with its terms without being consummated, (ii) upon the mutual written agreement of each of the parties hereto to terminate this Subscription Agreement, (iii) Issuer’s notification to the Subscriber in writing that it has, with the prior written consent of Oculis, abandoned its plans to move forward with the Transactions and/or terminated the Subscriber’s obligations with respect to the subscription without the issuance of the Subscribed Shares having occurred, (iv) at the election of Subscriber following the date that is 30 days after the Acquisition Closing Date (as defined in the Business Combination Agreement as in effect on the date hereof) if the Closing shall not have occurred by such date (provided, that the right to terminate this Subscription Agreement pursuant to this clause (iv) shall not be available to Subscriber if Subscriber’s or its assignee’s breach of any of its covenants or obligations under this Subscription Agreement (or if an affiliate of Subscriber is one of the Subscribers under an Other Subscription Agreement, such other Subscriber’s breach of any of its covenants or obligations under the Other Subscription Agreement) either individually or in the aggregate, shall have proximately caused the failure of the consummation of the Acquisition Closing on or before the such date); provided that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination, and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from such breach. The Issuer shall promptly notify Subscriber in writing of the termination of the Business Combination Agreement promptly after the termination of such agreement. Upon the termination hereof in accordance with this Section 5,

 

26 

 

any monies paid by Subscriber to the Issuer in connection herewith shall promptly (and in any event within two (2) Business Days) be returned in full to Subscriber by wire transfer of U.S. dollars in immediately available funds to the account specified by Subscriber, without any deduction for or on account of any tax withholding, charges or set-off, whether or not the Transaction shall have been consummated.

 

6.   Miscellaneous.

 

6.1.   Further Assurances. At the Closing, the parties hereto shall execute and deliver such additional documents and take such additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the Subscription as contemplated by this Subscription Agreement.

 

6.1.1.   Subscriber acknowledges that the Issuer will rely on the acknowledgments, understandings, undertakings, agreements, representations and warranties made by Subscriber contained in this Subscription Agreement. Prior to the Closing, Subscriber agrees to promptly notify the Issuer if any of the acknowledgments, understandings, undertakings, agreements, representations and warranties made by Subscriber set forth herein are no longer accurate in all material respects. The Issuer acknowledges that Subscriber will rely on the acknowledgments, understandings, undertakings, agreements, representations and warranties made by the Issuer contained in this Subscription Agreement. Prior to the Closing, the Issuer agrees to promptly notify Subscriber if any of the acknowledgments, understandings, undertakings, agreements, representations and warranties made by Issuer set forth herein are no longer accurate in all material respects (other than those acknowledgments, understandings, agreements, undertakings, representations and warranties qualified by materiality, in which case the Issuer shall notify Subscriber if they are no longer accurate in any respect).

 

6.1.2.   Each of the Issuer and the Subscriber is entitled to rely upon this Subscription Agreement and is irrevocably authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby.

 

6.1.3.   The Issuer may request from Subscriber such additional information as the Issuer may reasonably deem necessary to evaluate the eligibility of Subscriber to acquire the Subscribed Shares, and Subscriber shall provide such information as may be reasonably requested, to the extent within Subscriber’s possession and control or otherwise readily available to Subscriber, provided that the Issuer agrees to keep confidential any such information provided by Subscriber.

 

6.1.4.   Each of Subscriber and the Issuer shall pay all of its own respective expenses in connection with this Subscription Agreement and the transactions contemplated herein (it being agreed that all expenses related to any Registration Statement are for the account of the Issuer to the extent provided in Section 4, and the Issuer shall be responsible for the fees of its transfer agent and all of DTC’s fees associated with the issuance of the Subscribed Shares).

 

27 

 

6.1.5.   Each of Subscriber and the Issuer shall take, or cause to be taken, all actions and do, or cause to be done, all things necessary, proper or advisable to consummate the transactions contemplated by this Subscription Agreement on the terms and conditions described therein no later than immediately prior to the Acquisition Closing.

 

6.2.   Subscriber hereby acknowledges and agrees that, except in respect of any stock lending program, it will not, nor will any person acting at Subscriber’s direction or pursuant to any understanding with Subscriber (including Subscriber’s controlled affiliates), directly or indirectly, offer, sell, pledge, contract to sell, sell any option in, or engage in hedging activities or execute any “short sales” (as defined in Rule 200 of Regulation SHO under the Exchange Act) with respect to, any Subscribed Shares or any securities of the Issuer or any instrument exchangeable for or convertible into any Subscribed Shares or any securities of the Issuer until the Acquisition Closing (or such earlier termination of this Subscription Agreement in accordance with its terms). Notwithstanding the foregoing, (i) nothing herein shall prohibit any entities under common management or that share an investment advisor with Subscriber (including Subscriber’s controlled affiliates and/or affiliates) from entering into any Short Sales; (ii) in the case of a Subscriber that is a multimanaged investment vehicle whereby separate portfolio managers manage separate portions of such Subscriber’s assets, this Section 6.2 shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Subscribed Shares covered by this Subscription Agreement. For the avoidance of doubt, this Section 6.2 shall not apply to (i) any sale (including the exercise of any redemption right) of securities of the Issuer (A) held by Subscriber, its controlled affiliates or any person or entity acting on behalf of Subscriber or any of its controlled affiliates prior to the execution of this Subscription Agreement or (B) purchased by Subscriber, its controlled affiliates or any person or entity acting on behalf of Subscriber or any of its controlled affiliates in an open market transaction after the execution of this Subscription Agreement or (ii) ordinary course, non-speculative hedging transactions. The Issuer acknowledges and agrees that, notwithstanding anything herein to the contrary, the Subscribed Shares may be pledged by Subscriber in connection with a bona fide margin agreement, provided that such pledge shall be (i) pursuant to an available exemption from the registration requirements of the Securities Act or (ii) pursuant to, and in accordance with, a registration statement that is effective under the Securities Act at the time of such pledge, and Subscriber effecting a pledge of the Subscribed Shares shall not be required to provide the Issuer with any notice thereof; provided, however, that neither the Issuer nor its counsel shall be required to take any action (or refrain from taking any action) in connection with any such pledge, other than providing any such lender of such margin agreement with an acknowledgment that the Subscribed Shares are not subject to any contractual lock up or prohibition on pledging, the form of such acknowledgment to be subject to review and comment by the Issuer in all respects.

 

6.3.   Notices. Any notice or communication required or permitted hereunder shall be in writing and either delivered personally, emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, and shall be deemed to be given and received (i) when so delivered personally, (ii) when sent, with no mail undeliverable or other rejection notice, if sent by email, or (iii) three (3) Business Days after the

 

28 

 

date of mailing to the address below or to such other address or addresses as such person may hereafter designate by notice given hereunder:

 

(i) if to Subscriber, to such address or addresses set forth on the signature page hereto;

 

(ii) if to the Issuer, to:

 

European Biotech Acquisition Corp.

Johannes Vermeerplein 9 

1071 DV Amsterdam, Netherlands

Attention:  

Eduardo Bravo Fernandez de Araoz

Email:  

ebrav@lspvc.com

 

with a required copy (which copy shall not constitute notice) to:

 

Davis Polk & Wardwell LLP

450 Lexington Avenue 

New York, NY 10017

Attention:  

Derek Dostal and Michael Davis

Email:  

derek.dostal@davispolk.com

michael.davis@davispolk.com

 

6.4.   Entire Agreement. This Subscription Agreement constitutes the entire agreement, and supersedes all other prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof, including any commitment letter entered into relating to the subject matter hereof.

 

6.5.   Modifications and Amendments. This Subscription Agreement may not be amended, modified, supplemented or waived except by an instrument in writing, signed by the party against whom enforcement of such amendment, modification, supplement or waiver is sought and also signed by Oculis.

 

6.6.   Assignment. Neither this Subscription Agreement nor any rights, interests or obligations that may accrue to the Issuer and Subscriber hereunder (other than the Subscribed Shares acquired hereunder and the rights set forth in Section 4) may be transferred or assigned without the prior written consent of Subscriber, Issuer and Oculis; provided that all or a portion of Subscriber’s rights and obligations hereunder (including Subscriber’s rights to purchase the Subscribed Shares) may be assigned to one or more of its affiliates (including any fund or account managed by the same investment manager as Subscriber), or by an affiliate of such investment manager, without the prior consent of the Issuer, provided that such assignee(s) agrees in writing to be bound by the terms hereof, and upon such assignment by a Subscriber, the assignee(s) shall become Subscriber hereunder and have the rights and obligations and be deemed to make the representations and warranties of Subscriber provided for herein to the extent of such assignment; provided further that, no assignment shall relieve the assigning party of any of its obligations hereunder, including any assignment to any fund or account managed by the same investment manager as Subscriber.

 

29 

 

6.7.   Benefit. Except as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations, warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors, administrators, successors, legal representatives and permitted assigns. This Subscription Agreement shall not confer rights or remedies upon any person other than the parties hereto and their respective successors and assigns, except that Oculis shall be a third-party beneficiary with respect to the entirety of this Subscription Agreement and as provided in Section 4.4.

 

6.8.   Governing Law. This Subscription Agreement, and any claim or cause of action hereunder based upon, arising out of or related to this Subscription Agreement (whether based on law, in equity, in contract, in tort or any other theory) or the negotiation, execution, performance or enforcement of this Subscription Agreement, shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the principles of conflicts of law thereof.

 

6.9.   Consent to Jurisdiction; Waiver of Jury Trial. Each of the parties irrevocably consents to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware, provided that if subject matter jurisdiction over the matter that is the subject of the legal proceeding is vested exclusively in the U.S. federal courts, such legal proceeding shall be heard in the U.S. District Court for the District of Delaware (together with the Court of Chancery of the State of Delaware, “Chosen Courts”), in connection with any matter based upon or arising out of this Subscription Agreement. Each party hereby waives, and shall not assert as a defense in any legal dispute, that (i) such person is not personally subject to the jurisdiction of the Chosen Courts for any reason, (ii) such legal proceeding may not be brought or is not maintainable in the Chosen Courts, (iii) such person’s property is exempt or immune from execution, (iv) such legal proceeding is brought in an inconvenient forum or (v) the venue of such legal proceeding is improper. Each party hereby consents to service of process in any such proceeding in any manner permitted by Delaware law, further consents to service of process by nationally recognized overnight courier service guaranteeing overnight delivery, or by registered or certified mail, return receipt requested, at its address specified pursuant to Section 6.3 and waives and covenants not to assert or plead any objection which they might otherwise have to such manner of service of process. Notwithstanding the foregoing in this Section 6.9, a party may commence any action, claim, cause of action or suit in a court other than the Chosen Courts solely for the purpose of enforcing an order or judgment issued by the Chosen Courts. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH OF THE PARTIES WAIVES ANY RIGHT TO TRIAL BY JURY ON ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN ANY LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT WHETHER NOW EXISTING OR HEREAFTER ARISING. IF THE SUBJECT MATTER OF ANY SUCH LEGAL DISPUTE IS ONE IN WHICH THE WAIVER OF JURY TRIAL IS PROHIBITED, NO PARTY SHALL ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT. FURTHERMORE, NO PARTY SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE

 

30 

 

ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL CANNOT BE WAIVED.

 

6.10.   Severability. If any provision of this Subscription Agreement shall be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected or impaired thereby and shall continue in full force and effect.

 

6.11.   No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this Subscription Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of such party. No single or partial exercise of any right, power or remedy under this Subscription Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Subscription Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.

 

6.12.   Remedies.

 

6.12.1.   The parties agree that irreparable damage would occur if this Subscription Agreement is not performed or the Closing is not consummated in accordance with its specific terms or is otherwise breached and that money damages or other legal remedies would not be an adequate remedy for any such damage. It is accordingly agreed that the parties hereto shall be entitled to equitable relief, including in the form of an injunction or injunctions, to prevent breaches or threatened breaches of this Subscription Agreement and to enforce specifically the terms and provisions of this Subscription Agreement in an appropriate court of competent jurisdiction as set forth in Section 6.9, this being in addition to any other remedy to which any party is entitled at law or in equity, including money damages. The right to specific enforcement shall include the right of the parties hereto to cause the other parties hereto to cause the transactions contemplated hereby to be consummated on the terms and subject to the conditions and limitations set forth in this Subscription Agreement. The parties hereto further agree (i) to waive any requirement for the security or posting of any bond in connection with any such equitable remedy, (ii) not to assert that a remedy of specific enforcement pursuant to this Section 6.12 is unenforceable, invalid, contrary to applicable law or inequitable for any reason and (iii) to waive any defenses in any action for specific performance, including the defense that a remedy at law would be adequate.

 

6.12.2.   The parties acknowledge and agree that this Section 6.12 is an integral part of the transactions contemplated hereby and without that right, the parties hereto would not have entered into this Subscription Agreement.

 

31 

 

6.13.   Survival of Representations and Warranties and Covenants. All representations and warranties made by the parties hereto, and all covenants and other agreements of the parties hereto, in this Subscription Agreement shall survive the Closing.

 

6.14.   No Liability. Subscriber agrees that none of the Placement Agents shall be liable to it (including in contract, tort, under federal or state securities laws or otherwise) for any action heretofore or hereafter taken or omitted to be taken by any of them in good faith in connection with the Transactions and the purchase and sale of the Subscribed Shares hereunder. On behalf of Subscriber and its affiliates, Subscriber releases the Placement Agents in respect of any Losses related to the Transactions and the purchase and sale of the Subscribed Shares hereunder. Subscriber agrees not to commence any litigation or bring any claim against any of the Placement Agents in any court or any other forum which relates to, may arise out of, or is in connection with, the Transactions and the purchase and sale of the Subscribed Shares hereunder. This undertaking is given freely and after obtaining independent legal advice, except for such party’s own gross negligence, willful misconduct or bad faith.

 

6.15.   Headings and Captions. The headings and captions of the various subdivisions of this Subscription Agreement are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

6.16.   Counterparts. This Subscription Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other parties, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or any other form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

6.17.   Construction. The words “include,” “includes,” and “including” will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires. The words “this Subscription Agreement,” “herein,” “hereof,” “hereby,” “hereunder,” and words of similar import refer to this Subscription Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or covenant. All references in this Subscription Agreement to numbers of shares, per share amounts and purchase prices shall be appropriately adjusted to reflect any stock split, stock dividend, stock combination, recapitalization or the like occurring after the date hereof.

 

32 

 

6.18.   Mutual Drafting. This Subscription Agreement is the joint product of the parties hereto and each provision hereof has been subject to the mutual consultation, negotiation and agreement of the parties and shall not be construed for or against any party hereto.

 

7.   Cleansing Statement; Disclosure.

 

7.1.   The Issuer shall, or shall cause New Parent to, on the first (1st) Business Day immediately following the date of this Subscription Agreement, issue one or more press releases or file with the Commission a Current Report on Form 8-K (collectively, the “Disclosure Document”) disclosing all material terms of the transactions contemplated hereby and by the Other Subscription Agreements and the Transactions and any other material nonpublic information that the Issuer or its officers, directors, employees or agents has provided to Subscriber prior to the filing of the Disclosure Document. Upon the issuance of the Disclosure Document, to the actual knowledge of the Issuer, Subscriber shall not be in possession of any material, non-public information received from the Issuer or any of its officers, directors, employees or agents, and Subscriber shall no longer be subject to any confidentiality or similar obligations under any current agreement, whether written or oral, with the Issuer or any of its affiliates, relating to the transactions contemplated by this Subscription Agreement.

 

7.2.   Notwithstanding anything in this Subscription Agreement to the contrary, the Issuer shall not (and shall cause its officers, directors, employees and agents not to) publicly disclose the name of Subscriber or any affiliate or investment adviser of Subscriber, or include the name of Subscriber or any affiliate or investment adviser of Subscriber without the prior written consent (including by e-mail) of Subscriber (i) in any press release or marketing materials, or (ii) in any filing with the Commission or any regulatory agency or trading market, except as required by the federal securities laws, rules or regulations and to the extent such disclosure is required by other laws, rules or regulations, at the request of the staff of the Commission or regulatory agency or under regulations of Nasdaq, in which case the Issuer shall provide Subscriber with prior written notice (including by e-mail) of such permitted disclosure, and shall reasonably consult with Subscriber regarding such disclosure.

 

8.   Trust Account Waiver. In addition to the waiver of the Issuer pursuant to Section 12.01 of the Business Combination Agreement, and notwithstanding anything to the contrary set forth herein, each of the Issuer and Subscriber acknowledges that the Issuer has established a trust account containing the proceeds of its initial public offering and from certain private placements (collectively, with interest accrued from time to time thereon, the “Trust Account”). Each of the Issuer and Subscriber agrees that (i) it has no right, title, interest or claim of any kind in or to any monies held in the Trust Account, and (ii) it shall have no right of set-off or any right, title, interest or claim of any kind (“Claim”) to, or to any monies in, the Trust Account, in each case in connection with this Subscription Agreement, and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that it may have in connection with this Subscription Agreement; provided, however, that nothing in this Section 8 shall (x) serve to limit or prohibit Subscriber’s right to pursue a claim against the Issuer for legal relief against assets held outside the Trust Account, for specific performance or other equitable relief, (y) serve to limit or prohibit any claims that Subscriber may have in the future against the Issuer’s assets or funds that are not held in the Trust Account (including any funds that have been released from

 

33 

 

the Trust Account and any assets that have been purchased or acquired with any such funds) or (z) be deemed to limit Subscriber’s right, title, interest or claim to the Trust Account by virtue of such Subscriber’s record or beneficial ownership of securities of the Issuer, including, but not limited to, any redemption right with respect to any such securities of the Issuer. In the event Subscriber has any Claim against the Issuer under this Subscription Agreement, Subscriber shall pursue such Claim solely against the Issuer and its assets outside the Trust Account and not against the property or any monies in the Trust Account. Subscriber agrees and acknowledges that such waiver is material to this Subscription Agreement and has been specifically relied upon by the Issuer to induce the Issuer to enter into this Subscription Agreement and Subscriber further intends and understands such waiver to be valid, binding and enforceable under applicable law.
Notwithstanding the foregoing, in no event shall the terms of this Section 8 apply to any money or other assets held outside the Trust Account.

 

9.   Non-Reliance. Subscriber acknowledges that it is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, firm or corporation, (including, without limitation, Oculis, any of its affiliates or any of its control persons, officers, directors or employees), other than the representations and warranties of the Issuer expressly set forth in this Subscription Agreement, in making its investment or decision to invest in the Issuer. Subscriber agrees that neither (i) an Other Subscriber pursuant to this Subscription Agreement or any other agreement related to the private placement of shares of the Issuer’s capital stock (including the controlling persons, officers, directors, partners, agents or employees of any such Subscriber) nor (ii) Oculis, its affiliates or any of its control persons, officers, directors, partners, agents or employees shall be liable to any Other Subscriber pursuant to this Subscription Agreement or any other agreement related to the private placement of shares of the Issuer’s capital stock for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Subscribed Shares hereunder.

 

10.   Rule 144. From and after such time as the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or regulation of the Commission that may allow Subscriber to sell securities of the Issuer to the public without registration are available to holders of the Issuer’s shares of common stock and for so long as Subscriber holds the Subscribed Shares, the Issuer agrees to, and shall cause New Parent to agree to:

 

10.1.   make and keep public information available, as those terms are understood and defined in Rule 144; and

 

10.2.   file with the Commission in a timely manner all reports and other documents required of the Issuer under the Securities Act and the Exchange Act so long as the Issuer remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and

 

10.3.   furnish to Subscriber so long as it owns Subscribed Shares, as promptly as practicable upon request, (x) a written statement by the Issuer or New Parent, as applicable, if true, that it has complied with the reporting requirements of Rule 144, the Securities Act and the

 

34 

 

Exchange Act, and (y) such other information as may be reasonably requested to permit Subscriber to sell such securities pursuant to Rule 144 without registration.

 

The Issuer shall, or shall cause New Parent to, if requested by Subscriber, use commercially reasonable efforts to (i) cause the removal of any restrictive legend related to compliance with the federal securities laws set forth on the Subscribed Shares, (ii) cause its legal counsel to deliver an opinion, if necessary, to the transfer agent in connection with the instruction under subclause (i) to the effect that removal of such legends in such circumstances may be effected in compliance under the Securities Act, and (iii) issue Subscribed Shares without any such legend in certificated or book-entry form or by electronic delivery through The Depository Trust Company, at Subscriber’s option, within two (2) Business Days of such request, if (A) such Subscribed Shares may be sold by Subscriber without restriction under Rule 144, including without limitation, any volume and manner of sale restrictions, or (B) Subscriber has sold or transferred Subscribed Shares pursuant to the Registration Statement or in compliance with Rule 144. The Issuer’s or New Parent’s obligation to remove legends under this paragraph may be conditioned upon Subscriber providing such representations and documentation (including broker representation letters) as are reasonably necessary and customarily required in connection with the removal of restrictive legends related to compliance with the federal securities laws. Subscriber agrees to disclose its beneficial ownership, as determined in accordance with Rule 13d-3 of the Exchange Act, of Ordinary Shares to the Issuer (or its successor) upon reasonable request to assist the Issuer or New Parent, as applicable, in making the determination described above. Notwithstanding the foregoing, the Issuer will not be required to deliver any such opinion, authorization, certificate, or direction if it reasonably believes that removal of the legend could result in or facilitate transfers of securities in violation of applicable law.

 

[Signature Page Follows]

 

35 

 

IN WITNESS WHEREOF, each of the Issuer and Subscriber has executed or caused this Subscription Agreement to be executed by its duly authorized representative as of the date set forth below.

 

  EUROPEAN BIOTECH ACQUISITION CORP.
   
   
  By:  
  Name:
  Title:

 

 

Accepted and agreed this 17th day of October 2022.

 

SUBSCRIBER:

 

Signature of Subscriber:   Signature of Joint Subscriber, if applicable:
By:     By:  
Name:   Name:
Title:   Title:
         

Date: October 17, 2022

 

Name of Subscriber:   Name of Joint Subscriber, if applicable:   
             
(Please print. Please indicate name and      (Please print. Please indicate name and
Capacity of person signing above)   Capacity of person signing above)
     
     
     
Name in which securities are to be registered    
(if different from the name of Subscriber listed directly above):    

 

Email Address:

 

If there are joint investors, please check one:

 

Joint Tenants with Rights of Survivorship

 

Tenants-in-Common

 

Community Property

 

Subscriber’s EIN:     Joint Subscriber’s EIN:  

 

Business Address-Street:   Mailing Address-Street (if different):
     
     

 

 

City, State, Zip:   City, State, Zip:

 

Attn:   Attn:

 

Telephone No.: _________________________   Telephone No.: _____________________
     

Facsimile No.: __________________________ 

 

  Facsimile No.: ______________________

Aggregate Number of Subscribed Shares subscribed for:

 

_____________________________________________

 

Aggregate Purchase Price: $______________.

 

You must pay the Purchase Price by wire transfer of U.S. dollars in immediately available funds to the account specified by the Issuer in the Closing Notice.

 

 

 

SCHEDULE I

 

ELIGIBILITY REPRESENTATIONS OF SUBSCRIBER

 

A.QUALIFIED INSTITUTIONAL BUYER STATUS

 

(Please check the applicable subparagraphs):

 

1.We are a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) (a “QIB”)).

 

2.We are subscribing for the Subscribed Shares as a fiduciary or agent for one or more investor accounts, and each owner of such account is a QIB.

 

*** OR ***

 

B.INSTITUTIONAL ACCREDITED INVESTOR STATUS (Please check the applicable subparagraphs):

 

1.We are an “accredited investor” (within the meaning of Rule 501(a) under the Securities Act) or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act, and have marked and initialed the appropriate box on the following page indicating the provision under which we qualify as an “accredited investor.”

 

2.We are not a natural person.

 

*** AND ***

 

C.AFFILIATE STATUS

 

(Please check the applicable box) SUBSCRIBER:

 

is:

 

is not:

 

an “affiliate” (as defined in Rule 144 under the Securities Act) of the Issuer or acting on behalf of an affiliate of the Issuer.

 

This page should be completed by Subscriber
and constitutes a part of the Subscription Agreement.

 

 

 

Rule 501(a) under the Securities Act, in relevant part, states that an “accredited investor” shall mean any person who comes within any of the below listed categories, or who the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person. Subscriber has indicated, by marking and initialing the appropriate box below, the provision(s) below which apply to Subscriber and under which Subscriber accordingly qualifies as an “accredited investor.”

 

Any bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity;

 

Any broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934, as amended;

 

Any insurance company as defined in section 2(a)(13) of the Securities Act;

 

Any investment company registered under the Investment Company Act of 1940, as amended (the “Investment Company Act”) or a business development company as defined in section 2(a)(48) of the Investment Company Act;

 

Any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958, as amended;

 

Any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

Any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), if (i) the investment decision is made by a plan fiduciary, as defined in section 3(21) of ERISA, which is either a bank, a savings and loan association, an insurance company, or a registered investment adviser, (ii) the employee benefit plan has total assets in excess of $5,000,000 or, (iii) such plan is a self-directed plan, with investment decisions made solely by persons that are “accredited investors”;

 

Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940, as amended;

 

Any (i) corporation, limited liability company or partnership, (ii) Massachusetts or similar business trust, or (iii) organization described in section 501(c)(3) of the Internal Revenue Code of 1986, as amended, not formed for the specific purpose of acquiring the securities offered, and with total assets in excess of $5,000,000; or

 

Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in Section 230.506(b)(2)(ii) of Regulation D.

 

 

Exhibit 10.2

 

 

CONVERTIBLE LOAN AGREEMENT

 


made as of 17 October 2022 

by and among

 

Earlybird Growth GmbH
(represented by Dr. Hendrik Brandis as General Partner of Earlybird Growth Opportunities Fund V GmbH & Co. KG)
Harry Blum-Platz 2
50678 Cologne
Germany

 

("Earlybird")

 

Pivotal bioVenture Partners Fund I L.P.
c/o Pivotal bioVenture Partners
501 Second Street, Suite 200
San Francisco, CA, 94107
USA

 

("Pivotal")

 

NFLS Beta Limited
Vistra Corporate Services Centre, Wickhams Cay II
Road Town, Tortola, VG1110, British Virgin Islands

 

("NFLS")

 

Any other shareholder of Oculis SA executing the adherence declaration in Annex A

 

("Adhering Shareholders")

 

(Earlybird, Pivotal, NFLS and the Adhering Shareholders
collectively the "Lenders" and individually a "Lender")

 

and

 

Oculis SA
EPFL Innovation Park Building D
1015 Lausanne
Switzerland

 

(the "Borrower" or "Oculis")

 

 

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 2022 2/ 21

 

and

 

VISCHER AG
represented by Dr. Matthias Staehelin
Aeschenvorstadt 4
4010 Basel, Switzerland

 

(the "Escrow Agent")

 

regarding the grant of a convertible loan

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 20223/ 21

Table of Contents

 

Preamble    4

 

1.Definitions 5

 

2.Convertible Loan 5

 

2.1Loan Amount 5

 

2.2No Joint Liability 6

 

3.Interest 6

 

4.Transfer to New Parent and Disbursment 6

 

5.Term and Maturity 7

 

5.1Coming into Effect 7

 

5.2Repayment 7

 

6.Events of Default 7

 

7.Security 8

 

8.Conversion 8

 

8.1Conversion upon Acquisition Closing 8

 

8.2Conversion at Maturity 8

 

8.3Execution of the conversion 8

 

8.4Payment of conversion price 8

 

8.5Registration Rights 8

 

9.Representations and Warranties 9

 

10.General Provisions 9

 

10.1No Set-off 9

 

10.2Costs and Expenses 9

 

10.3Notices 9

 

10.4No Waiver 10

 

10.5Entire Agreement 10

 

10.6Severability 10

 

10.7Amendments 11

 

10.8Transfers or Assignments 11

 

10.9Counterparts 12

 

11.Governing Law and Jurisdiction 12

 

Annexes  15

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 20224/ 21

 

Preamble

 

A

 

Oculis SA is a Swiss corporation (Aktiengesellschaft /société anonyme) registered under the number CHE-237.826.774, duly existing under the laws of Switzerland with registered seat at Ecublens (VD), Switzerland.

 

B       

 

Oculis intends to enter into a certain Business Combination Agreement ("BCA) with European Biotech Acquisition Corp., a Cayman Islands exempted company ("EBAC") and certain other parties named in the BCA. EBAC is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

 

C

 

Contemporaneously with the execution and delivery of the BCA, in connection with the Transactions (as defined in the BCA), EBAC and certain investors (the "PIPE Investors") are entering into subscription agreements (the "Subscription Agreements"), pursuant to which the PIPE Investors who are parties thereto have committed, on the terms and subject to the conditions of the Subscription Agreements, to subscribe for and purchase a certain number of shares of EBAC Class A Common Stock (the "PIPE Shares") before the First Merger Effective Time (as defined in the BCA).

 

D

 

Contemporaneously with the execution and delivery of the BCA, in connection with the Transactions (as defined in the BCA), certain shareholders of Oculis are entering into this convertible loan agreement (the "Loan Agreement") pursuant to which the Lenders, on the terms and subject to the conditions of this Loan Agreement, grant to Oculis the right to issue a convertible loan with certain conversion rights. All Oculis shareholders are able to participate in the Loan Agreement pro-rata in proportion to their equity interest in Oculis, on substantially identical principal terms and conditions as those of the PIPE Investors in the PIPE shares.

 

E

 

Following the Second Merger Effective Time and prior to the Company Share Contribution, it is the intent of the parties hereto that New Parent shall assume this Loan Agreement and if New Parent does not assume this Loan Agreement it shall terminate in accordance with the provisions of this Loan Agreement and which, if such assumption is made, will become the new Borrower.

 

F

 

Immediately after such assumption (assuming such assumption has been made) but before the Company Share Contribution, the Lenders shall exercise their conversion rights (in exchange for New Parent Shares at economically the same conditions as the PIPE Investors who have entered into Subscription Agreements and have received first Surviving EBAC Shares and thereafter New Parent Shares) by Conversion Declarations in the form set forth in Annex 8.2 of this Loan Agreement.

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 20225/ 21

G

 

For U.S. federal income tax purposes, the parties hereto intend that (i) the Loans shall be treated as issued solely by New Parent following the Second Merger Effective Time and prior to the Company Share Contribution and not at any other time or by any other person or entity (including, for the avoidance of doubt, Oculis), (ii) the Loans shall not be treated as issued until the receipt by New Parent of cash to fund the Loans from the Lenders following the Second Merger Effective Time, and (iii) until such time as cash to fund the Loans has been paid to New Parent, the Escrow Agent shall hold any such cash on behalf of the Lenders that funded such payment, and such Lenders shall be treated for U.S. federal income tax purposes as the owners of such cash (and interest or other proceeds, if any, earned thereon) unless and until such cash is delivered to New Parent.

 

H

 

On the Acquisition Closing Date, New Parent and other parties are entering into a Registration Rights Agreement in substantially the form attached to the BCA (as amended in writing by EBAC and Oculis), which grants registration rights to shareholders of New Parent and imposes certain lock-up obligations on shareholders of New Parent which received their shares in exchange of shares of Oculis pursuant to the BCA or upon the conversion of the Loans pursuant to this Loan Agreement.

 

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereto hereby agree as follows:

 

1.Definitions

 

Capitalized terms used in this Loan Agreement shall have in first priority the meaning as set forth in Annex 1 and in second priority as defined in the BCA.

 

2.Convertible Loan

 

2.1Loan Amount

 

The Lenders hereby grants to the Borrower a convertible loan (each a "Loan") as follows:

 

Name of Lender Amount in USD
(the "Principal Amount")
Earlybird [***]
Pivotal [***]
NFLS [***]
Adhering Lenders [***]
Maximum Total [***]

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 20226/ 21

For U.S. tax purposes, the Parties agree that Oculis shall not be treated as a borrower of this instrument, and the Loans contemplated hereunder shall not be treated as issued until such time as the Escrow Agent releases the Lenders’ funds to New Parent (assuming New Parent has assumed this Loan Agreement).

 

2.2No Joint Liability

 

The rights and obligations of the Lenders under this Loan Agreement shall be several (and not joint). Each Lender may exercise and enforce its rights hereunder individually in accordance with this Loan Agreement, and the non-performance by the Borrower or another Party (the "Defaulting Party") shall not relieve either the Borrower nor any other Party from performing its obligations under this Loan Agreement, nor shall Oculis (provided it is not the Defaulting Party) or any other Party be liable for the non-performance by the Defaulting Party.

 

The obligations of the Parties hereunder are contractual in nature and the Parties agree that they do not form, and this Loan Agreement shall not be deemed to constitute, a simple partnership (einfache Gesellschaft / société simple).

 

3.Interest

 

The Loan shall be interest-free.

 

4.Transfer to New Parent and Disbursment

 

Following the Second Merger Effective Time and prior to the Company Share Contribution, it is the intention of the parties hereto that New Parent shall assume this Loan Agreement. Each party hereto hereby consents to such assumption and, following such assumption, shall fully release Oculis from any obligation under this Loan Agreement.

 

In preparation of the Acquisition Closing, each Lender shall wire the Principal Amount in full within five (5) Business Days upon the request of the Escrow Agent to the following notarial escrow account of the Escrow Agent:

 

IBAN No: CH94 0029 2292 1057 6311 3
Currency: USD
Account holder: VISCHER AG, Aeschenvorstadt 4, 4010 Basel, Switzerland
Bank: UBS Switzerland AG, Aeschenvorstadt 1, 4002 Basel, Switzerland
SWIFT: UBSWCHZH80A
Reference: Convertible Loan Oculis

 

The Escrow Agent shall hold the Principal Amount in its own name but for the account of and the benefit of the respective Lenders that funded the Principal Amount, and such Lenders shall be treated as the owners of the Principal Amount and any earnings thereon for U.S. federal income tax purposes, unless and until the Principal Amount is delivered by the Escrow Agent to New Parent as provided herein. New Parent shall have no right to and shall not be entitled to receive the Principal Amount pursuant to this Agreement until after the Second Merger Effective Time.

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 20227/ 21

If BCA is terminated prior to the Second Merger Effective Time or the Second Merger does not take place, the amounts funded by each Lender shall be promptly returned to such Lenders.

 

In no event will Oculis have any right or entitlement to all or any portion of the Principal Amount (or any interest or proceeds earned thereon). Oculis shall not be entitled to receive or call the disbursement of the Principal Amount.

 

Any disbursement of the Principal Amount (other than a return of the amounts funded by the Lenders to the Lenders if the BCA is terminated prior to the Second Merger Effective Time or the Second Merger does not take place) (i) may only be made upon instruction of the Escrow Agent solely in preparation of the Acquisition Closing (ii) shall be made only after the Second Merger Effective Time, (iii) shall be made only after Oculis effectively assigns this Loan Agreement to New Parent and (iv) shall be made only to New Parent if New Parent has assumed the Loan Agreement.

 

5.Term and Maturity

 

5.1Coming into Effect

 

This Loan Agreement only comes into force if signed by the respective Lender and the Borrower and only upon completion of the Second Merger.

 

5.2Repayment

 

The obligation to disburse the Principal amount shall terminate and any Outstanding Loan Amount shall become due for repayment in cash on the earlier of:

 

a)immediately following the occurrence of an Event of Default as set forth in Section 6 below;

 

b)within 10 Business Days after termination of the BCA;

 

c)immediately following the failure of the Second Merger to occur in accordance with the BCA; or

 

d)on 31 March 2023 ("Maturity Date"), but in any event not earlier than 20 Business Days after the consummation of the BCA if the Loan has not been converted into New Parent Shares and the BCA has not been terminated.

 

6.Events of Default

 

If any of the events listed hereafter (each an "Event of Default") occurs, each Lender may terminate this Loan Agreement with immediate effect:

 

a)the Borrower is declared bankrupt by a court, applies for bankruptcy (Konkurs) or reorganization (Nachlassstundung), or has a resolution passed for its winding-up, a creditor files a petition for bankruptcy (Konkursbegehren); and

 

b)any representation or warranty set forth in Section 0 proves to have been inaccurate or misleading in any material respect and the consequences of such breach are not fully cured within 10 calendar days from the date of receipt of a respective written notice by the Borrower from the Lender.

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 20228/ 21
7.Security

 

The Loan shall not be secured.

 

8.Conversion

 

8.1Conversion upon Acquisition Closing

 

Following the Second Merger Effective Time and prior to the Company Share Contribution, it is the intent of the parties that New Parent shall assume this Loan Agreement from Oculis.

 

Immediately after such assumption (if such assumption occurs), by Conversion Declarations in the form set forth in Annex 8.2, the Lenders shall exercise their conversion rights in exchange for Shares of the new Borrower at economically the same conditions as the PIPE Investors who have entered into Subscription Agreements have received first Surviving EBAC Shares and thereafter New Parent Shares.

 

8.2Conversion at Maturity

 

On Maturity, if the Loan Agreement has been assumed by the new Borrower and if the Loan has been disbursed and this Loan Agreement has not been terminated, each Lender shall have the right to convert the Outstanding Loan into Shares of the new Borrower at economically the same conditions as the PIPE Investors who have entered into Subscription Agreements and have received first Surviving EBAC Shares and thereafter New Parent Shares.

 

8.3Execution of the conversion

 

To execute the conversion, the Lender shall submit a conversion declaration to the Borrower, substantially in the form as set out in Annex 8.2 ("Conversion Declaration"). The Borrower undertakes and is obliged to take all necessary corporate and other steps to give effect to, and to complete, the conversion as set forth in this Section. No fractional shares of the new Borrower shall be issued upon conversion. In lieu of any fractional shares to which a Lender would otherwise be entitled, the Borrower shall pay cash equal to such fraction multiplied by the applicable conversion price. In no event will shares of Oculis be delivered to Lenders as a result of any conversion of any Loan.

 

8.4Payment of conversion price

 

Following the Second Merger Effective Time and prior to the Company Share Contribution, the Escrow Agent shall wire to the new Borrower the nominal value of each Share of the new Borrower (CHF 0.01 per Share of the new Borrower) to be received in exchange of the Principal Amount. The disbursement of the Principal Amount to the new Borrower shall be subject to the issuance of the shares of the new Borrower resulting from the conversion to the Lenders, as evidenced by an extract from the share register of the new Borrower.

 

8.5Registration Rights

 

Each Lender shall be offered the opportunity to enter at conversion with the new Borrower into a registration rights agreement with the terms not less favorable to such Lender as outlined in Annex 8.5. Absent such agreement the Borrower shall use commercially reasonable efforts that such Lender is treated equally to any PIPE Investor.

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 20229/ 21
9.Representations and Warranties

 

The Borrower represents and warrants as per the date of this Loan Agreement the following:

 

a)the Borrower is a Swiss stock corporation duly incorporated and validly existing under the laws of Switzerland, with the power and authority (corporate and other) to own its properties and conduct its business in the ordinary course;

 

b)the Borrower has good title to or valid leases or licenses of or is otherwise entitled to use, all material assets required by it to carry on its business as it is being, or is proposed to be, conducted;

 

c)the Borrower is duly authorized to enter into and perform its obligations under or in connection with this Loan Agreement; and

 

d)the obligations of the Borrower according to this Loan Agreement are valid, binding and enforceable against the Borrower subject only to bankruptcy, insolvency, reorganization, and composition or similar laws affecting creditors' rights in general.

 

10.General Provisions

 

10.1No Set-off

 

Other than in connection with a conversion as set forth in Section 8, the Lender shall not be allowed to set-off any claim under this Loan Agreement with any debts owed to Oculis.

 

10.2Costs and Expenses

 

Each Party shall bear its own costs and expenses in connection with negotiation of this Loan Agreement.

 

10.3Notices

 

All notices and other communications to be given under or in connection with this Loan Agreement shall be made in writing and shall be delivered by registered mail (return receipt requested) or by an internationally recognized courier, in all cases additionally in advance by e-mail, to the following address:

 

If to Oculis or, after the Acquisition Closing Date, New Parent to:

 

Oculis SA
EPFL Innovation Park Building D
1015 Lausanne, Switzerland

 

Attention: Riad Sherif
Email: riad.sherif@oculis.com

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202210/ 21

 

with a copy to (which shall not constitute notice to Oculis or New Parent):

 

Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ, UK 

Attention: Michal Berkner
  Divakar Gupta
  Ryan Sansom
E-mail: mberkner@cooley.com
  dgupta@cooley.com
  rsansom@cooley.com

 

and

 

VISCHER AG 

Aeschenvorstadt 4  
4010 Basel, Switzerland  

Attention: Matthias Staehelin
  Vincent Reardon
E-mail: mstaehelin@vischer.com
  vreardon@vischer.com

 

If to any Oculis Shareholder to the address included in the share register of Oculis SA and if to any other Lender to the address indicated in the Adherence Declaration.

 

10.4No Waiver

 

Failure by either Party to enforce any rights under this Loan Agreement shall not be construed as a waiver of such rights nor shall a waiver by either Party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances.

 

10.5Entire Agreement

 

This Loan Agreement including its annex embodies the entire agreement between the Parties concerning the subject matter hereof and supersede all written or oral prior agreements or understandings with respect thereto.

 

10.6Severability

 

If any term or provision of this Loan Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Loan Agreement shall be interpreted and construed as if such term or provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never been contained herein.

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202211/ 21
10.7Amendments

 

This Loan Agreement may be amended only in writing through a document duly signed by all Parties and any waivers to this Loan Agreement require prior written approval of Oculis and the respective Lender.

 

10.8Transfers or Assignments

 

No Lender shall transfer the Loan or assign any of its rights or obligations under the Loan or under this Loan Agreement to any third party without the prior written consent of the Borrower other than the transfer to New Parent following the Second Merger Effective Time in accordance with the terms of this Loan Agreement.

 

The Borrower shall not transfer the Loan or assign any of its rights or obligations to any person other than the transfer to New Parent following the Second Merger Effective Time in accordance with the terms of this Loan Agreement without the prior written consent of the Borrower.

 

This Loan Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective permitted successors and assigns. The rights and obligations under this Loan Agreement may only be transferred together with the shares held in Oculis, such transfer of shares to take place in accordance with this shareholders' agreement dated 1 April 2021 entered into the other shareholders of Oculis (the "Oculis Shareholders' Agreement"). Furthermore, any transfer shall be permitted pursuant which a Lender transfers by will or intestate succession upon the death of a Lender, including insofar as any of the Loan Amount are held pursuant to any grant of probate or letters of administration in respect of the estate of any deceased Lender, transfers to the executors, administrators or any other similar personal representatives of such Lender, or any other beneficiaries, in accordance with the will of such Lender or the applicable laws or otherwise as directed by the order of any relevant courts or tribunals of competent jurisdiction.

 

Each Party undertakes individually for itself vis-à-vis each other Party, to impose on its individual legal successors, if any, the rights and obligations arising under this Loan Agreement in such a way, that its individual legal successors are bound by the rights and obligations under the Oculis Shareholders' Agreement as if they had themselves undertaken these rights and obligations.

 

Notwithstanding the foregoing, no Party shall enter into any arrangement with any other person, as a result of which Swiss stamp duties and withholding tax on interest payments could be triggered. The Parties agree and shall procure that during the term of this Loan Agreement, the Borrower shall at no time be the recipient of loans or other debt capital (including the Loan) from more than twenty creditors and the Company shall not accept Additional Lenders if this would result in to more than twenty such creditors.

 

Notwithstanding anything to the contrary in this Loan Agreement, the Lender shall not enter into any arrangement with another person under which it substantially transfers all or part of its Loan or its exposure under this Loan Agreement to that other person (including any sub-participation), except to the extent that legal counsel to Oculis express its belief that such transaction will not trigger adverse legal or tax consequences.

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202212/ 21

Notwithstanding the above, NFLS and Pivotal (each an "Affiliated Party") are to be considered and treated as Affiliates (as such term is defined in the Shareholders' Agreement) and may freely transfer any rights and obligations under this Loan Agreement between themselves. Satisfaction of an aggregate obligation of Affiliated Parties by one Affiliated Party or by some combination of Affiliated Parties shall be deemed to be satisfaction of such obligation by all Affiliated Parties and the right to satisfy such obligation shall not be offered to other Shareholders if so satisfied by the Affiliated Parties.

 

10.9Counterparts

 

This Loan Agreement may be executed in so many counterparts as there are Parties to it, each of which shall constitute an original, and all counterparts shall constitute an original, and all counterparts shall together constitute one and the same instrument. Execution copies may be delivered as a PDF by e-mail (in which case original copies shall subsequently be sent by mail as soon as possible).

 

11.Governing Law and Jurisdiction

 

This Loan Agreement shall be governed by and construed in accordance with the substantive laws of Switzerland excluding its conflict of law rules.

 

Any dispute, controversy or claim arising out of, or in relation to this Loan Agreement, including the validity, invalidity, breach, or termination thereof, shall be exclusively resolved by the ordinary courts of Lausanne (Switzerland).

 

***

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202213/ 21

Signatures

 

The Lenders

 

Place   Date

 

 

Earlybird Growth GmbH

 

Represented by Dr. Hendrik Brandis as General Partner of Earlybird Growth Opportunities Fund V GmbH & Co. KG 

 

Signature   Signature
 
Name   Name
Title   Title
     
Place   Date

 

 

Pivotal bioVenture Partners Fund I L.P.

Pivotal bioVenture Partners Fund I G.P., L.P., represented by its general partner

Pivotal bioVenture Partners Fund I U.G.P. Ltd, represented by its general partner

 

Signature   Signature
 
Name   Name
Title   Title

 

Place   Date

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202214/ 21

Signatures

 

The Lenders

 

Place   Date

 

 

Earlybird Growth GmbH

 

Represented by Dr. Hendrik Brandis as General Partner of Earlybird Growth Opportunities Fund V GmbH & Co. KG

 

 
Name   Name
Title   Title
     
Place   Date

 

 

NFLS Beta Limited

 

 
Name   Name
Title   Title
     
Place   Date

 

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202215/ 21

 

The Borrower

 

Place   Date

 

 

Oculis SA

 

 
Name   Name
Title   Title
     

 

Annexes

 

Annex A Adherence Declaration
Annex 1 Definitions
Annex 8.2 Conversion Declaration
Annex 8.5 Registration Rights

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202216/ 21

 

Annex A

 

Adherence Declaration

 

as of [DATE]

 

made by

 

Name: _____________________

 


Address: _____________________

 

(hereinafter "Additional Lender")

 

WHEREAS, the Convertible Loan Agreement as of 14 October 2022 regarding Oculis SA, a Swiss corporation (Aktiengesellschaft /société anonyme) registered under the number CHE-237.826.774, duly existing under the laws of Switzerland with registered seat at Ecublens (VD) ("Oculis"), was executed between Oculis and certain lenders (the "Loan Agreement", enclosed to this Adherence Declaration);

 

WHEREAS, pursuant to the Loan Agreement existing shareholders and, if applicable, third parties may participate in the investment in Oculis by way of adherence to the Loan Agreement;

 

WHEREAS, the Additional Lender is willing participate in the investment in Oculis by way of executing this Adherence Declaration;

 

NOW, THEREFORE, the Additional Lender hereby declares and agrees to the following:

 

1.DEFINITIONS

 

Unless otherwise defined in this Adherence Declaration, all capitalized terms shall have the meaning according to the definition in the Loan Agreement.

 

2.Adherence to the Loan Agreement

 

The Additional Lender hereby agrees to become a Party to the Loan Agreement (as an Additional Lender), to be bound by the terms of the Loan Agreement and to grant a Loan to Oculis under the Loan Agreement in the amount of

 

USD ______________________

 

according to the terms in this Adherence Declaration and according to the terms of the Loan Agreement.

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202217/ 21
3.Notices

 

All Notices pursuant to Section 10.3 of the Loan Agreement shall, with respect to the Additional Lender, be given to the address indicated on the first page.

 

4.Governing Law and Jurisdiction

 

This Adherence Declaration shall be governed by and construed in accordance with the substantive laws of Switzerland excluding its conflict of law rules.

 

Any dispute, controversy or claim arising out of, or in relation to this Adherence Declaration, including the validity, invalidity, breach, or termination thereof, shall be exclusively resolved by the ordinary courts of Lausanne (Switzerland).

 

IN WITNESS WHEREOF the Additional Lender and Oculis have caused this Adherence Declaration to be duly executed

 

Place   Date

 

 

 

The Adhering Lender: ___________

 

Signature   Signature
 
Name   Name
Title   Title

 

 

The Borrower

 

Place   Date

 

 

 

Oculis SA

 

Signature   Signature
 
Name   Name
Title   Title

 

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202218/ 21

 

Annex 1

 

Definitions

 

Acquisition Closing Date shall have the meaning set forth in the BCA.
Additional Lender shall have the meaning as defined in the introduction of this Loan Agreement.
Annex means an annex to this Loan Agreement.
BCA shall have the meaning set forth in recital B.
Borrower shall have the meaning as defined on the first page of the Loan Agreement.
Business Day shall mean a day (other than a Saturday or Sunday) on which banks in Lausanne are opened for general business during the full day.
Conversion Declaration shall have the meaning set forth in Section 0.
Loan Agreement(s) shall have the meaning set forth in recital F.
Defaulting Party shall have the meaning set forth in Section 0.
EBAC shall have the meaning set forth in the introduction of this Loan Agreement.
EBAC shall have the meaning set forth in recital B.
Event of Default shall have the meaning set forth in Section 6.
First Merger shall have the meaning set forth in the BCA.
First Merger Effective Time shall have the meaning set forth in the BCA.
Governing Documents shall have the meaning set forth in the BCA.
Law(s) shall have the meaning set forth in the BCA.
Lender(s) shall have the meaning as defined in the introduction of this Loan Agreement.
Maturity Date shall have the meaning set forth in Section 0 c).
New Parent shall have the meaning set forth in the introduction of this Loan Agreement.
New Parent Shares shall have the meaning set forth in recital H.

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202219/ 21
Oculis shall have the meaning set forth in the introduction of this Loan Agreement.
Oculis Shareholder shall mean a holder of shares in Oculis
Oculis Shareholders' Agreement shall have the meaning set forth in Section 10.8.
Outstanding Loan Amount(s) shall mean any amount outstanding as loan pursuant to this Loan Agreement
Party or Parties means the parties to this Loan Agreement.
PIPE Investor shall have the meaning set forth in the BCA.
Principal Amount shall have the meaning set forth in Section 2.1.
Second Merger Effective Time shall have the meaning set forth in the BCA.
Series B Preferred Shares shall mean the Series B Preferred Shares issued by Oculis as listed in Annex A.
Series C Preferred Shares shall mean the Series C Preferred Shares issued by Oculis as listed in Annex A.
Sponsor shall have the meaning set forth in the BCA.
Subscription Agreement(s) shall have the meaning set forth in the BCA.
Surviving EBAC Shares shall have the meaning set forth in the BCA.
Taxes shall have the meaning set forth in the BCA.
Transactions shall have the meaning set forth in the BCA.

 

***

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202220/ 21

 

Annex 8.5

 

Conversion Declaration

 

To:[New Parent]

 

From:[Lender]

 

[Place/Date]

 

Convertible Loan Agreement – Conversion Declaration

 

Ladies and Gentlemen,

 

We refer to the convertible loan agreement dated [DATE] (the "Loan Agreement") between Oculis SA as Borrower and [Lender] as Lender. We take note that New Parent has assumed the Loan Agreement. Capitalized terms used in this Conversion Declaration but not otherwise defined herein shall have the meaning as ascribed to them in the Loan Agreement.

 

In full knowledge of the [New Parent's] articles of association, we herewith:

 

1.exercise our conversion right as pursuant to Section 8 of the Loan Agreement in respect of ___ [number] of ___ [category of shares] with an aggregate nominal amount of CHF ___ [nominal amount] and an aggregate issue price of CHF ___ [issue price];

 

2.unconditionally undertake to make a corresponding capital contribution to the Borrower by setting off the aggregate issue price of USD ___ [issue price] with our claim for payment of the Outstanding Loan Amount under the Loan Agreement in the aggregate amount of USD ___ [claim under Loan Agreement];

 

3.request that [New Parent] accepts this Conversion Declaration and procures the booking of ___ [number] of respective shares into the share register; and

 

4.request the Borrower to provide us with an excerpt from the Borrower 's share register giving evidence of the new shares being registered in our name.

 

Yours faithfully,

 

[Lender]    

  

 
Name   Name
Title   Title

 

 

Convertible Loan Agreement regarding Oculis SA, 17 October 202221/ 21

 

We confirm that the Conversion Declaration is duly completed, accurate and correct in all respects and that we accept the above.

 

Yours faithfully,

 

Place: Date:  
       
     
[New Parent]    
     

 

***

 
Name   Name
Title   Title

 

 

 

 

 

 

 

Exhibit 10.3

 

SHAREHOLDER NON-REDEMPTION AGREEMENT

 

THIS SHAREHOLDER NON-REDEMPTION AGREEMENT (this “Agreement”) is made and entered into as of October 17, 2022 by and among European Biotech Acquisition Corp., a Cayman Islands exempted company (“EBAC”), LSP Sponsor EBAC B.V., a Dutch limited liability company (the “Sponsor”) and [__________], a holder of certain EBAC Shares (as defined below) (the “EBAC Shareholder”). Each of EBAC, the Sponsor and the EBAC Shareholder will individually be referred to herein as a “Party” and, collectively, as the “Parties”. For purposes of this agreement, an “EBAC Share” means a Class A ordinary share of EBAC, par value $0.0001 per share. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Business Combination Agreement (as defined below).

 

WHEREAS, EBAC and Oculis SA, a corporation (société anonyme) incorporated and existing under the laws of Switzerland (“Oculis”) entered into that certain Business Combination Agreement, dated as of the date hereof (as it may be amended, restated or otherwise modified from time to time in accordance with its terms, the “Business Combination Agreement”);

 

WHEREAS, as soon as practicable following the execution of the Business Combination Agreement, (a) EBAC will form (i) Oculis Holding AG, a public limited liability company incorporated and existing under the laws of Switzerland and a direct wholly owned subsidiary of EBAC (“New Parent”), (ii) a new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 1”), (iii) another new Cayman Islands exempted company that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 2”) and (iv) a new public limited liability company (société anonyme)  incorporated and existing under the laws of Switzerland that will be a direct wholly owned subsidiary of New Parent (“Merger Sub 3”) and (b) EBAC will cause New Parent, Merger Sub 1, Merger Sub 2 and Merger Sub 3 to become a party to the Business Combination Agreement as a “Party” and “EBAC Party” by executing a joinder agreement;

 

WHEREAS, the EBAC Shareholder is the record and beneficial owner of the number of EBAC Shares set forth on the signature page hereto (together with any other shares, capital stock or any other equity interests, as applicable, of EBAC that the EBAC Shareholder holds of record or beneficially, as of the date of this Agreement, or acquires record or beneficial ownership after the date hereof (including any New Parent Shares received pursuant to Section 4 below), collectively, the “Subject EBAC Equity Securities”);

 

WHEREAS, the EBAC Shareholder acknowledges and agrees that EBAC and the other parties to the Business Combination Agreement would not have entered into and agreed to consummate the transactions contemplated by the Business Combination Agreement without the EBAC Shareholder entering into this Agreement and agreeing to be bound by the agreements, covenants and obligations contained in this Agreement; and

 

WHEREAS, in consideration of the EBAC Shareholder’s commitment to, among other things, not redeem the Subject EBAC Equity Securities, and subject to the conditions set forth herein, the Sponsor agrees to transfer to the EBAC Shareholder one (1) New Parent Class A Share, nominal value CHF 0.01 per share (the “New Parent Class A Shares”) for every ten (10) Subject EBAC Equity Securities (the “New Parent Shares”), on or promptly following the Acquisition Closing Date;

 

NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of the Parties, intending to be legally bound, hereby agrees as follows:

 

1. Agreement to Vote. The EBAC Shareholder hereby unconditionally and irrevocably agrees to be present at any meeting of the shareholders of EBAC, and to vote (in person or by proxy), or consent to any action by written consent or resolution with respect to, all of the Subject EBAC Equity Securities (i) in favor of the Transaction Proposals, and (ii) in opposition to: (A) any and all other proposals (1) that could reasonably be expected to delay or impair the ability of EBAC to consummate the transactions contemplated by the Business Combination Agreement or any Ancillary Agreement or (2) which are in competition with or materially inconsistent with the Business Combination Agreement, any Transaction and the transactions contemplated thereby, or (B) any other action,

 

 

 

proposal, transaction or agreement involving EBAC or any of its Subsidiaries that is intended, or would reasonably be expected, to prevent, impede, interfere with, delay, postpone or adversely affect in any material respect the transactions contemplated by the Business Combination Agreement or any Ancillary Agreement or would reasonably be expected to result in (y) any breach of any representation, warranty, covenant, obligation or agreement of EBAC in the Business Combination Agreement or any Ancillary Agreement or (z) any of the conditions to EBAC’s obligations under the Business Combination Agreement or any Ancillary Agreement not being fulfilled.

 

2. No Redemption. The EBAC Shareholder hereby agrees that it shall not redeem, or submit a request to EBAC’s transfer agent or otherwise exercise any right to redeem, any Subject EBAC Equity Securities.

 

3. Transfer of Shares. The EBAC Shareholder hereby agrees that, from the date hereof through the date that is ninety (90) calendar days after the Acquisition Closing Date, it shall not, directly or indirectly, (i) sell, assign, transfer (including by operation of law), place a lien on, pledge, dispose of or otherwise encumber any of the Subject EBAC Equity Securities or otherwise agree to do any of the foregoing (each, a “Transfer”), (ii) deposit any of the Subject EBAC Equity Securities into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect to any of the Subject EBAC Equity Securities that conflicts with any of the covenants or agreements set forth in this Agreement, (iii) enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer (including by operation of law) or other disposition of any of the Subject EBAC Equity Securities, (iv) engage in any hedging or other transaction which is designed to, or which would (either alone or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition of the Subject EBAC Equity Securities even if such Subject EBAC Equity Securities would be disposed of by a Person other than the EBAC Shareholder or (v) take any action that would have the effect of preventing or materially delaying the performance of its obligations.

 

4. Agreement of Sponsor.

 

(a)In consideration of the EBAC Shareholder’s performance of its obligations described herein and upon satisfaction (or, if applicable, waiver) of the conditions set forth in clause (b) of this Section, effective as of and conditioned on the consummation of the Acquisition Closing, the Sponsor shall transfer the New Parent Shares to the EBAC Shareholder, on or promptly following the Acquisition Closing Date. Upon written notice from (or on behalf of) the Sponsor to the EBAC Shareholder at least five (5) Business Days prior to the expected Acquisition Merger Closing Date, the EBAC Shareholder may designate in writing to the Sponsor any managed accounts or fund entities for which the EBAC Shareholder exercises investment discretion to receive the New Parent Shares.

 

(b)The obligations of the Sponsor pursuant to Section 4 of this Agreement shall be subject to the satisfaction, or valid waiver by the Sponsor, of the following conditions: (i) the EBAC Shareholder shall have fully complied with, performed and satisfied its obligations set out in Sections 1-3 hereof, and shall have performed, satisfied and complied in all material respects with all other covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by it at or prior to the Acquisition Closing Date, (ii) the Acquisition Closing shall have occurred, and (iii) all representations and warranties of the EBAC Shareholder contained in this Agreement shall be true and correct in all material respects (other than representations and warranties that are qualified as to materiality, which representations and warranties shall be true and correct in all respects) at and as of the Acquisition Closing Date (except for representations and warranties made as of a specific date, which shall be true and correct in all material respects (other than representations and warranties that are qualified as to materiality, which representations and warranties shall be true and correct in all respects) as of such date).

 

5. EBAC Representations and Warranties. EBAC represents and warrants as of the date hereof to the EBAC Shareholder as follows:

 

(a)EBAC is duly incorporated, validly existing and in good standing under the laws of the Cayman Islands, and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby are within EBAC’s corporate powers and have been duly authorized by all necessary corporate actions on the part of EBAC. This Agreement has been duly executed and delivered by EBAC

 

 

 

and, assuming due authorization, execution and delivery by the EBAC Shareholder, this Agreement constitutes a legally valid and binding obligation of EBAC, enforceable against EBAC in accordance with the terms hereof (except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (ii) principles of equity, whether considered at law or equity).

 

(b)The execution and delivery of this Agreement by EBAC does not, and the performance by EBAC of its obligations hereunder will not, (i) conflict with or result in a violation of the organizational documents of EBAC, (ii) result in a violation of any law, rule, regulation, order, judgment or decree or (iii) require any consent or approval that has not been given or other action that has not been taken by any person, in each case to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by EBAC of its obligations under this Agreement. EBAC has full right and power to enter into this Agreement.

 

(c)As of the date of this Agreement, the authorized share capital of EBAC consists of 200,000,000 Class A ordinary shares, 20,000,000 Class B ordinary shares and 1,000,000 preference shares, $0.0001 par value each and as of the date immediately prior to the Transactions, the authorized share capital of EBAC will consist of 200,000,000 Class A ordinary shares, 20,000,000 Class B ordinary shares and 1,000,000 preference shares, $0.0001 par value each. All issued and outstanding ordinary shares of EBAC have been duly authorized and validly issued, are fully paid, non-assessable and are not subject to preemptive or similar rights. There are no shareholder agreements, voting trusts or other agreements or understandings to which the EBAC is a party or by which it is bound relating to the voting of any securities of the EBAC, other than as contemplated by the Business Combination Agreement and the Ancillary Agreements.

 

6. Sponsor Representations and Warranties. Sponsor represents and warrants as of the date hereof to the EBAC Shareholder as follows:

 

(a)Sponsor is duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation or formation, and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby are within Sponsor’s corporate powers and have been duly authorized by all necessary corporate actions on the part of Sponsor. This Agreement has been duly executed and delivered by Sponsor and, assuming due authorization, execution and delivery by the EBAC Shareholder, this Agreement constitutes a legally valid and binding obligation of Sponsor, enforceable against Sponsor in accordance with the terms hereof (except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (ii) principles of equity, whether considered at law or equity).

 

(b)The execution and delivery of this Agreement by Sponsor does not, and the performance by Sponsor of its obligations hereunder, including the transfer of  New Parent Shares to the EBAC Shareholder, will not, (i) conflict with or result in a violation of the organizational documents of Sponsor, (ii) result in a violation of any law, rule, regulation, order, judgment or decree or (iii) require any consent or approval that has not been given or other action that has not been taken by any person, in each case to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by Sponsor of its obligations under this Agreement. Sponsor has full right and power to enter into this Agreement.

 

(c)Sponsor has, and on the Acquisition Closing Date will have, good and valid title to the New Parent Shares to be transferred to the EBAC Shareholder, free and clear of all security interests, claims, liens, equities or other encumbrances and the legal right and power, and all authorization and approval required by law, to enter into this Agreement and to transfer and deliver the New Parent Shares to be transferred by the Sponsor or a security entitlement in respect of such Shares.

 

7. EBAC Shareholder Representations and Warranties. The EBAC Shareholder hereby represents and warrants to EBAC as follows:

 

 

 

(a)If the EBAC Shareholder is a corporation, company, limited liability company or other applicable business entity, it is duly organized, incorporated or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Legal Requirements of its jurisdiction of formation or organization (as applicable).

 

(b)If the EBAC Shareholder is not an individual, the EBAC Shareholder has the requisite corporate, limited liability company or other similar power and authority to execute and deliver this Agreement, to perform its covenants, agreements and obligations hereunder. The execution and delivery of this Agreement has been duly authorized by all necessary corporate (or other similar) action on the part of the EBAC Shareholder. If the EBAC Shareholder is an individual, EBAC Shareholder has the capacity to enter into, deliver and perform its obligations under this Agreement. This Agreement has been duly and validly executed and delivered by the EBAC Shareholder. If the EBAC Shareholder is an individual, the signature on this Agreement is genuine, and the EBAC Shareholder has legal competence and capacity to execute the same. This Agreement constitutes a valid, legal and binding agreement of the EBAC Shareholder (assuming that this Agreement is duly authorized, executed and delivered by EBAC and New Parent), enforceable against the EBAC Shareholder in accordance with its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors’ rights and subject to general principles of equity).

 

(c)The execution and delivery of this Agreement by the EBAC Shareholder does not, and the performance by the EBAC Shareholder of its obligations hereunder will not, (i) conflict with or result in a violation of the organizational documents of the EBAC Shareholder if it is not an individual, (ii) result in a violation of any law, rule, regulation, order, judgment or decree or (iii) require any consent or approval that has not been given or other action that has not been taken by any person, in each case to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by the EBAC Shareholder of its obligations under this Agreement.

 

(d)The EBAC Shareholder (i) is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an institutional “accredited investor” (within the meaning of Rule 501(a)(1), (2), (3) or (7) under the Securities Act), in each case, satisfying the applicable requirements set forth on Annex A, (ii) is not a "U.S. person" as defined in Regulation S promulgated under the Securities Act, (iii) is acquiring any New Parent Shares that may be transferred to the EBAC Shareholder pursuant to this Agreement only for its own account and not for the account of others, or if the EBAC Shareholder is acquiring any New Parent Shares that may be transferred to the EBAC Shareholder pursuant to this Agreement as a fiduciary or agent for one or more investor accounts, each owner of such account is a qualified institutional buyer or institutional accredited investor (as the case may be) and the EBAC Shareholder has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each such account, and (iv) is not acquiring any New Parent Shares that may be transferred to the EBAC Shareholder pursuant to this Agreement with a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act (and shall provide the requested information on Annex A). The EBAC Shareholder is not an entity formed for the specific purpose of acquiring any New Parent Shares that may be transferred to the EBAC Shareholder pursuant to this Agreement, unless such newly formed entity is an entity in which all of the investors are institutional accredited investors and is an “institutional account” as defined by FINRA Rule 4512(c). The EBAC Shareholder is a sophisticated institutional investor, experienced in investing in private equity transactions and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities. Accordingly, the EBAC Shareholder understands that the acquisition of any New Parent Shares that may be transferred to the EBAC Shareholder pursuant to this Agreement meets (i) the exemptions from filing under FINRA Rule 5123(b)(1)(A) and (ii) the institutional customer exemption under FINRA Rule 2111(b).

 

(e)The EBAC Shareholder understands that any New Parent Shares that may be transferred to the EBAC Shareholder pursuant to this Agreement are being offered in a transaction not involving any public offering within the meaning of the Securities Act and that the New Parent Shares have not been registered under the Securities Act. The EBAC Shareholder understands that the New Parent Shares may not be offered, resold,

 

 

 

transferred, pledged or otherwise disposed of by the EBAC Shareholder except (i) pursuant to an effective registration statement under the Securities Act, (ii) to the extent the EBAC Shareholder has delivered to the New Parent (if requested by New Parent) an opinion of counsel, in a form reasonably acceptable to New Parent, to the effect that such New Parent Shares to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (iii) to the extent that such EBAC Shareholder provides the New Parent with reasonable assurance (which shall not include a legal opinion) that such New Parent Shares can be sold, assigned or transferred pursuant to Rule 144, Rule 144A or Regulation S promulgated under the Securities Act (or a successor rule thereto) or (iv) otherwise pursuant to an applicable exemption from the registration requirements of the Securities Act, and in accordance with any applicable securities laws of the applicable states and other jurisdictions of the United States, and that any certificates or book-entry records representing the New Parent Shares shall contain a restrictive legend to such effect. The EBAC Shareholder acknowledges and agrees that the New Parent Shares will be subject to these securities law transfer restrictions and, as a result of these transfer restrictions, the EBAC Shareholder may not be able to readily resell the New Parent Shares and may be required to bear the financial risk of an investment in the New Parent Shares for an indefinite period of time. The EBAC Shareholder understands that it has been advised to consult legal counsel prior to making any offer, resale, pledge or transfer of any of the New Parent Shares. Notwithstanding the foregoing, the New Parent Shares may be pledged in connection with a bona fide margin account or other loan or financing arrangement secured by the New Parent Shares and such pledge of New Parent Shares shall not be deemed to be a transfer, sale or assignment of the New Parent Shares hereunder, and the EBAC Shareholder, by effecting a pledge of New Parent Shares, shall not be required to provide New Parent with any notice thereof or otherwise make any delivery to New Parent pursuant to this Agreement.

 

(f)In making its decision to invest in the New Parent Shares, the EBAC Shareholder has relied solely upon independent investigation made by the EBAC Shareholder and New Parent’s, Sponsor’s and EBAC’s representations, warranties and covenants contained herein. The EBAC Shareholder has not relied on any statements or other information provided by anyone other than New Parent, Sponsor and EBAC concerning EBAC, Oculis, the Mergers, the New Parent Shares or the offer of the New Parent Shares. The EBAC Shareholder acknowledges and agrees that the EBAC Shareholder has received such information as the EBAC Shareholder deems necessary in order to make an investment decision with respect to the New Parent Shares, including with respect to Oculis, EBAC and the Mergers, and made its own assessment and is satisfied concerning the relevant tax and other economic considerations relevant to the EBAC Shareholder’s investment in the New Parent Shares. The EBAC Shareholder represents and agrees that the EBAC Shareholder and the EBAC Shareholder’s professional advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such information as the EBAC Shareholder and its professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the New Parent Shares. Without limiting the generality of the foregoing, the EBAC Shareholder acknowledges that it has had an opportunity to review the SEC Reports.

 

(g)EBAC Shareholder became aware of the offering of the New Parent Shares solely by means of direct contact between the EBAC Shareholder, New Parent, EBAC or their representatives or affiliates. The EBAC Shareholder did not become aware of the offering of the New Parent Shares, nor were the New Parent Shares offered to the EBAC Shareholder, by any other means. The EBAC Shareholder acknowledges that New Parent Shares (i) were not offered by any form of general solicitation or general advertising and (ii) are not being offered in a manner involving a public offering under the Securities Act or any state securities laws.

 

(h)EBAC Shareholder acknowledges that it is aware that there are substantial risks incident to the ownership of the New Parent Shares. The EBAC Shareholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the New Parent Shares, and the EBAC Shareholder has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice as the EBAC Shareholder has considered necessary to make an informed investment decision. The EBAC Shareholder is not relying on any statements or representations of New Parent or EBAC or any of its agents for legal, tax or investment advice with respect to this Agreement or the transactions contemplated by the Agreement.

 

 

 

(i)The EBAC Shareholder has fully considered the risks of an investment in the New Parent Shares and determined that the New Parent Shares are a suitable investment for the EBAC Shareholder and that the EBAC Shareholder is able at this time and in the foreseeable future to bear the economic risk of a total loss of the EBAC Shareholder’s investment in the New Parent Shares. The EBAC Shareholder acknowledges specifically that a possibility of total loss exists.

 

(j)The EBAC Shareholder understands and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the New Parent Shares or made any findings or determination as to the fairness of this investment.

 

(k)No broker or finder has acted on behalf of the EBAC Shareholder in such a way as to create any liability on New Parent or EBAC in connection with this Agreement.

 

(l)The EBAC Shareholder is not entering into the transactions contemplated by this Agreement to create actual or apparent trading activity in the New Parent Class A Shares (or any security convertible into or exchangeable for New Parent Class A Shares) or to raise or depress or otherwise manipulate the price of the New Parent Class A Shares (or any security convertible into or exchangeable for the New Parent Class A Shares) or otherwise in violation of the Exchange Act.

 

8. Termination. This Agreement shall automatically terminate, without any notice or other action by any Party, and be void ab initio upon the earlier of (a) the termination of the Business Combination Agreement in accordance with its terms and (b) the date upon which none of the Parties have any further obligations or liabilities with respect to any covenant or agreement herein. Upon termination of this Agreement as provided in the immediately preceding sentence, none of the Parties shall have any further obligations or liabilities under, or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, the termination of this Agreement pursuant to Section 10(b) shall not affect any liability on the part of any Party for an intentional breach of this Agreement or Intentional Fraud.

 

9. Third Party Beneficiary. This Agreement shall be for the sole benefit of the Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns, any legal or equitable right, benefit or remedy of any nature whatsoever by reason this Agreement. Except as otherwise provided in the following sentence, nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties, partners or participants in a joint venture. Notwithstanding anything to the contrary contained herein, Oculis is an intended third party beneficiary of and may enforce this Section 6 and Sections 1, 2, 3 and 10 of the Agreement.

 

10. Miscellaneous.

 

(a)This Agreement constitutes the entire agreement among the Parties relating to the transactions and supersede any other agreements, whether written or oral, that may have been made or entered into by or among any of the Parties or any of their respective subsidiaries relating to the transactions.  No representations, warranties, covenants, understandings, agreements, oral or otherwise, relating to the transactions exist between the Parties except as expressly set forth or referenced in this Agreement.

 

(b)No Party shall assign this Agreement or any part hereof without the prior written consent of the other Parties.  Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties and their respective permitted successors and assigns.  Any attempted assignment in violation of the terms of this Section 10(b) shall be null and void, ab initio.

 

(c)This Agreement may be amended or modified in whole or in part, only by a duly authorized agreement in writing executed by each of the Parties in the same manner as this Agreement and which makes reference to this Agreement.  The approval of this Agreement by the stockholders of any of the Parties shall not restrict the ability of the board of directors or managers (or other body performing similar functions) of any of the Parties to terminate this Agreement in accordance with Section 5 or to cause such Party to enter into an amendment to this Agreement pursuant to this Section 10(c).

 

 

 

(d)This Agreement, and all claims or causes of action based upon, arising out of, or related to this Agreement or the transactions, shall be governed by, and construed in accordance with, the internal substantive Laws of the State of Delaware applicable to contracts entered into and to be performed solely within such state, without giving effect to principles or rules of conflict of laws to the extent such principles or rules would require or permit the application of Laws of another jurisdiction.

 

(e)If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect.  The Parties further agree that if any provision contained herein is, to any extent, held invalid or unenforceable in any respect under the Laws governing this Agreement, they shall take any actions necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent permitted by Law and, to the extent necessary, shall amend or otherwise modify this Agreement to replace any provision contained herein that is held invalid or unenforceable with a valid and enforceable provision giving effect to the intent of the Parties.

 

(f)This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

(g)Any action based upon, arising out of or related to this Agreement or the Transactions may be brought in federal and state courts located in the State of Delaware, and each of the Parties irrevocably submits to the exclusive jurisdiction of each such court in any such action, waives any objection it may now or hereafter have to personal jurisdiction, venue or to convenience of forum, agrees that all claims in respect of the action shall be heard and determined only in any such court, and agrees not to bring any action arising out of or relating to this Agreement or the transactions in any other court.  Nothing herein contained shall be deemed to affect the right of any Party to serve process in any manner permitted by Law or to commence legal proceedings or otherwise proceed against any other Party in any other jurisdiction, in each case, to enforce judgments obtained in any action brought pursuant to this ‎Section 10(g).  EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION BASED UPON, ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS.

 

(h)The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur if the Parties do not perform their obligations under the provisions of this Agreement (including failing to take such actions as are required of them hereunder to consummate this Agreement) in accordance with its specified terms or otherwise breach such provisions.  The Parties acknowledge and agree that  (i) EBAC shall be entitled to an injunction, specific performance, or other equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof and thereof, without proof of damages, prior to the valid termination of this Agreement in accordance with Section 5, this being in addition to any other remedy to which they are entitled under this Agreement, and (ii) the right of specific enforcement is an integral part of the transactions and without that right, none of the Parties would have entered into this Agreement.  Each Party agrees that it will not oppose the granting of specific performance and other equitable relief on the basis that the other Parties have an adequate remedy at law or that an award of specific performance is not an appropriate remedy for any reason at Law or equity.  The Parties acknowledge and agree that EBAC, in seeking an injunction to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this Section 10(h), shall not be required to provide any bond or other security in connection with any such injunction.

 

(i)The EBAC Stockholder acknowledges that EBAC has established a trust account (the “Trust Account”) containing the proceeds of its initial public offering (“IPO”) and certain proceeds of the private placement (including interest accrued from time to time thereon) for the benefit of its public stockholders and certain other parties (including the underwriters of the IPO). For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the EBAC Stockholder hereby agrees (on its own behalf and on behalf of its related parties) that it does not now and shall not at any time hereafter have any right, title, interest or claim of any kind in or to any assets held in the Trust Account, and it shall not make any claim against the Trust Account, regardless of whether such claim arises as a result of, in connection with or relating in any way to this Agreement or any other matter, and regardless of whether such claim arises

 

 

 

based on contract, tort, equity or any other theory of legal liability (any and all such claims are collectively referred to hereafter as the “Released Claims”); provided, that the Released Claims shall not include any rights or claims of the EBAC Stockholder or any of its related parties as a shareholder of EBAC to the extent related to or arising from any shares of capital stock of EBAC other than the Subject EBAC Equity Securities hereby irrevocably waives (on its own behalf and on behalf of its related parties) any Released Claims that it may have against the Trust Account now or in the future as a result of, or arising out of, this Agreement and will not seek recourse against the Trust Account with respect to the Released Claims.

 

[signature page follows]

 

 

 

IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be duly executed on its behalf as of the day and year first above written.

 

  EUROPEAN BIOTECH ACQUISITION CORP.
     
  By:  
    Name: Eduardo Bravo Fernandez de Araoz
    Title: Chief Executive Officer
     
  LSP SPONSOR EBAC B.V.
     
  By:  
    Name: Mark Wegter
    Title: Director
  By:  
    Name: Martijn Kleijwegt
    Title: Director
   
  EBAC SHAREHOLDER:
     
  By:  
    Name:
   

Title:

Class A New Parent Shares of EBAC: [__________]

 

[Signature Page to Shareholder Non-Redemption Agreement]

 

 

 

ANNEX A

ELIGIBILITY

REPRESENTATIONS OF

EBAC SHAREHOLDER

 

This page should be completed by the EBAC

Shareholder and constitutes a part of the Non-

Redemption Agreement.

 

A.QUALIFIED INSTITUTIONAL BUYER STATUS (Please check the applicable subparagraphs):
We are a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act (a “QIB”)).
B.NON-US PERSON
We are not a “U.S. Person” (as defined in Regulation S promulgated under the Securities Act (a “Non-U.S. Person”)).
C.INSTITUTIONAL ACCREDITED INVESTOR STATUS (Please check the applicable subparagraphs):
1. We are an “accredited investor” (within the meaning of Rule 501(a))(1), (2), (3) or (7) under the Securities Act) or an entity in which

all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act, and have marked and initialed the appropriate box below indicating the provision under which we qualify as an “accredited investor.”

2.We are not a natural person.

 

Rule 501(a), in relevant part, states that an “accredited investor” shall mean any person who comes within any of the below listed categories, or who the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person. The EBAC Shareholder has indicated, by marking and initialing the appropriate box below, the provision(s) below which apply to the EBAC Shareholder and under which the EBAC Shareholder accordingly qualifies as an “accredited investor.”

Any bank, registered broker or dealer, insurance company, registered investment company, business development company, or small

business investment company;

Any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000;
Any employee benefit plan, within the meaning of the Employee Retirement Income Security Act of 1974, if a bank, insurance company, or registered investment adviser makes the investment decisions, or if the plan has total assets in excess of $5,000,000;
Any organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;
Any trust with assets in excess of $5,000,000, not formed to acquire the securities offered, whose purchase is directed by a sophisticated person; or
Any entity in which all of the equity owners are accredited investors meeting one or more of the above tests.

 

 

 

Exhibit 10.4

 

 

OCULIS Shareholder Support AGREEMENT

 


made as of 17 October 2022

 

by and among

 

Oculis SA
EPFL Innovation Park Building D
1015 Lausanne
Switzerland

 

("Oculis")

 

and

 

European Biotech Acquisition Corp.
EPFL Innovation Park Building D
1015 Lausanne
Switzerland

 

("EBAC")

 

and

 

Oculis Holding AG under formation
Bahnhofstrasse 7
6300 Zug, Switzerland

 

(the "New Parent")

 

and

 

the shareholders of Oculis SA as listed in Annex A

 

(the "Oculis Shareholders", each individually an "Oculis Shareholder")

 

(Each a "Party" and collectively the "Parties")

 

with respect to the Business Combination Agreement dated 17 October 2022.

 

 

 

Oculis Shareholder Support Agreement 2/ 27
   

 

Table of Contents

 

Preamble 3
1.        Definitions 4
2.        Voting, Waiver of Appraisal Rights 4
2.1     Voting and Waiver 4
2.2     No Joint Liability 4
3.        Representations and Warranties of each Oculis Shareholder 4
4.        Business Combination Agreement Obligations 6
4.1     Transfer Restrictions 6
4.2     General Obligations 6
4.3     Disclaimer 7
5.        Covenants of each Oculis Shareholder 7
5.1     Support 7
5.2     Transfer at the Acquisition Closing Date 7
5.3     Dividends 8
5.4     Stock Options 8
5.5     Convertible Loan 8
5.6     Non-Competition 9
5.7     Non-Solicitation 9
5.8     Confidentiality 9
5.9     Further Assurances 10
6.        General Waiver and Release 10
7.        General Provisions 11
7.1     Taxes and Expenses 11
7.2     No Set-Off 11
7.3     Termination 11
7.4     Notices 12
7.5     Legal Successors and Assignment 13
7.6     Waiver 13
7.7     Acknowledgment 13
7.8     Interpretation 14
7.9     Counterparts; Electronic Signatures Interpretation 15
7.10   Severability 15
7.11   Amendment 15
7.12   Entire Agreement; No Third Party Beneficiaries 15
7.13   No Ownership Interest 16
7.14   Capacity as a Shareholder 16
7.15   Shareholders' Agreement 16
8.        Governing Law / Arbitration 16
8.1     Governing Law 16
8.2     Jurisdiction 16
8.3     Enforcement 17
8.4     Non-Recourse 17
Annexes 21

 

 

 

 

Oculis Shareholder Support Agreement3/ 27
  

 

Preamble

 

A

 

Oculis SA is a Swiss corporation (Aktiengesellschaft /société anonyme) registered under the number CHE-237.826.774, duly existing under the laws of Switzerland with registered seat at Ecublens (VD), Switzerland. Each Oculis Shareholder is the legal owner of Shares as set forth in Annex A and is a party to the shareholders' agreement dated April 1, 2021 (the "Oculis Shareholders' Agreement").

 

B       

 

Oculis intends to enter into a certain Business Combination Agreement ("BCA") with European Biotech Acquisition Corp., a Cayman Islands exempted company ("EBAC") and certain other parties named in the BCA. EBAC is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

 

C

 

As a condition and inducement to EBAC’s willingness to enter into this Agreement, simultaneously with the execution and delivery of this Agreement, Oculis' Shareholders shall execute and deliver to EBAC this Agreement. Each Oculis Shareholder acknowledges to receive substantial benefits from the consummation of the transactions contemplated by the BCA. The representations, warranties, covenants and other agreements set forth in this Agreement are a material inducement to EBAC, New Parent and Oculis to enter into the BCA and to perform their obligations thereunder and each of EBAC, New Parent and Oculis would not obtain the benefit of the bargain set forth in the BCA as specifically negotiated by the parties thereto unless this Agreement was specifically performed and enforced. Any breach of this Agreement by an Oculis Shareholder would cause immediate irreparable harm to EBAC, New Parent and Oculis. The Oculis Shareholders acknowledge and agree that each of EBAC, New Parent and Oculis has substantial legitimate business interests necessitating the covenants provided in Section 5 of this Agreement, and that such covenants are reasonable to protect such business interests.

 

D

 

Contemporaneously with the execution and delivery of the BCA and the Subscription Agreements, in connection with the Transactions, certain shareholders of Oculis that are not PIPE Investors, as defined in the BCA (the "CLA Investors"), are entering into a Convertible Loan Agreements, pursuant to which the CLA Investors, on the terms and subject to the conditions of the Convertible Loan Agreements, grant to Oculis a convertible loan with certain conversion rights. Oculis is offering to all its shareholders to participate pro-rata in the Convertible Loan Agreement on the basis of substantially identical principal terms and conditions.

 

E

 

This Agreement shall govern the commitment of each Oculis Shareholder to support the BCA and the Convertible Loan Agreements and agree to the transactions contained therein.

 

 

Oculis Shareholder Support Agreement4/ 27
  

 

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereto hereby agree as follows:

 

1.Definitions

 

For the purposes of this Agreement (including the introductory paragraphs and the annexes), capitalized terms shall have in first priority the meanings set forth in Annex 1, in second priority as defined in the Convertible Loan Agreement and in third priority in the BCA.

 

2.Voting, Waiver of Appraisal Rights

 

2.1Voting and Waiver

 

In line with the BCA, each Oculis Shareholder shall:

 

a)promptly cooperate with each of Oculis, EBAC, and New Parent in taking such actions as are both reasonably necessary and requested by each of Oculis, EBAC or New Parent to consummate the Transactions;

 

b)vote or cause to be voted all of its shares in Oculis SA ("Oculis Shares") in favor of approving and adopting the BCA, including any Transaction contemplated by the BCA (including the Mergers), and will not withdraw or rescind such vote or otherwise take action to make such vote ineffective; and

 

c)hereby irrevocably and unconditionally waive, or shall cause to be waived, any rights of appraisal, any dissenters' rights and any similar rights relating to the Transaction, or any other transaction contemplated by BCA in connection with their outstanding Oculis Shares.

 

2.2No Joint Liability

 

The rights and obligations of the each Oculis Shareholder hereunder shall be several (and not joint) and no Oculis Shareholder shall be responsible for the obligations of any other Oculis Shareholder. The non-performance by a Party (the "Defaulting Party") shall not relieve any other Party from performing its obligations under this Agreement, nor shall Oculis (provided it is not the Defaulting Party) or any other Party be liable for the non-performance by the Defaulting Party.

 

The obligations of the Parties hereunder are contractual in nature and the Parties agree that they do not form, and this Agreement shall not be deemed to constitute, a simple partnership (einfache Gesellschaft / société simple).

 

3.Representations and Warranties of each Oculis Shareholder

 

Each Oculis Shareholder hereby represents and warrants to each of Oculis, EBAC, and New Parent that:

 

a)the Oculis Shares listed in Annex A beside the name of such Oculis Shareholder constitute all of the shares owned (both beneficially and of record) by such Oculis Shareholder as of the date hereof;

 

 

Oculis Shareholder Support Agreement5/ 27
  

 

b)such Oculis Shareholder does not hold or own any rights to acquire (directly or indirectly) any other equity securities issued by Oculis or any equity securities convertible into, or which can be exchanged for equity securities issued by Oculis;

 

c)such Oculis Shareholder has good and valid title to such Oculis Shares as of the date hereof, free and clear of all Liens, subject to any transfer restrictions under applicable securities Laws and other restrictions as set forth in the Oculis Shareholders Agreement;

 

d)the Oculis Shareholder is duly organized or incorporated, validly existing and where applicable, in good standing under the laws of the jurisdiction of its formation, incorporation or organization, and has all requisite capacity and authorization to execute and deliver this Agreement, and to perform and to execute the obligations hereunder and thereunder and to consummate the Transactions contemplated hereby and thereby;

 

e)such Oculis Shareholder has not entered into, and shall not enter into, any agreement that would restrict, limit or interfere with the performance of such Oculis Shareholder’s obligations hereunder;

 

f)there are no actions pending against such Oculis Shareholder or, to the knowledge of such Oculis Shareholder, threatened against such Oculis Shareholder, before (or, in the case of threatened actions) that would be before any arbitrator or any Governmental Authority, which in any manner challenges or seeks to prevent or materially delay the performance by such Oculis Shareholder of such Oculis Shareholder’s obligations under this Agreement;

 

g)the execution, delivery and performance of this Agreement and any other agreements contemplated by the BCA to which the Oculis Shareholder is a party, does not conflict with or result in any breach of any provision of the Governing Documents of the Oculis Shareholder and no other act or proceeding on the part of the Oculis Shareholder is necessary to authorize the execution, delivery, and performance of this Agreement and any other agreements contemplated by the BCA to which the Oculis Shareholder is a party;

 

h)this Agreement and any other agreements contemplated by the BCA to which the Oculis Shareholder is a party, shall be duly executed and delivered by the Oculis Shareholder and, assuming the due authorization, execution, and delivery by each other party to this Agreement, constitutes a valid and binding obligation of the Oculis Shareholder, enforceable in accordance with its terms, subject to any Law applicable to the Oculis Shareholder; and

 

i)neither the execution and delivery of this Agreement nor the consummation of the Transactions will (i) require any filing with, or the obtaining of any consent or approval of any Governmental Authority (other than as required under the Securities Act or the Exchange Act, by Nasdaq or Nasdaq First North, or implementing the Transactions under the applicable laws of Switzerland) nor (ii) conflict with or result in any breach of, or violate in any respect any Law applicable to the Oculis Shareholder, unless such conflict or violations would not prevent or materially delay the consummation of the Transactions.

 

 

Oculis Shareholder Support Agreement6/ 27
  

 

4.Business Combination Agreement Obligations

 

4.1Transfer Restrictions

 

Each Oculis Shareholder hereby agrees that, except pursuant to the Transactions from the date hereof through the earlier of (i) the Acquisition Closing Date or (ii) the termination of the BCA, it will not directly or indirectly:

 

a)sell, transfer, assign, tender in any tender or exchange offer, pledge, encumber, hypothecate or similarly dispose of (by merger, by testamentary disposition, by operation of law or otherwise), either voluntarily or involuntarily, or enter into any contract, option or other arrangement or understanding with respect to the sale, transfer, assignment, Lien or similar disposition of (by operation of law or otherwise), any Oculis Shares;

 

b)deposit any Oculis Shares into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect thereto that is inconsistent with this Agreement; or

 

c)agree (whether or not in writing) to take any of the actions referred to in the foregoing clause (a) or (b) of this Section 4.1; provided that the Oculis Shareholder may transfer, assign or sell Oculis Shares (i) to such Oculis Shareholder’s Affiliates; (ii) in the case of an individual, by gift to a member of the individual’s immediate family or to a trust, the beneficiary of which is a member of one of the individual’s immediate family, an affiliate of such person or to a charitable organization; (iii) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual; (iv) in the case of an individual, pursuant to a qualified domestic relations order; or (v) if such transfer, assignment or sale shall be in line and compliance with the Oculis Shareholders' Agreement; provided, further, that, in the case of each of the forgoing clauses (i) through (v), such transferee agrees in writing to be bound by terms and obligations of this Agreement and any other agreement contemplated in the BCA to which the Oculis Shareholder is party to pursuant to a joinder in form and substance reasonably acceptable to EBAC, New Parent and Oculis;.

 

For clarity, this Section 4.1 shall not apply to New Parent shares received as of Acquisition Closing Date for which certain lock-up provisions agreed in a separate Registration Rights and Lock-Up Agreement attached to the BCA may apply.

 

4.2General Obligations

 

Each Oculis Shareholder hereby agrees to be bound by the terms and conditions set forth in Section 7.05 (Acquisition Proposals), Section 9.03. (Support of Transaction), Section 12.01 (Trust Account Waiver), Section 12.16 (No Recourse), and, to the extent applicable to any of the foregoing, the remaining provisions of Article 12 (Miscellaneous) of the BCA fully and to the same extent as if the Oculis Shareholder was a party and signatory to such provisions of the BCA.

 

 

Oculis Shareholder Support Agreement7/ 27
  

 

4.3Disclaimer

 

Notwithstanding anything in this Agreement to the contrary: (a) each Oculis Shareholder (in its capacity as such) shall not be responsible for the actions of Oculis, its board of directors (or any committee thereof), or any officers, directors (in their capacity as such), employees and professional advisors of any of the foregoing (the "Oculis Related Parties"), with respect to any of the matters contemplated by the preceding sentence; (b) such Oculis Shareholder shall not make any representations or warranties with respect to the actions of any of the Oculis Related Parties; and (c) any breach by Oculis of its obligations under the BCA shall not, in and of itself, be considered a breach of the preceding sentence (it being understood for the avoidance of doubt that the Oculis Shareholder shall remain responsible for any breach by it or its Representatives (other than any such Representative that is a Oculis Related Party in its capacity as such) of the preceding sentence).

 

5.Covenants of each Oculis Shareholder

 

5.1Support

 

Each Oculis Shareholder hereby agrees that it shall not take any action that would have the effect of preventing or materially delaying the Transactions except permitted under the BCA.

 

5.2Transfer at the Acquisition Closing Date

 

Each Oculis Shareholder shall procure that

 

a)such Oculis Shareholder shall have good and valid title to its Oculis Shares at the Acquisition Closing Date, it free and clear of all Liens, subject to any transfer restrictions under applicable securities Laws and other restrictions as set forth in the Oculis Shareholders Agreement;

 

b)such Oculis Shareholder has at the Acquisition Closing Date all requisite capacity and authorization to execute and deliver this Agreement, and to perform and to execute the obligations hereunder;

 

c)the fulfillment of this Agreement at the at the Acquisition Closing Date shall not require any filing with, or the obtaining of any consent or approval of, any Governmental Authority by the Oculis Shareholder (other than as required under the Securities Act or the Exchange Act, by Nasdaq or Nasdaq First North, or implementing the Transactions under the applicable laws of Switzerland);

 

d)the fulfillment of this Agreement at the Acquisition Closing Date does not violate in any respect any Law applicable to the Oculis Shareholder, except, in the case of violations which would not prevent or materially delay the consummation of the Transactions.

 

e)The fulfillment of this Agreement at the at the Acquisition Closing Date, in particular the proxy for the exchange form to be submitted by such Oculis Shareholder at the Acquisition Closing Date exchanging his, her or its Oculis shares into New Parent Shares shall be duly executed and delivered by such Oculis Shareholder and, assuming the due authorization, execution and delivery by

 

 

Oculis Shareholder Support Agreement8/ 27
  

 

each other party hereto and thereto, shall constitute a valid and binding obligation of such Oculis Shareholder, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency and other similar Laws affecting the enforceability of creditors’ rights generally, and where applicable general equitable principles and the discretion of courts in granting equitable remedies, and neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will conflict with or result in any breach of any provision of the Governing Documents of such Oculis Shareholder and any necessary approvals (if any) have been duly obtained.

 

5.3Dividends

 

Each Oculis Shareholder hereby agrees that its entitlement to accumulating dividends for its Series B Preferred Shares or Series C Preferred Shares pursuant to section 8.6 of the Oculis Shareholder's Agreement shall be calculated on the basis that the dividend entitlement ends on the last day of the calendar month prior to Acquisition Closing Date.

 

A sample calculation thereof is attached in Annex 5.3 for illustration purposes.

 

5.4Stock Options

 

Each Oculis Shareholder who is also a holder of options for shares of Oculis takes note and agrees not to exercise any options between December 31, 2022, and the earlier of (i) one calendar day after the Acquisition Closing Date or (ii) the termination of the BCA.

 

5.5Convertible Loan

 

Each Oculis Shareholder takes note that the Oculis Shareholder are invited to participate in the transaction by the means of a convertible loan agreement substantially in the form of Annex 5.5 (the "Convertible Loan Agreement"). In this context, each Oculis Shareholders:

 

a)acknowledges that such Oculis Shareholder has been offered the right to participate in the transactions foreseen by the Convertible Loan Agreement and waives any pre-emptive subscription rights (Vorwegzeichnungsrecht /droit de souscription préférentiel) other than for loans granted pursuant to such Convertible Loan Agreement either as listed in such Convertible Loan Agreement or in an Adherence Declaration delivered to Oculis not later than the public announcement of the BCA (such declaration to be acknowledged and countersigned by Oculis not later than 10 calendar days after such announcement) and waives any subscription rights with regard to any New Parent Shares to be issued to the lender under the Convertible Loan Agreement (Bezugsrecht /droit de souscription) to the extent necessary;

 

b)acknowledges, approves and ratifies the execution of the Convertible Loan Agreement and the discharge of the obligations of the Borrower thereunder, including the issuance of any share in the Borrower, with the rights and preferences, if any, as set forth in the Convertible Loan Agreement; and

 

 

Oculis Shareholder Support Agreement9/ 27
  

 

c)undertakes to the Lenders under the Convertible Loan Agreement to vote its shares in New Parent in favor of the capital increase to the extent necessary for the issuance of New Parent Shares in favor of the Lender to the extent necessary.

 

5.6Non-Competition

 

Oculis Shareholders, who are also key employees and engaged in research and development activities of Oculis, hereby severally confirm that they are bound by appropriate non-compete undertakings, for as long they are employed or retained as a consultant by Oculis or any subsidiary and for twelve (12) months thereafter and shall refrain from engaging, directly or indirectly, in any activity which competes with the business and/or the therapies and targets that are actively being researched, developed, commercialized or licensed by Oculis (or any successor entity thereto) at the time of such officer's termination of employment or consulting relationship, unless such non-compete is waived for a valid and objective reason by Oculis’s board (or the board of any successor entity thereto).

 

5.7Non-Solicitation

 

Each Oculis Shareholder employed by Oculis or in a consultant relationship with Oculis hereby severally covenants that such Oculis Shareholder shall not, directly or indirectly, at any time during the period of twelve (12) months after such Shareholder ceases to be employed or retained as a consultant by Oculis (or any successor entity thereto) or any subsidiary, hire or solicit (a) any person who is, or within the preceding year was, an employee of Oculis (or any successor entity thereto) or any of its subsidiaries nor induce such person to leave his employment with Oculis (or any successor entity thereto) or any of its subsidiaries or (b) induce an independent contractor who provided services or products to or on behalf of Oculis (or any successor entity thereto) within the preceding year to terminate his business relationship with Oculis (or any successor entity thereto) or (c) induce a customer of Oculis (or any successor entity thereto) to terminate its business relationship with Oculis (or any successor entity thereto).

 

5.8Confidentiality

 

Each Oculis Shareholder hereby covenants and agrees not to, and to cause the Oculis Shareholder’s controlled Affiliates (and any other Affiliates of such Oculis Shareholder that have been provided Confidential Information) not to, at any time, directly or indirectly, (a) retain or use for the benefit, purposes or account of the Oculis Shareholder or any other Person other than Oculis, or (b) disclose, divulge, reveal, communicate, share, transfer or provide access to any Person outside of EBAC, New Parent or Oculis or any of their Affiliates, any Confidential Information, other than (i) to the Oculis Shareholder’s (1) officers, directors and employees, managers, general partners and investment advisors and (2) legal, tax and financial advisors, in the case of each of the forgoing clauses (1) and (2), who agree to maintain the confidentiality of such information or are subject to equivalent obligations of confidentiality or (ii) to the extent required of the Oculis Shareholder by Law or any Governmental Authority or judicial, administrative or legal process (including complying with any oral or written questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process to which such disclosing party is subject); provided, that, the Oculis Shareholder must (1) give notice (except to the extent such

 

 

Oculis Shareholder Support Agreement10/ 27
  

 

notice is prohibited by Law) to each of EBAC, New Parent and Oculis of such request or requirement, (2) use commercially reasonable efforts to assist EBAC, New Parent and Oculis with obtaining, at EBAC's, New Parent's and Oculis' election and expense, an appropriate protective order with respect to such disclosure (to the extent not prohibited by Law), (3) disclose such Confidential Information only to the extent required by such Law and use commercially reasonable efforts to obtain confidential treatment thereof and (4) otherwise maintain the confidentiality of the disclosed Confidential Information in accordance with the terms hereof; provided, further, that the Oculis Shareholder shall not be required to take any action described in the foregoing clauses (1) or (2) in connection with any routine audit or examination by a regulatory or self-regulatory authority, bank examiner or relevant examiner, or auditor not targeted at Oculis, the Confidential Information or the Transaction.

 

5.9Further Assurances

 

From time to time and without additional consideration, each Oculis Shareholder shall execute and deliver, or cause to be executed and delivered, such additional transfers, assignments, endorsements, proxies, consents and other instruments, and shall take such further necessary and reasonable actions as each of EBAC, New Parent and Oculis may reasonably request for the purpose of carrying out and furthering the intent of this Agreement or the BCA.

 

6.General Waiver and Release

 

Each Oculis Shareholder, on behalf of itself and any of its heirs, executors, beneficiaries, administrators, successors, assigns and controlled Affiliates, as applicable (each, a "Releasor"), hereby forever, unconditionally and irrevocably acquits, remises, discharges and releases, effective as of the Acquisition Closing Date, any Group Company, each of their respective officers, directors, equity holders, employees, partners, trustees and representatives, and each successor and assign of any of the foregoing (collectively, the "Oculis Released Persons"), from any and all claims, obligations, liabilities, charges, demands, and causes of action of every kind and character, whether accrued or fixed, absolute or contingent, matured or un-matured, suspected or unsuspected or determined or determinable, and whether at law or in equity, which any Releasor now has, ever had or may have against or with the Oculis Released Persons, or any of them, in any capacity, whether directly or derivatively through another Person, for, upon, or by reason of any matter, cause or thing, whatsoever, on or at any time prior to the Acquisition Closing Date, relating to (i) the Oculis Shareholder’s relationship as an equity holder, (ii) the negotiation, approval, execution or consummation of the transactions contemplated hereby, the BCA, any Ancillary Agreement or any other agreement contemplated herein or therein and (iii) breaches of fiduciary duties with respect to the transactions contemplated by the BCA and agrees not to bring or threaten to bring or otherwise join in any action against the Oculis Released Persons, or any of them, for, upon, or by reason of any matter, cause or thing, whatsoever, on or at any time prior to the Acquisition Closing Date relating to each Oculis Shareholder's relationship as an equity holder of Oculis; provided, however, that, to the extent applicable to each Releasor, the claims, obligations, liabilities, charges, demands, and causes of action released pursuant to this Section 6) (collectively, the "Released Claims") does not apply to the following: (a) regular salary and vacation or other

 

 

Oculis Shareholder Support Agreement11/ 27
  

 

compensation or benefit that is accrued and earned but unpaid by any Group Company at the Closing; (b) any unreimbursed travel or other expenses and advances that are reimbursable under the current policies of any Group Company; (c) any benefits that are accrued and earned but unpaid at the Closing under any employee benefit plan of any Group Company or any rights under health insurance plans, retirement plans or other similar plans sponsored by any Group Company; (d) any rights to indemnification, exculpation and/or advancement of expenses pursuant to the Governing Documents of any Group Company, indemnification agreements with any Group Company or any directors’ and officers’ liability insurance policies with respect to actions taken or not taken by such Releasor in his or her capacity as an officer or director of any Group Company; or (e) any rights of the Releasors under this Agreement or the BCA.

 

Without limiting the foregoing, each Oculis Shareholder, on behalf of itself and each Releasor, understands and agrees that the claims released in this Section 6 include not only claims presently known but also include all unknown or unanticipated claims, obligations, liabilities, charges, demands, and causes of action of every kind and character that would otherwise come within the scope of the Released Claims. Each Oculis Shareholder, on behalf of itself and each Releasor, understands that he, she or it may hereafter discover facts different from what he, she or it now believes to be true, which if known, could have materially affected this Agreement, but the Oculis Shareholder, on behalf of itself and each Releasor, nevertheless waives any claims or rights based on different or additional facts.

 

Each Oculis Shareholder, on behalf of itself and each Releasor, assumes the risk of any mistake of fact or applicable Law with regard to any potential claim or with regard to any of the facts that are now unknown to it relating thereto. Each Oculis Shareholder, on behalf of itself and each Releasor, acknowledges and agrees that the foregoing waiver is an essential and material term of the release provided pursuant to this Section 4 and that, without such waiver, each of EBAC, New Parent and Oculis would not have agreed to the terms of this Agreement. Each Oculis Shareholder, on behalf of itself and each Releasor, represents and warrants that no Releasor has transferred or otherwise alienated any of the claims or causes of action released herein.

 

7.General Provisions

 

7.1Taxes and Expenses

 

Unless provided otherwise herein, each Party shall bear all Taxes, costs and expenses incurred by it in connection with the negotiation, execution and consummation of this Agreement or for which it is statutorily liable.

 

7.2No Set-Off

 

No Party may set off any claim or payment under or in connection with this Agreement with any counterclaim.

 

7.3Termination

 

This Agreement shall terminate upon the termination of the BCA in accordance with its terms prior to the consummation of the Transaction. No such termination shall relieve any Oculis Shareholder from any obligation accruing, or liability resulting from an intentional breach of this Agreement occurring prior to such termination.

 

 

Oculis Shareholder Support Agreement12/ 27
  

 

7.4Notices

 

All notices and other communications to be given under or in connection with this Agreement shall be made in writing and shall be delivered by registered mail (return receipt requested) or by an internationally recognized courier, in all cases additionally in advance by e-mail, to the following address:

 

If to EBAC to:

 

European Biotech Acquisition Corp.
EPFL Innovation Park Building D
1015 Lausanne
Switzerland 

Attention: Eduardo Bravo
Email: eduardo.bravo@eqtpartners.com

 

with a copy to (which shall not constitute notice to EBAC):

 

Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, New York 10017 

Attention: Michael Davis
  Derek Dostal
Email: michael.davis@davispolk.com
  derek.dostal@davispolk.com

 

If to Oculis or, after the Acquisition Closing Date, New Parent to:

 

Oculis SA
EPFL Innovation Park Building D
1015 Lausanne
Switzerland 

Attention: Riad Sherif
Email: riad.sherif@oculis.com

 

with a copy to (which shall not constitute notice to Oculis or New Parent):

 

Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ
UK 

Attention: Michal Berkner
  Divakar Gupta
  Ryan Sansom
E-mail: mberkner@cooley.com
  dgupta@cooley.com
  rsansom@cooley.com

 

and

 

 

Oculis Shareholder Support Agreement13/ 27
  

 

 

VISCHER AG
Aeschenvorstadt 4
4010 Basel
Switzerland 

Attention: Matthias Staehelin
  Vincent Reardon
E-mail: mstaehelin@vischer.com
  vreardon@vischer.com

 

If to any Oculis Shareholder to the address included in the share register of Oculis SA attached as Annex A.

 

Each Party may at any time change its address by giving notice to Oculis and EBAC in the manner described above.

 

7.5Legal Successors and Assignment

 

This Agreement and all of the provisions hereof shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned, directly or indirectly by any Party without the prior written consent of the other Parties; provided, that (a) an Oculis Shareholder shall be permitted to transfer the rights and obligations under this Agreement together with all Oculis Shares held to an acquirer if such transfer of Oculis Shares shall be in line and compliance with the Oculis Shareholders' Agreement and (b) EBAC shall be permitted, without the consent of the Oculis Shareholder, to make an assignment of any or all of its rights and interests hereunder to New Parent, Oculis or an Affiliate thereof following the Acquisition Closing Date; provided, that, such successors or permitted assignees agree in writing to be bound by terms and obligations of this Agreement and any other agreement contemplated in the BCA to which the Oculis Shareholder is party to pursuant to a joinder in form and substance reasonably acceptable to EBAC, New Parent and Oculis. Any purported assignment in violation of this Section 7.5 shall be null and void ab initio.

 

7.6Waiver

 

The failure of any of the Parties to enforce any of the provisions of this Agreement or any rights with respect thereto shall (a) in no way be considered as a waiver of such provisions or rights and (b) not in any way affect the validity of this Agreement. The waiver of any breach of agreement by any Party shall not operate to be construed as a waiver of any other prior or subsequent breach.

 

7.7Acknowledgment

 

Each Oculis Shareholder acknowledges and agrees that such Oculis Shareholder is entering into this Agreement on its own free will and not under any duress or undue influence. Each Oculis Shareholder Has entered into this Agreement freely and without coercion. Each Oculis Shareholder has been advised by each of EBAC, New Parent and Oculis to consult with counsel of such Oculis Shareholder’s choice with regard to the execution of this Agreement and the covenants included herein.

 

 

Oculis Shareholder Support Agreement14/ 27
  

 

Each Oculis Shareholder has had an adequate opportunity to consult with such counsel and either so consulted or freely determined in such Oculis' Shareholder’s own discretion not to so consult with such counsel. Such Oculis Shareholder understands that each of EBAC, new Parent and Oculis has been advised by counsel. Each Oculis Shareholder confirms to have read this Agreement and the business combination agreement (BCA) and fully and completely understands this Agreement and the business combination agreement (BCA) and each of such Oculis Shareholder’s representations, warranties, covenants and other agreements hereunder and thereunder. EACH Oculis Shareholder (i) has relied solely on his, her or its own investigation and analysis and the representations and warranties OF NEW PARENT, EBAC AND OCULIS expressly set forth in the BCA and in any Ancillary Agreement and (ii) acknowledges and agrees that (A) none of New Parent, EBAC or Oculis has made any other representation or warranty, either express or implied, in connection with or related to this Agreement, the BCA or any other Ancillary Agreement or the transactions contemplated hereby or thereby and (B) it has not relied, and is not relying on any other representations, warranties or other statements whatsoever, whether written or oral;

 

This agreement shall be interpreted and construed as having been drafted jointly by such Oculis Shareholder and each of EBAC, New Parent, Oculis and no presumption or burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of any or all of the provisions of this Agreement.

 

7.8Interpretation

 

Unless otherwise indicated to the contrary herein by the context or use thereof: (a) the words, "herein", "hereto", "hereof" and words of similar import refer to this Agreement as a whole, including the schedules hereto, and not to any particular section, subsection, paragraph, subparagraph or clause set forth in this Agreement; (b) masculine gender shall also include the feminine and neutral genders, and vice versa; (c) words importing the singular shall also include the plural, and vice versa; (d) the words "include", "includes" or "including" shall be deemed to be followed by the words "without limitation"; (e) references to "$" or "dollar" or "US$" shall be references to United States dollars; (f) the word "or" is disjunctive but not necessarily exclusive; (g) the words "writing", "written" and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form; (h) the word "day" means calendar day unless Business Day is expressly specified; (i) the word "extent" in the phrase "to the extent" means the degree to which a subject or other thing extends, and such phrase shall not mean simply "if"; (j) all references to Sections or schedules are to Sections and schedules of this Agreement; (k) all references to any Law will be to such Law as amended, supplemented or otherwise modified from time to time; and (l) all references to any Contract are to that Contract as amended or modified from time to time in accordance with the terms thereof (subject to any restrictions on amendments or modifications set forth in this Agreement). If any action under this Agreement is required to be done or taken on a day that is not

 

 

Oculis Shareholder Support Agreement15/ 27
  

 

a Business Day, then such action shall be required to be done or taken not on such day but on the first succeeding Business Day thereafter. The headings set forth in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.

 

7.9Counterparts; Electronic Signatures Interpretation

 

This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile, e-mail in .pdf or .tif format (and including any electronic signature complying with the U.S. ESIGN Act of 2000, e.g., www.docusign.com), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by combination of such means, shall be as effective as delivery of a manually executed counterpart of the Agreement. Minor variations in the form of the signature page, including footers from earlier versions of this Agreement or any such other document, will be disregarded in determining a Party’s intent or the effectiveness of such signature.

 

7.10Severability

 

Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under applicable Law, all other provisions of this Agreement shall remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision of this Agreement is invalid, illegal or unenforceable under applicable Law, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible.

 

7.11Amendment

 

This Agreement (including this Section 7.11) may be amended or modified only by a written agreement executed and delivered by (a) EBAC, New Parent and Oculis on the one hand, and such Oculis Shareholder, on the other hand, prior to the Acquisition Date Closing and (b) the Sponsor, New Parent and Oculis, on the one hand, such Oculis Shareholder, on the other hand, after the Acquisition Date Closing; provided, however, that none of the provisions that survive the Closing shall be amended or modified without the prior written consent of the Sponsor. This Agreement may not be modified or amended except as provided in the immediately preceding sentence and any purported amendment by any party or parties effected in a manner which does not comply with this Section 7.11 shall be void, ab initio.

 

7.12Entire Agreement; No Third Party Beneficiaries

 

The agreement of the Parties that is comprised of this Agreement and the provisions of the BCA above in Section 4, to which such Oculis Shareholder has expressly agreed to be bound, constitute the entire agreement and understanding among the parties hereto with respect to the subject matter hereof and thereof and supersedes all other

 

 

Oculis Shareholder Support Agreement16/ 27
  

 

prior agreements and understandings, both oral and written, relating to the subject matter of this Agreement, and is not intended to confer upon any Person other than the Parties any rights or remedies hereunder; provided, however, that the Company Released Parties and the Sponsor are express third party beneficiaries of this Agreement and shall each be entitled to enforce this Agreement as if they were original signatories hereto. For the avoidance of doubt, this Agreement does not and shall not affect any prior understandings, agreements or representations with respect to any similar subject matter entered into in connection with or as a result of the Oculis Shareholder’s ownership of Oculis Shares.

 

7.13No Ownership Interest

 

Nothing contained in this Agreement shall in and of itself be deemed to vest in EBAC or New Parent any direct or indirect ownership or incidence of ownership of or with respect Oculis Shares held by any Oculis Shareholder. All rights, ownership and economic benefits (but excluding, for the avoidance of doubt, any voting rights to the extent described herein) of and relating to the Oculis Shares of each Oculis Shareholder shall remain fully vested in and belong to any such Oculis Shareholder until the consummation of the Transactions, and neither EBAC nor New Parent shall have no authority to direct such Oculis Shareholder in the voting or disposition of any of Oculis Shares, except as otherwise provided herein.

 

7.14Capacity as a Shareholder

 

Notwithstanding anything herein to the contrary, each Oculis Shareholder signs this Agreement solely in such Oculis Shareholder’s capacity as shareholder of Oculis and not in any other capacity (including as an officer, employee, agent or director of Oculis) and this Agreement shall not limit or otherwise affect the actions of such Oculis Shareholder (or any affiliate, employee or designee of such Oculis Shareholder) in his or her capacity, if applicable, as an officer, employee, agent or director of Oculis or any other Person.

 

7.15         Shareholders' Agreement

 

For clarity, each Oculis Shareholder takes notes and agrees that with the exchange of its Oculis shares into New Parent Shares at the Acquisition Closing Date, such Oculis Shareholder ceases to be a party of the Shareholders' Agreement regarding Oculis.

 

8.Governing Law / Arbitration

 

8.1Governing Law

 

This Agreement, and all claims or causes of action based upon, arising out of, or related to this Agreement or the Transactions, shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without giving effect to any choice of law or conflict of Laws provisions to the extent such principles or rules would require or permit the application of Laws of another jurisdiction.

 

8.2Jurisdiction

 

Any dispute, controversy or claim arising out of, or in relation to, this Agreement, including the validity, invalidity, breach, or termination thereof, must be brought in the Court of Chancery of the State of Delaware (or, to the extent such court does not

 

 

Oculis Shareholder Support Agreement17/ 27
  

 

have subject matter jurisdiction, the Superior Court of the State of Delaware), or, if it has or can acquire jurisdiction, in the United States District Court for the District of Delaware, and each of the parties irrevocably (a) submits to the exclusive jurisdiction of each such court in any such proceeding or Action, (b) waives any objection it may now or hereafter have to personal jurisdiction, venue or to convenience of forum, (c) agrees that all claims in respect of the proceeding or Action shall be heard and determined only in any such court, and (d) agrees not to bring any proceeding or Action arising out of or relating to this Agreement or the Transactions in any other court. Nothing herein contained shall be deemed to affect the right of any party to serve process in any manner permitted by Law or to commence Legal Proceedings or otherwise proceed against any other party in any other jurisdiction, in each case, to enforce judgments obtained in any Action, suit or proceeding brought pursuant to this Section 8.2.

 

EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY BE BASED ON, ARISE UNDER OR RELATE TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THE BUSINESS COMBINATION AGREEMENT (BCA) IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY, UNCONDITIONALLY AND VOLUNTARILY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM, DEMAND, ACTION, SUIT, PROCEEDING OR CAUSE DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS.

 

8.3Enforcement

 

The Parties hereto agree that irreparable damage could occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. The parties accordingly acknowledge and agree that the Parties shall be entitled to seek an injunction or injunctions, specific performance or other equitable relief to prevent any breach, or threatened breach, of this Agreement and to specific enforcement of the terms and provisions of this Agreement in any court in the United States or in any state or province having jurisdiction over the Parties, in addition to any other remedy to which any party is entitled at law or in equity. In the event that any action shall be brought in equity to enforce the provisions of this Agreement, no party shall allege, and each party hereby waives the defense, that there is an adequate remedy at law, and each party agrees to waive any requirement for the securing or posting of any bond in connection therewith.

 

8.4Non-Recourse

 

Except in the case of claims against a Person in respect of such Person’s actual fraud:

 

a)Solely with respect to Oculis and EBAC, this Agreement may only be enforced against, and any claim or cause of action based upon, arising out of, or related to this Agreement or the Transactions may only be brought against, Oculis and EBAC as named parties hereto; and

 

b)except to the extent a Party hereto (and then only to the extent of the specific obligations undertaken by such party hereto), (i) no past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate,

 

 

Oculis Shareholder Support Agreement18/ 27
  

 

agent, attorney, advisor or representative or Affiliate of Oculis or EBAC and (ii) no past, present or future director, officer, employee, incorporator, member, partner, stockholder, Affiliate, agent, attorney, advisor or representative or Affiliate of any of the foregoing shall have any liability (whether in contract, tort, equity or otherwise) for any one or more of the representations, warranties, covenants, agreements or other obligations or liabilities of any one or more of Oculis or EBAC under this Agreement for any claim based on, arising out of, or related to this Agreement or the Transactions.

 

[Remainder of this page intentionally left blank]

 

 

Oculis Shareholder Support Agreement19/ 27
  

 

Signatures

 

Place Date

 

Oculis SA

 

Signature Signature
Name   Name
Title   Title

 

Place   Date

 

European Biotech Acquisition Corp.

 

Signature Signature
Name   Name
Title   Title

 

Place   Date

 

 

 

Oculis Shareholder Support Agreement20/ 27
  

 

Name of Shareholder: ___________________

 

Signature Signature
Name   Name
Title   Title

 

 

 

Oculis Shareholder Support Agreement21/ 27
  

 

Annexes

 

Annex A Share Register of Oculis
Annex 1 Definitions
Annex 5.3 Dividend Sample Calculation
Annex 5.5 Convertible Loan Agreement

 

 

Oculis Shareholder Support Agreement22/ 27
  

 

 

Annex A

 

Share Register of Oculis

 

 

Oculis Shareholder Support Agreement23/ 27
  

 

 

Annex 1

 

Definitions

 

Acquisition Closing shall have the meaning set forth in the BCA.
Acquisition Closing Date shall have the meaning set forth in the BCA.
Action shall have the meaning set forth in the BCA.
Affiliate shall have the meaning set forth in the BCA.
Agreement shall mean this agreement including its Annexes.
Ancillary Agreement shall have the meaning set forth in the BCA.
Annex means an annex to this Agreement.
BCA shall have the meaning set forth in recital B.
Borrower shall have the meaning set forth in the Convertible Loan Agreement(s).
CLA Investors shall have the meaning set forth in in recital D.
Confidential Information means all information (regardless of whether specifically identified as confidential), in any form or medium that relates to the business, products, operations, financial condition, services, research or development of any Group Company, or their customers, development partners, commercialization partners, vendors, suppliers, independent contractors or other business relations, including: (a) internal business information (including information relating to strategic plans and practices, business, accounting, financial or marketing plans, practices or programs, training practices and programs, salaries, bonuses, incentive plans and other compensation and benefits information and accounting and business methods); (b) identities of, individual requirements of, specific contractual arrangements with, and information about any Group Company and their customers, development partners, commercialization partners, suppliers, licensees, licensors, or other business relations of Group Company and confidential information; (c) industry research compiled by, or on behalf of any Group Company, including identities of potential target companies, management teams,

 

 

Oculis Shareholder Support Agreement24/ 27
  

 

  and transaction sources identified by, or on behalf of, any Group Company; (d) compilations of data and analyses, processes, methods, track and performance records, data and databases relating thereto; (e) personally identifiable information of any Group Company's customers, development partners, commercialization partners; (f) information related to the any Group Company's Intellectual Property Rights and updates of any of the foregoing and (g) the existence or contents of this Agreement; provided, however, that "Confidential Information" shall not include any information that (A) is or becomes generally available to the public other than as a result of the Oculis Shareholder’s or the Oculis Shareholder’s Affiliates’ acts or omissions in violation hereof, (B) becomes available to the Oculis Shareholder on a non-confidential basis from a source other than a Group Company, provided, that, such source is not bound by a confidentiality agreement with, or other contractual, legal or fiduciary obligation of confidentiality to, any Group Company or any other party with respect to such information, or (C) is or was independently developed by the Oculis Shareholder without use of or reference to any Confidential Information (as evidenced by contemporaneous records).
Convertible Loan Agreement(s) shall have the meaning set forth in Section 5.5.
EBAC shall have the meaning set forth in recital B.
First Merger shall have the meaning set forth in the BCA.
First Merger Effective Time shall have the meaning set forth in the BCA.
Governing Documents shall have the meaning set forth in the BCA.
Governmental Authority shall have the meaning set forth in the BCA.
Group Company Shall mean EBAC, New Parent, Oculis and any Affiliate of EBAC, New Parent and Oculis.
Law(s) shall have the meaning set forth in the BCA.
Lien shall have the meaning set forth in the BCA.
New Parent shall have the meaning set forth in the introduction of this Agreement.

 

 

Oculis Shareholder Support Agreement25/ 27
  

 

New Parent Shares shall have the meaning set forth in the BCA.
Oculis shall have the meaning set forth in the introduction of this Agreement.
Oculis Related Parties shall have the meaning set forth in Section 4.
Oculis Released Persons shall have the meaning set forth in Section 6.
Oculis Shareholder shall have the meaning set forth in the introduction of this Agreement.
Oculis Shareholders' Agreement shall have the meaning set forth in recital A.
Oculis Shares shall have the meaning set forth in Section 2.1 b).
Party shall have the meaning set forth in the introduction of this Agreement.
PIPE Investor shall have the meaning set forth in the BCA.
Registration Rights Agreement shall have the meaning set forth in the BCA.
Released Claims shall have the meaning set forth in Section 6.
Releasor shall have the meaning set forth in Section 6.
Second Merger Effective Time shall have the meaning set forth in the BCA.
Series B Preferred Shares shall mean the Series B Preferred Shares issued by Oculis as listed in Annex A.
Series C Preferred Shares shall mean the Series C Preferred Shares issued by Oculis as listed in Annex A.
Sponsor shall have the meaning set forth in the BCA.
Subscription Agreement shall have the meaning set forth in the BCA.
Surviving EBAC Shares shall have the meaning set forth in the BCA.
Taxes shall have the meaning set forth in the BCA.
Transactions shall have the meaning set forth in the BCA.

 

 

Oculis Shareholder Support Agreement26/ 27
  

 

 

Annex 5.3

 

Dividend Sample Calculation

 

 

Oculis Shareholder Support Agreement27/ 27
  

 

 

 

Annex 5.5

 

Convertible Loan Agreement

 

 

 

 

 

 

 

Exhibit 10.5

 

October 17, 2022

 

European Biotech Acquisition Corp.
Johannes Vermeerplein 9

Amsterdam, P7 1071 DV

 

Oculis SA

EPFL Innovation Park Building D

1015 Lausanne

Switzerland

 

Ladies and Gentlemen:

 

Re: Sponsor Support Agreement (“Sponsor Letter Agreement”)

 

Reference is made to that certain Business Combination Agreement, dated as of October 17, 2022 (as amended, the “Business Combination Agreement”) by and between European Biotech Acquisition Corp., a Cayman Islands exempted company (including any successor entity thereto, “EBAC”) and Oculis SA, a public limited liability company (société anonyme) incorporated and existing under the laws of Switzerland (the “Company”). Any capitalized term used but not defined herein will have the meanings ascribed thereto in the Business Combination Agreement.

 

As of the date of this Sponsor Letter Agreement, LSP Sponsor EBAC B.V., a Dutch limited liability company (“Sponsor”) is the record and beneficial owner of 3,188,696 shares of EBAC Class B Common Stock (the “Founder Shares”).

 

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Sponsor, the Company and EBAC agree as follows:

 

1.             Redemption and Voting.

 

(a)            Sponsor agrees that if EBAC seeks shareholder approval of the transactions contemplated by the Business Combination Agreement, Sponsor shall not redeem any Founder Shares or EBAC Class A Common Stock it Beneficially Owns (as defined in the Exchange Act) in connection with shareholder approval of the transactions contemplated by the Business Combination Agreement (the “Proposed Transaction”).

 

(b)            Prior to the earlier of (x) date on which this Sponsor Letter Agreement is terminated in accordance with its terms and (y) the Acquisition Closing (the “Voting Period”), at each meeting of the holders of EBAC Common Stock (the “EBAC Shareholders”), and in each written consent or resolutions of any of the EBAC Shareholders in which Sponsor is entitled to vote or consent, Sponsor hereby unconditionally and irrevocably agrees to vote (in person or by proxy), or consent to any action by written consent or resolution with respect to,

 

 

 

as applicable, the Founder Shares or other equity interests of EBAC over which Sponsor has voting power (i) in favor of, and to adopt, the Business Combination Agreement, the Ancillary Agreements and the transactions contemplated thereby, (ii) in favor of the other matters set forth in the Business Combination Agreement to the extent required for EBAC to carry out its obligations thereunder, and (iii) in opposition to: (A) any Acquisition Proposal and any and all other proposals (1) that could reasonably be expected to delay or impair the ability of EBAC to consummate the transactions contemplated by the Business Combination Agreement or any Ancillary Agreement or (2) which are in competition with or materially inconsistent with the Business Combination Agreement or any Ancillary Agreement or (B) any other action or proposal involving EBAC or any of its Subsidiaries that is intended, or would reasonably be expected, to prevent, impede, interfere with, delay, postpone or adversely affect in any material respect the transactions contemplated by the Business Combination Agreement or any Ancillary Agreement or would reasonably be expected to result in any of the conditions to EBAC’s obligations under the Business Combination Agreement not being fulfilled.

 

(c)            Sponsor agrees not to deposit, and to cause its Affiliates not to deposit, any Founder Shares in a voting trust or subject any Founder Shares to any arrangement or agreement with respect to the voting of such Founder Shares, unless specifically requested to do so by the Company and EBAC in connection with the Business Combination Agreement, the Ancillary Agreements or the transactions contemplated thereby.

 

(d)            Sponsor agrees, except as contemplated by the Business Combination Agreement or any Ancillary Agreement, not to make, or in any manner participate in, directly or indirectly, a “solicitation” of “proxies” or consents (as such terms are used in the rules of the SEC) or powers of attorney or similar rights to vote, or seek to advise or influence any Person with respect to the voting of, any equity interests of EBAC in connection with any vote or other action with respect to transactions contemplated by the Business Combination Agreement or any Ancillary Agreement, other than to recommend that the EBAC Shareholders vote in favor of the adoption of the Business Combination Agreement, the Ancillary Agreements and the transactions contemplated thereby (and any actions required in furtherance thereof and otherwise as expressly provided in this Section 1).

 

(e)            Sponsor agrees that during the Voting Period it shall not, without EBAC’s and the Company’s prior written consent, (i) grant any proxies or powers of attorney with respect to any or all of the Founder Shares, (ii) take any action with the intent to prevent, impede, interfere with or adversely affect Sponsor’s ability to perform its obligations under this Section 1 or (iii) effectuate the Transfer of any EBAC Common Stock or EBAC Warrants that Sponsor Beneficially owns. EBAC hereby agrees to reasonably cooperate with the Company in enforcing the transfer restrictions set forth in this Section 1. As used herein, “Transfer” shall mean the (i) sale of, offer to sell, contract or agreement

 

 

 

to sell, hypothecate, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Exchange Act and the rules and regulations of the SEC promulgated thereunder with respect to, any security, (ii) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (iii) public announcement of any intention to effect any transaction specified in clause (i) or (ii); provided that any Transfers (a) to EBAC’s officers or directors, any affiliates or family member of any of EBAC’s officers or directors, any members or partners of the Sponsor or their affiliates, any affiliates of the Sponsor, or any employees of such affiliates; (b) in the case of an individual, by gift to a member of one of the individual’s immediate family or to a trust, the beneficiary of which is a member of the individual’s immediate family, an affiliate of such person or to a charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers made in connection with the consummation of a Business Combination at prices no greater than the price at which the Founder Shares, private placement warrants, EBAC Class A Common Stock or EBAC Class B Common Stock, as applicable, were originally purchased; (f) by virtue of the Sponsor’s organizational documents upon liquidation or dissolution of the Sponsor; (g) to EBAC for no value for cancellation in connection with the consummation of its initial Business Combination, (h) in the event of EBAC’s liquidation prior to the completion of its initial Business Combination; (i) to EBAC Shareholders in connection with executing a Non-Redemption Agreement or (j) in the event of completion of a liquidation, merger, share exchange or other similar transaction which results in all of EBAC’s public shareholders having the right to exchange their EBAC Class A Common Stock for cash, securities or other property subsequent to the completion of an initial Business Combination shall not be deemed a “Transfer” for purposes hereunder.

 

(f)            In the event of any equity dividend or distribution, or any change in the equity interests of EBAC by reason of any equity dividend or distribution, equity split, recapitalization, combination, conversion, exchange of equity interests or the like, the term “Founder Shares” shall be deemed to refer to and include the Founder Shares as well as all such equity dividends and distributions and any securities into which or for which any or all of the Founder Shares may be changed or exchanged or which are received in such transaction.

 

(g)            During the Voting Period, Sponsor agrees to provide to EBAC, the Company and their respective Representatives any information regarding Sponsor or the Founder Shares that is reasonably requested by EBAC, the Company or their respective Representatives and required in order for the Company and EBAC to comply with Sections 9.01, 9.02 and 9.04 of the Business Combination Agreement. To the extent required by applicable Law, Sponsor hereby authorizes

 

 

 

the Company and EBAC to publish and disclose in any announcement or disclosure required by the SEC, Nasdaq or the Registration Statement (including all documents and schedules filed with the SEC in connection with the foregoing), Sponsor’s identity and ownership of Founder Shares and the nature of Sponsor’s commitments and agreements under this Agreement, the Business Combination Agreement and any other Ancillary Agreements; provided that such disclosure is made in compliance with the provisions of the Business Combination Agreement.

 

2.             Waiver of Anti-Dilution Rights. Contingent upon and effective as of the Acquisition Closing, pursuant to Section 17.4 of EBAC’s Governing Document, the Sponsor, in its capacity as holder of a majority of the Founder Shares, hereby waives the adjustment to the Initial Conversion Ratio (as defined in EBAC’s Governing Documents) that would otherwise apply pursuant to Section 17.3 of EBAC’s Governing Documents in connection with the transactions contemplated by the Business Combination Agreement. For the avoidance of doubt, the foregoing waiver does not waive the Sponsor’s rights under Section 17.8 of the EBAC Governing Document, which provides that in no event may any Founder Share convert into EBAC Class A Common Stock at a ratio that is less than one-for-one.

 

3.             This Sponsor Letter Agreement and the other agreements referenced herein constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersede all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Sponsor Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument executed by EBAC, or after the Acquisition Closing, Oculis Holding AG, a public limited liability company to be incorporated and existing after the date hereof under the laws of Switzerland and, before the Acquisition Closing, the Company and the other parties charged with such change, amendment, modification or waiver, it being acknowledged and agreed that the Company’s execution of such an instrument will not be required after any valid termination of the Business Combination Agreement.

 

4.             No party hereto may, except as set forth herein, assign either this Sponsor Letter Agreement or any of its rights, interests, or obligations hereunder without the prior written consent of the other parties. Any purported assignment in violation of this Section shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee. This Sponsor Letter Agreement shall be binding on, and inure to the benefit of, the Sponsor, EBAC and the Company and their respective successors, heirs, personal representatives and assigns and permitted transferees.

 

5.             Any notice, consent or request to be given in connection with any of the terms or provisions of this Sponsor Letter Agreement shall be in writing and shall be sent or given in accordance with the terms of Section 12.03 of the Business Combination Agreement to the applicable party at its principal place of business. Any notice to the Sponsor shall be sent to the address set forth on the signature page hereto.

 

 

 

6.             This Sponsor Letter Agreement shall terminate at such time, if any, as the Business Combination Agreement is terminated in accordance with its terms prior to the Acquisition Closing. In the event of a valid termination of the Business Combination Agreement, this Sponsor Letter Agreement shall be of no force and effect. No such termination or reversion shall relieve the Sponsor, EBAC or the Company from any obligation accruing, or liability resulting from an intentional breach of this Sponsor Letter Agreement occurring prior to such termination or reversion.

 

7.             Each of the parties hereto represents and warrants that (a) it has the power and authority, or capacity, as the case may be, to enter into this Sponsor Letter Agreement and to carry out its obligations hereunder, (b) the execution and delivery of this Sponsor Letter Agreement and the performance of its obligations hereunder have been duly and validly authorized by all corporate or limited liability company action on its part and (c) this Sponsor Letter Agreement has been duly and validly executed and delivered by each of the parties hereto and constitutes, a legal, valid and binding obligation of each such party enforceable in accordance with its terms, except as such enforceability may be limited by bankruptcy Laws, other similar Laws affecting creditors’ rights and general principles of equity affecting the availability of specific performance and other equitable remedies.

 

8.             Each of the parties hereto agrees to execute and deliver hereafter any further document, agreement or instrument of assignment, transfer or conveyance as may be necessary or desirable to effectuate the purposes hereof and as may be reasonably requested in writing by another party hereto.

 

9.             Sections 12.05, 12.07, 12.08 and 12.12 through 12.15 of the Business Combination Agreement shall apply mutatis mutandis to this Sponsor Letter Agreement.

 

[Signature page follows]

 

 

 

 

  Sincerely,
   
   
  LSP SPONSOR EBAC B.V.
   
   
  By:  
    Name:
    Title:

 

 

Email:

[●]

  Address: [●]
    [●]

 

 

[Signature Page to Sponsor Letter Agreement]

 

 

 

Acknowledged and Agreed:

 

 

EUROPEAN BIOTECH ACQUISITION CORP.

 

 

  By:  
    Name:
    Title:

 

 

[Signature Page to Sponsor Letter Agreement]

 

 

 

Acknowledged and Agreed:

 

OCULIS SA

 

 

 
By:    
  Name:  
  Title:  

 

 

[Signature Page to Sponsor Letter Agreement]

 

 

 

 

 

 

Exhibit 10.6

 

 

 

 

 

AMENDED AND RESTATED REGISTRATION RIGHTS AND LOCK-UP AGREEMENT

 

by and among

 

OCULIS HOLDING AG

 

and

 

THE SHAREHOLDERS THAT ARE SIGNATORIES HERETO

 

Dated as of [·], 2022

 

 

 

 

 

 

 

 

Table of Contents

 

Page

 

Section 1. Certain Definitions 2
Section 2. Registration Rights. 6
2.1. Demand Registrations. 6
2.2. Piggyback Registrations. 11
2.3. Allocation of Securities Included in Registration Statement. 12
2.4. Registration Procedures 14
2.5. Registration Expenses. 21
2.6. Certain Limitations on Registration Rights 21
2.7. Limitations on Sale or Distribution of Other Securities 22
2.8. No Required Sale 22
2.9. Indemnification. 22
2.10. No Inconsistent Agreements 26
Section 3. Underwritten Offerings. 26
3.1. Requested Underwritten Offerings 26
3.2. Piggyback Underwritten Offerings 27
Section 4. Lock-Up Agreements. 27
4.1. Transfer Restrictions. 27
4.2. Exceptions. 27
Section 5. General. 30
5.1. Adjustments Affecting Registrable Securities 30
5.2. Rule 144 30
5.3. Nominees for Beneficial Owners 30
5.4. Amendments and Waivers 30
5.5. Notices 30
5.6. Successors and Assigns 31
5.7. Termination. 32
5.8. Entire Agreement 32
5.9. Governing Law; Jurisdiction; Waiver of Jury Trial. 32
5.10. Interpretation; Construction. 33
5.11. Counterparts 33

 

-i-

 

Table of Contents

(continued)

 

Page

 

5.12. Severability 33
5.13. Specific Enforcement 33
5.14. Further Assurances 33
5.15. Confidentiality 34
5.16. Opt-Out Requests 34
5.17. Original Registration Rights Agreement 34

 

-ii-

 

AMENDED AND RESTATED REGISTRATION RIGHTS AND LOCK-UP AGREEMENT, dated as of [·], 2022 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), is made and entered into by and among (i) Oculis Holding AG, a public limited liability company incorporated and existing under the laws of Switzerland (the “Company”), (ii) the shareholders of the Company party hereto, as listed on Schedule 1 attached hereto (the “Shareholders”) and (iii) any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.6 of this Agreement (each, a “Holder” and collectively with the Shareholders, the “Holders”).

 

RECITALS:

 

WHEREAS, European Biotech Acquisition Corp., a Cayman Islands exempted company (“EBAC”) and Oculis SA, a public limited liability company (société anonyme) incorporated and existing under the laws of Switzerland (“Oculis”), have entered into a Business Combination Agreement, dated as of [·], 2022 (as amended from time to time on or prior to the date hereof, the “Business Combination Agreement”);

 

WHEREAS, following the execution of the Business Combination Agreement, EBAC formed, or caused to be formed, (a) the Company, (b) [Merger Sub 1], a new Cayman Islands exempted company and a wholly owned subsidiary of the Company (“Merger Sub 1”), (c) [Merger Sub 2], another new Cayman Islands exempted company and a wholly owned subsidiary of the Company (“Merger Sub 2”) and (d)[Merger Sub 3], a new limited liability company (Gesellschaft mit beschränkter Haftung) incorporated and existing under the laws of Switzerland and a wholly owned subsidiary of the Company (“Merger Sub 3”);

 

WHEREAS, the Company, Merger Sub 1, Merger Sub 2 and Merger Sub 3 became a party to the Business Combination Agreement by executing a joinder thereto, and pursuant to the Business Combination Agreement, among other things, (a) Merger Sub 1 will merge with and into EBAC, with EBAC as the surviving corporation (the “First SPAC Merger”), (b) approximately 30 minutes after the consummation of the First SPAC Merger, EBAC will merge with and into Merger Sub 2, with Merger Sub 2 as the surviving company and remaining a wholly owned subsidiary of New Parent (the “Second SPAC Merger”), (c) after consummation of the Second SPAC Merger, consenting Oculis shareholders will contribute their shares of Oculis to New Parent in exchange for New Parent common shares (the “Company Share Contribution”, together with the First SPAC Merger and the Second SPAC Merger, the “Primary Transactions” and the closing of the Primary Transactions, the “Acquisition Closing” and such date, the “Closing Date”) and (d) approximately 30 days after the Closing Date, Oculis will merge with and into Merger Sub 3, with Merger Sub 3 as the surviving company and remaining a wholly owned subsidiary of New Parent (the “Third Merger” and together with the other transactions contemplated by the Business Combination Agreement, the “Mergers”);

 

WHEREAS, the Company and LSP Sponsor EBAC B.V., a Cayman Island limited liability company and a Shareholder (the “Sponsor”) are parties to that certain Registration and Shareholder Rights Agreement, dated as of March 15, 2021 (the “Original Registration Rights Agreement”), which shall be amended and restated by this Agreement;

 

 

 

WHEREAS, following the Acquisition Closing, the Sponsor and the other Shareholders owned Class A ordinary shares, par value $[●] per share of the Company (the “Class A Ordinary Shares”), Class A Ordinary Share Equivalents (as defined herein), Class B ordinary shares, par value $[●] per share of the Company (the “Class B Ordinary Shares”), which are convertible on a share for share basis into Class A Ordinary Shares, and/or Class B Ordinary Share Equivalents (as defined herein); and

 

WHEREAS, in connection with the Mergers, the Company has agreed to provide the registration rights set forth in this Agreement.

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants and obligations hereinafter set forth, the parties hereto hereby agree as follows:

 

Section 1.   Certain Definitions. As used herein, the following terms shall have the following meanings:

 

Additional Piggyback Rights” has the meaning ascribed to such term in Section 2.6(a).

 

Affiliate” means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with, such Person. For the purposes of this definition “control” (including, with correlative meanings, the terms “controlling”, “controlled by” and “under common control with”), with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such specified Person, whether through the ownership of voting securities, by contract or otherwise. For the avoidance of doubt, neither the Company nor any Person controlled by the Company shall be deemed to be an Affiliate of any Holder.

 

Agreement” has the meaning ascribed to such term in the Preamble.

 

Automatic shelf registration statement” has the meaning ascribed to such term in Section 2.4.

 

Board” means the Board of Directors of the Company.

 

“Business Combination Agreement” has the meaning ascribed to such term in the Recitals.

 

Business Day” means a day, other than Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law to close.

 

Claims” has the meaning ascribed to such term in Section 2.9(a).

 

Class A Ordinary Shares” has the meaning ascribed to such term in the recitals.

 

Class A Ordinary Share Equivalents” means all Class B Ordinary Shares, all Class B Ordinary Share Equivalents, and all options, warrants and other securities convertible into, or exchangeable or exercisable for (at any time or upon the occurrence of any event or contingency and without regard to any vesting or other conditions to which such securities may be subject),

 

2 

 

Class A Ordinary Shares (including any note or debt security convertible into or exchangeable for Class A Ordinary Shares).

 

Class B Ordinary Shares” has the meaning ascribed to such term in the recitals.

 

Class B Ordinary Share Equivalents” means all options, warrants and other securities convertible into, or exchangeable or exercisable for (at any time or upon the occurrence of any event or contingency and without regard to any vesting or other conditions to which such securities may be subject), Class B Ordinary Shares (including any note or debt security convertible into or exchangeable for Class B Ordinary Shares).

 

Company” has the meaning ascribed to such term in the Preamble.

 

Confidential Information” has the meaning ascribed to such term in Section 5.15.

 

Demand Exercise Notice” has the meaning ascribed to such term in Section 2.1(b)(i).

 

Demand Registration” has the meaning ascribed to such term in Section 2.1(b)(i).

 

Demand Registration Period” has the meaning ascribed to such term in Section 2.1(b)(i).

 

Demand Registration Request” has the meaning ascribed to such term in Section 2.1(b)(i).

 

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC issued under such Act, as they may from time to time be in effect.

 

Expenses” means any and all fees and expenses incident to the Company’s performance of or compliance with Section 2, including: (i) SEC, stock exchange, FINRA and all other registration and filing fees and all listing fees and fees with respect to the inclusion of securities on the Nasdaq or on any other U.S. or non-U.S. securities market on which the Registrable Securities are listed or quoted, (ii) fees and expenses of compliance with state securities or “blue sky” laws of any state or jurisdiction of the United States or compliance with the securities laws of foreign jurisdictions and in connection with the preparation of a “blue sky” survey, including reasonable fees and expenses of outside “blue sky” counsel and securities counsel in foreign jurisdictions, (iii) word processing, printing and copying expenses, (iv) messenger and delivery expenses, (v) expenses incurred in connection with any road show, (vi) fees and disbursements of counsel for the Company, (vii) with respect to each registration or underwritten offering, the reasonable fees and disbursements of one counsel for the Initiating Holder and all other Participating Holder(s) collectively (selected by the holders of a majority of the Registrable Securities held by the Initiating Holder and such other Participating Holder(s)), together in each case with any local counsel, provided that expenses payable by the Company pursuant to this clause (vii) shall not exceed (1) $75,000 for the first registration pursuant to this Agreement and (2) $50,000 for each subsequent registration, (viii) fees and disbursements of all independent public accountants (including the expenses of any opinion and/or audit/review and/or “comfort” letter and updates thereof) and fees and expenses of other Persons, including special experts, retained by the Company, (ix) fees and expenses payable to a Qualified Independent Underwriter (but expressly excluding any underwriting discounts and commissions), (x) fees and expenses of

 

3 

 

any transfer agent or custodian, (xi) any other fees and disbursements of underwriters, if any, customarily paid by issuers or sellers of securities, including reasonable fees and expenses of counsel for the underwriters in connection with any filing with or review by FINRA (but expressly excluding any underwriting discounts and commissions) and (xii) rating agency fees and expenses.

 

Final Merger” has the meaning ascribed to such term in the Recitals.

 

FINRA” means the Financial Industry Regulatory Authority, Inc.

 

Initial Merger” has the meaning ascribed to such term in the Recitals.

 

Initiating Holders” means (a) Holders of at least thirty percent (30%) of the Registrable Securities then outstanding or (b) the Sponsor.

 

Joinder Agreement” means a writing in the form set forth in Exhibit A hereto whereby a new Holder of Registrable Securities becomes a party to, and agrees to be bound, to the same extent as its transferor, as applicable, by the terms of this Agreement.

 

Majority Participating Holders” means Participating Holders holding more than 50% of the Registrable Securities proposed to be included in any offering of Registrable Securities by such Participating Holders pursuant to Section 2.1 or Section 2.2.

 

Manager” means the lead managing underwriter of an underwritten offering.

 

Merger Sub I” has the meaning ascribed to such term in the Recitals.

 

Merger Sub II” has the meaning ascribed to such term in the Recitals.

 

Mergers” has the meaning ascribed to such term in the Recitals.

 

Minimum Threshold” means $[40.0] million.

 

Opt-Out Request” has the meaning ascribed to such term in Section 5.16.

 

Ordinary Share” means existing or hereafter authorized Class A Ordinary Shares and Class B Ordinary Shares, and any class of ordinary shares of the Company and any and all securities of any kind whatsoever which may be issued after the date hereof in respect of, or in exchange for, such ordinary shares of the Company pursuant to a merger, consolidation, stock split, stock dividend or recapitalization of the Company or otherwise.

 

Participating Holders” means all Holders of Registrable Securities which are proposed to be included in any offering of Registrable Securities pursuant to Section 2.1 or Section 2.2.

 

Person” means any individual, firm, corporation, company, limited liability company, partnership, trust, joint stock company, business trust, incorporated or unincorporated association, joint venture, governmental authority or other legal entity of any nature whatsoever.

 

Piggyback Notice” has the meaning ascribed to such term in Section 2.2(a).

 

4 

 

Piggyback Shares” has the meaning ascribed to such term in Section 2.3(a)(ii).

 

Postponement Period” has the meaning ascribed to such term in Section 2.1(c).

 

Qualified Independent Underwriter” means a “qualified independent underwriter” within the meaning of FINRA Rule 5121.

 

Registrable Securities” means (a) any Class A Ordinary Shares held by the Holders at any time (including those held as a result of, or issuable upon, the conversion or exercise of Class A Ordinary Share Equivalents) or any other equity security other than Class B Ordinary Shares or Class B Ordinary Share Equivalents (including warrants to purchase Class A Ordinary Shares), whether now owned or acquired by the Holders at a later time, (b) any Class A Ordinary Shares or any other equity security other than Class B Ordinary Shares or Class B Ordinary Share Equivalents (including warrants to purchase Class A Ordinary Shares) issued or issuable, directly or indirectly, in exchange for or with respect to the Ordinary Shares or any other equity security (including warrants to purchase Class A Ordinary Shares) referenced in clause (a) above by way of stock dividend, stock split or combination of shares or in connection with a reclassification, recapitalization, merger, share exchange, consolidation or other reorganization and (c) any securities other than Class B Ordinary Shares or Class B Ordinary Share Equivalents issued in replacement of or exchange for any securities described in clause (a) or (b) above. Class B Ordinary Shares and Class B Ordinary Share Equivalents shall not constitute Registrable Securities hereunder, provided that the Class A Ordinary Shares issuable upon conversion of such Class B Ordinary Shares and underlying Class B Ordinary Share Equivalents are Registrable Securities for all purposes hereunder as though, in each case, such Class A Ordinary Shares were outstanding on the date hereof. For purposes of this Agreement, a Person will be deemed to be a holder of Registrable Securities whenever such Person has the right to acquire, directly or indirectly, such Registrable Securities (including upon conversion, exercise or exchange of any equity interests but disregarding any restrictions or limitations upon the exercise of such right), whether or not such acquisition has actually been effected, and such Person shall not be required to convert, exercise or exchange such equity interests (or otherwise acquire such Registrable Securities) to participate in any registered offering hereunder until the closing of such offering. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when (A) a registration statement with respect to the sale of such securities shall have been declared effective under the Securities Act and such securities shall have been disposed of in accordance with such registration statement, (B) such securities shall have been otherwise transferred, new certificates or book-entry positions for such securities not bearing a legend restricting further transfer shall have been delivered by the Company and subsequent public distribution of such securities shall not require registration under the Securities Act, (C) such securities may be sold without registration pursuant to Rule 144, (D) such securities have been sold in a public offering of securities or (E) such securities have ceased to be outstanding.

 

Rule 144” have the meaning ascribed to such term in Section 5.2.

 

SEC” means the U.S. Securities and Exchange Commission or such other federal agency which at such time administers the Securities Act.

 

Section 2.3(a) Sale Number” has the meaning ascribed to such term in Section 2.3(a).

 

5 

 

Section 2.3(b) Sale Number” has the meaning ascribed to such term in Section 2.3(b).

 

Section 2.3(c) Sale Number” has the meaning ascribed to such term in Section 2.3(c).

 

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations of the SEC issued under such Act, as they may from time to time be in effect.

 

Shelf Registrable Securities” has the meaning ascribed to such term in Section 2.1(a)(ii).

 

Shelf Registration Statement” has the meaning ascribed to such term in Section 2.1(a)(i).

 

Shelf Underwriting” has the meaning ascribed to such term in Section 2.1(a)(ii).

 

Shelf Underwriting Initiating Holders” has the meaning ascribed to such term in Section 2.1(a)(ii).

 

Shelf Underwriting Notice” has the meaning ascribed to such term in Section 2.1(a)(ii).

 

Shelf Underwriting Request” has the meaning ascribed to such term in Section 2.1(a)(ii).

 

Subsidiary” means any direct or indirect subsidiary of the Company on the date hereof and any direct or indirect subsidiary of the Company organized or acquired after the date hereof.

 

Underwritten Block Trade” has the meaning ascribed to such term in Section 2.1(a)(ii).

 

Valid Business Reason” has the meaning ascribed to such term in Section 2.1(c).

 

WKSI” means a “well-known seasoned issuer” (as defined in Rule 405 of the Securities Act).

 

Section 2.   Registration Rights.

 

2.1.   Demand Registrations.

 

(a)   (i) As soon as practicable but no later than thirty (30) Business Days following the Closing Date (the “Filing Date”), the Company shall prepare and file with the SEC a shelf registration statement under Rule 415 of the Securities Act (such registration statement, a “Shelf Registration Statement”) covering the resale of all the Registrable Securities (determined as of two Business Days prior to such filing) on a delayed or continuous basis and shall use its commercially reasonable efforts to have such Shelf Registration Statement declared effective as soon as practicable after the filing thereof and no later than the earlier of (x) the 60th calendar day (or the ninetieth (90th) calendar day if the SEC notifies the Company that it will “review” the Shelf Registration Statement) following the Closing Date and (y) the tenth (10th) business day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Shelf Registration Statement will not be “reviewed” or will not be subject to further review. Such Shelf Registration Statement shall provide for the resale of the Registrable Securities included therein pursuant to any method or combination of methods legally available to, and requested by, any Holder named therein. The Company shall maintain the Shelf Registration Statement in

 

6 

 

accordance with the terms hereof, and shall prepare and file with the SEC such amendments, including post-effective amendments, and supplements as may be necessary to keep a Shelf Registration Statement continuously effective, available for use to permit all Holders named therein to sell their Registrable Securities included therein and in compliance with the provisions of the Securities Act until such time as there are no longer any Registrable Securities. In the event the Company files a Shelf Registration Statement on Form F-1, the Company shall use commercially reasonable efforts to convert such Shelf Registration Statement to a Shelf Registration Statement on Form F-3 as soon as practicable after the Company is eligible to use Form F-3.

 

(ii)   Subject to Section 2.1(c) and the provisions below with respect to the Minimum Threshold, following the expiration of any applicable lock-up period, each Holder (or Holders) shall have the right at any time and from time to time to elect to sell all or any part of its Registrable Securities pursuant to an underwritten offering pursuant to the Shelf Registration Statement by delivering a written request therefor to the Company specifying the number of Registrable Securities to be included in such registration and the intended method of distribution thereof. The Holder or Holders shall make such election by delivering to the Company a written request (a “Shelf Underwriting Request”) for such underwritten offering specifying the number of Registrable Securities that the Holder or Holders desire to sell pursuant to such underwritten offering (the “Shelf Underwriting”). With respect to any Shelf Underwriting Request, the Holder or Holders making such demand shall be referred to as the “Shelf Underwriting Initiating Holders”. As promptly as practicable, but at least five (5) Business Days prior to the anticipated filing date of the prospectus or prospectus supplement relating to such Shelf Underwriting Request, the Company shall give written notice (the “Shelf Underwriting Notice”) of such Shelf Underwriting Request to the Holders of record of other Registrable Securities registered on such Shelf Registration Statement (“Shelf Registrable Securities”). The Company, subject to Sections 2.3 and 2.6, shall include in such Shelf Underwriting (x) the Registrable Securities of the Shelf Underwriting Initiating Holders and (y) the Shelf Registrable Securities of any other Holder of Shelf Registrable Securities which shall have made a written request to the Company for inclusion in such Shelf Underwriting (which request shall specify the maximum number of Shelf Registrable Securities intended to be disposed of by such Holder) within two (2) days after the receipt of the Shelf Underwriting Notice. The Company shall, subject to Section 2.1(b), use commercially reasonable efforts to effect such Shelf Underwriting as promptly as is reasonably practicable. The Company shall, at the request of any Shelf Underwriting Initiating Holder or any other Holder of Registrable Securities registered on such Shelf Registration Statement, file any prospectus supplement or, if the applicable Shelf Registration Statement is an automatic shelf registration statement, any post-effective amendments and otherwise take any action necessary to include therein all disclosure and language deemed necessary or advisable by the Shelf Underwriting Initiating Holders or any other Holder of Shelf Registrable Securities to effect such Shelf Underwriting. Notwithstanding anything to the contrary in this Section 2.2, each Shelf Underwriting must include, in the aggregate, Registrable Securities having an aggregate market value of at least the Minimum Threshold (based on the Registrable Securities included in such Shelf Underwriting by all Participating Holders). In connection with any Shelf Underwriting (including an Underwritten Block Trade), the Company shall have the right to designate the Manager and each other managing underwriter in connection with any such Shelf Underwriting or Underwritten Block Trade, subject to Shelf Underwriting Initiating Holders’ reasonable approval.

 

7 

 

Shelf Underwritings effected pursuant to this Section 2.1(a)(ii) shall be counted as Demand Registrations effected pursuant to Section 2.1(b).

 

Notwithstanding any other provision of this Article 2, if a Shelf Underwriting Initiating Holder wishes to engage in an underwritten block trade or similar transaction or other transaction with a 2-day or less marketing period (collectively, “Underwritten Block Trade”) off of a Shelf Registration Statement, then notwithstanding the foregoing time periods, such Shelf Underwriting Initiating Holder shall notify the Company of the Underwritten Block Trade three (3) Business Days prior to the day such offering is to commence and the Holders of record of other Registrable Securities shall not be entitled to notice of such Underwritten Block Trade and shall not be entitled to participate in such Underwritten Block Trade. The Holders shall use commercially reasonable efforts to work with the Company and the Underwriters (including by disclosing the maximum number of Registrable Securities proposed to be the subject of such Underwritten Block Trade) in order to facilitate preparation of the Registration Statement, Prospectus and other offering documentation related to the Underwritten Block Trade and any related due diligence and comfort procedures. In the event of a Underwritten Block Trade, and after consultation with the Company, the Demanding Holders and the Requesting Holders (if any) shall determine the maximum number of securities, the underwriter or underwriters and share price of such offering.

 

(b)   (i) At any time after the first anniversary of the Closing Date that a Shelf Registration Statement as required by Section 2.1(a) is not available for use by the Holders (a “Demand Registration Period”) other than pursuant to Section 2.1(c), subject to this Section 2.1(b) and Sections 2.1(c) and 2.3) and the provisions below with respect to the Minimum Threshold, at any time and from time to time during such Demand Registration Period, each Initiating Holder (or Initiating Holders) shall have the right to require the Company to effect one or more registration statements under the Securities Act covering all or any part of its Registrable Securities by delivering a written request therefor to the Company specifying the number of Registrable Securities to be included in such registration and the intended method of distribution thereof. Any such request by any Initiating Holder or Initiating Holders pursuant to this Section 2.1(b)(i) is referred to herein as a “Demand Registration Request,” and the registration so requested is referred to herein as a “Demand Registration”. Subject to Section 2.1(c), the Initiating Holders shall not be entitled to request (and the Company shall not be required to effect) (A) more than one (1) Demand Registration during any six-month period; (B) any Demand Registration at any time there is an effective Shelf Registration Statement on file with the Commission pursuant to Section 2.1; (C) more than three (3) Underwritten Demand Registrations in respect of all Registrable Securities held by Sponsor; or (D) more than three (3) Shelf Underwritings in respect of all Registrable Securities held by Shareholders in any 24-month period. The Company shall give written notice (the “Demand Exercise Notice”) of such Demand Registration Request to each of the Holders of record of Registrable Securities in accordance with Section 2.2, and, subject to Sections 2.3 and 2.6, shall include in a Demand Registration (x) the Registrable Securities of the Initiating Holders and (y) the Registrable Securities of any other Holder of Registrable Securities which shall have made a written request to the Company for inclusion in such registration pursuant to Section 2.2. Notwithstanding anything to the contrary in this Section 2.1(b)(i), each Demand Registration must include, in the aggregate, Registrable Securities having an aggregate market value of at least the Minimum Threshold (based on the Registrable Securities included in such Demand Registration by all Holders participating in such Demand Registration). In connection with any Demand

 

8 

 

Registration, the Company shall have the right to designate the Manager and each other managing underwriter in connection with any underwritten offering pursuant to such registration, subject to the Initiating Holders’ reasonable approval; provided that in each case, each such underwriter is reasonably satisfactory to the Company, which approval shall not be unreasonably withheld or delayed.

 

(ii)   The Company shall, as expeditiously as possible, but subject to Section 2.4(b), use commercially reasonable efforts to (x) file or confidentially submit with the SEC (no later than (A) sixty (60) days from the Company’s receipt of the applicable Demand Registration Request if the Demand Registration is on Form F-1 or similar long-form registration and or (B) thirty (30) days from the Company’s receipt of the applicable Demand Registration Request if the Demand Registration is on Form F-3 or any similar short-form registration), (y) cause to be declared effective as soon as reasonably practicable such registration statement under the Securities Act that includes the Registrable Securities which the Company has been so requested to register for distribution in accordance with the intended method of distribution, and (z) if requested by the Initiating Holders, obtain acceleration of the effective date of the registration statement relating to such registration.

 

(d)   Notwithstanding anything to the contrary in Section 2.1(a) or Section 2.1(b), the Shelf Underwriting and Demand Registration rights granted in Section 2.1 (a) and Section 2.1(b) are subject to the following limitations: (i) the Company shall not be required to cause a registration statement filed pursuant to Section 2.1(b) to be declared effective within a period of ninety (90) days after the effective date of any other registration statement of the Company filed pursuant to the Securities Act (other than a Form S-4, Form F-4, Form S-8 or a comparable form or an equivalent registration form then in effect); (ii) the Company shall not be required to effect more than two (2) Demand Registrations on Form F-1 or any similar long-form registration statement at the request of the Holders in the aggregate; (iii)  if the Board, in its good faith judgment, determines that any registration of Registrable Securities or Shelf Underwriting should not be made or continued because it would materially and adversely interfere with any existing or potential financing, acquisition, corporate reorganization, merger, share exchange or other transaction or event involving the Company or any of its subsidiaries or would otherwise result in the public disclosure of information that the Board in good faith has a bona fide business purpose for keeping confidential (a “Valid Business Reason”), then (x) the Company may postpone filing or confidentially submitting a registration statement relating to a Demand Registration Request or a prospectus supplement relating to a Shelf Underwriting Request until such Valid Business Reason no longer exists and will then file or submit such registration statement or prospectus supplement as soon as practicable thereafter or (y) if a registration statement has been filed or confidentially submitted relating to a Demand Registration Request or a prospectus supplement has been filed relating to a Shelf Underwriting Request, the Company may, to the extent determined in the good faith judgment of the Board to be reasonably necessary to avoid interference with any of the transactions described above, suspend use of or, if required by the SEC, cause such registration statement to be withdrawn and its effectiveness terminated or may postpone amending or supplementing such registration statement until such Valid Business Reason no longer exists and will then file or submit such registration statement or prospectus supplement as soon as practicable thereafter (such period of postponement or withdrawal under this clause (iv), the “Postponement Period”). The Company shall give written notice to the

 

9 

 

Initiating Holders or Shelf Underwriting Initiating Holders and any other Holders that have requested registration pursuant to Section 2.2 of its determination to postpone or suspend use of or withdraw a registration statement and of the fact that the Valid Business Reason for such postponement or suspension or withdrawal no longer exists, in each case, promptly after the occurrence thereof; provided, however, that the Company shall not be entitled to more than two (2) Postponement Periods during any twelve (12) month period.

 

Each Holder of Registrable Securities agrees that, upon receipt of any notice from the Company that the Company has determined to suspend use of, withdraw, terminate or postpone amending or supplementing any registration statement pursuant to clause (c)(iii) above, such Holder will discontinue its disposition of Registrable Securities pursuant to such registration statement. If the Company shall have suspended use of, withdrawn or terminated a registration statement filed under Section 2.1(b)(i) (whether pursuant to clause (c)(iii) above or as a result of any stop order, injunction or other order or requirement of the SEC or any other governmental agency or court), the Company shall not be considered to have effected a Demand Registration for the purposes of this Agreement and such request shall not count as a Demand Registration Request under this Agreement until the Company shall have permitted use of such suspended registration statement or filed a new registration statement covering the Registrable Securities covered by the withdrawn or terminated registration statement and such registration statement shall have been declared effective and shall not have been withdrawn. If the Company shall give any notice of suspension, withdrawal or postponement of a registration statement, the Company shall, as soon as reasonably practicable after the Valid Business Reason that caused such suspension, withdrawal or postponement no longer exists (but, with respect to a suspension, withdrawal or postponement pursuant to clause (c)(iii) above, in no event later than forty-five (45) days after the date of the suspension, postponement or withdrawal), as applicable, permit use of such suspended registration statement or use commercially reasonable efforts to effect the registration under the Securities Act of the Registrable Securities covered by the withdrawn or postponed registration statement in accordance with this Section 2.1 (unless the Initiating Holders or Shelf Underwriting Initiating Holders shall have withdrawn such request, in which case the Company shall not be considered to have effected a Demand Registration for the purposes of this Agreement and such request shall not count as a Demand Registration Request under this Agreement), and following such permission or such effectiveness such registration shall no longer be deemed to be suspended, withdrawn or postponed pursuant to clause (iv) of Section 2.1(c) above.

 

(e)   No Demand Registration shall be deemed to have occurred for purposes of Section 2.1(b) (i) if the registration statement relating thereto does not become effective, (ii) for each Initiating Holder, if less than seventy five percent (75%) of the Registrable Securities requested by such Initiating Holder to be included in such Demand Registration are not so included pursuant to Section 2.3, (iii) if the method of disposition is a firm commitment underwritten public offering and less than seventy five percent (75%) of the applicable Registrable Securities have not been sold pursuant thereto (excluding any Registrable Securities included for sale in the underwriters’ overallotment option) or (iv) if the conditions to closing specified in any underwriting agreement, purchase agreement or similar agreement entered into in connection with the registration relating to such request are not satisfied (other than as a result of a default or breach

 

10 

 

thereunder by such Initiating Holder(s) or its Affiliates or are otherwise waived by such Initiating Holder(s)).

 

(f)   Any Initiating Holder may withdraw or revoke a Demand Registration Request delivered by such Initiating Holder at any time prior to the effectiveness of such Demand Registration by giving written notice to the Company of such withdrawal or revocation and such Demand Registration shall have no further force or effect and such request shall not count as a Demand Registration Request under this Agreement.

 

2.2.   Piggyback Registrations.

 

(a)   If the Company proposes or is required to register any of its equity securities for its own account or for the account of any other shareholder under the Securities Act (other than pursuant to registrations on Form S-4, Form F-4, or Form S-8 or any similar successor forms thereto), the Company shall give written notice (the “Piggyback Notice”) of its intention to do so to each of the Holders of record of Registrable Securities, at least five (5) Business Days prior to the filing of any registration statement under the Securities Act. Notwithstanding the foregoing, the Company may delay any Piggyback Notice until after filing a registration statement, so long as all recipients of such notice have the same amount of time to determine whether to participate in an offering as they would have had if such notice had not been so delayed. Upon the written request of any such Holder, made within two (2) days following the receipt of any such Piggyback Notice (which request shall specify the maximum number of Registrable Securities intended to be disposed of by such Holder and the intended method of distribution thereof), the Company shall, subject to Sections 2.2(c), 2.3 and 2.6 hereof, use commercially reasonable efforts to cause all such Registrable Securities, the Holders of which have so requested the registration thereof, to be registered under the Securities Act with the securities which the Company at the time proposes to register to permit the sale or other disposition by the Holders (in accordance with the intended method of distribution thereof) of the Registrable Securities to be so registered, including, if necessary, by filing with the SEC a post-effective amendment or a supplement to the registration statement filed by the Company or the prospectus related thereto. There is no limitation on the number of such piggyback registrations which the Company is obligated to effect pursuant to the preceding sentence. No registration of Registrable Securities effected under this Section 2.2(a) shall relieve the Company of its obligations to effect Demand Registrations under Section 2.1 hereof. For the avoidance of doubt, this Section 2.2 shall not apply to any Underwritten Block Trade.

 

(b)   Other than in connection with a Demand Registration or a Shelf Underwriting, at any time after giving a Piggyback Notice and prior to the effective date of the registration statement filed in connection with such registration, if the Company shall determine for any reason not to register or to delay registration of such equity securities, the Company may, at its election, give written notice of such determination to all Holders of record of Registrable Securities and (x) in the case of a determination not to register, shall be relieved of its obligation to register any Registrable Securities in connection with such abandoned registration, without prejudice, however, to the rights of Holders under Section 2.1, and (y) in the case of a determination to delay such registration of its equity securities, shall be permitted to delay the

 

11 

 

registration of such Registrable Securities for the same period as the delay in registering such other equity securities.

 

(c)   Any Holder shall have the right to withdraw its request for inclusion of its Registrable Securities in any registration statement pursuant to this Section 2.2 by giving written notice to the Company of its request to withdraw; provided, however, that such request must be made in writing prior to the earlier of the execution by such Holder of the underwriting agreement or the execution by such Holder of the custody agreement with respect to such registration or as otherwise required by the underwriters (after which such underwriting agreement or custody agreement, as applicable, shall govern).

 

2.3.   Allocation of Securities Included in Registration Statement.

 

(a)   If any requested registration or offering made pursuant to Section 2.1 (including a Shelf Underwriting) involves an underwritten offering and the Manager of such offering shall advise the Company in good faith that, in its view, the number of securities requested to be included in such underwritten offering by the Holders of Registrable Securities, the Company or any other Persons exercising contractual registration rights (“Additional Piggyback Rights”) exceeds the largest number of securities (the “Section 2.3(a) Sale Number”) that can be sold in an orderly manner in such underwritten offering within a price range acceptable to the Initiating Holders and the Majority Participating Holders, the Company shall include in such underwritten offering:

 

(i)   first, all Registrable Securities requested to be included in such underwritten offering by the Holders thereof (including pursuant to the exercise of piggyback rights pursuant to Section 2.2); provided, however, that if the number of such Registrable Securities exceeds the Section 2.3(a) Sale Number, the number of such Registrable Securities (not to exceed the Section 2.3(a) Sale Number) to be included in such underwritten offering shall be allocated on a pro rata basis among all Holders (including each Initiating Holder) requesting that Registrable Securities be included in such underwritten offering (including pursuant to the exercise of piggyback rights pursuant to Section 2.2), based on the number of Registrable Securities then owned by each such Holder requesting inclusion in relation to the aggregate number of Registrable Securities owned by all Holders requesting inclusion; and

 

(ii)   second, to the extent that the number of Registrable Securities to be included pursuant to clause (i) of this Section 2.3(a) is less than the Section 2.3(a) Sale Number, any securities that the Company proposes to register for its own account, up to the Section 2.3(a) Sale Number; and (iii) third, to the extent that the number of securities to be included pursuant to clauses (i) and (ii) of this Section 2.3(a) is less than the Section 2.3(a) Sale Number, the remaining securities to be included in such underwritten offering shall be allocated on a pro rata basis among all Persons other than Holders requesting that securities be included in such underwritten offering pursuant to the exercise of Additional Piggyback Rights (“Piggyback Shares”), based on the aggregate number of Piggyback Shares then owned by each Person requesting inclusion in relation to the aggregate number of Piggyback Shares owned by all Persons requesting inclusion, up to the Section 2.3(a) Sale Number.

 

12 

 

(b)   If any registration or offering made pursuant to Section 2.2 involves an underwritten primary offering on behalf of the Company and the Manager shall advise the Company that, in its view, the number of securities requested to be included in such underwritten offering by the Holders of Registrable Securities, the Company or any other Persons exercising Additional Piggyback Rights exceeds the largest number of securities (the “Section 2.3(b) Sale Number”) that can be sold in an orderly manner in such underwritten offering within a price range acceptable to the Company, the Company shall include in such underwritten offering:

 

(i)   first, all equity securities that the Company proposes to register for its own account; and

 

(ii)   second, to the extent that the number of securities to be included pursuant to clause (i) of this Section 2.3(b) is less than the Section 2.3(b) Sale Number, the remaining Registrable Securities to be included in such underwritten offering shall be allocated on a pro rata basis among all Holders requesting that Registrable Securities be included in such underwritten offering pursuant to the exercise of piggyback rights pursuant to Section 2.2(a), based on the aggregate number of Registrable Securities then owned by each such Holder requesting inclusion in relation to the aggregate number of Registrable Securities owned by all Holders requesting inclusion, up to the Section 2.3(b) Sale Number; and (iii) third, to the extent that the number of securities to be included pursuant to clauses (i) and (ii) of this Section 2.3(b) is less than the Section 2.3(b) Sale Number, the remaining securities to be included in such underwritten offering shall be allocated on a pro rata basis among all Persons requesting that Piggyback Shares be included in such underwritten offering pursuant to the exercise of Additional Piggyback Rights, based on the aggregate number of Piggyback Shares then owned by each Person requesting inclusion in relation to the aggregate number of Piggyback Shares owned by all Persons requesting inclusion, up to the Section 2.3(b) Sale Number.

 

(c)   If any registration pursuant to Section 2.2 involves an underwritten offering that was initially requested by any Person(s) (other than a Holder) to whom the Company has granted registration rights which are not inconsistent with the rights granted in, and do not otherwise conflict with the terms of, this Agreement and the Manager shall advise the Company that, in its view, the number of securities requested to be included in such underwritten offering exceeds the largest number of securities (the “Section 2.3(c) Sale Number”) that can be sold in an orderly manner in such underwritten offering within a price range acceptable to the Company, the Company shall include in such underwritten offering:

 

(i)   first, the shares requested to be included in such underwritten offering shall be allocated on a pro rata basis among such Person(s) requesting the registration and all Holders requesting that Registrable Securities be included in such underwritten offering pursuant to the exercise of piggyback rights pursuant to Section 2.2(a), based on the aggregate number of securities or Registrable Securities, as applicable, then owned by each of the foregoing requesting inclusion in relation to the aggregate number of securities or Registrable Securities, as applicable, owned by all such Persons and Holders requesting inclusion, up to the Section 2.3(c) Sale Number; and

 

(ii)   second, to the extent that the number of securities to be included pursuant to clause (i) of this Section 2.3(c) is less than the Section 2.3(c) Sale Number, the

 

13 

 

remaining securities to be included in such underwritten offering shall be allocated on a pro rata basis among all Persons requesting that Piggyback Shares be included in such underwritten offering pursuant to the exercise of Additional Piggyback Rights, based on the aggregate number of Piggyback Shares then owned by each Person requesting inclusion in relation to the aggregate number of Piggyback Shares owned by all Persons requesting inclusion, up to the Section 2.3(c) Sale Number; and (iii) third, to the extent that the number of securities to be included pursuant to clauses (i) and (ii) of this Section 2.3(c) is less than the Section 2.3(c) Sale Number, any equity securities that the Company proposes to register for its own account, up to the Section 2.3(c) Sale Number.

 

(d)   If, as a result of the proration provisions set forth in clauses (a), (b) or (c) of this Section 2.3, any Holder shall not be entitled to include all Registrable Securities in an underwritten offering that such Holder has requested be included, such Holder may elect to withdraw such Holder’s request to include Registrable Securities in the registration to which such underwritten offering relates or may reduce the number requested to be included; provided, however, that (x) such request must be made in writing prior to the earlier of such Holder’s execution of the underwriting agreement or such Holder’s execution of the custody agreement with respect to such registration and (y) such withdrawal or reduction shall be irrevocable and, after making such withdrawal or reduction, such Holder shall no longer have any right to include Registrable Securities in the registration as to which such withdrawal or reduction was made to the extent of the Registrable Securities so withdrawn or reduced.

 

2.4.   Registration Procedures. If and whenever the Company is required by the provisions of this Agreement to effect or cause the registration of and/or participate in any offering or sale of any Registrable Securities under the Securities Act as provided in this Agreement (or use commercially reasonable efforts to accomplish the same), the Company shall, as expeditiously as practicable:

 

(a)   prepare and file all filings with the SEC and FINRA as soon as practicable required for the consummation of the offering, including preparing and filing with the SEC a registration statement on an appropriate registration form of the SEC for the disposition of such Registrable Securities in accordance with the intended method of disposition thereof, which registration form (i) shall be selected by the Company (except as provided for in a Demand Registration Request) and (ii) shall, in the case of a shelf registration, be available for the sale of the Registrable Securities by the selling Holders thereof and such registration statement shall comply as to form in all material respects with the requirements of the applicable registration form and include all financial statements required by the SEC to be filed therewith, and the Company shall use commercially reasonable efforts to cause such registration statement to become effective and remain effective until all Registrable Securities covered by such registration statement are sold in accordance with the intended plan of distribution set forth in such registration statement or have ceased to be Registrable Securities (provided, however, that as far in advance as reasonably practicable before filing a registration statement or prospectus or any amendments or supplements thereto, or comparable statements under securities or state “blue sky” laws of any jurisdiction, or any free writing prospectus related thereto, the Company will furnish to the Holders’ legal counsel participating in the planned offering and to the Manager’s legal counsel, if any, copies of all such documents proposed to be filed (including all exhibits thereto), which documents will be subject

 

14 

 

to their reasonable review and reasonable comment and the Company shall not file any registration statement or amendment thereto, any prospectus or supplement thereto or any free writing prospectus related thereto to which the Initiating Holders, the Majority Participating Holders or the underwriters, if any, shall reasonably object); provided, however, that, notwithstanding the foregoing, in no event shall the Company be required to file any document with the SEC which in the view of the Company or its counsel contains an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make any statement therein not misleading;

 

(b)   prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection therewith and such free writing prospectuses and Exchange Act reports as may be necessary to keep such registration statement effective until all Registrable Securities covered by such registration statement are sold in accordance with the intended plan of distribution set forth in such registration statement or have ceased to be Registrable Securities and to comply with the provisions of the Securities Act with respect to the sale or other disposition of all Registrable Securities covered by such registration statement, and any prospectus so supplemented to be filed pursuant to Rule 424 under the Securities Act, in accordance with the intended methods of disposition by the seller or sellers thereof set forth in such registration statement;

 

(c)   furnish, without charge, to each Participating Holder and each underwriter, if any, of the securities covered by such registration statement such number of copies of such registration statement, each amendment and supplement thereto (in each case including all exhibits), the prospectus included in such registration statement (including each preliminary prospectus and any summary prospectus) and any other prospectus filed under Rule 424 under the Securities Act, each free writing prospectus utilized in connection therewith, in each case, in conformity with the requirements of the Securities Act, and other documents, as such seller and underwriter may reasonably request in order to facilitate the public sale or other disposition of the Registrable Securities owned by such seller (the Company hereby consenting to the use in accordance with all applicable laws of each such registration statement (or amendment or post-effective amendment thereto) and each such prospectus (or preliminary prospectus or supplement thereto) or free writing prospectus by each such Participating Holder and the underwriters, if any, in connection with the offering and sale of the Registrable Securities covered by such registration statement or prospectus);

 

(d)   use commercially reasonable efforts to register or qualify the Registrable Securities covered by such registration statement under such other securities or state “blue sky” laws of such jurisdictions as any sellers of Registrable Securities or any managing underwriter, if any, shall reasonably request in writing (or provide evidence satisfactory to such seller or managing underwriter that the Registrable Securities are exempt from such registration or qualification), and do any and all other acts and things which may be reasonably necessary or advisable to enable such sellers or underwriter, if any, to consummate the disposition of the Registrable Securities in such jurisdictions (including keeping such registration or qualification in effect for so long as such registration statement remains in effect), except that in no event shall the Company be required to qualify to do business as a foreign corporation in any jurisdiction where it would not, but for the requirements of this paragraph (d), be required to be so qualified, to subject

 

15 

 

itself to taxation in any such jurisdiction or to consent to general service of process in any such jurisdiction;

 

(e)   promptly notify each Participating Holder and each managing underwriter, if any: (i) when the registration statement, any pre-effective amendment, the prospectus or any prospectus supplement related thereto, any post-effective amendment to the registration statement or any free writing prospectus has been filed with the SEC and, with respect to the registration statement or any post-effective amendment, when the same has become effective; (ii) of any request by the SEC or state securities authority for amendments or supplements to the registration statement or the prospectus related thereto or for additional information; (iii) of the issuance by the SEC of any stop order suspending the effectiveness of the registration statement or the initiation of any proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification of any Registrable Securities for sale under the securities or state “blue sky” laws of any jurisdiction or the initiation of any proceeding for such purpose; (v) of the existence of any fact of which the Company becomes aware which results in the registration statement or any amendment thereto, the prospectus related thereto or any supplement thereto, any document incorporated therein by reference, any free writing prospectus or the information conveyed at the time of sale to any purchaser containing an untrue statement of a material fact or omitting to state a material fact required to be stated therein or necessary to make any statement therein not misleading; and (vi) if at any time the representations and warranties contemplated by any underwriting agreement, securities sale agreement, or other similar agreement, relating to the offering shall cease to be true and correct in all material respects (unless otherwise qualified by materiality in which case such representations and warranties shall cease to be true and correct in all respects); and, if the notification relates to an event described in clause (v), unless the Company has declared that a Postponement Period exists, the Company shall promptly prepare and furnish to each such seller and each underwriter, if any, a reasonable number of copies of a prospectus supplemented or amended so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein in the light of the circumstances under which they were made not misleading;

 

(f)   use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC (including maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) in accordance with the Exchange Act), and make generally available to its security holders (including by way of filings with the SEC), as soon as reasonably practicable after the effective date of the registration statement, an earnings statement (which need not be audited) covering the period of at least twelve (12) consecutive months beginning with the first day of the Company’s first calendar quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder;

 

(g)   (i) (A) use commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on the principal securities exchange on which similar securities issued by the Company are then listed, if the listing of such Registrable Securities is then permitted under the rules of such exchange, or (B) if no similar securities are

 

16 

 

then so listed, use commercially reasonable efforts to either cause all such Registrable Securities to be listed on a national securities exchange or to secure designation of all such Registrable Securities as a New York Stock Exchange “national market system security” within the meaning of Rule 11Aa2-1 of the Exchange Act or, failing that, secure New York Stock Exchange authorization for such shares and, without limiting the generality of the foregoing, take all actions that may be required by the Company as the issuer of such Registrable Securities in order to facilitate the managing underwriter’s arranging for the registration of at least two market makers as such with respect to such shares with FINRA, and (ii) comply (and continue to comply) with the requirements of any self-regulatory organization applicable to the Company, including all corporate governance requirements;

 

(h)   use commercially reasonable efforts to make available its senior management, officers and employees to participate in, and to otherwise facilitate and cooperate with the preparation of the registration statement and prospectus and any amendments or supplements thereto (including participating in meetings, drafting sessions, due diligence sessions and rating agency presentations) taking into account the Company’s reasonable business needs;

 

(i)   provide and cause to be maintained a transfer agent and registrar for all such Registrable Securities covered by such registration statement not later than the effective date of such registration statement and, in the case of any secondary equity offering, provide and enter into any reasonable agreements with a custodian for the Registrable Securities;

 

(j)   enter into such customary agreements (including, if applicable, an underwriting agreement) and take such other actions as the Initiating Holder or the Majority Participating Holders or the underwriters shall reasonably request in order to expedite or facilitate the disposition of such Registrable Securities (it being understood that the Holders of the Registrable Securities which are to be distributed by any underwriters shall be parties to any such underwriting agreement and may, at their option, require that the Company make for the benefit of such Holders the representations, warranties and covenants of the Company which are being made to and for the benefit of such underwriters);

 

(k)   use commercially reasonable efforts (i) to obtain opinions from the Company’s counsel, including local and/or regulatory counsel, and a “comfort” letter and updates thereof from the independent public accountants who have certified the financial statements of the Company (and/or any other financial statements) included or incorporated by reference in such registration statement, in each case, in customary form and covering such matters as are customarily covered by such opinions and “comfort” letters (including, in the case of such “comfort” letter, events subsequent to the date of such financial statements) for a transaction of its type as the Manager may reasonably request and as are customarily included in such opinions and letters, which opinions and letters shall be dated the dates such opinions and “comfort” letters are customarily dated and otherwise reasonably satisfactory to the underwriters, if any, and (ii) furnish to each Participating Holder and to each underwriter, if any, a copy of such opinions and letters addressed to such underwriter;

 

(l)   upon receipt of such confidentiality agreements as the Company may reasonably request, give counsel for the Majority Participating Holders, counsel for any underwriter participating in any disposition to be effected pursuant to such registration statement

 

17 

 

and by any attorney, accountant or other agent retained by the Majority Participating Holders or any such underwriter such reasonable access to its books and records and such opportunities to discuss the business, finances and accounts of the Company and its subsidiaries with its officers, directors and the independent public accountants who have certified its financial statements as shall be necessary, in the opinion of such Majority Participating Holders’ and such underwriters’ respective counsel, to conduct a reasonable investigation within the meaning of the Securities Act, and will cause the Company’s officers, directors and employees to supply all information reasonably requested by any such representative, Underwriter, attorney or accountant in connection with the Registration;

 

(m)   use commercially reasonable efforts to prevent the issuance or obtain the prompt withdrawal of any order suspending the effectiveness of the registration statement, or the prompt lifting of any suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction, in each case, as promptly as reasonably practicable;

 

(n)   provide a CUSIP number for all Registrable Securities, not later than the effective date of the registration statement;

 

(o)   use commercially reasonable efforts to make available its senior management for participation in “road shows” and other marketing efforts and otherwise provide reasonable assistance to the underwriters (taking into account the Company’s reasonable business needs and the requirements of the marketing process) in the marketing of Registrable Securities in any underwritten offering;

 

(p)   promptly prior to the filing of any document which is to be incorporated by reference into the registration statement or the prospectus (after the initial filing or confidential submission of such registration statement), and prior to the filing or use of any free writing prospectus, provide copies of such document to counsel for the Majority Participating Holders and to each managing underwriter, if any, and make the Company’s representatives reasonably available for discussion of such document and make such changes in such document concerning the information regarding the Participating Holders contained therein prior to the filing thereof as counsel for the Majority Participating Holders or underwriters may reasonably request (provided, however, that, notwithstanding the foregoing, in no event shall the Company be required to file or confidentially submit any document with the SEC which in the view of the Company or its counsel contains an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make any statement therein not misleading);

 

(q)   furnish to counsel for the Majority Participating Holders and to each managing underwriter, without charge, upon request, at least one conformed copy of the registration statement and any post-effective amendments or supplements thereto, including financial statements and schedules, all documents incorporated therein by reference, the prospectus contained in such registration statement (including each preliminary prospectus and any summary prospectus), any other prospectus and prospectus supplement filed under Rule 424 under the Securities Act and all exhibits (including those incorporated by reference) and any free writing prospectus utilized in connection therewith;

 

18 

 

(r)   cooperate with the Participating Holders and the managing underwriter, if any, to facilitate the timely preparation and delivery of certificates not bearing (or book entry positions not subject to) any restrictive legends representing the Registrable Securities to be sold, and cause such Registrable Securities to be issued in such denominations and registered in such names in accordance with the underwriting agreement at least two (2) Business Days prior to any sale of Registrable Securities to the underwriters or, if not an underwritten offering, in accordance with the instructions of the Participating Holders at least two (2) Business Days prior to any sale of Registrable Securities and instruct any transfer agent and registrar of Registrable Securities to release any stop transfer orders in respect thereof (and, in the case of Registrable Securities registered on a Shelf Registration Statement, at the request of any Holder, prepare and deliver certificates representing such Registrable Securities not bearing any restrictive legends and deliver or cause to be delivered an opinion or instructions to the transfer agent in order to allow such Registrable Securities to be sold from time to time);

 

(s)   include in any prospectus or prospectus supplement if requested by any managing underwriter updated financial or business information for the Company’s most recent period or current quarterly period (including estimated results or ranges of results) if required for purposes of marketing the offering in the view of the managing underwriter;

 

(t)   take no direct or indirect action prohibited by Regulation M under the Exchange Act; provided, however, that to the extent that any prohibition is applicable to the Company, the Company will use commercially reasonable efforts to make any such prohibition inapplicable;

 

(u)   use commercially reasonable efforts to cause the Registrable Securities covered by the applicable registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the Participating Holders or the underwriters, if any, to consummate the disposition of such Registrable Securities;

 

(v)   take all such other commercially reasonable actions as are necessary or advisable in order to expedite or facilitate the disposition of such Registrable Securities;

 

(w)   take reasonable action to ensure that any free writing prospectus utilized in connection with any registration covered by Section 2.1 or 2.2 complies in all material respects with the Securities Act, is filed in accordance with the Securities Act to the extent required thereby, is retained in accordance with the Securities Act to the extent required thereby and, when taken together with the related prospectus, prospectus supplement and related documents, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;

 

(x)   in connection with any underwritten offering, if at any time the information conveyed to a purchaser at the time of sale includes any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, promptly file with the SEC such amendments or supplements to such information as may be necessary so that the statements as so amended or supplemented will not, in the light of the circumstances, be misleading;

 

19 

 

(y)   to the extent required by the rules and regulations of FINRA, retain a Qualified Independent Underwriter acceptable to the managing underwriter; and

 

(z)   use commercially reasonable efforts, in good faith, to cooperate with the managing underwriters, Participating Holders, any indemnitee of the Company and their respective counsel in connection with the preparation and filing of any applications, notices, registrations and responses to requests for additional information with FINRA, Nasdaq, or any other national securities exchange on which the Class A Ordinary Shares are listed.

 

To the extent the Company is a WKSI at the time any Demand Registration Request is submitted to the Company, the Company shall file an automatic shelf registration statement (as defined in Rule 405 under the Securities Act) (an “automatic shelf registration statement”) on Form F-3 which covers those Registrable Securities which are requested to be registered. The Company shall not take any action that would result in it not remaining a WKSI or would result in it becoming an ineligible issuer (as defined in Rule 405 under the Securities Act) during the period during which such automatic shelf registration statement is required to remain effective. If the Company does not pay the filing fee covering the Registrable Securities at the time the automatic shelf registration statement is filed, the Company agrees to pay such fee at such time or times as the Registrable Securities are to be sold in compliance with the SEC rules. If the automatic shelf registration statement has been outstanding for at least three (3) years, at or prior to the end of the third year the Company shall refile a new automatic shelf registration statement covering the Registrable Securities. If at any time when the Company is required to re-evaluate its WKSI status the Company determines that it is not a WKSI, the Company shall use commercially reasonable efforts to refile the shelf registration statement on Form F-3 and, if such form is not available, Form F-1 and keep such registration statement effective during the period which such registration statement is required to be kept effective.

 

If the Company files any shelf registration statement for the benefit of the holders of any of its securities other than the Holders, and the Holders do not request that their Registrable Securities be included in such Shelf Registration Statement, the Company agrees that it shall include in such registration statement such disclosures as may be required by Rule 430B under the Securities Act (referring to the unnamed selling security holders in a generic manner by identifying the initial offering of the securities to the Holders) in order to ensure that the Holders may be added to such shelf registration statement at a later time through the filing of a prospectus supplement rather than a post-effective amendment.

 

The Company may require as a condition precedent to the Company’s obligations under this Section 2.4 that each Participating Holder as to which any registration is being effected (i) furnish the Company such information regarding such seller and the distribution of such securities as the Company may from time to time reasonably request (including as required under state securities laws), provided that such information is necessary for the Company to consummate such registration and shall be used only in connection with such registration and (ii) provide any underwriters participating in the distribution of such securities such information as the underwriters may request and execute and deliver any agreements, certificates or other documents as the underwriters may request.

 

20 

 

Each Holder of Registrable Securities agrees that upon receipt of any notice from the Company of the happening of any event of the kind described in clause (v) of paragraph (e) of this Section 2.4, such Holder will discontinue such Holder’s disposition of Registrable Securities pursuant to the registration statement covering such Registrable Securities until such Holder’s receipt of the copies of the supplemented or amended prospectus contemplated by paragraph (e) of this Section 2.4 and, if so directed by the Company, will deliver to the Company (at the Company’s expense) all copies, other than permanent file copies, then in such Holder’s possession of the prospectus covering such Registrable Securities that was in effect at the time of receipt of such notice. In the event the Company shall give any such notice, the applicable period mentioned in paragraph (b) of this Section 2.4 shall be extended by the number of days during such period from and including the date of the giving of such notice to and including the date when each Participating Holder covered by such registration statement shall have received the copies of the supplemented or amended prospectus contemplated by paragraph (e) of this Section 2.4.

 

The Company agrees not to file or make any amendment to any registration statement with respect to any Registrable Securities, or any amendment of or supplement to the prospectus, or any free writing prospectus, which amendment refers to any Holder covered thereby by name, or otherwise identifies such Holder, without the consent of such Holder, such consent not to be unreasonably withheld or delayed, unless such disclosure is required by law, in which case the Company shall provide written notice to such Holders no less than five (5) Business Days prior to the filing.

 

2.5.   Registration Expenses.

 

(a)   The Company shall pay all Expenses with respect to any registration or offering of Registrable Securities pursuant to Section 2, whether or not a registration statement becomes effective or the offering is consummated.

 

(b)   Notwithstanding the foregoing, (x) the provisions of this Section 2.5 shall be deemed amended to the extent necessary to cause these expense provisions to comply with state “blue sky” laws of each state in which the offering is made and (y) in connection with any underwritten offering hereunder, each Participating Holder shall pay all underwriting discounts and commissions and any transfer taxes, if any, attributable to the sale of such Registrable Securities, pro rata with respect to payments of discounts and commissions in accordance with the number of shares sold in the offering by such Participating Holder.

 

2.6.   Certain Limitations on Registration Rights. In the case of any registration under Section 2.1 involving an underwritten offering, or, in the case of a registration under Section 2.2, if the Company has determined to enter into an underwriting agreement in connection therewith, all securities to be included in such underwritten offering shall be subject to such underwriting agreement and no Person may participate in such underwritten offering unless such Person (i) agrees to sell such Person’s securities on the basis provided therein and completes and executes all reasonable questionnaires, and other customary documents (including custody agreements, powers of attorney, indemnities, lock-up agreements) which must be executed in connection therewith; provided, however, that all such documents shall be consistent with the provisions

 

21 

 

hereof and (ii) provides such other information to the Company or the underwriter as may be necessary to register such Person’s securities.

 

2.7.   Limitations on Sale or Distribution of Other Securities.

 

(a)   Each Holder that is a director or officer of the Company agrees, to the extent requested by the Manager of any underwritten public offering pursuant to a registration or offering effected pursuant to Section 2.1 (including any Shelf Underwriting pursuant to Section 2.1) or Section 2.2 (including any offering effected by the Company for its own account ), not to sell, transfer or otherwise dispose of, including any sale pursuant to Rule 144, any Class A Ordinary Shares or Class A Ordinary Share Equivalents (other than as part of such underwritten public offering) during the time period reasonably requested by the Manager, not to exceed the period from seven days prior to the pricing date of such offering until ninety (90) days after the pricing date of such offering or such shorter period as the Manager, the Company or any executive officer or director of the Company shall agree to.

 

2.8.   No Required Sale. Nothing in this Agreement shall be deemed to create an independent obligation on the part of any Holder to sell any Registrable Securities pursuant to any effective registration statement. A Holder is not required to include any of its Registrable Securities in any registration statement, is not required to sell any of its Registrable Securities which are included in any effective registration statement, and may sell any of its Registrable Securities in any manner in compliance with applicable law (subject to applicable lock-up restrictions) even if such shares are already included on an effective registration statement.

 

2.9.   Indemnification.

 

(a)   In the event of any registration or offer and sale of any securities of the Company under the Securities Act pursuant to this Section 2, the Company will (without limitation as to time), and hereby agrees to, and hereby does, indemnify and hold harmless, to the fullest extent permitted by law, each Participating Holder, its directors, officers, employees, stockholders, members, general and limited partners, agents, affiliates, representatives, successors and assigns (and the directors, officers, employees, stockholders, members, general and limited partners, agents, affiliates, representatives, successors and assigns thereof), each other Person who participates as a seller (and its directors, officers, employees, stockholders, members, general and limited partners, agents, affiliates, representatives, successors and assigns), underwriter or Qualified Independent Underwriter, if any, in the offering or sale of such securities, each officer, director, employee, stockholder, managing director, agent, affiliate, representative, successor, assign or partner of such underwriter or Qualified Independent Underwriter, and each other Person, if any, who controls (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) such seller or any such underwriter or Qualified Independent Underwriter and each director, officer, employee, stockholder, managing director, agent, affiliate, representative, successor, assign or partner of such controlling Person, from and against any and all losses, claims, damages or liabilities, joint or several, actions or proceedings (whether commenced or threatened) and expenses (including reasonable fees of counsel and any amounts paid in any settlement effected with the Company’s consent, which consent shall not be unreasonably withheld or delayed) to which each such indemnified party may become subject under the Securities Act or otherwise in respect thereof (collectively, “Claims”), insofar as such Claims arise out of, are based

 

22 

 

upon, relate to or are in connection with (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement under which such securities were registered under the Securities Act or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary, final or summary prospectus or any amendment or supplement thereto, together with the documents incorporated by reference therein, or any free writing prospectus utilized in connection therewith, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, or (iii) any untrue statement or alleged untrue statement of a material fact in the information conveyed by the Company or any underwriter to any purchaser at the time of the sale to such purchaser, or the omission or alleged omission to state therein a material fact required to be stated therein, or (iv) any violation by the Company of any federal, state or common law rule or regulation applicable to the Company and relating to any action required of or inaction by the Company in connection with any such offering of Registrable Securities, and the Company will reimburse any such indemnified party for any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such Claim as such expenses are incurred; provided, however, that the Company shall not be liable to any such indemnified party in any such case to the extent such Claim arises out of or is based upon any untrue statement or alleged untrue statement of a material fact or omission or alleged omission of a material fact made in such registration statement or amendment thereof or supplement thereto or in any such prospectus or any preliminary, final or summary prospectus or free writing prospectus in reliance upon and in conformity with written information furnished to the Company by or on behalf of such indemnified party specifically for use therein. Such indemnity and reimbursement of expenses shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified party and shall survive the transfer of such securities by such seller.

 

(b)   Each Participating Holder (and, if the Company requires as a condition to including any Registrable Securities in any registration statement filed in accordance with Section 2.1 or 2.2, any underwriter and Qualified Independent Underwriter, if any) shall, severally and not jointly, indemnify and hold harmless (in the same manner and to the same extent as set forth in paragraph (a) of this Section 2.9) to the extent permitted by law the Company, its officers and its directors, each Person controlling the Company within the meaning of the Securities Act and all other prospective sellers and their directors, officers, stockholders, fiduciaries, managing directors, agents, affiliates, representatives, successors, assigns or general and limited partners and respective controlling Persons with respect to any untrue statement or alleged untrue statement of any material fact in, or omission or alleged omission of any material fact from, such registration statement, any preliminary, final or summary prospectus contained therein, or any amendment or supplement thereto, or any free writing prospectus utilized in connection therewith, if such statement or alleged statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company or its representatives by or on behalf of such Participating Holder or underwriter or Qualified Independent Underwriter, if any, specifically for use therein, and each such Participating Holder, underwriter or Qualified Independent Underwriter, if any, shall reimburse such indemnified party for any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such Claim as such expenses are incurred; provided, however, that the aggregate

 

23 

 

amount which any such Participating Holder shall be required to pay pursuant to this Section 2.9 (including pursuant to indemnity, contribution or otherwise) shall in no case be greater than the amount of the net proceeds received by such Participating Holder upon the sale of the Registrable Securities pursuant to the registration statement giving rise to such Claim; provided, further, that such Participating Holder shall not be liable in any such case to the extent that prior to the filing or confidential submission of any such registration statement or prospectus or amendment thereof or supplement thereto, or any free writing prospectus utilized in connection therewith, such Participating Holder has furnished in writing to the Company information expressly for use in such registration statement or prospectus or any amendment thereof or supplement thereto or free writing prospectus which corrected or made not misleading information previously furnished to the Company. The Company and each Participating Holder hereby acknowledge and agree that, unless otherwise expressly agreed to in writing by such Participating Holders to the contrary, for all purposes of this Agreement, the only information furnished or to be furnished to the Company for use in any such registration statement, preliminary, final or summary prospectus or amendment or supplement thereto, or any free writing prospectus, are statements specifically relating to (i) the beneficial ownership of shares of Ordinary Shares by such Participating Holder and its Affiliates as disclosed in the section of such document entitled “Selling Shareholders” or “Principal and Selling Shareholders” and (ii) the name and address of such Participating Holder. If any additional information about such Holder or the plan of distribution (other than for an underwritten offering) is required by law to be disclosed in any such document, then such Holder shall not unreasonably withhold its agreement referred to in the immediately preceding sentence. Such indemnity and reimbursement of expenses shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified party and shall survive the transfer of such securities by such Holder.

 

(c)   Indemnification similar to that specified in the preceding paragraphs (a) and (b) of this Section 2.9 (with appropriate modifications) shall be given by the Company and each Participating Holder with respect to any required registration or other qualification of securities under any applicable securities and state “blue sky” laws.

 

(d)   Any Person entitled to indemnification under this Agreement shall notify promptly the indemnifying party in writing of the commencement of any action or proceeding with respect to which a claim for indemnification may be made pursuant to this Section 2.9, but the failure of any indemnified party to provide such notice shall not relieve the indemnifying party of its obligations under the preceding paragraphs of this Section 2.9, except to the extent the indemnifying party is materially and actually prejudiced thereby and shall not relieve the indemnifying party from any liability which it may have to any indemnified party otherwise than under this Section 2.9. In case any action or proceeding is brought against an indemnified party and such indemnified party shall have notified the indemnifying party of the commencement thereof (as required above), the indemnifying party shall be entitled to participate therein and, unless in the reasonable opinion of outside counsel to the indemnified party a conflict of interest between such indemnified and indemnifying parties exists in respect of such Claim, to assume the defense thereof jointly with any other indemnifying party similarly notified, to the extent that it chooses, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party that it so chooses, the indemnifying party shall not be liable to such indemnified party for any legal or other expenses subsequently incurred by such

 

24 

 

indemnified party in connection with the defense thereof other than reasonable costs of investigation; provided, however, that (i) if the indemnifying party fails to take reasonable steps necessary to defend diligently the action or proceeding within twenty (20) days after receiving notice from such indemnified party that the indemnified party believes it has failed to do so; or (ii) if such indemnified party who is a defendant in any action or proceeding which is also brought against the indemnifying party reasonably shall have concluded that there may be one or more legal or equitable defenses available to such indemnified party which are not available to the indemnifying party or which may conflict with or be different from those available to another indemnified party with respect to such Claim; or (iii) if representation of both parties by the same counsel is otherwise inappropriate under applicable standards of professional conduct, then, in any such case, the indemnified party shall have the right to assume or continue its own defense as set forth above (but with no more than one firm of counsel for all indemnified parties in each jurisdiction, except to the extent any indemnified party or parties reasonably shall have made a conclusion described in clause (ii) or (iii) above) and the indemnifying party shall be liable for any expenses therefor. No indemnifying party shall be liable for any settlement of any proceeding effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with such consent or if there be a final judgment for the plaintiff, such indemnifying party agrees to indemnify each indemnified party from and against any loss, claim, damage, liability or expense by reason of such settlement or judgment. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (A) includes an unconditional release of the indemnified party from all liability arising out of such action or claim and (B) does not include a statement as to or an admission of fault or culpability, by or on behalf of any indemnified party.

 

(e)   If for any reason the foregoing indemnity is unavailable, unenforceable or is insufficient to hold harmless an indemnified party under Sections 2.9(a), (b) or (c), then each applicable indemnifying party shall contribute to the amount paid or payable to such indemnified party as a result of any Claim in such proportion as is appropriate to reflect the relative fault of the indemnifying party, on the one hand, and the indemnified party, on the other hand, with respect to such Claim. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. If, however, the allocation provided in the second preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative faults but also the relative benefits of the indemnifying party and the indemnified party as well as any other relevant equitable considerations. The parties hereto agree that it would not be just and equitable if any contribution pursuant to this Section 2.9(e) were to be determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the preceding sentences of this Section 2.9(e). The amount paid or payable in respect of any Claim shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection

 

25 

 

with investigating or defending any such Claim. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. Notwithstanding anything in this Section 2.9(e) to the contrary, no indemnifying party (other than the Company) shall be required pursuant to this Section 2.9(e) to contribute any amount greater than the amount of the net proceeds received by such indemnifying party from the sale of Registrable Securities pursuant to the registration statement giving rise to such Claim, less the amount of any indemnification payment made by such indemnifying party pursuant to Sections 2.9(b) and (c). In addition, no Holder of Registrable Securities or any Affiliate thereof shall be required to pay any amount under this Section 2.9(e) unless such Person or entity would have been required to pay an amount pursuant to Section 2.9(b) if it had been applicable in accordance with its terms.

 

(f)   The indemnity and contribution agreements contained herein shall be in addition to any other rights to indemnification or contribution which any indemnified party may have pursuant to law or contract and shall remain operative and in full force and effect regardless of any investigation made or omitted by or on behalf of any indemnified party and shall survive the transfer of the Registrable Securities by any such party.

 

(g)   The indemnification and contribution required by this Section 2.9 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or expense, loss, damage or liability is incurred.

 

2.10.   No Inconsistent Agreements. The Company shall not hereafter enter into any agreement with respect to its securities that is inconsistent in any material respects with the rights granted to the Holders in this Agreement.

 

Section 3.   Underwritten Offerings.

 

3.1.   Requested Underwritten Offerings. If requested by the underwriters for any underwritten offering pursuant to a registration requested under Section 2.1, the Company shall enter into a customary underwriting agreement with the underwriters. Such underwriting agreement shall (i) be satisfactory in form and substance to the Initiating Holders and the Majority Participating Holders, (ii) contain terms not inconsistent with the provisions of this Agreement and (iii) contain such representations and warranties by, and such other agreements on the part of, the Company and such other terms as are generally prevailing in agreements of that type, including indemnities and contribution agreements on substantially the same terms as those contained herein or as otherwise customary for the lead underwriter. Every Participating Holder shall be a party to such underwriting agreement. Each Participating Holder shall not be required to make any representations or warranties to or agreements with the Company or the underwriters other than customary representations of a selling shareholder, including representations, warranties or agreements regarding its ownership of and title to the Registrable Securities, any written information specifically provided by such Participating Holder for inclusion in the registration statement and its intended method of distribution; and any liability of such Participating Holder to any underwriter or other Person under such underwriting agreement for indemnity, contribution or otherwise shall in no case be greater than the amount of the net proceeds received by such Participating Holder upon the sale of Registrable Securities pursuant to such registration statement

 

26 

 

and in no event shall relate to anything other than information about such Holder specifically provided by such Holder for use in the registration statement and prospectus.

 

3.2.   Piggyback Underwritten Offerings. In the case of a registration pursuant to Section 2.2, if the Company shall have determined to enter into an underwriting agreement in connection therewith, all of the Participating Holders’ Registrable Securities to be included in such registration shall be subject to such underwriting agreement. Each such Participating Holder shall not be required to make any representations or warranties to or agreements with the Company or the underwriters other than customary representations of a selling shareholder, including representations, warranties or agreements regarding its ownership of and title to the Registrable Securities, any written information specifically provided by such Participating Holder for inclusion in the registration statement and its intended method of distribution; and any liability of such Participating Holder to any underwriter or other Person under such underwriting agreement shall in no case be greater than the amount of the net proceeds received by such Participating Holder upon the sale of Registrable Securities pursuant to such registration statement and in no event shall relate to anything other than information about such Holder specifically provided by such Holder for use in the registration statement and prospectus.

 

Section 4.   Lock-Up Agreements.

 

4.1.   Transfer Restrictions. Except as permitted by Section 4.2:

 

(a)   Target Holder Lock-Up. Each Target Holder (as identified on Schedule 1) agrees that such Target Holder (and its assignees) shall not Transfer any Ordinary Shares or other Registrable Securities beneficially owned or owned of record by such Target Holder for a period of nine 180 days from the Closing Date (the “Target Holder Lock-Up Period”).

 

(b)   Sponsor Lock-Up. Sponsor agrees that Sponsor (and its assignees) shall not Transfer any Ordinary Shares or other Registrable Securities beneficially owned or owned of record by the Sponsor for a period of 270 days from the date hereof (the “Sponsor Lock-Up Period”).

 

Notwithstanding the foregoing, the Ordinary Shares and other Registrable Securities in Section 4.1(b) above shall be automatically released from the foregoing restrictions on the date on which the last reported trading price of the Ordinary Shares on Nasdaq exceeds $15.00 for 20 trading days within any 30 trading day period commencing at least 150 days after the Closing Date.

 

4.2.   Exceptions. The provisions of Section 4.1 shall not apply to:

 

(a)   Transactions relating to Ordinary Shares acquired in open market transactions;

 

(b)   Transfers of Ordinary Shares or any security convertible into or exercisable or exchangeable for Ordinary Shares as a bona fide gift;

 

(c)   Transfers of Ordinary Shares to a trust, or other entity formed for estate planning purposes for the primary benefit of the spouse, domestic partner, parent, sibling, child or

 

27 

 

grandchild of the undersigned or any other person with whom the undersigned has a relationship by blood, marriage or adoption not more remote than first cousin;

 

(d)   With respect to any Ordinary Shares held by or subject to any trust or foundation, then the trustees of such trust or foundation and any entity controlled by such trust or foundation, or any other trust or foundation established for the benefit of such trust or foundation;

 

(e)   Transfers by will or intestate succession upon the death of the Holder, including transfers to the executors, administrators or any other similar personal representatives of such Holder in accordance with the will of such Holder or the applicable laws or otherwise as directed by the order of any relevant courts or tribunals of competent jurisdiction;

 

(f)   Transfer of Ordinary Shares pursuant to a qualified domestic order or in connection with a divorce settlement;

 

(g)   If the Holder is a corporation, partnership (whether general, limited or otherwise), limited liability company, trust or other business entity:

 

(i)   Transfers to another corporation, partnership, limited liability company, trust or other business entity that controls, is controlled by or is under common control or management with the Holder or

 

(ii)   distributions of Ordinary Shares to partners, limited liability company members or stockholders of the Holder;

 

(h)   Transfers to the Company’s officers, directors or their Affiliates;

 

(i)   Pledges of Ordinary Shares or other Registrable Securities as security or collateral in connection with any borrowing or the incurrence of any indebtedness by any Holder (provided such borrowing or incurrence of indebtedness is secured by a portfolio of assets or equity interests issued by multiple issuers);

 

(j)   Transfers pursuant to a bona fide third-party tender offer, merger, stock sale, recapitalization, consolidation or other transaction involving a change in control of the Company, provided that in the event that such tender offer, merger, recapitalization, consolidation or other such transaction is not completed, the Ordinary Shares subject to this Agreement shall remain subject to this Agreement;

 

(k)   the establishment of a trading plan pursuant to Rule 10b5-1 promulgated under the Exchange Act, provided that such plan does not provide for the transfer of Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares during the Target Holder Lock-up Period or Sponsor Lock-up Period, as applicable;

 

(l)   Transfers by the Sponsor to the parties to the Non Redemption Agreements (as defined in the Business Combination Agreement) pursuant to the terms thereof;

 

(m)   Transfers to any Affiliate;

 

28 

 

(n)   Transfers to the Company in the case of a repurchase of Ordinary Shares by the Company at a price no greater than that originally paid by a Holder for such Ordinary Shares and pursuant to an agreement containing vesting and/or repurchase provisions approved by the Company’s Board of Directors;

 

(o)   In the case of an owner of any direct or indirect interest in the Holder (the "Principal Owner"), then, transfers to any of that Principal Owner's Family Members, or any entity controlled by such Principal Owner or any such Family Members, or any trust or foundation established for the benefit of such Principal Owner or any such Family Members, and transfers among the Principal Owners by one to another;

 

(p)   as regards Nan Fung and Pivotal, any transfers in connection with or for the purpose of any solvent corporate reconstruction, reorganization or restructuring, then any of the group of companies comprising Chen's Group International Limited and its Subsidiaries;

 

(q)   as regards BEYEOTECH, any transfers in connection with or for the purpose of any corporate reconstruction, reorganisation or restructuring, then any of portfolio companies under the common control or management with BEYEOTECH; and

 

(r)   as regards a Holder that is an investment entity, any transfers in connection with or for the purpose of any transfer or sale of equity securities in other portfolio companies to one or more purchasers that are professional investment entities for the purpose of winding up or restructuring some or all of the Holder’s investment portfolio (whether in a particular industry sector or segment or as part of liquidating its legacy positions).

 

provided, that in the case of any Transfer or distribution pursuant to Sections 4.2(a) through (h) and (m) through (r), each donee, distributee or other transferee shall agree in writing, in form and substance reasonably satisfactory to the Company, to be bound by the provisions of this Agreement.

 

For purposes of this Section 4, “Affiliate” shall mean any person (including any investment fund or investor, venture capital fund, registered investment company, investment adviser, partnership or limited partnership but excluding portfolio companies) which a Holder directly or indirectly controls or by which such Holder is directly or indirectly controlled or which is directly or indirectly under common control with such Holder, including without limitation, any general partner, managing member, stockholder, investment adviser, officer, director or trustee of such person or any investment fund or investor, venture capital fund, registered investment company or other investment fund now or hereafter existing that is controlled by one of the general partners, managing members, stockholders or investment advisers of, or shares the same management company or investment adviser with, such person. An Affiliate shall also mean any Family Member or a trust or foundation for the benefit of such Family Member. “Family Member” shall mean any child, parent, sibling, spouse or other first or second degree family member of a Holder who is a natural person.

 

Notwithstanding anything to the contrary in Section 5.4, the lock-up provisions of this Section 4 may be waived by a majority of the Board.

 

29 

 

Section 5.   General.

 

5.1.   Adjustments Affecting Registrable Securities. The provisions of this Agreement shall apply, to the full extent set forth herein with respect to the Registrable Securities, to any and all shares of capital stock of the Company, any successor or assign of the Company (whether by merger, share exchange, consolidation, sale of assets or otherwise) or any Subsidiary or parent company of the Company which may be issued in respect of, in exchange for or in substitution of, Registrable Securities and shall be appropriately adjusted for any stock dividends, splits, reverse splits, combinations, recapitalizations and the like occurring after the date hereof.

 

5.2.   Rule 144. (i) So long as it remains subject to the reporting provisions of the Exchange Act, the Company will timely file the reports required to be filed by it under the Securities Act or the Exchange Act (including, but not limited to, the reports under Sections 13 and 15(d) of the Exchange Act referred to in subparagraph (c)(1)(i) of Rule 144 under the Securities Act, as such Rule may be amended (“Rule 144”)) or, if the Company is not required to file such reports, it will, upon the request of any Holder, make publicly available other information so long as necessary to permit sales by such Holder under Rule 144, or any similar rules or regulations hereafter adopted by the SEC, and (ii) it will take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder to sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by Rule 144, or  any similar rule or regulation hereafter adopted by the SEC. Upon the request of any Holder of Registrable Securities, the Company will promptly deliver to such Holder a written statement as to whether it has complied with such requirements.

 

5.3.   Nominees for Beneficial Owners. If Registrable Securities are held by a nominee for the beneficial owner thereof, the beneficial owner thereof may, at its option, be treated as the Holder of such Registrable Securities for purposes of any request or other action by any Holder or Holders of Registrable Securities pursuant to this Agreement (or any determination of any number or percentage of shares constituting Registrable Securities held by any Holder or Holders of Registrable Securities contemplated by this Agreement); provided, however, that the Company shall have received evidence reasonably satisfactory to it of such beneficial ownership.

 

5.4.   Amendments and Waivers. Except as otherwise provided herein, no modification, amendment or waiver of any provision of this Agreement shall be effective against the Company or any Holder unless such modification, amendment or waiver is approved in writing by the Company and the Holders holding a majority of the Registrable Securities then held by all Holders; provided that notwithstanding the foregoing, any amendment hereto or waiver hereof that adversely affects one Holder, solely in its capacity as a Holder of Registrable Securities, in a manner that is materially different from the other Holders (in such capacity) shall require the consent of the Holder so affected. No waiver of any of the provisions of this Agreement shall be deemed to or shall constitute a waiver of any other provision hereof (whether or not similar). No failure or delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof or of any other or future exercise of any such right, power or privilege.

 

5.5.   Notices. All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (i) if personally delivered, on the date of delivery, (ii) if delivered by express

 

30 

 

courier service of national standing (with charges prepaid), on the Business Day following the date of delivery to such courier service, (iii) if deposited in the United States mail, first-class postage prepaid, on the fifth (5th) Business Day following the date of such deposit, (iv) if delivered by facsimile transmission, upon confirmation of successful transmission, (x) on the date of such transmission, if such transmission is completed at or prior to 5:00 p.m., local time of the recipient party on a Business Day, and (y) on the next Business Day following the date of transmission, if such transmission is completed after 5:00 p.m., local time of the recipient party, or is transmitted on a day that is not a Business Day, or (v) if via e-mail communication, on the date of delivery. All notices, demands and other communications hereunder shall be delivered as set forth below and to any subsequent holder of Stock subject to this Agreement at such address as indicated by the Company’s records, or pursuant to such other instructions as may be designated in writing by the party to receive such notice:

 

if to the Company, to:

 

Oculis SA
EPFL Innovation Park Building D
1015 Lausanne

Switzerland
Attention:  

Riad Sherif, Chief Executive Officer

Email:  

riad.sherif@oculis.com

 

with copies to (which shall not constitute notice):

 

Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ, UK

Attention:  

Michal Berkner

Divakar Gupta

Ryan Sansom 

E-mail:

mberkner@cooley.com 

dgupta@cooley.com

rsansom@cooley.com

 

if to any Holder, to the address set forth opposite the name of such Holder on the signature pages hereto or such other address indicated in the records of the Company.

 

5.6.   Successors and Assigns. Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and the respective successors, permitted assigns, heirs and personal representatives of the parties hereto, whether so expressed or not. This Agreement may not be assigned by the Company without the prior written consent of the Holders. No Holder shall have the right to assign all or part of its or his rights and obligations under this Agreement to any Person without the consent of the Company and unless such Person duly executes and delivers to the Company a Joinder Agreement. Upon any such assignment, such assignee shall have and be able to exercise and enforce all rights of the

 

31 

 

assigning Holder which are assigned to it and, to the extent such rights are assigned, any reference to the assigning Holder shall be treated as a reference to the assignee. If any Holder shall acquire additional Registrable Securities, such Registrable Securities shall be subject to all of the terms, and entitled to all the benefits, of this Agreement. Additional Persons may become parties to this Agreement as Holders with the consent of the Company (not to be unreasonably withheld or delayed), by executing and delivering to the Company the Joinder Agreement.

 

5.7.   Termination.

 

(a)   The obligations of the Company and a Holder under this Agreement, in each case solely with respect to such Holder, will terminate upon the earlier of:

 

(i)   the date on which such Holder no longer holds any Registrable Securities; or

 

(ii)   the date on which such the Holder is eligible to sell its Registrable Securities pursuant to Rule 144 (without limitation as to volume or manner of sale).

 

(b)   This Agreement shall terminate on the date that is five (5) years from date hereof.

 

(c)   Notwithstanding clauses (a) and (b) above, Section 2.5, Section 2.9, Section 4, Section 5.2, Section 5.9 and Section 5.13 shall survive termination of this Agreement.

 

5.8.   Entire Agreement. This Agreement and the other documents referred to herein or delivered pursuant hereto which form part hereof constitute the entire agreement and understanding between the parties hereto and supersedes all prior agreements and understandings relating to the subject matter hereof.

 

5.9.   Governing Law; Jurisdiction; Waiver of Jury Trial.

 

(a)   This Agreement will be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the principles of conflict of laws thereof.

 

(b)   Any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement may be brought against any of the parties in the United States District Court for the Southern District of New York or any New York state court located in New York, New York, and each of the parties hereby consents to the exclusive jurisdiction of such court (and of the appropriate appellate courts) in any such suit, action or proceeding and waives any objection to venue laid therein. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT.

 

32 

 

5.10.   Interpretation; Construction.

 

(a)   The table of contents and headings in this Agreement are for convenience of reference only, do not constitute part of this Agreement and shall not be deemed to limit or otherwise affect any of the provisions hereof. Where a reference in this Agreement is made to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.”

 

(b)   The parties have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 

5.11.   Counterparts. This Agreement may be executed and delivered in any number of separate counterparts (including by facsimile or electronic mail), each of which shall be an original, but all of which together shall constitute one and the same agreement.

 

5.12.   Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application thereof to any person or any circumstance, is invalid or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction.

 

5.13.   Specific Enforcement. It is agreed and understood that monetary damages would not adequately compensate an injured party for the breach of this Agreement by any party hereto and, accordingly, that this Agreement shall be specifically enforceable, in addition to any other remedy to which such injured party is entitled at law or in equity, and that any breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order. Further, each party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach or an award of specific performance is not an appropriate remedy for any reason at law or equity and agrees that a party’s rights would be materially and adversely affected if the obligations of the other parties under this Agreement were not carried out in accordance with the terms and conditions hereof. Each party further agrees that no party shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtain any remedy referred to in this Section 5.13, and each party irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument.

 

5.14.   Further Assurances. Each party hereto shall do and perform or cause to be done and performed all such further acts and things and shall execute and deliver all such other agreements, certificates, instruments, and documents as any other party hereto reasonably may request in order

 

33 

 

to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

5.15.   Confidentiality. Each Holder agrees that any non-public information which they may receive relating to the Company and its Subsidiaries (the “Confidential Information”) including notices of proposed offerings or any suspension thereof will be held strictly confidential and will not be disclosed by it to any Person without the express written permission of the Company; provided, however, that the Confidential Information may be disclosed (i) in the event of any compulsory legal process or compliance with any applicable law, subpoena or other legal process, as required by an administrative requirement, order, decree or the rules of any relevant stock exchange or in connection with any filings that the Holder may be required to make with any regulatory authority; provided, however, that in the event of compulsory legal process, unless prohibited by applicable law or that process, each Holder agrees (A) to give the Company prompt notice thereof and to cooperate with the Company in securing a protective order in the event of compulsory disclosure and (B) that any disclosure made pursuant to public filings will be subject to the prior reasonable review of the Company, (ii) to any foreign or domestic governmental or quasi-governmental regulatory authority, including any stock exchange or other self-regulatory organization having jurisdiction over such party, (iii) to each Holder’s or its Affiliate’s, officers, directors, employees, partners, accountants, lawyers and other professional advisors for use relating solely to management of the investment or administrative purposes with respect to such Holder and (iv) to a proposed transferee of securities of the Company held by a Holder; provided, however, that the Holder informs the proposed transferee of the confidential nature of the information and the proposed transferee agrees in writing to comply with the restrictions in this Section 4.15 and delivers a copy of such writing to the Company.

 

5.16.   Opt-Out Requests. Each Holder shall have the right, at any time and from time to time (including after receiving information regarding any potential public offering), to elect to not receive any notice that the Company or any other Holders otherwise are required to deliver pursuant to this Agreement by delivering to the Company a written statement signed by such Holder that it does not want to receive any notices hereunder (an “Opt-Out Request”); in which case and notwithstanding anything to the contrary in this Agreement the Company and other Holders shall not be required to, and shall not, deliver any notice or other information required to be provided to Holders hereunder to the extent that the Company or such other Holders reasonably expect would result in a Holder acquiring material non-public information within the meaning of Regulation FD promulgated under the Exchange Act. An Opt-Out Request may state a date on which it expires or, if no such date is specified, shall remain in effect indefinitely. A Holder who previously has given the Company an Opt-Out Request may revoke such request at any time, and there shall be no limit on the ability of a Holder to issue and revoke subsequent Opt-Out Requests; provided that each Holder shall use commercially reasonable efforts to minimize the administrative burden on the Company arising in connection with any such Opt-Out Requests.

 

5.17.   Original Registration Rights Agreement. The Sponsor hereby agrees that upon execution of this Agreement by the Sponsor, the Original Registration Rights Agreement shall be automatically terminated and superseded in its entirety by this Agreement.

 

[Remainder of Page Intentionally Left Blank]

 

34 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first above written.

 

  THE COMPANY:
  Oculis Holding AG,
  a public limited liability company incorporated and existing under the laws of Switzerland
       
  By:  
    Name:  
    Title:     

[Signature Page to Amended and Registration Rights Agreement]

 

  HOLDERS
  LSP Sponsor EBAC B.V.,
  a Cayman Islands limited liability company
       
  By:  
    Name:  
    Title:    
       
  [OTHER HOLDERS]

[Signature Page to Amended and Registration Rights Agreement]

 

Exhibit A

 

JOINDER AGREEMENT

 

This Joinder Agreement (this “Joinder Agreement”) is made as of [ ], by [and among [  ] (the “Transferring Holder”) and] [  ] (the “New Holder”), in accordance with that certain Amended and Restated Registration Rights and Lock-Up Agreement, dated as of [●], [●] (as amended from time to time, the “Agreement”), by and among Oculis Holding AG (the “Company”) and the other Holders party thereto.

 

WHEREAS, the Agreement requires the New Holder to become a party to the Agreement by executing this Joinder Agreement, and upon the New Holder signing this Joinder Agreement, the Agreement will be deemed to be amended to include the New Holder as a Holder thereunder;

 

NOW, THEREFORE, in consideration of the foregoing, and of the representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:

 

Section 1.   Party to the Agreement. By execution of this Joinder Agreement, as of the date hereof the New Holder is hereby made a party to the Agreement as a Holder. The New Holder hereby agrees to become a party to the Agreement and to be bound by, and subject to, all of the representations, covenants, terms and conditions of the Agreement in the same manner as if the New Holder were an original signatory to the Agreement. Execution and delivery of this Joinder Agreement by the New Holder shall also constitute execution and delivery by the New Holder of the Agreement, without further action of any party.

 

Section 2.   Defined Terms. Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement unless otherwise noted.

 

Section 3.   Representations and Warranties of the New Holder.

 

3.1.   Authorization. The New Holder has all requisite power and authority and has taken all action necessary in order to duly and validly approve the New Holder’s execution and delivery of, and performance of its obligations under, this Joinder Agreement. This Joinder Agreement has been duly executed and delivered by the New Holder and constitutes a legal, valid and binding agreement of the New Holder, enforceable against the New Holder in accordance with its terms.

 

3.2.   No Conflict. The New Holder is not under any obligation or restriction, nor shall it assume any such obligation or restriction, that does or would materially interfere or conflict with the performance of its obligations under this Joinder Agreement.

 

Section 4.   Further Assurances. The parties agree to execute and deliver any further instruments or perform any acts which are or may become necessary to effectuate the purposes of this Joinder Agreement.

 

Exhibit A-1

 

Section 5.   Governing Law. This Joinder Agreement will be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the principles of conflict of laws thereof.

 

Section 6.   Counterparts. This Joinder Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same amendatory instrument.

 

Section 7.   Entire Agreement. This Joinder Agreement and the Agreement contain the entire understanding, whether oral or written, of the parties hereto with respect to the matters covered hereby. Any amendment or change in this Joinder Agreement shall not be valid unless made in writing and signed by each of the parties hereto.

 

[Signature pages follow]

 

Exhibit A-2

 

Exhibit A

 

IN WITNESS WHEREOF, intending to be legally bound hereby, the undersigned parties have executed this Joinder Agreement as of the date first above written.

 

  [TRANSFERRING HOLDER]
   
  [ _____]
   
  By:  
    Name:  
    Title:  
       
  NEW HOLDER
   
  [ _____]
   
  By:  
    Name:  
    Title:  
       
  Notice Address: [_________________]
  [ _____]
  [ _____]
  Attn: [____  ]
  Facsimile: [__  ]

 

Accepted and Agreed to as of

 

the date first written above:

 

COMPANY

 

Oculis Holding AG

 

By:           
  Name:    
  Title:    

Exhibit A-3

 

SCHEDULE 1

 

HOLDERS

 

Target Holders:

 

 

Sponsor:

 

 

Schedule 1

Exhibit 99.1

 

Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology

 

·Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populations

 

Net proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the first biologic eye-drop for DED and the first neuroprotective agent for neuro-retina diseases, such as glaucoma

 

Combined company expected to have a post-transaction enterprise value of approximately $220 million and a cash balance exceeding $200 million, including gross PIPE and private investment proceeds and cash held in EBAC’s trust, assuming no redemptions by EBAC shareholders, and before deducting anticipated transaction expenses

 

Upsized PIPE and private investment financing of close to $80 million, anchored by LSP 7, with the participation of leading institutional investors, including Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, funds managed by Tekla Capital Management LLC, and VI Partners, among others

 

Business combination is expected to be completed in H1 2023

 

Lausanne, Switzerland & Amsterdam, Netherlands, October 17, 2022 -- Oculis, SA. (“Oculis”), a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (“EBAC”, NASDAQ: EBAC), a special purpose acquisition company (SPAC), today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named “Oculis Holding SA” and will work to accelerate the development of Oculis’s differentiated ophthalmology pipeline. The transaction includes commitments to an upsized PIPE and private investment of close to $80 million, anchored by LSP 7, with the participation of leading institutional investors, including Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, funds managed by Tekla Capital Management LLC, and VI Partners, among others.

 

Riad Sherif, M.D., CEO of Oculis, said: “Oculis’s purpose is to drive innovation to save sight and improve eye care. This transaction accelerates our mission and propels our pipeline of highly differentiated product candidates for patients and physicians. We are delighted to have the support of key investors. We look forward to delivering important milestones including Phase 3 clinical trials of OCS-01, a potential first topical eyedrop product to treat the retina, Phase 2b clinical trials of OCS-02, a first in class topical anti-TNF for the treatment of DED and uveitis, and a proof-of-concept trial of neuroprotective agent, OCS-05, in acute optic neuritis. These are crucial deliverables towards bringing to market new therapies to patients.”

  

Eduardo Bravo, CEO of EBAC, said: “Oculis has built a highly diversified late-stage pipeline that has the potential to revolutionize treatment in major ophthalmology segments. EBAC was formed to invest in the untapped potential in the European biotechnology sector and has screened over 100 European biotechnology companies. Oculis is a prime example of what we set out to invest in, with great innovation, a well thought out strategy and an experienced management team to bring promising therapies to market for patients suffering from eye disease.”

 

 

 

Oculis Overview

 

Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including DME, DED, and glaucoma, affecting growing patient populations.

 

Oculis is advancing its diversified product portfolio, which includes three clinical-stage product candidates:

 

OCS-01 was purposefully designed to enable a potential breakthrough approach in the treatment of retinal diseases; a topical, non-invasive approach. Current therapies require intra-ocular injections. Effective topical therapies would complement the existing approaches by adding an option with improved patient comfort, safety, accessibility, cost and allowing individualized dosing. OCS-01 combines dexamethasone, an approved active ingredient proven as effective and safe in the treatment of DME with a novel formulation technology that facilitates active ingredient access to the back-of-the-eye (Oculis’s Optireach® technology). This product candidate is currently in Phase 3 development, globally (USA, EU, CN) for DME with the potential to become the first non-invasive, topical eye drop for a back of the eye disease. OCS-01 is also in Phase 3 development in the USA for the treatment of inflammation and pain following cataract surgery, which would, if approved, potentially be the first once-a-day steroid for this indication.

 

OCS-02 is a topical anti-TNF alpha monoclonal antibody fragment. The proprietary biologic technology of antibody fragment has potential pharmaceutical advantages in terms of solubility and stability. TNF alpha has been shown to be involved in two ophthalmic conditions: dry eye disease (DED) where it interferes with both core inflammation and necrosis and in uveitis where a TNF-alpha antagonist was approved as a systemic treatment of posterior uveitis. OCS-02 has completed three, placebo controlled, double masked, clinical studies in which favorable efficacy and tolerability results were observed: two in dry eye disease (DED) symptoms and one in acute anterior uveitis (AAU). The candidate is now progressing into Phase 2b clinical studies. For the treatment of DED, it has the potential to, if approved, be the first topical biologic, with an additional upside in personalized treatment based on a proprietary genetic biomarker. For the uveitis indication, the goal is to evaluate OCS-02 as a steroid-sparing maintenance treatment for chronic anterior uveitis, an indication where no other non-steroidal topical solutions are approved.

 

OCS-05 is a serum-glucocorticoid kinase 2 (SGK-2) activator, in development as a potential disease-modifying neuroprotective agent to address neurological damage to the optic nerve. OCS-05 is initially in development as a potential therapeutic for acute optic neuritis, or AON, a rare disease with high unmet need as currently, there is no approved treatment for AON.  OCS-05 is currently in clinical studies in Europe. Oculis plans to evaluate OCS-05 to treat other pervasive ophthalmologic neurological pathologic disorders such as geographic atrophy, neuropathic keratitis and glaucoma.

 

In addition to these three clinical candidates, Oculis is engaged in several earlier preclinical development initiatives, including the evaluation of OCS-03 as a possible treatment for corneal neovascularization, a common disorder caused by the aberrant development of new blood vessels into the cornea and pterygium, a pink colored growth that originates in the conjunctiva. Oculis is also assessing the preclinical candidate OCS-04 as a potential therapeutic for use in corneal transplant.

 

 

 

Transaction Overview

 

The business combination is expected to deliver gross proceeds to Oculis in excess of $200 million (assuming no redemptions). This includes approximately $127.5 million held in EBAC’s trust (assuming no redemptions) and commitments to an upsized PIPE and private investment of close to $80 million, anchored by LSP 7, with the participation of leading institutional investors, including Earlybird, Novartis Venture Fund, Pivotal bioVenture Partners, funds managed by Tekla Capital Management LLC, and VI Partners, among others.

 

The proposed transaction was unanimously approved by the board of directors of all parties and is supported by existing shareholders of Oculis.

 

The proposed transaction is expected to be completed in the first half of 2023, subject to, among other things, the approval by EBAC shareholders and the satisfaction or waiver of other customary closing conditions. The newly listed entity Oculis Holding SA will be a company registered in Switzerland with its headquarters at the current office of Oculis at the EPFL Innovation Park in Lausanne, Switzerland.

 

Oculis Advisors

  

BofA Securities is acting as financial advisor and SVB Securities is acting as capital market’s advisor to Oculis. Cooley (UK) LLP serves as US legal counsel, VISCHER SA serves as Swiss legal counsel and PricewaterhouseCoopers SA serves as auditors to Oculis, SA.

 

EBAC Advisors

  

Credit Suisse and Kempen are acting as financial advisor and capital markets advisor. Davis Polk & Wardwell LLP serves as U.S. legal counsel, Stibbe N.V. serves as Dutch legal counsel, and Maples Group serves as Cayman legal counsel to EBAC.

 

Credit Suisse, BofA Securities, SVB Securities, Kempen, and Arctica Finance are acting as private placements agents for EBAC in connection with the PIPE Transaction. Shearman & Sterling LLP serves as legal counsel to the placement agents.

 

About EBAC

 

EBAC is a SPAC formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more business or entities. Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to Oculis. The EBAC team has substantial experience investing in and operating businesses in multiple sectors, as well as a long-term track record in creatively structuring transactions to unlock and maximize value.  

 

About Oculis

 

Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address medical needs with breakthrough innovations. Oculis’s differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculis is poised to deliver treatments to patients worldwide. Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculis is led by an experienced management team with an extensive track record and supported by leading international healthcare investors.

 

Additional Information and Where to Find It

 

In connection with the Merger Agreement and the proposed Transaction, EBAC intends to file with the U.S. Securities and Exchange Commission (the "SEC") a proxy statement on Schedule 14A relating

 

 

 

to the proposed Transaction. This communication is not intended to be, and is not, a substitute for the proxy statement or any other document that EBAC has filed or may file with the SEC in connection with the proposed Transaction. EBAC's shareholders and other interested persons are advised to read, when available, the preliminary proxy statement and the amendments thereto, the definitive proxy statement and documents incorporated by reference therein filed in connection with the proposed Transaction, as these materials will contain important information about EBAC, Oculis SA, the Merger Agreement, and the proposed Transaction. When available, the definitive proxy statement and other relevant materials for the proposed Transaction will be mailed to shareholders of EBAC as of a record date to be established for voting on the proposed Transaction. Before making any voting or investment decision, investors and shareholders of EBAC are urged to carefully read the entire proxy statement, when they become available, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed Transaction. EBAC investors and shareholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC's website at www.sec.gov, or by directing a request to: European Biotech Acquisition Corp., EPFL Innovation Park Building D, Route J-D. Colladon, 1015 Lausanne, Switzerland, Attention: Eduardo Bravo.

 

Participants in the Solicitation

 

EBAC, Oculis SA and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from EBAC's shareholders with respect to the proposed Transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed Transaction of EBAC's directors and officers in EBAC's filings with the SEC, including, when filed with the SEC, the preliminary proxy statement and the amendments thereto, the definitive proxy statement, and other documents filed with the SEC. Such information with respect to Oculis's directors and executive officers will also be included in the proxy statement.

 

No Offer or Solicitation

 

This press release is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

Forward-Looking Statements

 

This press release contains forward looking statements and information. The use of words such as “accelerate,” “address,” “approve,” “assess,” “assume,” “become,” “before,” “bring,” “continue,” “could,” “develop,” “drive,” “engage,” “evaluate,” “expect,” “include,” “first,” “follow,” “forward,” “further,” “goal,” “imminent,” “initiate,” “may,” “plan,” “poise,” “potential,” “progress,” “promise,” “propose,” “prove,” “ongoing,” “upcoming,” “upside,” “will,” “would,” and other similar expressions are intended to identify forward looking statements. For example, statements regarding the initiation, timing, progress and results of Oculis’s clinical studies, including with respect to OCS-01, OCS-02, and OCS-05, and of Oculis’ preclinical studies, including with respect to OCS-03 and OCS-04; Oculis’s research and development programs, regulatory and business strategy, future development plans, and management; Oculis’s ability to advance product candidates into, and successfully complete, and the timing or likelihood of regulatory filings and approvals, as well as any statements regarding EBAC’s

 

 

 

or Oculis’s ability to consummate the proposed business combination, are forward looking. All forward looking statements are based on estimates and assumptions that, while considered reasonable by EBAC and its management and Oculis and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond EBAC’s and Oculis’s control. These forward looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the SPAC and the Company. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. These risks and uncertainties include the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the proposed business combination; the outcome of any legal proceedings that may be instituted against EBAC, the combined company or others following this announcement of the proposed business combination and any definitive agreements with respect thereto; the inability to complete the proposed business combination due to the failure to obtain approval of the shareholders of EBAC, to obtain financing to complete the proposed business combination or to satisfy other conditions to closing; changes to the proposed structure of the proposed business combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the proposed business combination; the ability for Oculis Holding SA to meet stock exchange listing standards following the consummation of the proposed business combination; the risk that the proposed business combination disrupts current plans and operations of Oculis SA as a result of the announcement and consummation of the proposed business combination; the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain key relationships and retain its management and key employees; costs related to the proposed business combination; changes in applicable laws or regulations; the possibility that Oculis SA or the combined company may be adversely affected by changes in domestic and foreign business, market, financial, political and legal conditions; the inability of the parties to successfully or timely consummate the proposed business combination, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination; Oculis’s estimates of expenses and profitability; or other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements and Risk Factor Summary” in EBAC’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, or other documents filed by EBAC with the SEC.

 

Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to update or revise an y forward looking statement, whether as a result of new information, future events or otherwise, except as required by law.

 

Nothing in this Press Release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward looking statements will be achieved. You should not place undue reliance on forward looking statements, which speak only as of the date they are made. Neither EBAC nor Oculis undertakes any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this Press Release.

 

 

 

Oculis and EBAC disclaim any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this Press Release and such liability is expressly disclaimed.

 

The recipient agrees that it shall not seek to sue or otherwise hold the Oculis, EBAC or any of their respective directors, officers, employees, affiliates, agents, advisors or representatives liable in any respect for the provision of this Press Release, the information contained in this Press Release, or the omission of any information from this Press Release. Only those particular representations and warranties of Oculis or EBAC made in a definitive written agreement regarding the transaction (which will not contain any representation or warranty relating to this Press Release) when and if executed, and subject to such limitations and restrictions as specified therein, shall have any legal effect.

 

INVESTOR CONTACT:

 

Consilium Strategic Communications

 

Amber Fennell, Matthew Cole, David Daley

 

oculis@consilium-comms.com

 

 

 

 

 

 

 

 

 

Exhibit 99.2

 

Rethinking Ophthalmology Oculis Company Overview October 2022

 

 

2 2 Strictly private and confidential Commercially confidential information This investor presentation (this “ Presentation ” ) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed bu siness combination (the “ Business Combination ” ) between European Biotech Acquisition Corp. ( “ SPAC ” ) and Oculis SA (together with its subsidiaries, the “ Company ” ). The information contained herein does not purport to be all - inclusive and none of SPAC, the Company or their respective affil iates makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentati on. Industry and market data used in this presentation have been obtained from third - party industry publications and sources as wel l as from research reports prepared for other purposes. Neither the Company nor SPAC has verified, or will verify, any part of thi s P resentation, and the information in this Presentation is subject to change. The recipient should make its own independent investigations and analyses of the Company and its own assessment of all information and material provided, or made available , b y the Company, SPAC or any of their respective directors, officers, employees, affiliates, agents, advisors or representative s. This Presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendat ion to purchase any security of SPAC, the Company, or any of their respective affiliates. You should not construe the contents of th is Presentation as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentati on, you confirm that you are not relying upon the information contained herein to make any decision. The distribution of this Presentation may also be restricted by law and persons into whose possession this Presentation comes sh ould inform themselves about and observe any such restrictions. The recipient acknowledges that it is (a) aware that the Unit ed States securities laws prohibit any person who has material, non - public information concerning a company from purchasing or sell ing securities of such company or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities, and (b) familiar with the Securities E xch ange Act of 1934 , as amended, and the rules and regulations promulgated thereunder (collectively, the "Exchange Act"), and that the recipient will neither use, nor cause any third party to use, this Presentation or any information contained herein in contra ven tion of the Exchange Act, including, without limitation, Rule 10 b - 5 thereunder. This Presentation and information contained herein constitutes confidential information and is provided to you on the conditi on that you agree that you will hold it in strict confidence and not reproduce, disclose, forward or distribute it in whole or i n p art without the prior written consent of SPAC and the Company and is intended for the recipient hereof only. This Presentation supersedes all previous investor presentations delivered in connection with the Business Combination. You s hou ld only refer to the information in this version of the Presentation. Forward - Looking Statements These slides and the accompanying oral presentation contain forward - looking statements and information. The use of words such as “ may, ” “ might, ” “ will, ” “ should, ” “ expect, ” “ plan, ” “ anticipate, ” “ believe, ” “ estimate, ” “ project, ” “ intend, ” “ future, ” “ potential, ” “ poised, ” “ advance, ” “ reach, ” “ maintain, ” or “ continue, ” and other similar expressions are intended to identify forward - looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical studies, our clinical studies, our research and development programs, our regulatory strategy, our future develop men t plans, our ability to advance product candidates into, and successfully complete, and the timing or likelihood of regulator y f ilings and approvals, as well as any statements regarding our ability to consummate the proposed Business Combination, are forward l ook ing. All forward - looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. These forward - looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive state me nt of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumption s. Many actual events and circumstances are beyond the control of the SPAC and the Company All forward - looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. These risk s a nd uncertainties include changes in domestic and foreign business, market, financial, political and legal conditions; the ina bil ity of the parties to successfully or timely consummate the proposed Business Combination, including the risk that any regulatory ap pro vals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined compan y or the expected benefits of the proposed Business Combination or that required shareholder approvals are not obtained. Any forward - looking statement speaks only as of the date on which it was made. We undertake no obligation to update or revise an y forward - looking statement, whether as a result of new information, future events or otherwise, except as required by law. Nothing in this Presentation should be regarded as a representation by any person that the forward - looking statements set forth herein will be achieved or that any of the contemplated results of such forward - looking statements will be achieved. You should not place undue reliance on forward - looking statements, which speak only as of the date they are made. Neither SPAC nor the Comp any undertakes any duty to update these forward - looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this Presentation. The Company and SPAC disclaim any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this Presentation and such liability is expressly disc lai med. The recipient agrees that it shall not seek to sue or otherwise hold the Company, SPAC or any of their respective directors, off icers, employees, affiliates, agents, advisors or representatives liable in any respect for the provision of this Presentatio n, the information contained in this Presentation, or the omission of any information from this Presentation. Only those particular rep resentations and warranties of the Company or SPAC made in a definitive written agreement regarding the transaction (which wi ll not contain any representation or warranty relating to this Presentation) when and if executed, and subject to such limitatio ns and restrictions as specified therein, shall have any legal effect. Copyright of this Presentation is owned by the Company. No part of this presentation may be reproduced in any manner without the permission of the Company. Disclaimer (1 of 2)

 

 

3 3 Strictly private and confidential Commercially confidential information Industry and Market Data This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company’s industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, proje cti ons, assumptions, and estimates of the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk. This presentation concerns drugs that are in development and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). No representation is made as to the safety or effectiveness of any of the products in development, nor for any products which may have applications pending before the FDA. Any trademarks, servicemarks , trade names and copyrights of the Company and other companies contained in this Presentation are the property of their resp ect ive owners. Additional Information In connection with the proposed Business Combination, the parties will file a Registration Statement with the SEC containing a p reliminary proxy statement of SPAC and a preliminary prospectus of the combined company, and after the registration statement is declared effective, SPAC will mail a definitive proxy statement/prospectus r ela ting to the proposed Business Combination to its shareholders. This Presentation does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to for m t he basis of any investment decision or any other decision in respect of the Business Combination. SPAC’s shareholders and other interested persons are advised to read the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents which will be filed in connection with the proposed Business Combination, as these materials will contain important in formation about SPAC, the Company and the Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to sh are holders of SPAC as of a record date to be established for voting on the proposed Business Combination. Shareholders can obtain copies of the preliminary proxy statement/prospectus and will be able to obtain co pies of the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: European Biotech Acqu isi tion Corp., Johannes Vermeerplein 9, 1071 DV Amsterdam, Netherlands. Participants in the Solicitation SPAC and its directors and executive officers may be deemed participants in the solicitation of proxies from SPAC’s sharehold ers with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in SPAC will be contained in SPAC’s final prospectus related to i ts initial public offering, which will be filed with the SEC and will become available free of charge at the SEC’s web site at www.sec.gov, or by directing a request to European Biotech Acquisition Corp., Johannes Vermeerplein 9, 1071 DV Amsterdam, Netherlands. Additional information regarding the interests of such participants will be contained in the Registration Statement. The Company and its directors and executive officers may also be deemed to be participants in the solicitation of proxies fro m t he shareholders of SPAC in connection with the proposed Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combina tio n will be contained in the Registration Statement. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORI TY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN ANY REPRESENTATION TO THE CO NTRARY IS A CRIMINAL OFFENSE. The Company and SPAC reserve the right to negotiate with one or more parties and to enter into a definitive agreement relatin g t o the transaction at any time and without prior notice to the recipient or any other person or entity. The Company and SPAC also reserve the right, at any time and without prior notice and without assigning any reason th erefor, (i) to terminate the further participation by the recipient or any other person or entity in the consideration of, and proposed process relating to, the transaction, (ii) to modify any of the rules or procedu res relating to such consideration and proposed process and (iii) to terminate entirely such consideration and proposed process. No representation or warranty (whether express or implied) has been made by the Company, the SPAC or any of their respective directors, officers, employees, affiliates, agents, advisors or representatives with respect to the proposed process or the manner in which the proposed process is conducted, an d t he recipient disclaims any such representation or warranty. The recipient acknowledges that the Company, SPAC and their respective directors, officers, employees, affiliates, agents, advisors or representatives a re under no obligation to accept any offer or proposal by any person or entity regarding the transaction. None of the Company, SPAC or any of their respective directors, officers, employees, affiliates, agents, advisor s o r representatives has any legal, fiduciary or other duty to any recipient with respect to the manner in which the proposed process is conducted. Disclaimer (2 of 2)

 

 

4 4 Strictly private and confidential Commercially confidential information Risks Related to Our Financial Position and Need For Additional Capital • We are a clinical - stage biopharmaceutical company with a limited operating history and no products approved. We will need substa ntial additional funding to support our operations and pursue our growth strategy. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. Risks Related to Clinical Development • We depend heavily on the success of our candidates OCS - 01, OCS - 02, and OCS - 05. Our approaches to the treatment of ophthalmic dis eases are unproven, and clinical trials of our product candidates may not be successful. If we are unable to successfully complete clinical development of, and obtain marke tin g approvals for, our product candidates, or experience significant delays in doing so, or if after obtaining marketing approvals, we fail to commercialize these product can didates, our business will be materially harmed. • We have not yet successfully completed any Phase 3 clinical trials nor commercialized any pharmaceutical products, which may mak e it difficult to evaluate our future prospects. • The outcome of preclinical testing and early clinical trials may not be predictive of the success of later - stage clinical trials . • The ongoing COVID - 19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial co ndition. Risks Related to Technical Development / Manufacturing • The manufacture of our product development candidates may require outsourced, custom manufacturing and we may encounter diffi cul ties in production, particularly with respect to formulation, process development or scaling up of manufacturing capabilities. If we, or our CMOs, encounter such d iff iculties, our ability to provide supply of our product candidates for preclinical studies, clinical trials or our products for patients, if approved, could be delayed or st opp ed, or we may be unable to maintain a commercially viable cost structure. Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters • If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory ap provals could be delayed or prevented. • We may be required, or choose, to suspend, repeat or terminate our clinical trials if they are not conducted in accordance wi th regulatory requirements, the results are negative or inconclusive, the trials are not well - designed, or research participants experience adverse safety outcomes. Risks Related to Commercialization • If approved for marketing, sale, or distribution, our products may fail to achieve the degree of market acceptance by physici ans , patients, third - party payors and others in the medical community necessary for commercial success in the U.S. or internationally, and the market opportunity for these produ cts may be smaller than we estimate. • Any product candidate for which we obtain marketing approval may become subject to unfavorable pricing regulations, third - party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business. Risks Related to Our Intellectual Property • If our patent position does not adequately protect our product candidates, others could compete against us more directly, whi ch would harm our business. Risk Factors

 

 

5 5 Strictly private and confidential Commercially confidential information EBAC overview Eduardo Bravo Chief Executive Officer Onno van de Stolpe Independent Board Member Former CEO and Founder Galapagos Volkert Doeksen Independent Board Member Senior Advisor at The Carlyle Groups Koen Sintnicolaas Chief Financial Officer Gisela Wolf Legal Counsel Felice Verduyn Partner ▪ Over 25 years of senior management and board experience in the biopharmaceutical sector ▪ Previously CEO at Nordic Nanovector , Cellerix and TiGenix (oversaw several financing rounds, IPO on Nasdaq in 2016 and acquisition by Takeda in 2018) ▪ Currently Chairman of the Boards at Vivet Therapeutics and Engitix Therapeutics, and a Board Member at Sutura Therapeutics Martin Kleijwegt Chairman, Founder and Managing partner Mark Wegter Board member, Managing partner Board (Lead, Manage, Develop) Support team Geraldine O’Keeffe Partner Broader EQT Life Sciences team 19 PhDs and MDs 200+ KOLs 26 Investment professionals 17 Years at LSP / EQT Life Sciences (partner average) Executive team Sam Fazeli Independent Board Member Head of research EMEA at Bloomberg Intelligence, London Led by some of Europe’s most experienced healthcare investors EQT Life Sciences (formerly LSP) is an affiliate of EBAC Sponsor (LSP Sponsor EBAC B.V.).

 

 

6 6 Strictly private and confidential Commercially confidential information Transaction Overview • EBAC (NASDAQ: EBAC) to combine with Oculis at a $218 million pro forma enterprise value (1,2,3,4) • Transaction to be funded through a combination of EBAC’s $128 million Cash in Trust (1) and $76 million of committed PIPE financing (5) • EBAC sponsor to retain 2.8 million founder shares (2) • Existing shareholders of Oculis to roll 100% of holdings and maintain ~47% pro - forma ownership in the combined company (2) x Transaction proceeds to Oculis will fund the continued clinical development of pipeline products, as well as for working capital and other general corporate purposes EBAC is a compelling SPAC partner for Oculis x Supported by Life Sciences Partners, one of Europe’s largest and most experienced healthcare investment firms x Track record going back 30 years, Life Sciences Partners has raised more than €3 billion, and invested in over 150 private companies x 17 successful exits in the last 5 years, including 6 IPOs x Life Sciences Partners is a value - added partner to Oculis with a global portfolio of assets and relationships European Biotech Acquisition Corp. (“EBAC”) expects to enter into a definitive agreement to merge with Oculis (1) Assumes no redemptions from EBAC Trust. Excludes interest earned in the Trust. SPAC cash amount subject to change dependi ng on actual interest earned. Approximately $7m in non - redemption agreements committed from existing EBAC investors at announcement. (2) Pro forma share count includes 20.3m seller’s rollover shares, 12.8m EBAC public shares, 7.6m PIPE shares and 2.8m Sponso r S hares (including 1.6m of at - risk capital). Excludes impact of ~4.25m EBAC Public Warrants, ~0.15m Private Placement Warrants, 4m Seller Earn - out Shares and Proposed New Equity Incentive Plan. (3) Oculis cash position of $28.8m as of the end of Q3 2022. (4) Based on Company Equity Value under the terms of the BCA, with a pro - forma number of approximately 20.3m shares to be issued to Oculis shareholders as rollover equity. (5) $12.7m of the PIPE financing is in the form of a convertible loan agreement at zero percent interest and convertible at c los ing. 6

 

 

7 7 Strictly private and confidential Commercially confidential information To drive innovation to save sight and improve eye care Our Purpose

 

 

8 8 Strictly private and confidential Commercially confidential information Executive summary: Uniquely positioned to build significant value Advanced and diversified product portfolio ▪ Advanced pipeline with 2 Phase 3 and 2 Phase 2 b indications ▪ 10 + Innovative and differentiated clinical and preclinical programs ▪ 1 st Retina eye - drop for Diabetic Macular Edema (DME) ▪ 1 st Biologic eye - drop for Dry Eye Disease (DED) (upside potential from biomarker - driven precision medicine approach) ▪ 1 st Neuroprotective agent for neuro - retina treatments ▪ Targeting critical unmet needs in 3 major ophthalmology segments Poised to deliver innovative therapies Significant commercial potential 2023 2024 ▪ OCS - 01 Ocular Surgery Phase 3 readout ▪ OCS - 01 DME Phase 3 (Stage 1) readout ▪ OCS - 01 Ocular Surgery NDA ▪ OCS - 01 CME (1) PoC readout ▪ OCS - 02 DED Phase 2b readout ▪ OCS - 02 Uveitis Phase 2b readout ▪ OCS - 05 AON (2) PoC readout (1) Cystoid Macular Edema (CME). (2) Acute Optic Neuritis (AON). Near - term value inflection points expected

 

 

9 9 Strictly private and confidential Commercially confidential information OCS - 01: Optireach ® enables eye drops for retinal disease Phase 3 in DME and Ocular Surgery Proprietary technology for front and back of the eye Topical Diabetic Macular Edema treatment OCS - 02: Antibody fragment technology enables biologic eye drop Phase 2b in Dry Eye Disease and Uveitis Topical anti - TNF α for severe Dry Eye Disease with potential biomarker for precision medicines OCS - 05: Promising neuroprotective agent in clinical trial Phase 1/2a in Acute Optic Neuritis, with multiple additional applications SGK - 2 activator with neuroprotective potential for Glaucoma, Geographic Atrophy, Diabetic Retinopathy & Neurotrophic Keratitis To address neurological damage Cyclodextrin Drug molecule Single complex Complex aggregate water - soluble nanoparticle Addressing highly meaningful key unmet medical needs with 3 major innovations IgG Fab scFv Regions that bind to neutralize TNF α

 

 

10 10 Strictly private and confidential Commercially confidential information OCS - 01 is based on the OPTIREACH ® technology, OCS - 02 is a single chain antibody fragment ( ScFv ) against TNF α and OCS - 05 is a SGK - 2 activator peptidomimetic small molecule with novel MoA targeting the activation of the trophic factor pathways. (1) Age - related macular degeneration (AMD). (2) Retinal Vein Occlusion (RVO). (3) Diabetic Retinopathy (DR). Product Candidate(s) Investigational Indication(s) Pre - clinical Phase 1 Phase 2 Phase 3 OCS - 01 OCS - 02 OCS - 05 OCS - 03 (Undisclosed) DIABETIC MACULAR EDEMA INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY DRY EYE DISEASE UVEITIS ACUTE OPTIC NEURITIS GLAUCOMA DIABETIC RETINOPATHY CORNEAL NV, PTERYGIUM Wet - AMD (1) , RVO (2) , DR (3) GEOGRAPHIC ATROPHY OCS - 04 CORNEAL TRANSPLANT CYSTOID MACULAR EDEMA Innovative, diversified and late - stage pipeline 2023 2024 Ph3 Stage 1 readout Ph 3 readout NDA PoC readout Ph2b readout Ph2b readout PoC readout Next Catalysts NEUROTROPHIC KERATITIS

 

 

11 11 Strictly private and confidential Commercially confidential information Experienced leadership team with successful track record Thorsteinn Loftsson CRTO & co - founder Riad Sherif Chief Executive Officer Pall Johannesson Chief Strategy Officer Sylvia Cheung Chief Financial Officer Marc Maderi Quality SVP Joanne Chang Chief Medical Officer Webb Ding COO & China President Bastian Dehmel Chief Dev. Officer Gudrun Bachmann CMC SVP x Over 200 years of cumulative experience at leading industry and drug development organizations x Combined experience in drug development leading to approvals and launches with >40 drug products across the world x Experience in managing and growing public companies and launching new classes of therapeutics x Commitment to build an industry leader in ophthalmic innovation

 

 

OCS - 01 in Diabetic Macular Edema (DME) & Post Ocular Surgery (in High - Risk Patients) Normal Vision Effects of DME 1 Normal Vision Possible Effects of DME OCS-01 in Diabetic Macular Edema (DME) 1 Normal Vision Possible Effects of DME OCS-01 in Diabetic Macular Edema (DME) 1 Normal Vision Possible Effects of DME OCS-01 in Diabetic Macular Edema (DME) 1 Normal Vision Possible Effects of DME OCS-01 in Diabetic Macular Edema (DME) Image: Source and Copyright: © 2022 by The Angiogenesis Foundation, Inc., All Rights Reserved. www.scienceofdme.org

 

 

13 13 Strictly private and confidential Commercially confidential information OCS - 01 First retina eye - drop in Phase 3 High potential commercial impact $ Near - term value inflection points Positive Ph2 in both indications First and only eye drop for retina ▪ Addressing DME, Ocular Surgery and CME ▪ 2 positive phase 2’s in DME and Ocular Surgery ▪ Positive EoP2 meeting validates Phase 3 design ▪ Total addressable US patient population for DME ~ 1.3M (1)(2) and for Ocular Surgery ~2M (3)(4) ▪ DME: Phase 3 Stage 1 readout expected mid - 2023 ▪ Ocular Surgery: Phase 3 readout expected mid - 2023 (1) Decision Resources Group: DME – DR Landscape Forecast – Disease Landscape Forecast 2020(1) (2) Gonzalez et al. 2016, Early and long - term responses to Anti - VEGF therapy in DME: Analysis of protocol I Data (3) Meddevicetracker , HPCUnet (Clearview forecast) (4) ARVO Annual Meeting Abstract, June 2021, Hennings et al. Prognostic determinants of postoperative pseudophakic macular oedema in a tertiary hospital setting

 

 

14 14 Strictly private and confidential Commercially confidential information DME is a large and growing market with critical unmet needs Growing DME patient population size (1) Only invasive treatments approved Late start of treatment Global DME Patients (7% of diabetics (2) ) High burden of treatment $3bn $6bn $8bn 2019 2029 Untreated (58%) Treated (42%) Undiagnosed (46%) Diagnosed (54%) Not appropriate for early intervention A leading cause of new cases of blindness in US adults (3) 14 DME – Treatment rate and market size in G7 countries (US, EU5 and JP) (4) 20 21 37 m 20 45 53 m+ (1) International Diabetes Federation – diabetesatlas.org Estimated diabetes around the world in 2021: 537m, reaching 783m in 20 45 (2) Yau et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy, Diabetes Care 2012 Mar; 35(3): 556 - 564. (3) https://preventblindness.org/diabetic - macular - edema - dme/ (4) DRG Diabetic Macular Edema / Diabetic Retinopathy Disease Landscape & Forecast 2020 (5) Gonzalez 2016 Early and Long - term Responses to VEGF Therapy in DME: Analysis of protocol I data Among treated patients, ~40% have a suboptimal response at 12 weeks (5)

 

 

15 15 Strictly private and confidential Commercially confidential information Unmet Needs OCS - 01 | Current DME treatment paradigm leaves two patient segments undertreated and losing vision Patient presents with DME symptoms Diagnosed by OCT (1) Current Treatment Observation Laser Anti - VEGF Steroid implant Laser 1 st line 1 st line Early Onset Intervention ▪ Physician’s decision not to treat due to lack of appropriate treatment for early intervention ▪ ~ 19% of patients with good vision experience deterioration by ≥ 5 letters over 2 years (3) Complementary Non - invasive Treatment ▪ Suboptimal response: Only 40/50% of patients respond adequately to anti - VEGF (4) ▪ Anti - VEGF use in clinical practice only ~30% of use in clinical trials (5) ▪ Patients not able to receive injections 24% DME recent onset DME with mild visual impairment 43% 33% DME with moderate to severe visual impairment DME Disease Progression and Treatment Landscape (1) Optical coherence tomography (OCT) imaging. (2) Baseline Demographics and Clinical Characteristics of Treatment - Naïve Patients with Diabetic Macular Edema Listed in the IRI S Registry (Table S1) www.aao.org (3) Baker, Carl W., et al. "Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial." Jama 321.19 (2019): 1880 - 1894. Addressable US patient population: 1.3 million (4)(6) (4) Gonzalez 2016 Early and Long - term Responses to VEGF Therapy in DME: Analysis of protocol I data (5) Kiss 2014 ; Berenger and Kiss, Feb. 2016, Real - world Utilization of VEGF agents (DME section), Review of Ophthalmology https://www.reviewofophthalmology.com/article/realworld - utilization - of - antivegf - agents (6) Decision Resources Group: DME – DR Landscape Forecast – Disease Landscape Forecast 2020 (2) (2) (2)

 

 

16 16 Strictly private and confidential Commercially confidential information Unique product candidate Positive results in exploratory and Phase 2 studies in DME Phase 3 program initiated after positive Phase 2 results and EoP2 meeting OCS - 01 is a unique high - concentration nanoparticle formulation of Dexamethasone (15mg/ml) Patient Case (Phase 2 DX211 ) (3) OCS - 01 showed biological effect in CMT (1) reduction and BCVA (2) improvement OPTIREACH® Formulation Technology DME Exploratory 1 19 pts Tanito Study successfully completed DME Phase 2 144 pts Randomized & double - masked successfully completed DME Exploratory 2 22 pts Ohira Study successfully completed Age 55 Treatment Group OCS - 01 DME Dur. 4 m Prior DME Tx No Baseline CMT (1) 765 Week 12 CMT (1) 328 Baseline BCVA (2) 40 W12 BCVA (2) 56 OCS - 01 | First eye drop for DME Exploratory 1: Investigator - initiated, open - label, single - center study. Tanito M, et al. Invest Ophthalmol Vis Sci . 2011 ;52:7944 - 7948 Exploratory 2: Ohira A, et al. Acta Ophthalmologica . 2015 ;93:610 - 615. Ohira A, et al. Acta Ophthalmologica . 2015 ;93:610 - 615. DME Phase 2: Note: Data presented at Angiogenesis, Exudation and Degeneration, 2020 by KOL (Dugel P.) (1) Central macular thickness (CMT) (2) Best - corrected visual acuity (BCVA) (3) Dugel PU. The Oculis OCS - 01 phase 1/2 study: an effective topical therapeutic for DME. Presented at: Angiogenesis, Exudation, and Degeneration 2020; Feb. 8, 2020; Miami. Baseline Week 12

 

 

17 17 Strictly private and confidential Commercially confidential information Safety Results OCS - 01 (n=99) Vehicle (n=45) Patients n (%) Patients n (%) ≥1 Ocular treatment - emergent ADR 32 (32.3) 9 (20.0) Increased intraocular pressure (IOP) 21 (21.2) 0 Eye irritation 3 (3.0) 0 Ocular hypertension 3 (3.0) 0 Cataract subcapsular 1 (1.0) 1 (2.2) Eyelid erythema 1 (1.0) 1 (2.2) Ocular hyperaemia 1 (1.0) 1 (2.2) Posterior capsule opacification 1 (1.0) 1 (2.2) Loss in BCVA ≥ 15 Letters in BCVA 1 (1.0) 1 (2.2) - 56.83 - 20.06 -60 -45 -30 -15 0 LS mean change in CMT (µm) OCS-01 (n=99) Vehicle (n=45) 2.62 1.04 0 1 2 3 4 Change from baseline in BCVA (ETDRS Letters) OCS-01 (n=99) Vehicle (n=45) OCS - 01 Positive Phase 2 DME study with 144 patients Statistically significant results in CMT (1) and BCVA (2) Mean CMT (Central Macular Thickness) change from Baseline at week 12 (3) Significant d ifference - 36.77 µm (95% CI - 68.74, - 4.80); p=0.0123 per pre - specified statistical model Mean BCVA (Best Corrected Visual Acuity) change from Baseline at week 12 (3) Significant d ifference 1.58 letters (95% CI - 1.12, 4.28); p=0.1258 per pre - specified statistical model Notes: Data presented at Angiogenesis, Exudation and Degeneration, 2020 by KOL ( Dugel P.) ITT population, observed data only. CI = confidence interval; CMT = central macular thickness; ITT = intention - to - treat; LS = least squares; ADR = adverse drug reaction; IOP = intraocular pressure. (1) CMT: Central Macular Thickness (2) BCVA: Best Corrected Visual Acuity (3) Dugel PU. The Oculis OCS - 01 phase 1/2 study: an effective topical therapeutic for DME. Presented at: Angiogenesis, Exudation, and Degeneration 2020; Feb. 8, 2020; Miami.

 

 

18 18 Strictly private and confidential Commercially confidential information OCS - 01 | DME Phase 2: Higher response in both endpoints in typical Phase 3 population (1) Mean CMT change among patients with baseline BCVA ≤ 65 at Week 12 Mean BCVA change among patients with baseline BCVA ≤ 65 at week 12 3.8 0.9 0 1 2 3 4 5 6 Mean Change in BCVA From Baseline (ETDRS Letters) OCS-01 (n = 45) Vehicle (n = 14) - 77.4 - 23.1 -100 -80 -60 -40 -20 0 20 Mean ( ± SD) Change in CMT From Baseline ( μm ) OCS-01 (n = 45) Vehicle (n = 14) (1): Data presented at Angiogenesis, Exudation and Degeneration, 2020 by KOL (Dugel P.) Dugel PU. The Oculis OCS - 01 phase 1/2 study: an effective topical therapeutic for DME. Presented at: Angiogenesis, Exudation, and Degeneration 2020; Feb. 8, 2020; Miami. ETDRS: Early Treatment of Diabetic Retinopathy Study. Baseline vision (BCVA ≤ 65 ETDRS) for planned OCS - 01 Phase 3 studies in DME – confirmed by FDA in EoP2 meeting

 

 

19 19 Strictly private and confidential Commercially confidential information OCS - 01 | Data support OCS - 01 to meet two treatment gaps in DME Expands patient and prescriber base - 77.4 - 23.1 -100 -80 -60 -40 -20 0 Mean Change in CMT From Baseline ( μm ) - 41.9 - 10.6 -90 -40 Mean ( ± SD) Change in CMT From Baseline (μm) OCS-01 (n = 47) Vehicle (n = 28) Change in OCT among patients with baseline BCVA > 65 Change in OCT & BCVA among patients with baseline BCVA ≤ 65 3.8 0.9 0 1 2 3 4 5 6 Mean Change in BCVA From Baseline OCS-01 (n = 45) Vehicle (n = 14) Early intervention addresses retinal edema Standalone/Combination treatment as complementary alternative to anti - VEGF injection (1) Baseline Demographics and Clinical Characteristics of Treatment - Naïve Patients with Diabetic Macular Edema Listed in the IRIS Re gistry (Table S1) www.aao.org (2) Dugel PU. The Oculis OCS - 01 phase 1/2 study: an effective topical therapeutic for DME. Presented at: Angiogenesis, Exudation, and Degeneration 2020; Feb. 8, 2020; Miami. 24% DME recent onset DME with mild visual impairment 43% 33% DME with moderate to severe visual impairment OCS - 01 Topical Treatment Covers Entire Continuum of DME Care Physicians General Ophthalmologist Retina Specialists (1) (1) (1) Patient presents with DME symptoms Diagnosed by OCT A potential versatile and effective option to treat DME patients (2)

 

 

20 20 Strictly private and confidential Commercially confidential information Phase 3 study design: ▪ Multicenter, randomized, double - masked, vehicle - controlled ▪ Stage 1: selection of dose regimen with better efficacy, 130 patients ▪ Stage 2: two global Phase 3 with ~350 - 450 pts each 6 weeks 6weeks Screening Randomization 2:1 End of trial Primary Endpoints (EoP2 meeting w/FDA) : ▪ Mean change in BCVA vs baseline at 52 weeks Key Secondary Endpoints: ▪ Mean change in central retinal thickness assessed by SD - OCT ▪ % of patients with +15 ETDRS letters vs baseline 52 weeks OCS - 01 | Phase 3 DME study post positive EoP2 FDA meeting Protocol with loading dose & enriched population to drive probability of success Stage 1 Stage 2 6x/day 3x/day 6x/day 3x/day Selected dose regimen Matching vehicle End of treatment Stage 1 Key Enrollment Criteria: ▪ Diabetes mellitus 1 and 2 ▪ ETDRS BCVA letter score between 65 and 24 ▪ Macular thickness (CST) of ≥ 310 μ m Vehicle OCS - 01 Dose and sample size selection Successful EoP2 meeting with FDA supporting Phase 3 program

 

 

21 21 Strictly private and confidential Commercially confidential information Ocular Surgery Market OCS - 01 1x/day resulted in statistically significant effect in inflammation and pain reduction Cystoid Macular Edema (CME), the most significant cause of postoperative vision loss after ocular surgery (5) • Up to 56% of high - risk patients may experience clinically significant CME following ocular surgery (5) . Clinically significant CME occurs in up to 5.8 % of cataract surgeries (5) • Approximately 30% of patients who undergo ocular surgery have higher risk of CME , including patients with diabetes, uveitis and other risk factors (3) (1) Meddevicetracker , HPCUnet (Clearview forecast) (2) Data on file, Skyggn phase 2 study (3) ARVO Annual Meeting Abstract, June 2021, Hennings et al. Prognostic determinants of postoperative pseudophakic macular oedema in a tertiary hospital setting OCS - 01 in Ocular Surgery provides unique medical profile in high - risk patients Active Arm vs vehicle ZERO INFLAMMATION D15 51% vs 20% p - value: 0.0009 PAIN FREE D4 73% vs 45% p - value: 0.0049 ~10M total procedures in 2037 U.S. Ocular Anterior Procedures (1) (M) 2019 - 2037 Skyggn : 150 patient Phase 2 Study results (2) Addressable US patient population: 2 million (1)(3) (4) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790635/ (5) https://crstodayeurope.com/articles/2013 - julaug/prevention - of - cme - after - cataract - surgery

 

 

22 22 Strictly private and confidential Commercially confidential information Source: (1) Shulman, Shiri, et al. Topical dexamethasone – cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis – a pilot study. Acta ophthalmologica 93.5 (2015): 411 - 415. (2) Data on file, Skyggn phase 2 study The only eye - drop with confirmed retinal benefit in both DME and CME x OCS - 01 demonstrated improvement in retinal edema / CME (1) x Addresses critical unmet medical need for high - risk patients undergoing ocular surgery Next steps: x Proof of concept study to be conducted to confirm CME role x Readout expected in 2024 OCS - 01 | Unique profile to address major complication of surgery OCS - 01 (1) Ocular surgery development x Positive Phase 2 Skyggn study largely de - risks Phase 3 program (2) x Phase 3 study is to be conducted in US sites • 1x/day OCS - 01 vs vehicle • Design similar to Skyggn study • Recruitment starting in Q3 2022 • Readout expected around mid 2023 supporting NDA submission Launch platform for OCS - 01 x Approval in Ocular Surgery would provide earlier market access for OCS - 01 x CME role provides unique medical & access profile Shown retinal edema reduction to provide benefit against Cystoid Macular Edema

 

 

23 23 Strictly private and confidential Commercially confidential information OCS - 01 Recap | First retina eye - drop High potential commercial impact $ Near - term value inflection points Positive Ph2 in both indications First and only eye drop for retina ▪ First Eye drop in DME with unique match with two critical unmet medical needs: early intervention & treated patients with inadequate response ▪ A leading Ocular Surgery treatment with 1x/d dosing, combined with CME improvement as unique differentiation ▪ DME: CMT & BCVA endpoints reached with statistical significance in Ph2 with 144 patients (5) ▪ Ocular Surgery: Pain and inflammation endpoints reached in Ph2 with 150 patients (6) ▪ Positive EoP2 meeting validates DME Phase 3 design which further de - risks program via patient population enrichment & loading dose / dose - selection stage ▪ Expands DME patient and prescriber base; enables general ophthalmologists to treat retina ▪ Total addressable US patient population for DME ~ 1.3M (1)(2) and for Ocular Surgery ~2M (3)(4) ▪ DME: Phase 3 Stage 1 readout expected mid - 2023 ▪ Ocular Surgery: Phase 3 readout expected mid - 2023 (1) Decision Resources Group: DME – DR Landscape Forecast – Disease Landscape Forecast 2020(1) (2) Gonzalez et al. 2016, Early and long - term responses to Anti - VEGF therapy in DME: Analysis of protocol I Data (3) Meddevicetracker , HPCUnet (Clearview forecast) (4) ARVO Annual Meeting Abstract, June 2021, Hennings et al. Prognostic determinants of postoperative pseudophakic macular oedema in a tertiary hospital setting (5) Data presented at Angiogenesis, Exudation and Degeneration, 2020 by KOL ( Dugel P.) (6) Data on file, Skyggn phase 2 study

 

 

24 OCS - 02 in Dry Eye Disease & Uveitis

 

 

25 25 Strictly private and confidential Commercially confidential information OCS - 02 First anti - TNFα eye drop for DED & Uveitis High potential commercial impact $ (1) DED Disease and Landscape – DRG Report, Dec. 2020 Upcoming value inflection milestones Positive Ph2 in both indications First biologic eye drop in DED ▪ Next gen. ophthalmic anti - TNFα to directly address core inflammation in DED & Uveitis ▪ 3 clinical Phase 2 studies showed statistically significant efficacy and safety of OCS - 02 in DED and Uveitis ▪ Total addressable US patient population for DED: ~10M (1) ▪ DED: Phase 2b readout expected in 2024 ▪ Uveitis: Phase 2b readout expected in 2024

 

 

26 26 Strictly private and confidential Commercially confidential information Calcineurin inhibitors (Ophthalmic) , 72% LFA - 1 Antagonists , 20% Secretagogues , 5% Corticosteroids (ophthalmic) , 3% Aqueous supplements , 0% Mucolytics , 0% ~ $4bn in 2019 OCS - 02 | DED is a large & growing market opportunity Underpenetrated with very few patients experiencing lasting relief (1) DRG Dry Eye Disease Landscape and Forecast 2020 (2) Mukamal , R. Why is Dry Eye So Difficult to Treat? 2021 https://www.aao.org/eye - health/tips - prevention/fix - dry - eye - treatment - eyedrops Dry Eye Rx drug market in G7 countries in 2019 ( 1 ) Significant market opportunity ▪ Large and growing market forecasted to reach $7.3bn in 2029 (1) ▪ Underpenetrated with only 9% of diagnosed patients in the US receiving treatment (1) ▪ For those treated, the vast majority are receiving anti - inflammatory drugs (1) ▪ Despite current options, an under - addressed patient population with only 13% of patients achieving lasting relief (2) ▪ Next generation anti - inflammatory drug with novel MoA remains a key unmet medical need for DED (1)

 

 

27 27 Strictly private and confidential Commercially confidential information OCS - 02 | Ocular surface inflammation, a central role in DED Current understanding of DED has advanced TFOS DEWS II (2020) recognizes the etiological role of ocular surface inflammation and damage in DED (2,3) DED is initiated by desiccating stress and perpetuated by a vicious circle of ocular surface inflammation (3) I nflammation rapidly takes on a central role in sustaining the pathological state (4) Tears from dry eye patients contain significantly increased concentrations of inflammatory cytokines such as TNF α showing correlation to severity of the disease (5) OCS - 02 to provide next generation (biologic) anti - inflammation treatment in ophthalmic context (1) Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN g roup meeting. Ocul Surf, 2013;11:246 - 258. (2) TFOS DEWS II Definition and Classification report, The Ocular Surface 15 (2017), 276 - 283 (3) TFOS DEWS II Pathophysiology report The Ocular Surface 15 (2017) 438 - 510 (4) Baudoin C. Dry Eye Disease, the complex interactions of vicious cycles. EuDES European Dry Eye Society https://www.dryeye - society.com/resources/dry - eye - disease - complex - interactions - vicious - cycles (5) Massingale et al. 2009, Analysis of Inflammatory Cytokines in the Tears of Dry Eye Patients, CORNEA, October 2009, Vol. 28 Issue 9, p 10 23 - 1027 The vicious circles of DED (1)(4)

 

 

28 28 Strictly private and confidential Commercially confidential information Illustration of fragment technology IgG Fab scFv* (OCS-02) Regions that bind to neutralize TNF � Framework for OCS-02 optimized for stability and other drug-like properties Standard antibody frameworks 149 kDa 48 kDa 26 kDa Regions that bind to neutralize TNFα Topical Biologic Candidate OCS - 02 is an anti - TNFα antibody fragment formulation with potential to become the first approved topical biologic for DED x Clinically proven MoA Anti - inflammation and anti - necrosis MoA already approved as systemic treatment for ocular disease and with transformative impact in other areas x Enhanced ocular penetration Lower molecular weight allowing for enhanced ocular penetration and higher concentration x Proprietary genetic biomarker Associated with OCS - 02 response highlighting the opportunity for a precision treatment in DED OCS - 02 | First and only topical treatment candidate based on anti - TNFα antibody fragment Clinically proven MoA with potential transformative impact in ocular diseases of inflammation Innovative Antibody Fragment Technology

 

 

29 29 Strictly private and confidential Commercially confidential information Positive Phase 2 / PoC in DED and Uveitis Advancing into Phase 2b for both indications Significant Market Opportunity Dry Eye Disease Advance OCS - 02 in Phase 2b to evaluate signs in DED (with secondary endpoint in symptoms) Stratification to v alidate genetic biomarker in severe DED population Uveitis Advance OCS - 02 in Phase 2b as steroid - sparing alternative for chronic and recurring Non - Infectious Anterior Uveitis The potential to become the FIRST precision medicine in Dry Eye Disease – de - risks clinical trial and creates potential market pricing upside A unique benefit in DED given its multifactorial nature and heterogenous patient population Addressable US patient segment for DED: ~10M (1) DED#1 85 pts Phase 2 POC successfully completed Uveitis 32 pts Phase 2 POC successfully completed DED#2 131 pts Phase 2 POC successfully completed OCS - 02 | Anti - TNF α biologic eye drop, intended to address large unsatisfied market (1) DED Disease and Landscape – DRG Report, Dec. 2020

 

 

30 30 Strictly private and confidential Commercially confidential information -12 -8 -4 0 Reduction in global ocular discomfort score P=0.04 OCS - 02 OCS - 02 | Phase 2a positive results in DED Proof - of - Concept Phase 2 trial evaluating symptoms demonstrated statistically significant reduction in symptoms and well - tolerated profile (1) 0 10 20 Vehicle OCS-02 % Pts with > 20 points improvement P=0.02 18% (12/67 pts) 5% (3/64 pts) % Points Full study population High responders OCS - 02 Vehicle N 67 64 Consistent results in a previous study (2) with fast onset at day 14 reaching and maintaining statistical significance Statistical significance reached in both all - comers and biomarker / high responders Safety: ▪ No meaningful safety findings ▪ Well tolerated Vehicle (1) Predecessor of OCS - 02 (LME636) (1) Note: Presented at ARVO 2021 by KOL (Perez V.) (2) Phase 2a study in acute anterior uveitis; data presented at ARVO, 2021 by KOL ( Galor A.)

 

 

31 31 Strictly private and confidential Commercially confidential information OCS - 02 | Biomarker identified for high responders – potential for precision medicine approach Pre - specified exploratory pharmacogenetic analysis focused on the genes relevant to TNF pathway and Sjogren’s syndrome Genetic biomarker for OCS - 02 response Association between gene variants and global ocular discomfort score at treatment day 29 was tested : ▪ Among the gene variants tested, one variant out of 4 showed significant effect on the response to OCS - 02 . ▪ Patients with this gene variant tended to have larger improvement vs other p < 0.0001 ▪ Oculis is planning to further validate OCS - 02 biomarker in the upcoming Phase 2b study Successful Phase 2b will support advancement to Phase 3 while evaluating the potential for a precision medicine for DED Full analysis set 25 15 5 - 5 - 15 - 25 - 35 - 45 - 55 - 65 - 75 - 85 - 95 - 105 # subj. (%) VAS >20 OCS - 02 12 (18%) Vehicle 3 (5%) *P =0.018 High responders: VAS change from baseline >20 Change from Baseline Presented at ARVO 2021 by KOL (Perez V.)

 

 

32 32 Strictly private and confidential Commercially confidential information ▪ Significant reduction of anti - inflammatory factors IL1B, IL8, and TNF α was observed in patients with SNP rs1800693 CC genotype and treated with OCS - 02 ▪ High correlation with the biomarker and TNF α mRNA expression ▪ Phase 2b planned for further validation ▪ Biomarker / precision medicine approach provides potential to de - risk Phase 3 probability of success and potential for commercial pricing upside in DED OCS - 02 | Genetic biomarker correlated with TNF α mRNA expression Enables de - risking of program and potential commercial pricing upside IL1B IL8 TN F α LME636 Vehicle * Mixed model repeated measure analysis OCS - 02 Presented at ARVO 2021 by KOL (Perez V.)

 

 

33 33 Strictly private and confidential Commercially confidential information 8 weeks TBD OCS - 02 3x/day (TID) Follow - up Screening Vehicle (TID) Follow - up Phase 2b study design: ▪ Randomized, masked, vehicle - controlled study ▪ Multi - center , 10 - week, approx. 180 subjects ▪ Stratification based on genotype (CC SNP) 30 Patients Objectives: ▪ The objective of this study is to evaluate the safety and efficacy of OCS - 02 for the treatment of signs and symptoms of dry eye disease Key Enrollment Criteria: ▪ Subjects with history of DED for 6 mths ▪ Schirmer’s test at baseline < 10 mm ▪ Corneal fluorescein stain > 2 in at least 1 region (inferior, superior) 2 week run in, all subjects Randomization Artificial tears TID Patients who respond to artificial tears will not be randomized OCS - 02 | Phase 2b study in Dry Eye Disease A multi - center, randomized, double - masked, vehicle - controlled study evaluating the safety and efficacy of OCS - 02 for the treatment of signs and symptoms of DED

 

 

34 34 Strictly private and confidential Commercially confidential information OCS - 02 | Uveitis unmet need and market opportunity (1) 2020 US adult population (258.3 million): https://www.census.gov/library/stories/2021/08/united - states - adult - population - grew - fas ter - than - nations - total - population - from - 2010 - to - 2020.html#:~:text=In%202020%2C%20the%20U.S.%20Census,from%20234.6%20million%20in%202010 (2) Prevalence of Non - Infectious Uveitis (121 per 100,000): Thorne. JAMA Ophth . 2016 (3) Acharya. JAMA Ophthal. 2013;131(11):1405 Non - Infectious Uveitis Epidemiology 311 252 128 39 0 100 200 300 400 U.S. Patients (K) 81% of NIU are anterior segment (2) 51% of uveitis patients are either chronic or recurrent (3) About 30% experience steroid related SE (4)(5) Ant. Uveitis NIU Chronic or recurrent Patients with SE Future Treatment Paradigm with OCS - 02 (7) OCS - 02 completed positive Phase 2a with topical biologic in Anterior Uveitis Chronic/recurrent patients have the greatest unmet medical need Widespread willingness to Rx OCS - 02 given non - steroidal & topical profile (7) Phase 2 POC Study (6) ▪ OCS - 02 reached its endpoint with statistical significance in a Phase 2 POC study in acute Uveitis ▪ No significant ocular or non - ocular safety findings ▪ Lasting effect observed after end of treatment 56% Responders at Day 15 (Primary endpoint) (1)(2) (4) https://www.college - optometrists.org/clinical - guidance/clinical - management - guidelines/glaucoma_steroid (5) https://www.ncbi.nlm.nih.gov/books/NBK430903/ (6) Phase 2 POC study with OCS - 02 in Acute Anterior Uveitis (data on file & presented at ARVO 2021) (7) Interviews with physicians, Clearview market research

 

 

35 35 Strictly private and confidential Commercially confidential information OCS - 02 Recap | First anti - TNFα eye drop for DED & Uveitis High potential commercial impact $ (1) Mukamal , R. Why is Dry Eye So Difficult to Treat? 2021 https://www.aao.org/eye - health/tips - prevention/fix - dry - eye - treatment - eyedrops (2) DED Disease and Landscape – DRG Report, Dec. 2020 Upcoming value inflection milestones Positive Phase 2 in both indications First biologic eye drop, with new mode of action for DED ▪ Next gen. ophthalmic drug to directly address core inflammation conditions in DED & Uveitis ocs - 02: Anti - inflammatory & anti - necrosis (anti - TNFα) NCE ▪ 3 clinical Phase 2 studies showed statistically significant, positive results on efficacy measures and good tolerability profile of OCS - 02 in DED and Uveitis ▪ Biomarker as an upside has potential to further drive Phase 3 de - risking and unique commercial value proposition ▪ 48% of patients with DED said they followed their treatment carefully, but only 13% experienced lasting relief (1) ▪ Total addressable US patient population for DED: ~10M (2) ▪ DED: Phase 2b readout expected in 2024 ▪ Uveitis: Phase 2b readout expected in 2024

 

 

OCS - 05 in Neuroprotection Normal vision Early glaucoma Advanced glaucoma

 

 

37 37 Strictly private and confidential Commercially confidential information OCS - 05 First SGK neuroprotective candidate in ophthalmology High potential commercial impact $ Upcoming value inflection Data supporting MoA and safety First SGK neuroprotective ophthalmic candidate ▪ Disease modifying drug which protects and repairs neurons ▪ Preclinical data showing neuroprotection by preventing retinal ganglion cell death and improvement of function in MS (1) and AON (2) models ▪ Phase 1 study data demonstrated OCS - 05 was well - tolerated in 48 healthy volunteers ▪ Potential application in ophthalmology including Glaucoma, Geographic Atrophy, Diabetic Retinopathy, and corneal indications such as Neurotrophic Keratitis ▪ Proof - of - concept data readout in AON expected in 2024 (1) Multiple Sclerosis. (2) Acute Optic Neuritis.

 

 

38 38 Strictly private and confidential Commercially confidential information OCS - 05 | Candidate Overview SGK - 2 activator peptidomimetic small molecule with unique MoA for neuroprotection and potential applications in large ophthalmic disease areas OCS - 05 targets SGK as part of the neurotrophic factor signalling pathways triggering multiple beneficial affects on apoptosis, anti - oxidation and anti - inflammation Unique & Differentiated MOA (+) Disease modifying drug to protect and repair neurons ▪ Activates neurotrophic signalling pathways supporting neuronal survival and repair Multiple potential applications: ▪ Glaucoma ▪ Dry AMD / Geographic Atrophy ▪ Diabetic Retinopathy ▪ Acute Optic Neuritis ▪ Neurotrophic Keratitis (+) (+) ( - )

 

 

39 39 Strictly private and confidential Commercially confidential information OCS - 05 to meet critical unmet need in Glaucoma Large unmet need remains despite availability of effective IOP lowering drugs 0 20 40 60 80 100 120 2020 2040 Cumulative incidences of blindness (2) 0% 20% 40% 60% Bilateral At least one eye after 10 years after 20 years “Currently available therapies for Glaucoma only attempt to reduce intraocular pressure , the major risk factor, without addressing the associated Optic Neuropathy and Retinopathy.” (3) “Development of Glaucoma neuroprotective treatment is therefore a pressing unmet medical need . ” (3) “…subset of patients with Glaucoma may have more aggressive disease and may be particularly susceptible to progression, possi bly because of non - IOP - related factors that contribute to retinal ganglion cell (RGC) death and vision loss.” (4) ̴ 80 M people have Glaucoma worldwide – reaching ~ 110 M by 2040 Current medications are insufficient: >20% of patients still go blind in at least 1 eye after 10 years Global number of Glaucoma patients (1) (millions of patients) While SOC drugs reduce IOP (a risk factor), there is no treatment to protect against optic nerve damage SOC: IOP lowering (1) https://www.brightfocus.org/glaucoma/article/glaucoma - facts - figures (2) Peters D, Bengtsson B, Heijl A. Lifetime risk of blindness in open - angle glaucoma. Am J Ophthalmol . 2013;156:724 – 730 (3) Liu, Y., Pang, IH. Challenges in the development of glaucoma neuroprotection therapy. Cell Tissue Res 353, 253 – 260 (2013) (4) Malihi M, Moura Filho ER, Hodge DO, Sit AJ. Long - term trends in glaucoma - related blindness in Olmsted County, Minnesota. Ophthalmology. 2014;121:134 – 141 OCS - 05

 

 

40 40 Strictly private and confidential Commercially confidential information OCS - 05 | Promotes neuroprotection Compelling data showing neuroprotection in Glaucoma and AON models OCS – 05 | H&E (4) for RGC (3) density at week 6 (5) High - pressure Glaucoma rat model of neurodegeneration without inflammation Other pre - clinical data: ▪ Reduced axonal loss and demyelination in chemical AON models (curative regimen) with sustained efficacy ▪ Reduce axonal loss in POAG models ▪ Reduce axonal loss and demyelination in inflammatory AON models Eyedrops Intravitreal OCS - 05 shown to promote improvement of clinical function (disability due to vision loss) in experimental autoimmune encephalomyelitis model 0 1 2 3 4 5 D1 D3 D5 D7 D9 D11 D13 D15 D17 D19 D21 D23 D25 D27 D29 D31 D33 D35 D37 D39 D41 D43 D45 D47 Clinical assessment (score) Normal Severe disabilities OCS - 05 100 mpk OCS - 05 50 mpk Placebo Experimental Autoimmune Encephalomyelitis model in mice OCS – 05 | Model of autoimmune AON and MS (5) Treatment initiation OCS - 05, IVT and topical, shown to prevent RGCs (3) damage (the key element in Glaucoma vision loss) (1) Primary Open - Angle Glaucoma (POAG). (2) Experimental autoimmune encephalomyelitis (EAE). (3) Retinal ganglion cell (RGC). (4) Hematoxylin and eosin (H&E) staining. (5) Villoslada P. et al. Neurotherapeutics , published online: 27 February 2019.

 

 

41 41 Strictly private and confidential Commercially confidential information OCS - 05 | Protects against loss of Retinal Ganglion Cells AON model: Short term study (5 - day treatment, assessment at day 6) (1) Villoslada P. et al. Neurotherapeutics, published online: 27 February 2019 Sham control in healthy animals Path control: Pathological control 198 144 ** 163 *** 178 0 50 100 150 200 250 Sham control Path control BN201 (35 mg/kg) BN201 (70 mg/kg) Number of Ganglion cells / 6 high power field **p < 0.01 ; ***p < 0.001 compared to placebo Prevention of Retinal Ganglion Cell (RGC) loss (1) Sham control Loss of RGC Placebo OCS - 05 70 mg/kg % of Efficacy 35.9 64.0 Lysolecithin induced demyelinating model in rat ( model of acute optic neuritis) High loss No loss OCS - 05 (70 mg/Kg) OCS - 05 (35 mg/Kg) More RGC remain RGC Visual of RGC Protection

 

 

42 42 Strictly private and confidential Commercially confidential information OCS - 05 | ACUITY first - in - patients trial in AON Paving the way to multiple indications ACUITY PoC Study paving the way to multiple indications Acuity PoC Neuro - Retina Phase 1 Animal models Discovery Acute Optic Neuritis (AON) Glaucoma Geographic Atrophy Phase 1: No drug - related side effects ▪ Randomized, double - blind, placebo - controlled, single and multiple ascending dose study of the safety, tolerability and PK of OCS - 05 in adult healthy volunteers (UK, MHRA) ▪ Recruitment of 48 healthy volunteers (36 OCS - 05, 12 placebo) Phase 2a: First - in - Patients Trial in AON ▪ Objective to evaluate safety and efficacy of OCS - 05 compared to placebo in patients diagnosed with a first unilateral AON of a demyelinating origin ▪ Randomized double - blind placebo - controlled, multicentre trial in Europe Ongoing Diabetic Retinopathy CNS: Multiple Sclerosis (MS) Cornea: Neurotrophic Keratitis

 

 

43 43 Strictly private and confidential Commercially confidential information OCS - 05 recap | First SGK neuroprotective candidate in ophthalmology High potential commercial impact $ Upcoming value inflection Data supporting MoA and safety First SGK neuroprotective ophthalmic candidate ▪ Disease modifying drug which protects and repairs neurons ▪ Potential paradigm shift in treating major blinding diseases by acting directly on retinal neurons ▪ Preclinical data showing neuroprotection by preventing retinal ganglion cell death and improvement of function in MS (1) and AON (2) models ▪ Phase 1 study data demonstrated OCS - 05 was well - tolerated in 48 healthy volunteers ▪ Potential application in ophthalmology including Glaucoma, Geographic Atrophy, Diabetic Retinopathy, and corneal indications such as Neurotrophic Keratitis ▪ Proof - of - concept data readout in AON expected in 2024 (1) Multiple Sclerosis. (2) Acute Optic Neuritis.

 

 

44 Summary

 

 

45 45 Strictly private and confidential Commercially confidential information Proven track record of efficient capital deployment and execution of key milestone opportunities Financing < 2016 - 2017 Series A ~US $5m Series B1 ~US $20m Series B2 ~US $25m Series C ~US $60m 2018 - 2019 2021 2020 2022 Business Milestones OCS - 01 Optireach ® animal & human POC OCS - 01 Optireach ® clinical validation in DME/retina and Oc Sx OCS - 01 Positive EoP2 with FDA for DME and Ocular Sx commenced Phase 3 studies OCS - 02 Technical development advancement OCS - 05 Neuroprotective disease modifying technology in - licensing OCS - 02 Biologic eye drop Novartis in - licensing

 

 

46 46 Strictly private and confidential Commercially confidential information Oculis Intellectual Property Rights Strong IP and market exclusivity Patent Categories Data Exclusivity Last to expire OCS - 01 Formulation Manufacturing Methods of use n/a 2040 OCS - 02 Product Methods of use US biosimilar exclusivity for 12 years and similar in other jurisdictions 2037 (further patents in preparation) OCS - 05 Product Methods of use Up to 7 years in US based on orphan drug designation and similar in other jurisdictions 2040 (further patents in preparation)

 

 

47 47 Strictly private and confidential Commercially confidential information (1) $12.7m of the PIPE financing is in the form of a convertible loan agreement at zero percent interest and convertible at c los ing. (2) Pro forma share count includes 20.3m seller’s rollover shares, 12.8m EBAC public shares, 7.6m PIPE shares and 2.8m Sponso r S hares (including 1.6m of at - risk capital). Excludes impact of ~4.25m EBAC Public Warrants, ~0.15m Private Placement Warrants, 4m Seller Earn - out Shares and Proposed New Equity Incentive Plan. (3) Oculis cash position of $28.8m as of the end of Q3 2022. (4) Assumes no redemptions from EBAC trust. Excludes interest earned in the trust. SPAC cash amount subject to change dependi ng on actual interest earned. Approximately $7m in non - redemption agreements committed from existing EBAC investors at announcement . (5) Based on Company Equity Value under the terms of the BCA, with a pro - forma number of approximately 20.3m shares to be issued to Oculis shareholders as rollover equity. 47 Transaction overview Illustrative Pro - Forma Valuation ($m) Sources of Funds ($m) Uses of Funds ($m) Pro - Forma Ownership ( 2 ) PIPE Financing • Implied post - money enterprise value of $218 million • $76 million of committed PIPE financing (1) led by LSP 7 • To fund the continued clinical development of pipeline products, as well as for working capital and other general corporate purposes Share Price $10.00 Pro - Forma Shares Outstanding (2) 43.5 Equity Value $435 ( - ) Target Net Cash (3) ($29) ( - ) Net Cash to Balance Sheet (4) ($189) Pro - Forma Enterprise Value $218 EBAC Cash in Trust (4) $128 PIPE Proceeds $76 Rollover Equity $203 Total sources $407 Rollover Equity (5) $203 Cash to Balance Sheet $189 Transaction Fees (est.) $15 Total uses $407 47% 29% 17% 7% Seller's Rollover Equity EBAC Public Shareholders PIPE Investors Sponsor Shares

 

 

48 48 Strictly private and confidential Commercially confidential information Financing: Anticipated Use of Net Proceeds Overview ~$100m (1) to drive multiple value catalysts Use of Proceeds Value Driver US $m Purpose OCS - 01 NDA & DME Phase 3 Execution $35 ▪ DME NDA enabling OCS - 02 Phase 3 Readiness In DED and Uveitis $30 ▪ OCS - 02 technical development EoP 2 and Phase 3 readiness OCS - 05 AON PoC, NK, GA, Glaucoma Dev. $15 ▪ Novel technology development, IND enabling and neuroprotection pre - clinical and clinical validation General business including commercial readiness $20 ▪ Phased OCS - 01 Oc Sx commercial readiness Total $100 OCS - 01 35% OCS - 02 30% OCS - 05 15% General & commercial 20% (1) Minimum cash condition.

 

 

49 49 Strictly private and confidential Commercially confidential information Recap: Uniquely positioned to build significant value Advanced and diversified product portfolio ▪ Advanced pipeline with 2 Phase 3 and 2 Phase 2 b indications ▪ 10 + Innovative and differentiated clinical and preclinical programs ▪ 1 st Retina eye - drop for Diabetic Macular Edema (DME) ▪ 1 st Biologic eye - drop for Dry Eye Disease (DED) (upside potential from biomarker - driven precision medicine approach) ▪ 1 st Neuroprotective agent for neuro - retina treatment ▪ Targeting critical unmet needs in 3 major ophthalmology segments Poised to deliver innovative therapies Significant commercial potential Near - term value inflection points expected (1) Cystoid Macular Edema (CME). (2) Acute Optic Neuritis (AON). 2023 2024 ▪ OCS - 01 Ocular Surgery Phase 3 readout ▪ OCS - 01 DME Phase 3 (Stage 1) readout ▪ OCS - 01 Ocular Surgery NDA ▪ OCS - 01 CME (1) PoC readout ▪ OCS - 02 DED Phase 2b readout ▪ OCS - 02 Uveitis Phase 2b readout ▪ OCS - 05 AON (2) PoC readout

 

 

50 50 Strictly private and confidential Commercially confidential information To drive innovation to save sight and improve eye care Our Purpose